

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
**WO 02/10436 A2**

- (51) International Patent Classification<sup>7</sup>: **C12Q 1/00**
- (21) International Application Number: **PCT/US01/23642**
- (22) International Filing Date: **27 July 2001 (27.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
60/222,093                      28 July 2000 (28.07.2000)      US
- (71) Applicant: **THE BRIGHAM AND WOMEN'S HOSPITAL, INC.** [US/US]; 75 Francis Street, Boston, MA 02115 (US).
- (72) Inventor: **MUTTER, George, L.**; 230 Middlesex Road, Chestnut Hill, MA 02467-1841 (US).
- (74) Agent: **VAN AMSTERDAM, John, R.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (81) Designated States (*national*): CA, JP.
- (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- (71) Applicant and  
(72) Inventor: **BAAK, Jan** [NL/NO]; Risajev 66, N-4056 Tananger (NO).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PROGNOSTIC CLASSIFICATION OF BREAST CANCER



(57) Abstract: The invention provides particular sets of genes that are expressed differentially in tumors characterized as high MAI or low MAI tumors. These sets of genes can be used to discriminate between high and low MAI tumors. Diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression are also provided.

WO 02/10436 A2

## **PROGNOSTIC CLASSIFICATION OF BREAST CANCER**

### **Field of the Invention**

The invention relates to nucleic acid microarray markers for cancer, particularly for  
5 breast cancer. The invention also relates to methods for diagnosing cancer as well as  
optimizing cancer treatment strategies.

### **Background of the Invention**

Breast cancer is a malignant proliferation of epithelial cells lining the ducts or lobules  
10 of the breast (Harrison's Principles of Internal Medicine 1998). Although much progress has  
been made toward understanding the biological basis of cancer and in its diagnosis and  
treatment, it is still one of the leading causes of death in the United States. Inherent  
difficulties in the diagnosis and treatment of cancer include among other things, the existence  
of many different subgroups of cancer and the concomitant variation in appropriate treatment  
15 strategies to maximize the likelihood of positive patient outcome.

The traditional method of breast cancer diagnosis and staging is through the use of  
biopsy examination. Once a diagnosis is made, the options for treating breast cancer are  
assessed with respect to the needs of the patient. These options traditionally include surgical  
intervention, chemotherapy, radiotherapy, and adjuvant systemic therapies. Surgical therapy  
20 may be lumpectomy or more extensive mastectomy. Adjuvants may include but are not  
limited to chemotherapy, radiotherapy, and endocrine therapies such as castration;  
administration of LHRH agonists, antiestrogens, such as tamoxifen, high-dose progestogens;  
adrenalectomy; and/or aromatase inhibitors (Harrison's Principles of Internal Medicine  
1998).

25 Of key importance in the treatment of breast cancer is the selection and  
implementation of an appropriate combination of therapeutic approaches. For example,  
depending on a breast cancer patient's prognosis, therapy may include surgical intervention  
in combination with adjuvant therapy or it may only include surgical intervention. In  
addition, for some patients pretreatment with chemotherapy or radiotherapy is utilized prior  
30 to surgical intervention, but in other patients adjuvant therapies are used following surgical  
intervention.

It is difficult to predict from standard clinical and pathologic features the clinical  
course of early stage breast cancer, particularly lymph node-negative tumors in

premenopausal patients. Current practice in the United States is to offer systemic chemotherapy to most of these women. Because the majority of these women would have good outcome even without chemotherapy, the rate of “over-treatment” is high.

Chemotherapy itself carries a 1% mortality rate. Therefore, unnecessary deaths could be avoided if it were possible to subdivide these patients into high and low risk subgroups, and only undertake adjunctive treatment for those judged to be high risk.

Selection of a suitable treatment regimen for breast cancer is based on the subgroup of cancer. Current strategies used to make therapeutic decisions in the management of patients with breast cancer are based on several factors including hormone receptor status, her-2/neu staining, flow cytometry, and the mitotic activity index (MAI). The MAI is a widely utilized predictor of outcome in cancers, particularly in invasive breast cancer. The definition of the MAI is “the total number of mitoses counted in 10 consecutive high-power fields (objective, x40; numeric aperture, .75; field diameter, 450 microns), in the most cellular area at the periphery of the tumor, with the subjectively highest mitotic activity” (Jannink et al., 1995).

For the procedure, hematoxylin-eosin stained sections of breast cancer tumor are assessed for the total number of mitotic figures in ten consecutive high-power fields and based on these numbers the breast cancer is assigned to either good outcome (MAI<10) or poor outcome (MAI>10). MAI classification correlates to standard parameters such as death, recurrence, and metastases, which are known to those of ordinary skill in the art to predict clinical outcome.

Determination of appropriate treatment for an individual cancer patient is complex with a wide variety of treatments and possible treatment combinations. For example, chemotherapy is a common method of cancer treatment, with more than 50 different chemotherapeutic agents available. These therapeutic agents can be used in a wide range of dosages both singly and in combinational therapies with other chemotherapeutic agents, surgery, and/or radiotherapy.

The available methods for designing strategies for treating breast cancer patients are complex, time consuming, and inexact. The wide range of cancer subgroups and variations in disease progression limit the predictive ability of the healthcare professional. In addition, continuing development of novel treatment strategies and therapeutics will result in the addition of more variables to the already complex decision-making process involving matching the cancer patient with a treatment regimen that is appropriate and optimized for the cancer stage, extent of infiltration, tumor growth rate, and other factors central to the

- 3 -

individual patient's prognosis. Because of the critical importance of selecting appropriate treatment regimens for breast cancer patients, the development of guidelines for treatment selection is of key interest to those in the medical community and their patients. Thus, there presently is a need for objective, reproducible, and sensitive methods for predicting breast cancer patient outcome and selecting optimal treatment regimens.

### **Summary of the Invention**

It now has been discovered that particular sets of genes are expressed differentially in tumors characterized as high MAI or low MAI tumors. These sets of genes can be used to discriminate between high and low MAI tumors. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression can now be based on the expression of sets of genes.

According to one aspect of the invention, methods for diagnosing breast cancer in a subject suspected of having breast cancer are provided. The methods include obtaining from the subject a breast tissue sample and determining the expression of a set of nucleic acid molecules or expression products thereof in the breast tissue sample. The set of nucleic acid molecules includes at least two nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51. In preferred embodiments, the breast tissue sample suspected of being cancerous.

In some embodiments the set of nucleic acid molecules includes more than 2 and up to all of the nucleic acid molecules set forth as SEQ ID NOs:1-51, and any number of nucleic acid sequences between these two numbers. For example, in certain embodiments the set includes at least 3, 4, 5, 10, 15, 20, 30, 40 or more nucleic acid molecules of the nucleic acid molecules set forth as SEQ ID NOs:1-51.

In other embodiments, the method further includes determining the expression of the set of nucleic acid molecules or expression products thereof in a non-cancerous breast tissue sample, and comparing the expression of the set of nucleic acid molecules or expression products thereof in the breast tissue sample suspected of being cancerous and the non-cancerous breast tissue sample.

According to another aspect of the invention, methods for identifying a set of nucleic acid markers or expression products thereof are provided. The methods are effective for determining the prognosis of cancer. The methods include obtaining a plurality of tumor



- 4 -

tissue samples from a plurality of subjects afflicted with cancer, classifying the plurality of tumor tissue samples according to mitotic activity index (MAI) into high MAI and low MAI groups and determining differences in the expression of a plurality of nucleic acid molecules or expression products thereof in the tumor tissue samples. The methods further include  
5 selecting as a set of nucleic acid markers the nucleic acid molecules or expression products thereof which are differentially expressed in the high MAI and the low MAI groups. The set of nucleic acid markers or expression products thereof effective for determining poor prognosis of cancer includes one or more nucleic acid molecules or expression products thereof which are preferentially expressed in high MAI tumor tissue samples, and wherein the  
10 set of nucleic acid markers or expression products thereof effective for determining good prognosis of cancer comprises one or more nucleic acid molecules or expression products thereof which are preferentially expressed in low MAI tumor tissue samples. In preferred embodiments, the cancer is breast cancer.

According to still another aspect of the invention, methods for selecting a course of  
15 treatment of a subject having or suspected of having cancer are provided. The methods include obtaining from the subject a tissue sample suspected of being cancerous, determining the expression of a set of nucleic acid markers or expression products thereof which are differentially expressed in high MAI tumor tissue samples to determine the MAI of the tissue sample of the subject, and selecting a course of treatment appropriate to the cancer of the  
20 subject.

In preferred embodiments the cancer is breast cancer, and in some of these embodiments the methods include determining the expression of a set of nucleic acid markers that are differentially expressed in low MAI breast tumor tissue samples.

According to yet another aspect of the invention, methods for evaluating treatment of  
25 cancer are provided. The methods include obtaining a first determination of the expression of a set of nucleic acid molecules or expression products thereof, which are differentially expressed in high MAI tumor tissue samples to determine the MAI of the tissue sample from a subject undergoing treatment for cancer, and obtaining a second determination of the expression of a set of nucleic acid molecules or expression products thereof, which are  
30 differentially expressed in high MAI tumor tissue samples to determine the MAI of the second tissue sample from the subject after obtaining the first determination. The methods also include comparing the first determination of expression to the second determination of expression as an indication of evaluation of the treatment.

In preferred embodiments the cancer is breast cancer, and in some of these embodiments the methods include determining the expression of a set of nucleic acid markers that are differentially expressed in low MAI breast tumor tissue samples.

The invention in another aspect provides solid-phase nucleic acid molecule arrays.

5 The arrays have a cancer gene marker set that consists essentially of at least two and as many as all of the nucleic acid molecules set forth as SEQ ID NOs:1-51 fixed to a solid substrate. The set of nucleic acid markers can include any number of nucleic acid sequences between these two numbers, selected from SEQ ID NOs:1-51. For example, in certain embodiments the set includes at least 3, 4, 5, 10, 15, 20, 30, 40 or more nucleic acid molecules of the  
10 nucleic acid molecules set forth as SEQ ID NOs:1-51. In some embodiments, the solid-phase nucleic acid molecule array also includes at least one control nucleic acid molecule.

In certain embodiments, the solid substrate includes a material selected from the group consisting of glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and nickel oxide, various clays, nitrocellulose, or nylon. Preferably the substrate is glass.

15 In other embodiments, the nucleic acid molecules are fixed to the solid substrate by covalent bonding.

According to yet another aspect of the invention, protein microarrays are provided.

The protein microarrays include antibodies or antigen-binding fragments thereof, that specifically bind at least two different polypeptides selected from the group consisting of  
20 SEQ ID NOs:52-102, fixed to a solid substrate. In some embodiments, the microarray comprises antibodies or antigen-binding fragments thereof, that bind specifically to least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51 different polypeptides selected from the group consisting of SEQ ID NOs:52-102. In certain  
25 embodiments, the microarray also includes an antibody or antigen-binding fragment thereof, that binds specifically to a cancer-associated polypeptide other than those selected from the group consisting of SEQ ID NOs:52-102, preferably a breast cancer associated polypeptide. In some embodiments, the protein microarray also includes at least one control polypeptide molecule. In further embodiments, the antibodies are monoclonal or polyclonal antibodies.  
30 In other embodiments, the antibodies are chimeric, human, or humanized antibodies. In some embodiments, the antibodies are single chain antibodies. In still other embodiments, the antigen-binding fragments are F(ab')<sub>2</sub>, Fab, Fd, or Fv fragments.

- 6 -

In a further aspect of the invention, methods for identifying lead compounds for a pharmacological agent useful in the treatment of breast cancer are provided. The methods include contacting a breast cancer cell or tissue with a candidate pharmacological agent, and determining the expression of a set of nucleic acid molecules in the breast cancer cell or  
5 tissue sample under conditions which, in the absence of the candidate pharmacological agent, permit a first amount of expression of the set of nucleic acid molecules. The set of nucleic acid molecules includes at least two and as many as all of the nucleic acid molecules set forth as SEQ ID NOs:1-51. The methods also include detecting a test amount of the expression of the set of nucleic acid molecules, wherein a decrease in the test amount of expression in the  
10 presence of the candidate pharmacological agent relative to the first amount of expression indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which is useful in the treatment of breast cancer. In preferred embodiments, the set of nucleic acid molecules is differentially expressed in high MAI breast tumor tissue samples.

In some embodiments of any of the foregoing methods and products, the differences  
15 in the expression of a the nucleic acid molecules are determined by nucleic acid hybridization or nucleic acid amplification methods. Preferably the nucleic acid hybridization is performed using a solid-phase nucleic acid molecule array. In other embodiments, the differences in the expression of the nucleic acid molecules are determined by protein expression analysis, preferably SELDI mass spectroscopy.

20 These and other aspects of the invention will be described in greater detail below.

### **Brief Description of the Drawings**

Figure 1 is a scatterplot of gene expression level in low risk (x axis) and high risk (y axis) breast cancers. 422 genes whose mean expression between groups differs at least 2-fold  
25 and by 100 expression units are shown as small crosses. The top 51 t-test ranked genes with Permax 0.96 are indicated as solid circles, and appear in Table 1.

### **Detailed Description of the Invention**

The invention described herein relates to the identification of a set of genes expressed  
30 in breast cancer tissue that are predictive of the clinical outcome of the cancer. Changes in cell phenotype in cancer are often the result of one or more changes in the genome expression of the cell. Some genes are expressed in tumor cells, and not in normal cells. In addition, different genes are expressed in different subgroups of breast cancers, which have different

- 7 -

prognoses and require different treatment regimens to optimize patient outcome. The differential expression of breast cancer genes can be examined by the assessment of nucleic acid or protein expression in the breast cancer tissue.

The genes were identified by screening nucleic acid molecules isolated from various breast cancer samples for expression of the genes present on a high-density nucleic acid microarray. The breast cancer samples were categorized with respect to their mitotic activity index (MAI) and the MAI was correlated to gene expression to identify those genes differentially expressed between low and high-MAI breast cancer tissue. The MAI has been shown to correlate with the outcome of the cancer as defined by tumor metastasis, tumor recurrence or mortality. Accordingly the genes identified permit, *inter alia*, rapid screening of cancer samples by nucleic acid microarray hybridization or protein expression technology to determine the expression of the specific genes and thereby to predict the outcome of the cancer. Such screening is beneficial, for example, in selecting the course of treatment to provide to the cancer patient, and to monitor the efficacy of a treatment.

The invention differs from traditional breast cancer diagnostic and classification techniques including MAI, hormone receptor expression and her-2/neu expression, with respect to the speed, simplicity, and reproducibility of the cancer diagnostic assay. The invention also presents targets for drug development because it identifies genes that are differentially expressed in poor outcome breast tumors, which can be utilized in the development of drugs to treat such tumors, e.g., by reducing expression of the genes or reducing activity of proteins encoded by the genes.

The invention moves beyond the use of the MAI and simplifies prognosis determination by providing an identified set of genes whose expression in breast cancers predicts poor clinical outcome as defined by tumor metastasis, recurrence, or death. In the invention, the MAI was used in conjunction with RNA expression phenotyping performed using high density microarrays generated from quantitative expression data on over 5000 (estimated 5800) genes, which have been analyzed to identify 51 specific probe sets (genes) with divergent expression between MAI groups. The expression gene set has multifold uses including, but not limited to, the following examples. The expression gene set may be used as a prognostic tool for breast cancer patients, to make possible more finely tuned diagnosis of breast cancer and allow healthcare professionals to tailor treatment to individual patients' needs. The invention can also assess the efficacy of breast cancer treatment by determining progression or regression of breast cancer in patients before, during, and after breast cancer

treatment. Another utility of the expression gene set is in the biotechnology and pharmaceutical industries' research on disease pathway discovery for therapeutic targeting. The invention can identify alterations in gene expression in breast cancer and can also be used to uncover and test candidate pharmaceutical agents to treat breast cancer.

5           Although the invention is described primarily with respect to breast cancer, one of ordinary skill in the art will appreciate that the invention also is useful for diagnosis and prognosis determination of cancers that can be classified into subgroups for prognosis of the cancer based on MAI. For example, MAI has been used successfully in the classification of malignant melanoma, ovarian cancer, bladder cancer, and prostatic adenocarcinoma. Thus,  
10       the methods and products of the invention also are applicable to non-breast cancers that can be classified by MAI.

          The invention may also encompass cancers other than breast cancer, including but not limited to: biliary tract cancer; bladder cancer; brain cancer including glioblastomas and medulloblastomas; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer;  
15       esophageal cancer; gastric cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia; multiple myeloma; AIDS-associated leukemias and adult T-cell leukemia lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer including squamous cell carcinoma; ovarian cancer  
20       including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells; pancreatic cancer; prostate cancer; rectal cancer; sarcomas including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer including melanoma, Kaposi's sarcoma, basocellular cancer, and squamous cell cancer; testicular cancer including germinal tumors such as seminoma, non-seminoma (teratomas,  
25       choriocarcinomas), stromal tumors, and germ cell tumors; thyroid cancer including thyroid adenocarcinoma and medullar carcinoma; and renal cancer including adenocarcinoma and Wilms tumor.

          As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments human subjects are preferred. Preferably the  
30       subject is a human either suspected of having breast cancer, or having been diagnosed with breast cancer. In a preferred embodiment of the invention the cancer is pre-menopausal, lymph node-negative breast cancer. Methods for identifying subjects suspected of having breast cancer may include manual examination, biopsy, subject's family medical history,

subject's medical history, or a number of imaging technologies such as mammography, magnetic resonance imaging, magnetic resonance spectroscopy, or positron emission tomography. Diagnostic methods for breast cancer and the clinical delineation of breast cancer diagnoses are well-known to those of skill in the medical arts.

5 As used herein, breast tissue sample is tissue obtained from a breast tissue biopsy using methods well-known to those of ordinary skill in the related medical arts. The phrase "suspected of being cancerous" as used herein means a breast cancer tissue sample believed by one of ordinary skill in the medical arts to contain cancerous cells. Methods for obtaining the sample from the biopsy include gross apportioning of a mass, microdissection, laser-  
10 based microdissection, or other art-known cell-separation methods.

Because of the variability of the cell types in diseased-tissue biopsy material, and the variability in sensitivity of the diagnostic methods used, the sample size required for analysis may range from 1, 10, 50, 100, 200, 300, 500, 1000, 5000, 10,000, to 50,000 or more cells. The appropriate sample size may be determined based on the cellular composition and  
15 condition of the biopsy and the standard preparative steps for this determination and subsequent isolation of the nucleic acid for use in the invention are well known to one of ordinary skill in the art. An example of this, although not intended to be limiting, is that in some instances a sample from the biopsy may be sufficient for assessment of RNA expression without amplification, but in other instances the lack of suitable cells in a small  
20 biopsy region may require use of RNA conversion and/or amplification methods or other methods to enhance resolution of the nucleic acid molecules. Such methods, which allow use of limited biopsy materials, are well known to those of ordinary skill in the art and include, but are not limited to: direct RNA amplification, reverse transcription of RNA to cDNA, amplification of cDNA, or the generation of radio-labeled nucleic acids.

25 As used herein, the phrase "determining the expression of a set of nucleic acid molecules in the breast tissue" means identifying RNA transcripts in the tissue sample by analysis of nucleic acid or protein expression in the tissue sample. As used herein, "set" refers to a group of nucleic acid molecules that include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,  
30 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51 different nucleic acid sequences from the group of nucleic acid sequences numbered 1 through 51 in Table 1 (SEQ ID Nos: 1-51).

The expression of the set of nucleic acid molecules in the sample from the breast cancer patient can be compared to the expression of the set of nucleic acid molecules in a

sample of breast tissue that is non-cancerous. As used herein, non-cancerous breast tissue means tissue determined by one of ordinary skill in the medical art to have no evidence of breast cancer based on standard diagnostic methods including, but not limited to, histologic staining and microscopic analysis.

5 Nucleic acid markers for cancer are nucleic acid molecules that by their presence or absence indicate the presence of absence of breast cancer. In tissue, certain nucleic acid molecules are expressed at different levels depending on whether tissue is non-cancerous or cancerous. In cancerous tissue, nucleic acid molecule expression may be correlated with MAI prognostic analysis. As described herein, breast cancer nucleic acid markers were  
10 identified by evaluating the nucleic acid molecules present in breast tumor tissue samples and comparing expression levels of the nucleic acid molecules with MAI levels determined for the tissues. An aspect of the invention is that different nucleic acid molecules are expressed in breast cancers with different MAI levels (i.e., high MAI versus low MAI) and these expression variations are identifiable by nucleic acid expression analysis, such as microarray  
15 analysis or protein expression analysis. Some nucleic acids are more likely to be, in other words, are preferentially expressed in cancers with high MAI levels and other nucleic acids are preferentially expressed in cancers with low MAI levels. According to the invention, the correlation between the preferential expression of nucleic acid markers and MAI classification allows expression of nucleic acid markers to be used to directly categorize  
20 breast cancers as low MAI or high MAI. Thus, nucleic acid expression-based categorization of breast cancer (by measurement of nucleic acid or protein expression) as low or high MAI may be used by one of ordinary skill in the medical arts to select an appropriate treatment regimen based on a patient's specific breast cancer prognosis.

Hybridization methods for nucleic acids are well known to those of ordinary skill in  
25 the art (see, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York). The nucleic acid molecules from a breast cancer tissue sample hybridize under stringent conditions to nucleic acid markers expressed in breast cancer. In one embodiment  
30 the markers are sets of two or more of the nucleic acid molecules as set forth in SEQ ID NOs: 1 through 51.

The breast cancer nucleic acid markers disclosed herein are known genes and fragments thereof. It may be desirable to identify variants of those genes, such as allelic

variants or single nucleotide polymorphisms (SNPs) in tissues. Accordingly, methods for identifying breast cancer nucleic acid markers, including variants of the disclosed full-length cDNAs, genomic DNAs, and SNPs are also included in the invention. The methods include contacting a nucleic acid sample (such as a cDNA library, genomic library, genomic DNA isolate, etc.) with a nucleic acid probe or primer derived from one of SEQ ID NOs:1 through 51. The nucleic acid sample and the probe or primer hybridize to complementary nucleotide sequences of nucleic acids in the sample, if any are present, allowing detection of nucleic acids related to SEQ ID NOs: 1-51. Preferably the probe or primer is detectably labeled. The specific conditions, reagents, and the like can be selected by one of ordinary skill in the art to selectively identify nucleic acids related to sets of two or more of SEQ ID NOs:1 through 51. The isolated nucleic acid molecule can be sequenced according to standard procedures.

In addition to native nucleic acid markers (SEQ ID NOs:1-51), the invention also includes degenerate nucleic acids that include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT, and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Similarly, nucleotide sequence triplets that encode other amino acid residues include, but are not limited to: CCA, CCC, CCG, and CCT (proline codons); CGA, CGC, CGG, CGT, AGA, and AGG (arginine codons); ACA, ACC, ACG, and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC, and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides modified nucleic acid molecules, which include additions, substitutions, and deletions of one or more nucleotides such as the allelic variants and SNPs described above. In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as hybridization, antibody binding, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H;



(d) A, G; (e) S, T; (f) Q, N; and (g) E, D. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules that encode polypeptides having single amino acid changes can be prepared for use in the methods and products disclosed herein. Each of these nucleic acid molecules can have one, two, or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules that encode polypeptides having two amino acid changes can be prepared, which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions [e.g., by introduction of a stop codon or a splice site(s)] also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids can be tested by routine experimentation for retention of structural relation to or activity similar to the nucleic acids disclosed herein.

In the invention, standard hybridization techniques of microarray technology are utilized to assess patterns of nucleic acid expression and identify nucleic acid marker expression. Microarray technology, which is also known by other names including: DNA chip technology, gene chip technology, and solid-phase nucleic acid array technology, is well known to those of ordinary skill in the art and is based on, but not limited to, obtaining an array of identified nucleic acid probes on a fixed substrate, labeling target molecules with reporter molecules (e.g., radioactive, chemiluminescent, or fluorescent tags such as fluorescein, Cy3-dUTP, or Cy5-dUTP), hybridizing target nucleic acids to the probes, and evaluating target-probe hybridization. A probe with a nucleic acid sequence that perfectly matches the target sequence will, in general, result in detection of a stronger reporter-molecule signal than will probes with less perfect matches. Many components and techniques utilized in nucleic acid microarray technology are presented in *The Chipping*

*Forecast*, Nature Genetics, Vol.21, Jan 1999, the entire contents of which is incorporated by reference herein.

According to the present invention, microarray substrates may include but are not limited to glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and nickel oxide, various clays, nitrocellulose, or nylon. In all embodiments a glass substrate is preferred. According to the invention, probes are selected from the group of nucleic acids including, but not limited to: DNA, genomic DNA, cDNA, and oligonucleotides; and may be natural or synthetic. Oligonucleotide probes preferably are 20 to 25-mer oligonucleotides and DNA/cDNA probes preferably are 500 to 5000 bases in length, although other lengths may be used. Appropriate probe length may be determined by one of ordinary skill in the art by following art-known procedures. In one embodiment, preferred probes are sets of two or more of the nucleic acid molecules set forth as SEQ ID NO: 1 through 51 (see also Table 1). Probes may be purified to remove contaminants using standard methods known to those of ordinary skill in the art such as gel filtration or precipitation.

In one embodiment, the microarray substrate may be coated with a compound to enhance synthesis of the probe on the substrate. Such compounds include, but are not limited to, oligoethylene glycols. In another embodiment, coupling agents or groups on the substrate can be used to covalently link the first nucleotide or oligonucleotide to the substrate. These agents or groups may include, but are not limited to: amino, hydroxy, bromo, and carboxy groups. These reactive groups are preferably attached to the substrate through a hydrocarbyl radical such as an alkylene or phenylene divalent radical, one valence position occupied by the chain bonding and the remaining attached to the reactive groups. These hydrocarbyl groups may contain up to about ten carbon atoms, preferably up to about six carbon atoms. Alkylene radicals are usually preferred containing two to four carbon atoms in the principal chain. These and additional details of the process are disclosed, for example, in U.S. Patent 4,458,066, which is incorporated by reference in its entirety.

In one embodiment, probes are synthesized directly on the substrate in a predetermined grid pattern using methods such as light-directed chemical synthesis, photochemical deprotection, or delivery of nucleotide precursors to the substrate and subsequent probe production.

In another embodiment, the substrate may be coated with a compound to enhance binding of the probe to the substrate. Such compounds include, but are not limited to: polylysine, amino silanes, amino-reactive silanes (Chipping Forecast, 1999) or chromium

(Gwynne and Page, 2000). In this embodiment, presynthesized probes are applied to the substrate in a precise, predetermined volume and grid pattern, utilizing a computer-controlled robot to apply probe to the substrate in a contact-printing manner or in a non-contact manner such as ink jet or piezo-electric delivery. Probes may be covalently linked to the substrate with methods that include, but are not limited to, UV-irradiation. In another embodiment probes are linked to the substrate with heat.

Targets are nucleic acids selected from the group, including but not limited to: DNA, genomic DNA, cDNA, RNA, mRNA and may be natural or synthetic. In all embodiments, nucleic acid molecules from human breast tissue are preferred. The tissue may be obtained from a subject or may be grown in culture (e.g. from a breast cancer cell line).

In embodiments of the invention one or more control nucleic acid molecules are attached to the substrate. Preferably, control nucleic acid molecules allow determination of factors including but not limited to: nucleic acid quality and binding characteristics; reagent quality and effectiveness; hybridization success; and analysis thresholds and success. Control nucleic acids may include but are not limited to expression products of genes such as housekeeping genes or fragments thereof.

To select a set of tumor markers, the expression data generated by, for example, microarray analysis of gene expression, is preferably analyzed to determine which genes in different groups of cancer tissues are significantly differentially expressed. In the methods disclosed herein, the significance of gene expression was determined using Permax computer software, although any standard statistical package that can discriminate significant differences in expression may be used. Permax performs permutation 2-sample t-tests on large arrays of data. For high dimensional vectors of observations, the Permax software computes t-statistics for each attribute, and assesses significance using the permutation distribution of the maximum and minimum overall attributes. The main use is to determine the attributes (genes) that are the most different between two groups (e.g., high MAI tissues versus low MAI tissues), measuring "most different" using the value of the t-statistics, and their significance levels.

In one embodiment of the invention, expression of nucleic acid markers is used to select clinical treatment paradigms for breast cancer. Treatment options, as described herein, may include but are not limited to: chemotherapy, radiotherapy, adjuvant therapy, or any combination of the aforementioned methods. Aspects of treatment that may vary include, but are not limited to: dosages, timing of administration, or duration or therapy; and may or may

not be combined with other treatments, which may also vary in dosage, timing, or duration. Another treatment for breast cancer is surgery, which can be utilized either alone or in combination with any of the aforementioned treatment methods. One of ordinary skill in the medical arts may determine an appropriate treatment paradigm based on evaluation of differential expression of sets of two or more of the nucleic acid targets SEQ ID NOs:1-51. Cancers that express markers that are indicative of a more aggressive cancer or poor prognosis may be treated with more aggressive therapies.

Progression or regression of breast cancer is determined by comparison of two or more different breast cancer tissue samples taken at two or more different times from a subject. For example, progression or regression may be evaluated by assessments of expression of sets of two or more of the nucleic acid targets, including but not limited to SEQ ID NOs:1-51, in a breast cancer tissue sample from a subject before, during, and following treatment for breast cancer.

In another embodiment, novel pharmacological agents useful in the treatment of breast cancer can be identified by assessing variations in the expression of sets of two or more breast cancer nucleic acid markers, from among SEQ ID NOs:1-51, prior to and after contacting breast cancer cells or tissues with candidate pharmacological agents for the treatment of breast cancer. The cells may be grown in culture (e.g. from a breast cancer cell line), or may be obtained from a subject, (e.g. in a clinical trial of candidate pharmaceutical agents to treat breast cancer). Alterations in expression of two or more sets of breast cancer nucleic acid markers, from among SEQ ID NOs:1-51, in breast cancer cells or tissues tested before and after contact with a candidate pharmacological agent to treat breast cancer, indicate progression, regression, or stasis of the breast cancer thereby indicating efficacy of candidate agents and concomitant identification of lead compounds for therapeutic use in breast cancer.

The invention further provides efficient methods of identifying pharmacological agents or lead compounds for agents active at the level of breast cancer cellular function. Generally, the screening methods involve assaying for compounds that beneficially alter breast cancer nucleic acid molecule expression. Such methods are adaptable to automated, high throughput screening of compounds.

The assay mixture comprises a candidate pharmacological agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations

serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate pharmacological agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids as defined herein are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily be modified through conventional chemical, physical, and biochemical means. Further, known pharmacological agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease, inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, the anti-breast cancer candidate agent specifically binds the cellular binding target, a portion thereof or analog thereof. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such  
5 experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of specific binding between the anti-breast  
10 cancer candidate agent and one or more binding targets is detected by any convenient method available to the user. For cell-free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate  
15 can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximize signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a  
20 reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in  
25 specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as two-  
or three-hybrid screens. The transcript resulting from a reporter gene transcription assay of  
30 the anti-cancer agent binding to a target molecule typically encodes a directly or indirectly detectable product, e.g.,  $\beta$ -galactosidase activity, luciferase activity, and the like. For cell-free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g.,

radioactivity, luminescence, optical or electron density, etc). or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseshoe peroxidase, etc.). The label may be bound to an anti-cancer agent binding partner, or incorporated into the structure of the binding partner.

5 A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates,  
10 etc. Methods for detecting the labels are well known in the art.

The invention provides breast cancer gene-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, breast cancer gene-specific pharmacological agents are useful in a variety of diagnostic and therapeutic applications as described herein. In general, the  
15 specificity of a breast cancer gene binding to a binding agent is shown by binding equilibrium constants. Targets which are capable of selectively binding a breast cancer gene preferably have binding equilibrium constants of at least about  $10^7 \text{ M}^{-1}$ , more preferably at least about  $10^8 \text{ M}^{-1}$ , and most preferably at least about  $10^9 \text{ M}^{-1}$ . The wide variety of cell based and cell free assays may be used to demonstrate breast cancer gene-specific binding. Cell-based  
20 assays include one, two and three hybrid screens, assays in which breast cancer gene-mediated transcription is inhibited or increased, etc. Cell-free assays include breast cancer gene-protein binding assays, immunoassays, etc. Other assays useful for screening agents which bind breast cancer polypeptides include fluorescence resonance energy transfer (FRET), and electrophoretic mobility shift analysis (EMSA).

25 In another aspect of the invention, pre- and post-treatment alterations in expression of two or more sets of breast cancer nucleic acid markers including, but not limited to, SEQ ID NOs:1-51 in breast cancer cells or tissues may be used to assess treatment parameters including, but not limited to: dosage, method of administration, timing of administration, and combination with other treatments as described herein.

30 Candidate pharmacological agents may include antisense oligonucleotides that selectively binds to a breast cancer nucleic acid marker molecule, as identified herein, to reduce the expression of the marker molecules in breast cancer cells and tissues. One of ordinary skill in the art can test of the effects of a reduction of expression of breast cancer

nucleic acid marker sequences *in vivo* or *in vitro*, to determine the efficacy of one or more antisense oligonucleotides.

As used herein, the term “antisense oligonucleotide” or “antisense” describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified  
5 oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those  
10 skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more  
15 to the target sequence than to any other sequence in the target cell under physiological conditions.

Based upon the sequences of breast cancer expressed nucleic acids, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the  
20 present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases that are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., 1996). Most preferably, the antisense oligonucleotides  
25 comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen that are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used  
30 in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., 1994) and at which proteins are not expected to bind. Finally, although the listed sequences are cDNA sequences, one of ordinary skill in the art may easily



derive the genomic DNA corresponding to the cDNA of a breast cancer expressed polypeptide. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to breast cancer expressed nucleic acids. Similarly, the use of antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art-recognized methods, which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness. The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters, and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and

hybridizable with, under physiological conditions, breast cancer expressed nucleic acids, together with pharmaceutically acceptable carriers.

Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term “physiologically acceptable” refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials, which are well known in the art.

Expression of breast cancer nucleic acid molecules can also be determined using protein measurement methods to determine expression of SEQ ID NOs:1-51, e.g., by determining the expression of polypeptides encoded by SEQ ID NOs:1-51 (SEQ ID NOs: 52-102, respectively). Preferred methods of specifically and quantitatively measuring proteins include, but are not limited to: mass spectroscopy-based methods such as surface enhanced laser desorption ionization (SELDI; e.g., Ciphergen ProteinChip System), non-mass spectroscopy-based methods, antibody-capture protein arrays and immunohistochemistry-based methods such as 2-dimensional gel electrophoresis.

SELDI methodology may be used, through procedures known to those of ordinary skill in the art, to vaporize microscopic amounts of tumor protein and to create a “fingerprint” of individual proteins, thereby allowing simultaneous measurement of the abundance of many proteins in a single sample. Preferably SELDI-based assays may be utilized to classify breast cancer tumors. Such assays preferably include, but are not limited to the following examples. Gene products discovered by RNA microarrays may be selectively measured by specific (antibody mediated) capture to the SELDI protein disc (e.g., selective SELDI). Gene products discovered by protein screening (e.g., with 2-D gels), may be resolved by “total protein SELDI” optimized to visualize those particular markers of interest from among SEQ ID NOs:1-51. Predictive models of tumor classification from SELDI measurement of multiple markers from among SEQ ID NOs:1-51 may be utilized for the SELDI strategies. In an

additional embodiment a set of primary lymph node-negative premenopausal breast cancer tissues may be preferably utilized to determine the risk classification of breast cancer based on SELDI results.

The invention also involves agents such as polypeptides that bind to breast cancer-associated polypeptides, i.e., SEQ ID NOs:52-102. Such binding agents can be used, for example, in screening assays to detect the presence or absence of breast cancer-associated polypeptides and complexes of breast cancer-associated polypeptides and their binding partners and in purification protocols to isolate breast cancer-associated polypeptides and complexes of breast cancer-associated polypeptides and their binding partners. Such agents also may be used to inhibit the native activity of the breast cancer-associated polypeptides, for example, by binding to such polypeptides.

The invention, therefore, embraces peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to breast cancer-associated polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the

paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. See, e.g., U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205.

Fully human monoclonal antibodies also can be prepared by immunizing mice transgenic for large portions of human immunoglobulin heavy and light chain loci. Following immunization of these mice (e.g., XenoMouse (Abgenix), HuMAb mice (Medarex/GenPharm)), monoclonal antibodies can be prepared according to standard hybridoma technology. These monoclonal antibodies will have human immunoglobulin amino acid sequences and therefore will not provoke human anti-mouse antibody (HAMA) responses when administered to humans.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves polypeptides of numerous size and type that bind specifically to polypeptides selected from SEQ ID NOs:52-102, and complexes of both breast cancer-associated polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared

in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the breast cancer-associated polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the breast cancer-associated polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the breast cancer-associated polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the breast cancer-associated polypeptides.

Thus, the breast cancer-associated polypeptides of the invention, including fragments thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the breast cancer-associated polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of breast cancer-associated polypeptides and for other purposes that will be apparent to those of ordinary skill in the art. For example, isolated breast cancer-associated polypeptides can be attached to a substrate (e.g., chromatographic media, such as polystyrene beads, a filter, or an array substrate), and then a solution suspected of containing the binding partner may be applied to the substrate. If a binding partner that can interact with breast cancer-associated polypeptides is present in the solution, then it will bind to the substrate-bound breast cancer-associated polypeptide. The binding partner then may be isolated.

As detailed herein, the foregoing antibodies and other binding molecules may be used for example, to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific diagnostic labeling agents for imaging of cells and tissues that express breast cancer-associated polypeptides or to therapeutically useful agents according to

standard coupling procedures. Diagnostic agents include, but are not limited to, barium sulfate, iocetamic acid, iopanoic acid, ipodate calcium, diatrizoate sodium, diatrizoate meglumine, metrizamide, tyropanoate sodium and radiodiagnostics including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123,  
5 technitium-99m, iodine-131 and indium-111, nuclides for nuclear magnetic resonance such as fluorine and gadolinium.

The invention further includes protein microarrays for analyzing expression of breast cancer-associated peptides selected from SEQ ID NOs:52-102. In this aspect of the invention, standard techniques of microarray technology are utilized to assess expression of  
10 the breast cancer-associated polypeptides and/or identify biological constituents that bind such polypeptides. The constituents of biological samples include antibodies, lymphocytes (particularly T lymphocytes), and the like. Protein microarray technology, which is also known by other names including: protein chip technology and solid-phase protein array technology, is well known to those of ordinary skill in the art and is based on, but not limited  
15 to, obtaining an array of identified peptides or proteins on a fixed substrate, binding target molecules or biological constituents to the peptides, and evaluating such binding. See, e.g., G. MacBeath and S.L. Schreiber, "Printing Proteins as Microarrays for High-Throughput Function Determination," *Science* 289(5485):1760-1763, 2000.

Preferably antibodies or antigen binding fragments thereof that specifically bind  
20 polypeptides selected from the group consisting of SEQ ID NOs:52-102 are attached to the microarray substrate in accordance with standard attachment methods known in the art. These arrays can be used to quantify the expression of the polypeptides identified herein.

In some embodiments of the invention, one or more control peptide or protein molecules are attached to the substrate. Preferably, control peptide or protein molecules  
25 allow determination of factors such as peptide or protein quality and binding characteristics, reagent quality and effectiveness, hybridization success, and analysis thresholds and success.

The use of such methods to determine expression of breast cancer nucleic acids from among SEQ ID NOs:1-51 and/or proteins from among SEQ ID Nos:52-102 can be done with routine methods known to those of ordinary skill in the art and the expression determined by  
30 protein measurement methods may be correlated to MAI levels and used as a prognostic method for selecting treatment strategies for breast cancer patients.

## Examples

### Introduction

To establish a prognostic tool for designing breast cancer treatment regimens,  
5 expression patterns in primary breast cancer specimens were assessed and correlated with  
clinical outcome. Primary breast cancer tumors from premenopausal women with no lymph  
node metastases at the time of initial presentation were classified using the Mitotic Activity  
Index (MAI), which has been shown to predict disease-free survival in this type of disease.  
RNA was isolated, hybridized with Affymetrix HuFL human expression arrays, and analyzed  
10 to ascertain which genes discriminate the two groups.

### Methods

#### *Breast Cancers Used for RNA Microarray Expression Analysis*

Primary frozen breast cancers from premenopausal women with no lymph node  
15 metastases at the time of initial presentation were assembled from material discarded  
following routine surgical removal for diagnostic purposes. Institutional review and human  
subjects approval for this project was obtained from Brigham and Women's Hospital. Fresh  
tissue was frozen in liquid nitrogen, and a single fragment split for confirmatory histology  
and RNA isolation. Individual fragments of frozen tumor tissues (estimated as 500 mg  
20 minimum) were split by fracturing under liquid nitrogen, and a portion processed for  
confirmatory histology using standard methods. The remaining tissue was used for  
synchronous RNA, protein, and DNA isolations with TRIzol reagents (Life Technologies,  
Inc., Rockville, MD) using standard methods. Only tumors where the actual frozen tissue  
contained >50% tumor cells were used.

25

#### *Mitotic Activity Index*

All tumors were classified by Mitotic Activity Index (Baak et al., 1989; van Diest et  
al., 1991; van Diest et al., 1992(a); Uytterlinde et al., 1990; van Diest et al., 1992(b); Jannink  
et al., 1996; Baak et al., 1992; Baak et al., 1993) using paraffin H&E stained tissues sections  
30 prepared for diagnostic purposes at the time of excision. The MAI is the total number of  
mitoses counted in 10 consecutive high-power fields (objective, x40; numeric aperture, 0.75;  
field diameter, 450 microns) in the most cellular area at the periphery of the tumor, with the  
subjectively highest mitotic activity (Jannink et al., 1995). Risk groups have previously been

defined using a threshold of 10 mitoses/unit area (Tosi et al., 1986; Jannink et al., 1995; Theissig et al., 1996). Tumors with  $MAI \geq 10$  were assigned to the high risk group, and those with  $MAI \leq 3$  to the low risk group.

#### 5 *Microarray Expression Analysis*

RNA from 27 qualifying tumors was reverse transcribed and resultant cDNA used for *in vitro* transcriptional synthesis of fluorescently labeled nucleic acid probes which were then hybridized to Affymetrix HuFL human expression arrays (approximately 7100, probe sets, estimated 5800 unique genes). Hybridization images were analyzed with Affymetrix  
10 software to generate a data matrix of named probes by quantitative expression level in each tissue. RNA labeling, microarray hybridization, and microarray analysis were performed as per vendor's instructions for HuGeneFL array (Affymetrix, Santa Clara, CA). Four tumors were excluded from analysis because they failed to meet quality control criteria for microarray hybridization: 3 cases had low hybridization signal, one case had high  
15 background.

#### Results

Analysis of 23 primary breast cancer specimens from premenopausal lymph node negative women were split between two prognostic groups (Low MAI,  $MAI \leq 3$ ,  $n=11$  and  
20 High MAI,  $MAI \geq 10$ ,  $n=12$ ) and was accomplished as follows. Affymetrix HuFL expression values were normalized by scaling so the sum of AD (AD units are the quantitative expression units used by Affymetrix) values in each sample was 3,000,000; genes for which RNA abundance was absent or marginal were reset to a value of 0, then any values less than 20 were reset to 20. The result is the GPT dataset, which was then log transformed and  
25 discriminating genes selected by t-test comparison of the logged data between low and high MAI groups. Significance cutoffs for the t-tests used Permax  $< 0.96$  based on 10,000 random permutations of the data. Permax is a data analysis software tool for testing the significance of gene expression. It has been presented by Mutter, et al., 8th International Workshop on Chromosomes in Solid Tumors, Tucson, AZ, 2000; and is available online at  
30 [biowww.dfci.harvard.edu/~gray/permax.html](http://biowww.dfci.harvard.edu/~gray/permax.html) and from Robert J. Gray, Department of Biostatistical Science, Dana-Farber Cancer Institute, 44 Binney Street Boston, MA 02115. Permax details enclosed therein are incorporated by reference herein. Seventy eight of 7070 Affymetrix probe sets were selected by Permax.



-28-

Filters for minimum divergence between the average expression values of the two groups (Low vs. High MAI) were applied as follows: ratio of means  $\geq 2$ , and difference between means  $\geq 100$ . It was determined that 51/78 genes passed these filters. The final 51 selected genes which discriminate between low and high MAI subgroups appear in Table 1 and as SEQ ID NOs:1-51. Average expression in high MAI tumors and low MAI tumors is shown as HX and LX, respectively.

Table 1. Gene list identifying 51 genes that discriminate low from high MAI breast cancers.

SEQ ID NO	Short Name	GenBank Acc.No.	Permax	HX	LX	FOLDABS	DIFFABS
1	ABCB2	X57522	0.9577	501	83	6.0	417
2	ACTA2	X13839	0.7131	3098	6152	2.0	3054
3	AMD1	M21154	0.0808	257	50	5.1	207
4	APM2	D45370	0.3317	590	2682	4.5	2092
5	ASAH	U70063	0.8435	360	990	2.8	630
6	BARD1	U76638	0.5637	242	102	2.4	140
7	CCNH	U11791	0.9104	104	204	2.0	100
8	CCT2	U91327	0.8801	280	109	2.6	171
9	CDC20	U05340	0.0669	579	20	29.0	559
10	CDC34	L22005	0.6979	182	41	4.4	141
11	CDKN3	U02681	0.0072	454	63	7.2	391
12	CKS1	X54941	0.8823	539	219	2.5	320
13	CKS2	X54942	0.1881	413	119	3.5	294
14	COX7A1	M83186	0.9223	89	326	3.6	236
15	CPA3	M73720	0.8234	132	357	2.7	225
16	CPE	X51405	0.1984	80	243	3.0	163
17	CX3CR1	U20350	0.0317	70	328	4.7	258
18	DLG4	U83192	0.3427	20	179	8.9	159
19	DOC1	U53445	0.927	122	276	2.3	154
20	DXS9879E	X92896	0.9448	744	331	2.3	413
21	E2-EPF	M91670	0.9602	324	20	16.2	304
22	ElastinAlt2	U77846	0.8368	417	2210	5.3	1792
23	GTF2A1	U14193	0.7495	528	249	2.1	279
24	GUA5MPST	U10860	0.6129	599	114	5.2	485
25	H2AFX	X14850	0.8106	496	193	2.6	303
26	H2BFA	M60750	0.2334	508	143	3.6	365
27	Hevin	X86693	0.7484	529	1686	3.2	1157
28	HNRPH2	U01923	0.9056	106	231	2.2	126
29	HPV16E1Bind	U96131	0.2439	194	78	2.5	116
30	IDUA	M74715	0.1712	176	594	3.4	418
31	IGF1	X57025	0.9213	79	265	3.4	186
32	IQGAP2	U51903	0.9517	137	321	2.3	184
33	ISG15	M13755	0.9316	2133	386	5.5	1747
34	JAG1	U61276	0.9466	79	264	3.3	185
35	LAMA2	Z26653	0.8882	31	213	6.8	182
36	LAMB2	X79683	0.083	156	658	4.2	502
37	LBR	L25931	0.5991	221	68	3.2	153
38	MMP2	M55593	0.93	1765	3670	2.1	1905
39	MMSDH	M93405	0.9072	297	669	2.3	372
40	MYH11	AF001548	0.3109	164	777	4.7	612
41	MYLK	U48959	0.8351	158	680	4.3	522
42	PDE4A	L20965	0.8912	34	176	5.2	142
43	SCNN1A	X76180	0.694	352	864	2.5	511
44	SCYB10	X02530	0.4416	528	83	6.4	445
45	SNRPB	X17567	0.8965	1473	638	2.3	835
46	STAT1	M97936	0.9553	440	20	22.0	420
47	TAF2A	X07024	0.6819	193	65	2.9	127
48	TCEAL1	M99701	0.5595	241	749	3.1	508
49	TPM1	Z24727	0.5676	1266	2533	2.0	1267
50	TPS2	M33493	0.3638	194	892	4.6	698
51	UBCH10	U73379	0.1972	1519	639	2.4	880

Several features of selected genes provide reassurance that low frequency random events were not the cause of expression differences between groups. A review of the 51 selected genes (Table 1) shows that five pairs of genes known to be co-expressed were  
5 selected independently (two carboxypeptidases, two histones, two cdc28, two ubiquitins, two laminins, and myosin/tropomyosin), and reciprocal regulation of ligand and receptor, a common regulatory pattern, occurred once (laminin and lamin receptor) amongst genes selected.

The first expectation is that genes whose expression is linked to cell division would be  
10 represented in this comparison of tumors whose mitotic activity differs systematically. This was in fact the largest category of selected genes, with expression of 11/12 cell cycle genes greatest in the high MAI group. Genes which are preferentially expressed (at higher levels) in the low MAI group include those encoding extracellular matrix or enzymes which may remodel extracellular matrix (proteolytic enzymes).

The gene expression data presented in Table 1 can be used to generate an expression  
15 matrix of 51 selected genes by 23 tissues examined. Using standard clustering algorithms, dendrograms can be provided on the borders of the matrix (e.g., using Wards linkage and Euclidean distance) to show cluster relationships between tissues and genes. Similarly, a gene expression matrix can be generated using data normalized by standard deviation for  
20 each gene [STD(GPT)]. Dendrograms on borders of the matrix can be provided to show cluster relationships between tissues and genes. In this type of matrix, clustering of genes is based upon relative changes without bias due to absolute expression level, because each gene is expressed in standard deviation from the mean for that specific gene. However, unlike the other expression matrix described above, the absolute magnitude of expression cannot be  
25 directly inferred from this plot.

### References

Harrison's Principles of Internal Medicine, 14/e, (1998) McGraw-Hill Companies, New York.

30 Jannink, I, van Diest, P.J., Baak, J.P. (1995) Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random

mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol Oct;26(10):1086-92.

Baak JP, van Diest PJ, Ariens AT, van Beek MW, Bellot SM, Fijnheer J, van Gorp LH, Kwee  
5 WS, Los J, Peterse HC: The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 1989, 185:664-670.

van Diest PJ, Baak JP: The morphometric prognostic index is the strongest prognosticator in  
10 premenopausal lymph node-negative and lymph node-positive breast cancer patients. Hum Pathol 1991, 22:326-330.

van Diest PJ, Baak JP, Matze-Cok P, Bacus SS: Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with  
15 morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results. Pathol Res Pract 1992, 188:344-349.

Uyterlinde AM, Baak JP, Schipper NW, Peterse H, Matze E, Meijer CJ: Further evaluation of the prognostic value of morphometric and flow cytometric parameters in breast-cancer  
20 patients with long follow-up. Int J Cancer 1990, 45:1-7.

van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, Kurver PH, Bellot SM, Fijnheer J, van Gorp LH, Kwee WS: Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma  
25 Project. Hum Pathol 1992, 23:603-607.

Jannink I, Risberg B, van Diest PJ, Baak JP: Heterogeneity of mitotic activity in breast cancer. Histopathology 1996, 29:421-428.

Baak JP, Wisse-Brekelmans EC, Kurver PH, van Gorp LH, Voorhorst FJ, Miettinen OS: Regional differences in breast cancer survival are correlated with differences in differentiation and rate of proliferation. Hum Pathol 1992, 23:989-992.

Baak JP, van Diest PJ, Benraadt T, Matze-Cok E, Brugghe J, Schuurmans LT, Littooy JJ: The Multi-Center Morphometric Mammary Carcinoma Project (MMMCP) in The Netherlands: value of morphometrically assessed proliferation and differentiation. J Cell Biochem Suppl 1993, 17G:220-225.

5

Tosi P, Luzi P, Sforza V, Santopietro R, Bindi M, Tucci E, Barbini P, Baak JP: Correlation between morphometrical parameters and disease-free survival in ductal breast cancer treated only by surgery. Appl Pathol 1986, 4:33-42.

10

Theissig F, Baak JP, Schuurmans L, Haroske G, Meyer W, Kunze KD: 'Blind' multicenter evaluation of the prognostic value of DNA image cytometric and morphometric features in invasive breast cancer. Anal Cell Pathol 1996, 10:85-99.

The Chipping Forecast (1999) Nature Genetics, 21(1):1-60.

15

Gwynne, P., and Page, G., (1999) Microarray Analysis: the next revolution in Molecular Biology, Science eMarketplace, Science, August 6. ([sciencemag.org/feature/e-market/benchtop/micro.shl](http://sciencemag.org/feature/e-market/benchtop/micro.shl))

20

Wagner et al., *Nature Biotechnol.* (1996) 14:840-844.

Sainio, K., Saarma, M., Nonclercq, D., Paulin, L., and Sariola, H. (1994) Antisense inhibition of low-affinity nerve growth factor receptor in kidney cultures: power and pitfalls. Cell Mol. Neurobiol. 14(5):439-457.

25

*Molecular Cloning: A Laboratory Manual*, (1989) J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

*Current Protocols in Molecular Biology*, (1999) F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York.

30

Mutter, G.L., Baak, J.P.A., Cai, T., Fitzgerald, J., Gray, R., Gentleman, R., Gullans, S., Ibrahim, J., Neubergh, D., and Wilcox, M. Altered Gene Expression in Endometrioid

Endometrial Adenocarcinomas Analyzed by High Density Microarrays. 8th International Workshop on Chromosomes in Solid Tumors (Tucson,AZ) . 2000.

5 The present invention is not limited in scope by the examples provided, since the examples are intended as illustrations of various aspects of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown are described herein will become apparent to those skilled in the art for the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily  
10 encompassed by each embodiment of the invention. All references, patents, and patent publications that are recited in this application are incorporated in their entirety herein by reference.

We claim:

**Claims**

1. A method for diagnosing breast cancer in a subject suspected of having breast cancer comprising:

5 obtaining from the subject a breast tissue sample suspected of being cancerous,  
determining the expression of a set of nucleic acid molecules or expression products thereof in the breast tissue sample, wherein the set of nucleic acid molecules comprises at least two nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

10 2. The method of claim 1, wherein the set of nucleic acid molecules comprises at least 3 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

3. The method of claim 1, wherein the set includes at least 4 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

15 4. The method of claim 1, wherein the set includes at least 5 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

5. The method of claim 1, wherein the set includes at least 10 nucleic acid molecules  
20 selected from the group consisting of SEQ ID NOs:1-51.

6. The method of claim 1, wherein the set includes at least 15 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

25 7. The method of claim 1, wherein the set includes at least 20 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

8. The method of claim 1, wherein the set includes at least 30 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

30 9. The method of claim 1, wherein the set includes at least 40 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

10. The method of claim 1, further comprising:

determining the expression of the set of nucleic acid molecules or expression products thereof in a non-cancerous breast tissue sample, and comparing the expression of the set of nucleic acid molecules or expression products thereof in the breast tissue sample suspected of  
5 being cancerous and the non-cancerous breast tissue sample.

11. A method for identifying a set of nucleic acid markers or expression products thereof effective for determining the prognosis of cancer, comprising:

obtaining a plurality of tumor tissue samples from a plurality of subjects afflicted with  
10 cancer,

classifying the plurality of tumor tissue samples according to mitotic activity index (MAI) into high MAI and low MAI groups,

determining differences in the expression of a plurality of nucleic acid molecules or expression products thereof in the tumor tissue samples, and

15 selecting as a set of nucleic acid markers the nucleic acid molecules or expression products thereof which are differentially expressed in the high MAI and the low MAI groups,

wherein the set of nucleic acid markers or expression products thereof effective for determining poor prognosis of cancer comprises one or more nucleic acid molecules or expression products thereof which are preferentially expressed in high MAI tumor tissue  
20 samples, and wherein the set of nucleic acid markers or expression products thereof effective for determining good prognosis of cancer comprises one or more nucleic acid molecules or expression products thereof which are preferentially expressed in low MAI tumor tissue samples.

25 12. The method of claim 11, wherein the cancer is breast cancer.

13. The method of claim 11, wherein the differences in the expression of a plurality of nucleic acid molecules are determined by a method selected from the group consisting of nucleic acid hybridization and nucleic acid amplification.

30 14. The method of claim 13, wherein the nucleic acid hybridization is performed using a solid-phase nucleic acid molecule array.



-36-

15. A method for selecting a course of treatment of a subject having or suspected of having cancer, comprising:

obtaining from the subject a tissue sample suspected of being cancerous,

determining the expression of a set of nucleic acid markers or expression products

thereof which are differentially expressed in high MAI tumor tissue samples to determine the MAI of the tissue sample of the subject, and

selecting a course of treatment appropriate to the cancer of the subject.

16. The method of claim 15 wherein the cancer is breast cancer.

17. The method of claim 16, further comprising:

determining the expression of a set of nucleic acid markers that are differentially expressed in low MAI breast tumor tissue samples.

18. The method of claim 15, wherein the expression of a set of nucleic acid markers is determined by a method selected from the group consisting of nucleic acid hybridization and nucleic acid amplification.

19. The method of claim 18, wherein the nucleic acid hybridization is performed using a solid-phase nucleic acid molecule array.

20. A method for evaluating treatment of cancer, comprising:

obtaining a first determination of the expression of a set of nucleic acid molecules or expression products thereof, which are differentially expressed in high MAI tumor tissue samples to determine the MAI of the tissue sample from a subject undergoing treatment for cancer,

obtaining a second determination of the expression of a set of nucleic acid molecules or expression products thereof, which are differentially expressed in high MAI tumor tissue samples to determine the MAI of the second tissue sample from the subject after obtaining the first determination,

comparing the first determination of expression to the second determination of expression as an indication of evaluation of the treatment.

-37-

21. The method of claim 20, wherein the cancer is breast cancer.

22. The method of claim 21, further comprising:

determining the expression of a set of nucleic acid markers which are differentially  
5 expressed in low MAI breast tumor tissue samples.

23. The method of claim 20, wherein the expression of a set of nucleic acid markers is determined by a method selected from the group consisting of nucleic acid hybridization and nucleic acid amplification.

10 24. The method of claim 20, wherein the nucleic acid hybridization is performed using a solid-phase nucleic acid molecule array.

25. A solid-phase nucleic acid molecule array consisting essentially of at least two nucleic  
15 acid molecules selected from the group consisting of SEQ ID NOs:1-51 fixed to a solid substrate.

26. The solid-phase nucleic acid molecule array of claim 24, further comprising at least one control nucleic acid molecule.

20 27. The solid-phase nucleic acid molecule array of claim 24, wherein the set of nucleic acid molecules comprises at least 3 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

25 28. The solid-phase nucleic acid molecule array of claim 24, wherein the set includes at least 4 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

29. The solid-phase nucleic acid molecule array of claim 24, wherein the set includes at least 5 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

30 30. The solid-phase nucleic acid molecule array of claim 24, wherein the set includes at least 10 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

31. The solid-phase nucleic acid molecule array of claim 24, wherein the set includes at least 15 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

32. The solid-phase nucleic acid molecule array of claim 24, wherein the set includes at least 20 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

33. The solid-phase nucleic acid molecule array of claim 24, wherein the set includes at least 30 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

34. The solid-phase nucleic acid molecule array of claim 24, wherein the set includes at least 40 nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51.

35. The solid-phase nucleic acid molecule array of claim 24, wherein the solid substrate comprises a material selected from the group consisting of glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and nickel oxide, various clays, nitrocellulose, and nylon.

36. The solid-phase nucleic acid molecule array of claim 24, wherein the nucleic acid molecules are fixed to the solid substrate by covalent bonding.

37. A solid-phase protein microarray comprising at least two antibodies or antigen-binding fragments thereof, that specifically bind at least two different polypeptides selected from the group consisting of SEQ ID NOs:52-102, fixed to a solid substrate.

38. The protein microarray of claim 37, wherein the microarray further comprises an antibody or antigen-binding fragment thereof, that binds specifically to a cancer-associated polypeptide other than those selected from the group consisting of SEQ ID NOs:52-102.

39. The protein microarray of claim 38, wherein the cancer-associated polypeptide other than those selected from the group consisting of SEQ ID NOs:52-102 is a breast cancer associated polypeptide.

40. The protein microarray of claim 37, further comprising at least one control polypeptide molecule.

41. The protein microarray of claim 37, wherein the antibodies are monoclonal or polyclonal antibodies.

42. The protein microarray of claim 37, wherein the antibodies are chimeric, human, or humanized antibodies.

43. The protein microarray of claim 37, wherein the antibodies are single chain antibodies.

44. The protein microarray of claim 37, wherein the antigen-binding fragments are F(ab')<sub>2</sub>, Fab, Fd, or Fv fragments.

45. A method for identifying lead compounds for a pharmacological agent useful in the treatment of breast cancer, comprising:

contacting a breast cancer cell or tissue with a candidate pharmacological agent,


determining the expression of a set of nucleic acid molecules in the breast cancer cell

or tissue sample under conditions which, in the absence of the candidate pharmacological agent, permit a first amount of expression of the set of nucleic acid molecules wherein the set of nucleic acid molecules comprises at least two nucleic acid molecules selected from the group consisting of SEQ ID NOs:1-51, and

detecting a test amount of the expression of the set of nucleic acid molecules, wherein a decrease in the test amount of expression in the presence of the candidate pharmacological agent relative to the first amount of expression indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which is useful in the treatment of breast cancer.

46. The method of claim 45, wherein the set of nucleic acid molecules is differentially expressed in high MAI breast tumor tissue samples.

1/1

**Fig. 1**

- 1 -

## SEQUENCE LISTING

<110> The Brigham and Women's Hospital, Inc  
Baak, Jan

<120> Prognostic Classification of Breast Cancer

<130> B0801/7224WO(JRV)

<150> US 60/222,093

<151> 2000-07-28

<160> 102

<170> PatentIn version 3.0

<210> 1

<211> 2824

<212> DNA

<213> Homo Sapiens

<400> 1

```

gcggccgctt tcgatttcgc tttcccctaa atggctgagc ttctcgccag cgcaggatca      60
gcctgttcct gggactttcc gagagccccg cctcgttcc ctccccagc cgccagtagg      120
ggaggactcg gcgtacctcg gagcttcagg cccaccggg gcgcggagag tcccagacct      180
ggccgggacc gggacggcgt ccgagtcca atggctagct ctaggtgtcc cgctccccgc      240
gggtgccgct gcctccccgg agcttctctc gcattggctg ggacagtact gctacttctc      300
gccgactggg tgctgctccg gaccgcgctg ccccgcatat tctccctgct ggtgcccacc      360
gcgctgccac tgctccgggt ctgggcgggt ggccctgagcc gctgggccgt gctctggctg      420
ggggcctgcg gggtcctcag ggcaacggtt ggctccaaga gcgaaaacgc aggtgcccag      480
ggctggctgg ctgctttgaa gccattagct gcggcactgg gcttggccct gccgggactt      540
gccttgttcc gagagctgat ctcatgggga gccccgggt ccgcggatag caccaggcta      600
ctgcactggg gaagtcaccc taccgccttc gttgtcagtt atgcagcggc actgcccgca      660
gcagccctgt ggcacaaact cgggagcctc tgggtgcccg gcggtcaggg cggctctgga      720
aaccctgtgc gtcggcttct aggctgcctg ggctcggaga cgcgccgct ctgctgttc      780
ctggctcctg tggtcctctc ctctcttggg gagatggcca ttccattctt tacggggcgc      840
ctcactgact ggattctaca agatggctca gccgatacct tactcgaaa cttaactctc      900
atgtccattc tcacatagc cagtgcagtg ctggagttcg tgggtgacgg gatctataac      960
aacaccatgg gccacgtgca cagccacttg caggagagag tgtttggggc tgtcctgcgc     1020
caggagacgg agtttttcca acagaaccag acaggtaaca tcatgtctcg ggtaacagag     1080
gacacgtcca ccctgagtga ttctctgagt gagaatctga gcttatttct gtggtacctg     1140

```

- 2 -

gtgcgaggcc	tatgtctctt	ggggatcatg	ctctggggat	cagtgtccct	caccatggtc	1200
accctgatca	ccctgcctct	gcttttcctt	ctgcccaaga	aggtgggaaa	atggtaccag	1260
ttgctggaag	tgcaggtgcg	ggaatctctg	gcaaagtcca	gccaggtggc	cattgaggct	1320
ctgtcggcca	tgcctacagt	tcgaagcttt	gccaacgagg	agggcgaagc	ccagaagttt	1380
agggaaaagc	tgcaagaaat	aaagacactc	aaccagaagg	aggctgtggc	ctatgcagtc	1440
aactcctgga	ccactagtat	ttcaggtatg	ctgctgaaag	tgggaatcct	ctacattggt	1500
gggcagctgg	tgaccagtgg	ggctgtaagc	agtgggaacc	ttgtcacatt	tgttctctac	1560
cagatgcagt	tcaccaggc	tgtggaggta	ctgctctcca	tctaccccag	agtacagaag	1620
gctgtgggct	cctcagagaa	aatatttgag	tacctggacc	gcacccctcg	ctgeccaccc	1680
agtggctctgt	tgactccctt	acacttggag	ggccttgtcc	agttccaaga	tgtctccttt	1740
gcctacccaa	accgcccaga	tgtcttagtg	ctacaggggc	tgacattcac	cctacgccct	1800
ggcgagggtga	cggcgctggt	gggacccaat	gggtctggga	agagcacagt	ggctgccctg	1860
ctgcagaatc	tgtaccagcc	caccggggga	cagctgctgt	tggatgggaa	gccccttccc	1920
caatatgagc	accgctacct	gcacaggcag	gtggctgcag	tgggacaaga	gccacaggta	1980
tttggaaaga	gtcttcaaga	aaatattgcc	tatggcctga	cccagaagcc	aactatggag	2040
gaaatcacag	ctgctgcagt	aaagtctggg	gcccatagtt	tcattctctg	actccctcag	2100
ggctatgaca	cagaggtaga	cgaggctggg	agccagctgt	caggggggtca	gcgacaggca	2160
gtggcgttgg	cccagcatt	gatccggaaa	ccgtgtgtac	ttatcctgga	tgatgccacc	2220
agtgccctgg	atgcaaacag	ccagttacag	gtggagcagc	tcctgtacga	aagccctgag	2280
cggtaactccc	gctcagtgtc	tctcatcacc	cagcacctca	gcctgggtgga	gcaggctgac	2340
cacatcctct	ttctggaagg	aggcgctatc	cgggaggggg	gaaccaccca	gcagctcatg	2400
gagaaaaagg	ggtgctactg	ggccatgggtg	caggctcctg	cagatgctcc	agaatgaaag	2460
ccttctcaga	cctgcgcact	ccatctccct	cccttttctt	ctctctgtgg	tggagaacca	2520
cagctgcaga	gtagcagctg	cctccaggat	gagttacttg	aaatttgcct	tgagtgtggt	2580
acctcctttc	caagctcctc	gtgataatgc	agacttcctg	gagtacaaac	acaggatttg	2640
taattcctac	tgtaacggag	tttagagcca	gggctgatgc	tttgggtggtg	ccagcactct	2700
gaaactgaga	aatgttcaga	atgtacggaa	agatgatcag	ctattttcaa	cataactgaa	2760
ggcatatgct	ggccataaa	caccctgtag	gttcttgata	tttataataa	aattgggtgtt	2820
ttgt						2824

- 3 -

&lt;211&gt; 1330

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 2

```

gcagcccagc caagcactgt caggaatcct gtgaagcagc tccagctatg tgtgaagaag      60
aggacagcac tgccttgggtg tgtgacaatg gctctgggct ctgtaaggcc ggctttgctg      120
gggacgatgc tcccagggtc gttttcccat ccattgtggg acgtcccaga catcaggggg      180
tgatgggtggg aatgggacaa aaagacagct acgtgggtga cgaagcacag agcaaaagag      240
gaatcctgac cctgaagtac ccgatagaac atggcatcat caccaactgg gacgacatgg      300
aaaagatctg gcaccactct ttctacaatg agcttcgtgt tgcccctgaa gagcatccca      360
ccctgctcac ggaggcacc ctgaacccca aggccaaccg ggagaaaatg actcaaatta      420
tgtttgagac tttcaatgtc ccagccatgt atgtggctat ccaggcgggtg ctgtctctct      480
atgcctctgg acgcacaact ggcacgtgtc tggactctgg agatgggtgtc accacaatg      540
tccccatcta tgagggtat gccttgcccc atgccatcat gcgtctggat ctggctggcc      600
gagatctcac tgactacctc atgaagatcc tgactgagcg tggctattcc ttcgttacta      660
ctgctgagcg tgagattgtc cgggacatca aggagaaact gtgttatgta gctctggact      720
ttgaaaatga gatggccact gccgcatacct catcctccct tgagaagagt tacgagttgc      780
ctgatgggca agtgatcacc atcggaatg aacgtttccg ctgccagag accctgttcc      840
agccatcctt catcgggatg gagtctgctg gcatccatga aaccacctac aacagcatca      900
tgaagtgtga tattgacatc aggaaggacc tctatgctaa caatgtccta tcagggggca      960
ccactatgta ccctggcatt gccgaccgaa tgcagaagga gatcacggcc ctagcaccga      1020
gcaccatgaa gatcaagatc attgcccctc cggagcgcaa atactctgtc tggatcggtg      1080
gctccatcct ggcctctctg tccaccttcc agcagatgtg gatcagcaaa caggaatacg      1140
atgaagccgg gccttcatt gtccaccgca aatgcttcta aaacactttc ctgctcctct      1200
ctgtctctag cacacaactg tgaatgtcct gtggaattat gccttcagtt cttttccaaa      1260
tcattcctag ccaaagctct gactcgttac ctatgtgttt ttaataaat ctgaaatagg      1320
ctactggtaa                                         1330

```

&lt;210&gt; 3

&lt;211&gt; 1805

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 3

```

aagagactga actgtatctg cctctatttc caaaagactc acgttcaact ttcgctcaca      60

```



- 4 -

caaagccggg	aaaattttat	tagtcctttt	tttaaaaaaa	gttaatatataa	aattatagca	120
aaaaaaaaaa	ggaacctgaa	cttttagtaac	acagctggaa	caatcgcagc	ggcggcggca	180
gcggcggggag	aagaggttta	attttagttga	ttttctgtgg	ttgttggttg	ttcgctagtc	240
tcacggtgat	ggaagctgca	catttttttcg	aagggaccga	gaagctgctg	gaggtttggg	300
tctcccggca	gcagcccgac	gcaaaccaag	gatctgggga	tcttcgcact	atcccaagat	360
ctgagtggga	catacttttg	aaggatgtgc	aatgttcaat	cataagtgtg	acaaaaactg	420
acaagcagga	agcttatgta	ctcagtgaga	gtagcatgtt	tgtctccaag	agacgtttca	480
ttttgaagac	atgtggtacc	accctcttgc	tgaaagcact	ggttcccctg	ttgaagcttg	540
ctagggatta	cagtgggttt	gactcaattc	aaagcttctt	ttattctcgt	aagaatttca	600
tgaagccttc	tcaccaaggg	taccacacac	ggaatttcca	ggaagaaata	gagtttctta	660
atgcaatttt	cccaaaggga	gcaggatatt	gtatgggacg	tatgaattct	gactgttggg	720
acttatatac	tctggatttc	ccagagagtc	gggtaatcag	tcagccagat	caaaccttgg	780
aaattctgat	gagtgaagctt	gaccagcag	ttatggacca	gttctacatg	aaagatggg	840
ttactgcaaa	ggatgtcact	cgtgagagtg	gaattcgtga	cctgatacca	ggttctgtca	900
ttgatgccac	aatgttcaat	ccttgtgggt	attcgatgaa	tggaatgaaa	tcggatggaa	960
cttattggac	tattcacatc	actccagaac	cagaattttc	ttatgttagc	tttgaaacaa	1020
acttaagtca	gacctcctat	gatgacctga	tcaggaaagt	tgtagaagtc	ttcaagccag	1080
gaaaatttgt	gaccaccttg	tttgtaatac	agagttctaa	atgtcgcaca	gtgcttgctt	1140
cgccccagaa	gattgaaggt	tttaagcgtc	ttgattgcca	gagtgctatg	ttcaatgatt	1200
acaattttgt	ttttaccagt	tttgctaaga	agcagcaaca	acagcagagt	tgattaagaa	1260
aatgaagaa	aaaacgcaaa	aagagaacac	atgtagaagg	tggtggatgc	tttctagatg	1320
tcgatgctgg	gggcagtgtc	ttccataacc	accactgtgt	agttgcagaa	agccctagat	1380
gtaatgatag	tgtaatcatt	ttgaattgta	tgcattatta	tatcaaggag	ttagatatct	1440
tgcattgaatg	ctctcttctg	tgtttaggta	ttctctgcca	ctcttgctgt	gaaattgaag	1500
tggtatgtaga	aaaaaccttt	tactatatga	aactttacaa	cacttgtgaa	agcaactcaa	1560
tttggtttat	gcacagtgtg	atatttctcc	aagtatcatc	caaaattccc	cacagacaag	1620
gctttcgtcc	tcattaggtg	ttggcctcag	cctaaccctc	taggactgtt	ctattaaatt	1680
gctgccagaa	ttttacatcc	agttacctcc	actttctaga	acatattctt	tactaatgtt	1740
attgaaacca	atcttctactt	catactgatg	tttttggaag	cagcaattaa	agtttttctt	1800
ccatg						1805

- 5 -

<210> 4  
 <211> 419  
 <212> DNA  
 <213> Homo Sapiens

<400> 4  
 ctctttgacga ctccacagat accccgaagc catggcaagc aagggcttgc aggacctgaa 60  
 gcaacaggtg gaggggaccg cccaggaagc cgtgtcagcg gccggagcgg cagctcagca 120  
 agtgggtggac caggccacag aggcggggca gaaagccatg gaccagctgg ccaagaccac 180  
 ccaggaaacc atcgacaaga ctgctaacca ggctctctgac accttctctg ggatcgggaa 240  
 aaaattcggc ctctgaaat gacagcaggg agacttgggt cggcctcctg aaatgatagc 300  
 agggagactt ggggtgacccc ccttccaggc gccatctagc acagcctggc cctgatctcc 360  
 gggcagccac cacctcctcg gtctgcccc tcattaaaat tcacgttccc accctgaaa 419

<210> 5  
 <211> 2333  
 <212> DNA  
 <213> Homo Sapiens

<400> 5  
 ggcacgaggc tagagcgatg ccgggcccga gttgcgtcgc cttagtcctc ctggctgccg 60  
 ccgtcagctg tgccgtcgcg cagcacgcgc cgcctgggac agaggactgc agaaaatcaa 120  
 cctatcctcc ttcaggacca acgtacagag gtgcagttcc atggtacacc ataaatcttg 180  
 acttaccacc ctacaaaaga tggcatgaat tgatgcttga caaggcacca atgctaaagg 240  
 ttatagtga ttctctgaag aatatgataa atacattcgt gccaaagtga aaagttatgc 300  
 aggtgggtgga tgaaaaattg cctggcctac ttggcaactt tcctggccct tttgaagagg 360  
 aaatgaaggg tattgcccgt gttactgata taccttttagg agagattatt tcattcaata 420  
 ttttttatga attatttacc atttgtactt caatagtagc agaagacaaa aaaggctcatc 480  
 taatacatgg gagaaacatg gattttggag tatttcttgg gtggaacata aataatgata 540  
 cctgggtcat aactgagcaa ctaaaacctt taacagtga tttggatttc caaagaaaca 600  
 acaaaactgt cttcaaggct tcaagctttg ctggctatgt gggcatgtta acaggattca 660  
 aaccaggact gttcagtctt aactgaatg aacgtttcag tataaatggg ggttatctgg 720  
 gtattctaga atggattctg ggaaagaaag atgccatgtg gatagggttc ctactagaa 780  
 cagttctgga aaatagcaca agttatgaag aagccaagaa ttatttgacc aagaccaaga 840  
 tattggcccc agcctacttt atcctgggag gcaaccagtc tggggaagggt tgtgtgatta 900  
 cagagacag aaaggaatca ttggatgtat atgaactcga tgctaagcag ggtagatggg 960

- 6 -

```

atgtggtaca aacaaattat gaccgttggg aacatccctt cttccttgat gatcgcagaa 1020
cgccctgcaaa gatgtgtctg aaccgcacca gccaaagagaa tatctcattt gaaaccatgt 1080
atgatgtcct gtcaacaaaa cctgtcctca acaagctgac cgtatacaca accttgatag 1140
atgttacc aa aggtcaattc gaaacttacc tgcgggactg ccctgaccct tgtatagggt 1200
gggtgagcaca cgtctggcct acagaatgag gcctctgaga catgaagaca ccatctccat 1260
gtgaccgaac actgcagctg tctgaccttc caaagactaa gactcgcggc aggttctctt 1320
tgagtcaata gcttgtcttc gtccatctgt tgacaaatga cagatctttt tttttttccc 1380
cctatcagtt gatttttctt atttacagat aacttcttta ggggaagtaa aacagtcatt 1440
tagaattcac tgagttttgt ttcactttga catttgggga tctggtgggc agtcgaacca 1500
tggtgaactc cacctccgtg gaataaatgg agattcagcg tgggtgttga atccagcacg 1560
tctgtgtgag taacgggaca gtaaactctc cacattcttc agtttttcac ttctacctac 1620
atatattgtat gtttttctgt ataacagcct tttccttctg gttctaactg ctgttaaaat 1680
taatatatca ttatctttgc tgttattgac agcgatatta ttttattaca tatcattaga 1740
gggatgagac agacattcac ctgtatatat cttttaatgg gcacaaaatg ggcccttgcc 1800
tctaaatagc actttttggg gttcaagaag taatcagtat gcaaagcaat cttttataca 1860
ataattgaag tgttcccttt ttcataatta ctctacttcc cagtaaccct aaggaagttg 1920
ctaacttaaa aaactgcatt ccacgttctg ttaatttagt aaataaaca gtcaaagact 1980
tgtggaaaat aggaagtga cccatatttt aaattctcat aagtagcatt gatgtaataa 2040
acagggtttt agtttgttct tcagattgat agggagtttt aaagaaattt tagtagttac 2100
taaaattatg ttactgtatt tttcagaaat caaactgctt atgaaaagta ctaatagaac 2160
ttgttaacct ttctaacctt cagattaac tgtgaaatgt acgtcatttg tgcaagaccg 2220
tttgtccact tcattttgta taatcacagt tgtgttcctg acactcaata aacagtcact 2280
ggaaagagtg ccagtcagca gtcatgcacg ctgataaaaa aaaaaaaaaa aaa 2333

```

```

<210> 6
<211> 2530
<212> DNA
<213> Homo Sapiens

```

```

<400> 6
cagcttccct gtggtttccc gaggttccct tgcctcccg cctgcgagga gcctttcatt 60
cgaaggcggg acgatgccgg ataatcggca gccgaggaac cggcagccga ggatccgctc 120
cggaacagag cctcgttccg cggccgccat ggaaccggat ggtcgcggtg cctgggcccc 180
cagtcgcgcc gcgctcgacc gcctggagaa gctgctgcgc tgctcgcgtt gtactaacat 240

```

- 7 -

tctgagagag	cctgtgtgtt	taggaggatg	tgagcacatc	ttctgtagta	attgtgtaag	300
tgactgcatt	ggaactggat	gtccagtgtg	ttacaccccg	gcctggatac	aagacttgaa	360
gataaataga	caactggaca	gcatgattca	actttgtagt	aagcttcgaa	atttgctaca	420
tgacaatgag	ctgtcagatt	tgaaagaaga	taaacctagg	aaaagtttgt	ttaatgatgc	480
aggaaacaag	aagaattcaa	ttaaaatgtg	gttttagccct	cgaagtaaga	aagtcagata	540
tgttgtgagt	aaagcttcag	tgcaaaccga	gcctgcaata	aaaaaagatg	caagtgtctca	600
gcaagactca	tatgaatttg	tttccccaag	tcctcctgca	gatgtttctg	agaggggctaa	660
aaaggcttct	gcaagatctg	gaaaaaagca	aaaaaagaaa	actttagctg	aatcaacca	720
aaaatggaat	ttagaggcag	aaaaagaaga	tggtgaatth	gactccaaag	aggaatctaa	780
gcaaaagctg	gtatccttct	gtagccaacc	atctgttatc	tccagtcctc	agataaatgg	840
tgaaatagac	ttactagcaa	gtggctcctt	gacagaatct	gaatgttttg	gaagtthaac	900
tgaagtctct	ttaccattgg	ctgagcaaat	agagtctcca	gacactaaga	gcaggaatga	960
agtagtgact	cctgagaagg	tctgcaaaaa	ttatcttaca	tctaagaaat	ctttgccatt	1020
agaaaataat	ggaaaacgtg	gccatcacia	tagactttcc	agtcccatth	ctaagagatg	1080
tagaaccagc	attctgagca	ccagtggaga	ttttgttaag	caaaccgtgc	cctcagaaaa	1140
tataccattg	cctgaatgtt	cttcaccacc	ttcatgcaaa	cgtaaagttg	gtggtacatc	1200
aggaggagaa	aacagtaaca	tgtccgatga	attcattagt	ctttcaccag	gtacaccacc	1260
ttctacatta	agtagttcaa	gttacaggca	agtgatgtct	agtccttcag	caatgaagct	1320
gttgcccaat	atggctgtga	aaagaaatca	tagaggagag	actttgctcc	atattgcttc	1380
tattaagggc	gacatacctt	ctgttgaaata	ccttttacia	aatggaagtg	atccaaatgt	1440
taaagaccat	gctggatgga	caccattgca	tgaagcttgc	aatcatgggc	acctgaaggt	1500
agtggaatta	ttgctccagc	ataaggcatt	ggtgaacacc	accgggtatc	aaaatgactc	1560
accacttcac	gatgcagcca	agaatgggca	cgtggatata	gtcaagctgt	tactttccta	1620
tgagagcctc	agaaatgctg	ttaatatatt	tggtctgcgg	cctgtcgatt	atacagatga	1680
tgaaagtatg	aatcgctat	tgctgctacc	agagaagaat	gaatcatcct	cagctagcca	1740
ctgctcagta	atgaacactg	ggcagcgtag	ggatggacct	cttgacttta	taggcagtgg	1800
gctgtcttca	gaacaacaga	aatgctcag	tgagcttgca	gtaattctta	aggctaaaaa	1860
atatactgag	tttgacagta	cagtaactca	tgttgttggt	cctgggtgatg	cagttcaaag	1920
taccttgaag	tgtatgcttg	ggattctcaa	tggtatgctg	attctaaaaat	ttgaatgggt	1980
aaaagcatgt	ctacgaagaa	aagtatgtga	acaggaagaa	aagtatgaaa	ttcctgaagg	2040

- 8 -

```

tccacgcaga agcaggctca acagagaaca gctgttgcca aagctgtttg atggatgcta 2100
cttctatttg tggggaacct tcaaacacca tccaaaggac aaccttatta agctcgtcac 2160
tgcagggtggg ggccagatcc tcagtagaaa gccaagcca gacagtgacg tgactcagac 2220
catcaataca gtgcataacc atgcgagacc cgattctgat cagcgcttct gcacacagta 2280
tatcatctat gaagatttgt gtaattatca cccagagagg gttcggcagg gcaaagtctg 2340
gaaggctcct tcgagctggg ttatagactg tgtgatgtcc tttgagttgc ttcctcttga 2400
cagctgaata ttataccaga tgaacatttc aaattgaatt tgcacggttt gtgagagccc 2460
agtcattgta ctgtttttta tgttcacatt ttacaaata ggtagagtca ttcataattg 2520
tctttgaatc 2530

```

```

<210> 7
<211> 1203
<212> DNA
<213> Homo Sapiens

```

```

<400> 7
ggacgctgat gcgtttgggt tctcgtctgc agaccctctg gacctggtca cgattccata 60
atgtaccaca acagtagtca gaagcggcac tggaccttct ccagcgagga gcagctggca 120
agactgcggg ctgacgcaa cgcgaaattc agatgcaaag ccgtggccaa cgggaagggt 180
cttccgaatg atccagtctt tcttgagcct catgaagaaa tgacactctg caaatactat 240
gagaaaagggt tattggaatt ctgttcggtg tttaagccag caatgccaa atctgttgtg 300
ggtacggctt gtatgtatct caaacgtttt tatcttaata actcagtaat ggaatatcac 360
cccaggataa taatgctcac ttgtgcattt ttggcctgca aagtagatga attcaatgta 420
tctagtcctc agtttggttg aaacctccgg gagagtcctc ttggacagga gaaggcactt 480
gaacagatac tggaatatga actacttctt atacagcaac ttaatttcca ccttattgtc 540
cacaatcctt acagaccatt tgagggcttc ctcatcgact taaagacctg ctatcccata 600
ttggagaatc cagagatttt gaggaaaaca gctgatgact ttcttaatag aattgcattg 660
acggatgctt accttttata cacaccttcc caaattgccc tgactgccat tttatctagt 720
gcctccaggg ctggaattac tatggaaagt tatttatcag agagtctgat gctgaaagag 780
aacagaactt gcctgtcaca gttactagat ataatgaaaa gcatgagaaa cttagtaaag 840
aagtatgaac caccagatc tgaagaagtt gctgttctga aacagaagtt ggagcgatgt 900
cattctgctg agcttgctc taacgtaatc acgaagaaga ggaaaggcta tgaagatgat 960
gattacgtct caaagaaatc caaacatgag gaggaagaat ggactgatga cgacctggtg 1020

```

- 9 -

gaatctctct	aaccatttga	agttgatttc	tcaatgctaa	ctaatcaaga	gaagtaggaa	1080
gcatatcaaaa	cgtttaactt	tattttaaaaa	gtataatgtg	aaaacataaa	atatatttaa	1140
acttttctat	tgttttcttt	ccctttcaca	gtaactttat	gtaaaataaa	ccatcttcaa	1200
aag						1203

<210> 8  
 <211> 653  
 <212> DNA  
 <213> Homo Sapiens

<400> 8	
atggcgctccc	tttcccttgc acctgttaac atctttaagg caggagctga tgaagagaga 60
gcagagacag	ctcgtctgac ttcttttatt ggtgccatcg ccattggaga cttggtaaag 120
agcaccttgg	gacccaaagg catggacaaa attcttctaa gcagtggacg agatgcctct 180
cttatggtaa	ccaatgatgg tgccactatt ctaaaaaaca ttggtgttga caatccagca 240
gctaaagttt	tagttgatat gtcaaggggt caagatgatg aagttggtga tggcactacc 300
tctgttaccg	ttttagcagc agaattatta agggaagcag aatctttaat tgcaaaaaag 360
attcatccac	agaccatcat agcgggttgg agagaagcca cgaaggctgc aagagaggcg 420
ctgttgagtt	ctgcagttga tcatggttcc gatgaagtta aattccgtca agatttaatz 480
aatattgcgg	gcacaacatt atcctcaaaa cttcttactc atcacaaga ccactttaca 540
aagttagctg	tagaagcagt tctcagactg aaaggctctg gcaacctgga ggcaattcat 600
attatcaaga	agctaggagg aagtttggca gattcctatt tagatgaagg tat 653

<210> 9  
 <211> 1686  
 <212> DNA  
 <213> Homo Sapiens

<400> 9	
ccacgcgtcc	gggcgtaagc caggcggtgtt aaagccggtc ggaactgctc cggagggcac 60
gggctccgta	ggcaccaact gcaaggaccc ctccccctgc gggcgctccc atggcacagt 120
tcgcgttcga	gagtgcctg cactcgctgc ttcagctgga tgcacccatc cccaatgcac 180
cccctgcgcg	ctggcagcgc aaagccaagg aagccgcagg cccggccccc tcacccatgc 240
gggcccgcga	ccgatccac agcgcgggca ggactccggg ccgaactcct ggcaaatcca 300
gttccaaggt	tcagaccact cctagcaaac ctggcggtga ccgctatatc ccccatcgca 360
gtgctgcca	gatggaggtg gccagcttcc tctgagcaa ggagaaccag tctgaaaaca 420
gccagacgcc	caccaagaag gaacatcaga aagcctgggc tttgaacctg aacggttttg 480

- 10 -

```

atgtagagga agccaagatc cttcggctca gtggaaaacc acaaaatgcg ccagaggggtt 540
atcagaacag actgaaagta ctctacagcc aaaaggccac tcctggctcc agccggaaga 600
cctgccgtta cattccttcc ctgccagacc gtatcctgga tgcgcctgaa atccgaaatg 660
actattacct gaaccttgtg gattggagtt ctgggaatgt actggccgtg gcactggaca 720
acagtgtgta cctgtggagt gcaagctctg gtgacatcct gcagcttttg caaatggagc 780
agcctgggga atatatatcc tctgtggcct ggatcaaaga gggcaactac ttggctgtgg 840
gcaccagcag tgctgaggtg cagctatggg atgtgcagca gcagaaacgg cttcgaaata 900
tgaccagtca ctctgcccga gtgggctccc taagctggaa cagctatatc ctgtccagtg 960
gttcacgttc tggccacatc caccaccatg atgttcgggt agcagaacac catgtggcca 1020
cactgagtgg ccacagccag gaagtgtgtg ggctgcgctg ggccccagat ggacgacatt 1080
tggccagtgg tggtaatgat aacttggtea atgtgtggcc tagtgctcct ggagaggggtg 1140
gctgggttcc tctgcagaca ttcaccagc atcaaggggc tgtcaaggcc gtagcatggt 1200
gtccctggca gtccaatgtc ctggcaacag gagggggcac cagtgatcga cacattcgca 1260
tctggaatgt gtgctctggg gcctgtctga gtgccgtgga tgcccattcc caggtgtgct 1320
ccatcctctg gtctcccat tacaaggagc tcatctcagg ccatggcttt gcacagaacc 1380
agctagtatt ttggaagtac ccaaccatgg ccaagggtggc tgaactcaaa ggtcacacat 1440
cccgggtcct gagtctgacc atgagcccag atggggccac agtggcatcc gcagcagcag 1500
atgagaccct gaggctatgg cgctgttttg agttggaccc tgcgcggcgg cgggagcggg 1560
agaaggccag tgcagccaaa agcagcctca tccaccaagg catccgctga agaccaaccc 1620
atcacctcag ttgtttttta tttttctaataa agtcatgt ctcccttcat gttttttttt 1680
ttaaaa 1686

```

```

<210> 10
<211> 1374
<212> DNA
<213> Homo Sapiens

```

```

<400> 10
attgcggcgg cgccagagct gctggagcgc tcgggggtccc cgggcggcgg cggcggcgca 60
gaggaggagg caggcggcgg ccccggtggc tcccccccg acggtgcgcg gcccggccg 120
tctcgcaaac tcgcggtggt cgcgcggccc cgcgtgctc cgaccccggg cccctccgcc 180
gccgccatgg ctcggccgct agtgcccagc tcgcagaagg cgctgctgct ggagctcaag 240
gggctgcagg aagagccggt cgagggattc cgcgtgacac tgggtggacga gggcgatcta 300
tacaactggg aggtggccat tttcgggccc cccaacacct actacaggg cggctacttc 360

```

- 11 -

aaggcgcgcc tcaagttccc catcgactac ccatactctc caccagcctt tcggttcctg 420  
accaagatgt ggcaccctaa catctacgag acggggggacg tgtgtatctc catcctccac 480  
ccgccggtgg acgaccccca gagcgggggag ctgccctcag agaggtggaa cccacgcag 540  
aacgtcagga ccattctcct gagtgtgatc tccctcctga acgagcccaa caccttctcg 600  
cccgcaaacg tggacgcctc cgtgatgtac aggaagtgga aagagagcaa ggggaaggat 660  
cgggagtaca cagacatcat ccggaagcag gtcctgggga ccaaggtgga cgcgagcgt 720  
gacggcgtga aggtgcccac cacgctggcc gagtactgcg tgaagaccaa ggcgccggcg 780  
cccgacgagg gctcagacct cttctacgac gactactacg aggacggcga ggtggaggag 840  
gaggccgaca gctgcttcgg ggacgatgag gatgactctg gcacggagga gtcttgacac 900  
caccagaata aacttgccga gtttacctca ctagggccgg acccgtggct ccttagacga 960  
cagactacct cacggaggtt ttgtgctggg ccccgctctc tctggttggt tcgttttggc 1020  
tttttctccc tccccatgtc tgttctgggt tttcacgtgc ttcagagaag aggggctgcc 1080  
ccaccgccac tcacgtcact cggggctcgg tggacgggcc cagggtggga gcggccggcc 1140  
cacctgtccc ctcgggaggg gagctgagcc cgacttctac cgggggtcccc cagcttcggg 1200  
actggccgca ccccgaggga gccacggggg cgctgctggg aacgtgggcg gggggccggt 1260  
tcctgacact accagcctgg gagggccagg tgtagcggtc cgagggggccc ggtcctgcct 1320  
gtcagctcca ggtcctggag ccacgtccag cactgagtgg acggattcac caat 1374

<210> 11  
<211> 806  
<212> DNA  
<213> Homo Sapiens

<400> 11  
cggcactggt ctcgacgtgg ggcggccagc gatggagccg cccagttcaa tacaacaag 60  
tgagtttgac tcatcagatg aagagcctat tgaagatgaa cagactccaa ttcatatatc 120  
atggctatct ttgtcacgag tgaattgttc tcagtttctc ggtttatgtg ctcttccagg 180  
ttgtaaatth aaagatgtta gaagaaatgt ccaaaaagat acagaagaac taaagagctg 240  
tggtatacaa gacatatttg ttttctgcac cagaggggaa ctgtcaaaat atagagtccc 300  
aaaccttctg gatctctacc agcaatgtgg aattatcacc catcatcatc caatcgaga 360  
tggaggggact cctgacatag ccagctgctg tgaaataatg gaagagctta caacctgcct 420  
taaaaattac cgaaaaacct taatacactg ctatggagga cttgggagat cttgtcttgt 480  
agctgcttgt ctctactat acctgtctga cacaatatca ccagagcaag ccatagacag 540



- 12 -

```

cctgcgagac ctaagaggat ccggggcaat acagaccatc aagcaataca attatcttca    600
tgagtttcgg gacaaattag ctgcacatct atcatcaaga gattcacaat caagatctgt    660
atcaagataa aggaattcaa atagcatata tatgaccatg tctgaaatgt cagttctcta    720
gcataatttg tattgaaatg aaaccaccag tgttatcaac ttgaatgtaa atgtacatgt    780
gcagatattc ctaaagtttt attgac                                           806

```

```

<210> 12
<211> 717
<212> DNA
<213> Homo Sapiens

```

```

<400> 12
agagcgatca tgtcgcacaa acaaatttac tattcggaca aatacgacga cgaggagttt    60
gagtatcgac atgtcatgct gcccaaggac atagccaagc tggtcctaa aacctatctg    120
atgtctgaat ctgaatggag gaatcttggc gttcagcaga gtcagggatg ggtccattat    180
atgatccatg aaccagaacc tcacatcttg ctgttcggc gccactacc caagaaacca    240
aagaaatgaa gctggcaagc tacttttcag cctcaagctt tacacagctg tccttacttc    300
ctaacatctt tctgataaca ttattatggt gccttcttgt ttctcacttt gatatttaaa    360
agatgttcaa tacactgttt gaatgtgctg gtaactgctt tgcttcttga gtagagccac    420
caccaccata gccagccag atgagtgtc tgtggacca cagcctaagc tgagtgtgac    480
cccagaagcc acgatgtgct ctgtatccag aacacacttg gcagatggag gaagcatctg    540
agtttgagac catggctgtt acagggatca tgtaaacttg ctgtttttgt tttttctgcc    600
gggtgttgta tgtgtggtga cttgcggatt tatgtttcag tgtactggaa actttccatt    660
ttattcaaga aatctgttca tgttaaaagc cttgattaaa gaggaagttt ttataat      717

```

```

<210> 13
<211> 627
<212> DNA
<213> Homo Sapiens

```

```

<400> 13
agtctccggc gagttgttgc ctgggctgga cgtggttttg tctgctgcgc ccgtctctcg    60
cgctctcggt tcattttctg cagcgcgcca cgaggatggc ccacaagcag atctactact    120
cggacaagta cttcgacgaa cactacgagt accggcatgt tatgttacc agagaacttt    180
ccaaacaagt acctaaaact catctgatgt ctgaagagga gtggaggaga cttggtgtcc    240
aacagagtct aggtctgggt cattacatga ttcatgagcc agaaccacat attcttctct    300
ttagacgacc tcttccaaaa gatcaacaaa aatgaagttt atctggggat cgtcaaactct    360

```

-13-

```

ttttcaaatt taatgtatat gtgtatataa ggtagtattc agtgaatact tgagaaatgt 420
acaaatcttt catccatacc tgtgcatgag ctgtattctt cacagcaaca gagctcagtt 480
aatgcaact gcaagtaggt tactgtaaga tgtttaagat aaaagttctt ccagtcagtt 540
tttctcttaa gtgcctgttt gagtttactg aaacagttta cttttgttca ataaagtttg 600
tatgttgcat ttaaaaaaaaa aaaaaaa 627

```

```

<210> 14
<211> 341
<212> DNA
<213> Homo Sapiens

```

```

<400> 14
aggagaaggg aggtgactcc ggcggaagag gacaaggcag aatgcaggcc cttcgggtgt 60
cccaggcgct gatccgctcc ttcagctcca ccgcccggaa ccgctttcag aaccgagtgc 120
gcgagaaaca gaagctcttc caggaggaca atgacatccc gttgtacctg aagggcggca 180
tcgttgacaa catcctgtac cgagtgacaa tgacgctgtg tctgggcggc actgtctaca 240
gcttgactc ccttggtgg gctccttcc ccaggaatta agaccaagaa gctggggggg 300
cctgagagac ttgaacaagt gtcaataaac gctggcctct g 341

```

```

<210> 15
<211> 1581
<212> DNA
<213> Homo Sapiens

```

```

<400> 15
ataactaaat tacatcttct tggctctttg actatgaaat agtttaccct agcaacatga 60
aaaacaagag acctaagcta ttagaagaaa tgcagttcta tgtatcttgt gtgtatagtt 120
ttccctggg tggttttcaa cgaccagtga ctcttagct ggtttcctca gctgctagca 180
cttgctctgg gtacttgtcc tcaacacgtc catctgcaac aatgtgtgcc taggaaataa 240
actcaactta ctactacccc aacccaaatg taatttttta aacgcagcac aactgggtg 300
gattccaaag tcatgattat gctttactat gcaactctgta ctattcagac cactactctc 360
attcattact gcaattaact gcacacataa ctatttttta ttgctaatta tacaccactg 420
atttccactt taaaaaaca ttagcatttg tctctaatta aatatttact gcttgtgttt 480
tacagacccg atatcaggtt cttctttaga ctgggcttat gacctgggca tcaaacacac 540
atttgccttt gagctccgag ataaaggcaa atttggtttt ctcttccag aatcccggat 600
aaagccaacg tgcagagaga ccatgctagc tgtcaaattt attgccaagt atatcctcaa 660
gcatacttcc taaagaactg ccctctgttt ggaataagcc aattaatcct tttttgtgcc 720

```

- 14 -

```

tttcatcaga aagtcaatct tcagttatcc ccaaatgcag cttctatttc acctgaatcc 780
ttctcttgct catttaagtc ccatgttact gctgtttgct ttactttact ttcagtagca 840
ccataacgaa gtagctttaa gtgaaacctt ttaactacct ttctttgctc caagtgaagt 900
ttggaccocag cagaaagcat tattttgaaa ggtgatatac agtggggcac agaaaacaaa 960
tgaaaaccct cagttttctca cagattttca ccatgtggct tcatcaattt atgtgctaata 1020
acaataaaat aaaatgcact taatgcttta aaattcatct ttttatgata aacaatatct 1080
tctgtatttc tctatagcat taataatcaa tattaatgcc attcattcag tctgttaata 1140
agaaataata tcttcaattt tcaaaaacat aatttgcccta tctttttctg atagaagtag 1200
acattgttta tatcttcaaa aaagcaaaag gatgtcctag caggaaataa agtgggtcat 1260
atagagatga atctcagtc tttaaataac cgatccagtt ctcatcagca taatgtacat 1320
taaattcaaa atagtttaata ttaacctgcc ataatcagaa gaaaccacct gctaaaacat 1380
ctgtttgccg gtacagacac agacaagaca gtctgggtcag ctgtgacccc tgccctccta 1440
atggatagaa aggaaacctg gaaacatact gtaagttgag gacggaaagt catgttgacc 1500
aaaggcaatc agggttaactt gctgcatttg taccatttat actcctatta tttagatag 1560
tattattgga tagcttctcc c 1581

```

```

<210> 16
<211> 2443
<212> DNA
<213> Homo Sapiens

```

```

<400> 16
aaatggcgtg cccgtctctc cgccggcccc ctgcctcgca gtggtttctc ctgcagctcc 60
cctgggctcc gcgccagta gtgcagcccg tggagccgag gctttgcccg tctcctctgg 120
gtggccccag tgcgcgggct gacactcatt cagccgggga aggtgaggcg agtagaggct 180
ggtgcggaac ttgccgcccc cagcagcgcc ggcgggctaa gcccagggcc gggcagacaa 240
aagaggccgc ccgcgtagga aggcacggcc ggcggcggcg gagcgagcg atggccgggc 300
gagggggcag cgcgctgctg gctctgtgag gggcaactggc tgctgcgagg tggctcctgg 360
gcgccgaagc ccaggagccc ggggcgcccc cggcgggcat gaggcggcgc cggcggctgc 420
agcaagagga cggcatctcc ttcgagtacc accgctaccc cgagctgcgc gaggcgctcg 480
tgtccgtgtg gctgcagtgc accgccatca gcaggattta cacggtgggg cgcagcttcg 540
agggcgggga gctcctggct atcgagctgt ccgacaaccc tggcgtccat gagcctgggtg 600
agcctgaatt taaatacatt gggaatatgc atgggaatga ggctgttgga cgagaactgc 660
tcattttctt ggcccagtac ctatgcaacg aataccagaa ggggaacgag acaattgtca 720

```

-15-

acctgatcca	cagtaccgcg	attcacatca	tgccctccct	gaaccagat	ggctttgaga	780
aggcagcgtc	tcagcctggt	gaactcaagg	actgggtttgt	gggtcgaagc	aatgcccagg	840
gaatagatct	gaaccggaac	tttccagacc	tggataggat	agtgtacgtg	aatgagaaag	900
aaggtgggtcc	aaataatcat	ctgttgaaaa	atatgaagaa	aattgtggat	caaaacacaa	960
agcttgctcc	tgagaccaag	gctgtcattc	attggattat	ggatattcct	tttgtgcttt	1020
ctgccaatct	ccatggagga	gaccttggtg	ccaattatcc	atatgatgag	acgcggagtg	1080
gtagtgtca	cgaatacagc	tcctccccag	atgacgccat	tttccaaagc	ttggcccggg	1140
catactcttc	tttcaaccgc	gccatgtctg	accccaatcg	gccaccatgt	cgcaagaatg	1200
atgatgacag	cagctttgta	gatggaacca	ccaacgggtg	tgcttggtac	agcgtacctg	1260
gagggatgca	agacttcaat	taccttagca	gcaactgttt	tgagatcacc	gtggagctta	1320
gctgtgagaa	gttcccacct	gaagagactc	tgaagacctc	ctgggaggat	aacaaaaact	1380
ccctcattag	ctaccttgag	cagatacacc	gaggagttaa	aggatttgtc	cgagaccttc	1440
aaggtaaacc	aattgcgaat	gccaccatct	ccgtggaagg	aatagaccac	gatgttacat	1500
ccgcaaagga	tggtgattac	tggagattgc	ttatacctgg	aaactataaa	cttacagcct	1560
cagctccagg	ctatctggca	ataacaaaga	aagtggcagt	tccttacagc	cctgctgctg	1620
gggttgatth	tgaactggag	tcattttctg	aaaggaaaga	agaggagaag	gaagaattga	1680
tggaatggtg	gaaaatgatg	tcagaaactt	taaattttta	aaaaggcttc	tagttagctg	1740
ctttaaactc	atctatataa	tgtagtatga	tgtaatgtgg	tccttttttt	agattttgtg	1800
cagttaatac	ttaacattga	tttatttttt	aatcatttaa	atattaatca	actttcctta	1860
aaataaatag	cctcttaggt	aaaaatataa	gaacttgata	tatttcattc	tcttatatag	1920
tattcatttt	cctacctata	ttacacaaaa	aagtatagaa	aagatttaag	taattttgcc	1980
atcctaggct	taaatgcaat	attcctggta	ttattttaca	tgcagaattt	tttgagtaat	2040
tctagctttc	aaaaattagt	gaagttcttt	tactgtaatt	ggtgacaatg	tcacataatg	2100
aatgctattg	aaaagggtta	cagatacagc	tcggagttgt	gagcactcta	ctgcaagact	2160
taaatagtth	agtataaatt	gtcgtttttt	tcttgctgctg	actaactata	agcatgatct	2220
tgttaatgca	tttttgatgg	gaagaaaagg	tacatgttta	caaagagggt	ttatgaaaag	2280
aataaaaaatt	gacttcttgc	ttgtacatat	aggagcaata	ctattatatt	atgtagtccg	2340
ttaacactac	ttaaaagttt	agggttttct	cttggttgta	gagtggccca	gaattgcatt	2400
ctgaatgaat	aaagggttaa	aaaaaatccc	cagtgaaaaa	aaa		2443

- 16 -

<210> 17  
 <211> 3100  
 <212> DNA  
 <213> Homo Sapiens

<400> 17  
 actcgtctct ggtaaagtct gagcaggaca ggggtggctga ctggcagatc cagaggttcc 60  
 cttggcagtc cacgccaggc cttcaccatg gatcagttcc ctgaatcagt gacagaaaac 120  
 tttgagtacg atgatttggc tgaggcctgt tatattgggg acatcgtggg ctttgggact 180  
 gtgttctctgt ccatattcta ctccgtcatc tttgccattg gcctgggtggg aaatttgttg 240  
 gtagtgtttg ccctcaccaa cagcaagaag cccaagagtg tcaccgacat ttacctctctg 300  
 aacctggcct tgtctgatct gctgtttgta gccactttgc ctttctggac tcactatttg 360  
 ataaatgaaa agggcctcca caatgccatg tgcaaattca ctaccgcctt cttcttcatc 420  
 ggcttttttg gaagcatatt cttcatcacc gtcacagca ttgataggta cctggccatc 480  
 gtcttggccg ccaactccat gaacaaccgg accgtgcagc atggcgtcac catcagccta 540  
 ggcgtctggg cagcagccat tttggtggca gcacccagc tcatgttcac aaagcagaaa 600  
 gaaaatgaat gccttggtga ctaccccgag gtctccagg aaatctggcc cgtgctccgc 660  
 aatgtggaaa caaattttct tggcttctta ctccccctgc tcattatgag ttattgctac 720  
 ttcagaatca tccagacgct gttttctctgc aagaaccaca agaaagccaa agccattaaa 780  
 ctgatccttc tgggtggtcat cgtgtttttc ctcttctgga caccctacaa cgttatgatt 840  
 ttcttgagga cgcttaagct ctatgacttc tttcccagtt gtgacatgag gaaggatctg 900  
 aggctggccc tcagtgtgac tgagacgggt gcatttagcc attggtgcct gaatcctctc 960  
 atctatgcat ttgctgggga gaagttcaga agataccttt accacctgta tgggaaatgc 1020  
 ctggetgtcc tgttggtggc ctcagtccac gttgatttct cctcatctga atcacaagg 1080  
 agcaggcatg gaagtgttct gagcagcaat tttacttacc acacgagtga tggagatgca 1140  
 ttgctccttc tctgaaggga atcccaaagc cttgtgtcta cagagaacct ggagttcctg 1200  
 aacctgatgc tgactagtga ggaaagattt ttgttggttat ttcttacagg cacaaaatga 1260  
 tggacccaat gcacacaaaa caaccctaga gtgttggtga gaattgtgct caaaatttga 1320  
 agaatgaaca aattgaactc tttgaatgac aaagagtaga ctttctctt actgcaaattg 1380  
 tcatcagaac tttttggttt gcagatgaca aaaattcaac tcagactagt ttagttaaat 1440  
 gaggggtggg aatattgttc atattgtggc acaagcaaaa ggggtgtctga gccctcaaag 1500  
 tgaggggaaa ccagggcctg agccaagcta gaattccctc tctctgactc tcaaattctt 1560  
 tagtcattat agatcccca gactttacat gacacagctt tatcaccaga gagggactga 1620

-17-

caccatgtt tctctggccc caagggaaaa ttcccaggga agtgctctga taggccaagt 1680  
 ttgtatcagg tgcccatccc tggaagggtgc tggtatccat ggggaaggga tatataagat 1740  
 ggaagcttcc agtccaatct catggagaag cagaaataca tatttccaag aagttggatg 1800  
 ggtgggtact attctgatta cacaaaacaa atgccacaca tcacccttac catgtgcctg 1860  
 atccagcctc tcccctgatt acaccagcct cgtcttcatt aagccctctt ccatcatgtc 1920  
 cccaaacctg caaggggtcc cactgccta ctgcatcgag tcaaaactca aatgcttggc 1980  
 ttctcatacg tccaccatgg ggtcctacca atagattccc cattgcctcc tccttcccaa 2040  
 aggactccac ccatcctatc agcctgtctc ttccatatga cctcatgcat ctccacctgc 2100  
 tcccaggcca gtaagggaaa tagaaaaacc ctgcccccaa ataagaaggg atggattcca 2160  
 accccaactc cagtagcttg ggacaaatca agcttcagtt tcctgggtctg tagaagaggg 2220  
 ataagggtacc ttccacatag agatcatcct ttccagcatg aggaactagc caccaactct 2280  
 tgcagggtctc aacccttttg tctgcctctt agacttctgc tttccacacc tgcactgctg 2340  
 tgctgtgccc aagttgtggt gctgacaaag cttggaagag cctgcagggtg ccttggccgc 2400  
 gtgcatagcc cagacacaga agaggctggt tcttacgatg gcaccagtg agcactccca 2460  
 agtctacaga gtgatagcct tccgtaacct aactctcctg gactgccttg aatatcccct 2520  
 ccagtcacc ttgtgcaagc ccctgcccct ctgggaaaat accccatcat tcatgtact 2580  
 gccaacctgg ggagccaggg ctatgggagc agcttttttt tccccctag aaacgtttgg 2640  
 aacaatgtaa aacttttaaag ctcgaaaaca attgtaataa tgctaaagaa aaagtcatcc 2700  
 aatctaacca catcaatatt gtcattcctg tattcaccog tccagacctt gttcacactc 2760  
 tcacatgttt agagttgcaa tcgtaatgta cagatggttt tataatctga tttgttttcc 2820  
 tcttaacgtt agaccacaaa tagtgctcgc tttctatgta gtttggtaat tatcatttta 2880  
 gaagactcta ccagactgtg tattcattga agtcagatgt ggtaactgtt aaattgctgt 2940  
 gtatctgata gctctttggc agtctatatg tttgtataat gaatgagaga ataagtcatg 3000  
 ttcttcaag atcatgtacc ccaatttact tgccattact caattgataa acatttaact 3060  
 tgtttccaat gtttagcaaa tacatatatt atagaacttc 3100

<210> 18  
 <211> 3995  
 <212> DNA  
 <213> Homo Sapiens

<400> 18  
 ggatccgcgg gacagatgag gaaggggctt aagtcactgc agccagaggg atggagggtgg 60  
 actgatggga gggcttctcc ggtgggggtta gaagggaaaa gtagggaaag agaagtgtaa 120

- 18 -

ggtagatggc agaggcagag acatggaaag acagactcta gggttcctga tgatatctat	180
ctcggccaac acaaaagga gggtagagtg gtgggggcac ccaagctagg gtgtgagtag	240
cctaagtgtg ttcttctgag atgtaggcca ttcactaact cttggaacag ctacagtttc	300
acagtaggaa gacccccca gattcactgc ccctccctta gtaaagcctc tgagaccttc	360
ctgaacattc ctttctgtct ttgccctctg ttccttccag agactatgtg cccaggcaga	420
tggattcctc ccgggcctga gaggaactgc aggaattctc ctgcctctta cccgtaaaac	480
cccaacttct ctagccctag ggcaggaagt cccaaacaat ttctaccctt ttttctgcaa	540
ttctcattgg ggtgagagga ggcccaggag gagagagagc tgggctcagc ttctttttga	600
gctgctggag ccctctgtga ggaggccctc tttgctggct tctcaggaga gtgtggctag	660
gttctgcctg cctatgggaa gagggggcca ggggtgtgtg agcaagatgg tgcggtgctg	720
gtgccttggg acctggggga atgggacagc tggtcggctc agagacggcc tactttactc	780
acagctggaa ttagtgggg agaagcagct caactccaat cctggaggat tagggagatt	840
aaagtgagag aagagagaga tgtcccagag accaagagct cccaggtcag ccctctggct	900
cctggcacc ccactgctgc ggtgggcacc cccactcctc acagtgtgc atagcgacct	960
cttccaggcc ttgctggaca tcctggacta ttatgaggct tccctctcag agagtcagaa	1020
ataccgctac caagatgaag acacgcccc tctggagcac agcccgccc acctcccaa	1080
ccaggccaat tctccccag tgattgtcaa cacagatacc ctagaagccc caggatatga	1140
gttgcagggtg aacgggaccg agggggagat ggaatacgag gaaatcacat tggaaagggg	1200
taactcaggt ctgggcttca gcatcgagg tggcactgac aaccacaca tcggtgacga	1260
cccatccatt ttcacacca agatcattcc tggtaggggt gcggcccagg atggccgct	1320
cagggtcaac gacagcatcc tgtttgtaa tgaagtggac gtgcgcgagg tgaccactc	1380
agcggcggtg gaagccctca aagaggcagg ctccatcgtt cgcctctatg tcatgcgccg	1440
gaagccccg gctgagaagg tcatggagat caagctcatc aaggggccta aaggctcttg	1500
cttcagcatc gcagggggcg tagggaaacca gcacatcca ggagataata gcatctatgt	1560
aacaaagatc atcgaagggg gtgctgcca caaggatggg aggttgaga ttggagacaa	1620
gatcctggcg gtcaacagtg tggggctaga ggacgtcatg catgaagatg ctgtggcagc	1680
cctgaagaac acgtatgatg ttgtctacct aaaggtggcc aagcccagca atgcctacct	1740
gagtgcagc tatgctcccc cagacatcac aacctcttat tcccagcacc tggacaatga	1800
gatcagtcac agcagctacc tgggcaccga ctacccca gcatgaccc ccaacttcccc	1860
tcggcgctac tctccagtgg ccaaggacct gctcggggag gaagacattc cccgagaacc	1920

-19-

gaggcgaatt	gtgatccacc	ggggctccac	gggcctgggc	ttcaacatcg	tgggtggcga	1980
ggacgggtgaa	ggcatcttca	tctcctttat	cctggccggg	ggccctgcag	acctcagtgg	2040
ggagctgcgg	aagggggacc	agatcctgtc	ggtcaacggg	gtggacctcc	gaaatgccag	2100
ccatgagcag	gctgccattg	ccctgaagaa	tgcgggtcag	acggtcacga	tcatcgctca	2160
gtataaacca	gaagagtaca	gccgattcga	ggccaagatc	cacgaccttc	gggaacagct	2220
catgaacagc	agcctgggct	cagggactgc	gtccttgccg	agcaacccca	aaaggggttt	2280
ctacatcagg	gccctgtttg	attacgacaa	gaccaaggac	tgcggcttcc	tgagccaggc	2340
cctgagcttc	cgctttgggg	atgtgctgca	tgtcatcgat	gctagtgatg	aggagtgggtg	2400
gcaggcacgg	cgggtccact	ctgacagtga	gaccgacgac	attgggttca	tccccagcaa	2460
acggcggggt	gagcgacgag	agtgggtcaag	gttaaaggcc	aaggactggg	gctccagctc	2520
tggatcgag	ggtcgagaag	actcggttct	gagctacgag	acagtgacgc	agatggaagt	2580
gcactatgct	cgccccatca	tcatccttgg	gccaccaag	gaccgcgcca	acgatgatct	2640
tctctccgag	ttccccgaca	agtttggatc	ctgtgttccc	catacgacac	ggcccaagcg	2700
ggagtatgag	atagatggcc	gggattacca	ctttgtgtcg	tcccgggaga	aaatggagaa	2760
ggacattcag	gcgcacaagt	tcattgaggc	cggccagtac	aacagccacc	tctatgggac	2820
cagcgtccag	tccgtgagag	aggtggcaga	gcaggggaag	cactgcatcc	tcgatgtctc	2880
ggccaatgcc	gtgcggcggc	tgcaggcggc	ccacctgcac	cccatcgcca	tcttcatccg	2940
cccccgctcc	ctggagaatg	tgctagagat	taacaagcgg	atcacagagg	agcaagcccg	3000
caaagccttc	gacagagcca	ccaagctgga	gcaggagtgc	acagagtgc	tctcagccat	3060
cgtggagggg	gacagctttg	aggagatcta	ccacaagggtg	aagcgtgtca	tcgaggacct	3120
ctcaggcccc	tacatctggg	ttccagcccc	agagagactc	tgattcctgc	cctggcttgg	3180
cctggactcg	ccctgcctcc	atcacctggg	cccttgggtc	ggactgaatt	gccccagccc	3240
ttggctcccc	ccggcctccc	tcccacccct	tcttatttat	ttcctttcta	actggatcca	3300
gcctgttgga	ggggggacac	tcctctgcat	gtatccccgc	acccagaac	tgggtctctg	3360
aacgccagga	acctgggggc	tgggggggag	ctgggtcctc	tggtccgagc	ccttgcctct	3420
taggatcccc	gccccacct	gcccccaatg	cacacacaga	cccaccgggg	gccacctgcc	3480
ctcccccatc	ctctcccaca	cacattccag	aagtcagggc	cccctcgagg	agcaccgcct	3540
gcagggatgc	agggccacag	gcctccgctc	tctcctaagg	cagggtctgg	ggtcacccct	3600
gcctcatcgt	aattccccat	gttaccttga	tttctcattt	atTTTTTTcca	ctTTTTTTct	3660
tctcaaagggt	ggtTTTTTgg	ggggagaagc	aggggactcc	gcagcggggc	cctgccttcc	3720



-20-

```

acatgcccc accatttttc tttgccggtt tgcattgagt gaaggtctaa atgtggcttt 3780
tttttttttt ttcttgggaa ttttttttggg gaaaaggag ggatgggtct agggagtggg 3840
aaatgcggga gggagggtgg ggcaggggtc gggggtcggg tgtccgggag ccagggaaga 3900
ctggaaatgc tgccgccttc tgcaatttat ttattttttt cttttgagag agtgaaagga 3960
agagacagat acttgaaaaa aaaaaaaaaa aaaaa 3995

```

```

<210> 19
<211> 3025
<212> DNA
<213> Homo Sapiens

```

```

<400> 19
gcacgagcag gcagttcaga ttaaagaagc taattgatca agaaatcaag tctcaggagg 60
agaaggagca agaaaaggag aaaagggtca ccaccctgaa agaggagctg accaagctga 120
agtcttttgc tttgatggtg gtggatgaac agcaaaggct gacggcacag ctcacccttc 180
aaagacagaa aatccaagag ctgaccacaa atgcaaagga aacacatacc aaactagccc 240
ttgctgaagc cagagttcag gaggaagagc agaaggcaac cagactagag aaggaactgc 300
aaacgcagac caaaaagttt caccaagacc aagacacaat tatggcgaag ctcaccaatg 360
aggacagtca aaatcgccag cttcaacaaa agctggcagc actcagccgg cagattgatg 420
agttagaaga gacaaacagg tctttacgaa aagcagaaga ggagctgcaa gatataaaag 480
aaaaaatcag taaggagaga tatggaaacg ctggtatcat ggctgaagtg gaagagctca 540
taaaaatgga ggagcagtgc agagatctca ataagaggct tgaaaggag acgttacaga 600
gtaaagactt taaactagag gttgaaaaac tcagtaaaag aattatggct ctggaaaagt 660
tagaagacgc tttcaacaaa agcaaacaa aatgctactc tctgaaatgc aatttagaaa 720
aagaaaggat gaccacaaag cagttgtctc aagaactgga gagtttaaaa gtaaggatca 780
aagagctaga agccattgaa agtcggctag aaaagacaga attcactcta aaagaggatt 840
taactaaact gaaaacatta actgtgatgt ttgtagatga acggaaaaca atgagtgaaa 900
aattaaagaa aactgaagat aaattacaag ctgcttcttc tcagcttcaa gtggagcaaa 960
ataaagtaac aacagttact gagaagttaa ttgaggaaac taaaagggcg ctcaagtcca 1020
aaaccgatgt agaagaaaag atgtacagcg taaccaagga gagagatgat ttaaaaaaca 1080
aattgaaagc ggaagaagag aaaggaaatg atctcctgtc aagagttaat atgttgaaaa 1140
ataggcttca atcattggaa gcaattgaga aagatttcct aaaaaacaaa ttaaatcaag 1200
actctgggaa atccacaaca gcattacacc aagaaaacaa taagattaag gagctctctc 1260

```

-21-

aagaagtgga aagactgaaa ctgaagctaa aggacatgaa agccattgag gatgacctca	1320
tgaaaacaga agatgaatat gagactctag aacgaaggta tgctaataa cgagacaaag	1380
ctcaatTTTT atctaaagag ctagaacatg ttaaaatgga acttgctaag tacaagttag	1440
cagaaaagac agagaccagc catgaacaat ggcttttcaa aaggcttcaa gaagaagaag	1500
ctaagtcagg gcacctctca agagaagtgg atgcattaaa agagaaaatt catgaataca	1560
tggcaactga agacctataa tgtcacctcc agggagatca ctcagtctgc aaaaaaaaaac	1620
taaatcaaca agaaaacagg aacagagatt taggaagaga gattgaaaac ctactaagg	1680
agttagagag gtaccggcat ttcagtaaga gcctcaggcc tagtctcaat ggaagaagaa	1740
tttccgatcc tcaagtatTT tctaaagaag ttcagacaga agcagtagac aatgaaccac	1800
ctgattacaa gagcctcatt cctctggaac gtgcagtcac caatggtcag ttatatgagg	1860
agagtggaaa tcaagacgag gaccctaata atgagggatc tgtgctgtcc ttcaaatgca	1920
gccagtctac tccatgtcct gttaacagaa agctatggat tccctggatg aaatccaagg	1980
agggccatct tcagaatgga aaaatgcaaa ctaaacccaa tgccaacttt gtgcaacctg	2040
gagatctagt cctaagccac acacctgggc agccacttca tataaagggtt actccagacc	2100
atgtacaaaa cacagccact cttgaaatca caagtccaac cacagagagt cctcactctt	2160
acacgagtac tgcagtgata ccgaactgtg gcacgccaaa gcaaaggata accatcctcc	2220
aaaacgcctc cataacacca gtaaagtcca aaacctctac cgaagacctc atgaatttag	2280
aacaaggcat gtccccaatt accatggcaa cctttgccag agcacagacc ccagagtctt	2340
gtggttctct aactccagaa aggacaatgt ccctattcag gttttggctg tgactggttc	2400
agctagctct cctgagcagg gacgctcccc agaaccaaca gaaatcagtg ccaagcatgc	2460
gatattcaga gtctccccag accggcagtc atcatggcag tttcagcggt caaacagcaa	2520
tagctcaagt gtgataacta ctgaggataa taaaatccac attcacttag gaagtcctta	2580
catgcaagct gtagccagcc cttcagcacc actgcaggat aaccgaactc aaggcttaat	2640
taacggggca ctaaacaaaa caaccaataa agtcaccagc agtattacta tcacaccaac	2700
agccacacct cttcctcgac aatcacaaat tacagtaagt aatatatata actgaccacg	2760
ctcacctca tccagtccat actgatattt ttgcaaggaa ctcaatcctt ttttaatcat	2820
ccctccatat cccccaagac tgactgaact cgtactttgg gaaggtttgt gcatgaacta	2880
tacaagagta tctgaaacta actgttgccct gcatagtcac atcgagtgtg cacttactgt	2940
atatcttttc atttacatac ttgtatggaa aatatTTtagt ctgcacttgt ataaatacat	3000
ctttatgtat ttgaaaaaaa aaaaa	3025

-22-

<210> 20  
 <211> 599  
 <212> DNA  
 <213> Homo Sapiens

<400> 20  
 cgggacgcgg atgcagacgc aggcggaggg gctgacggcg gggatggccg ggggtggccac 60  
 agctgccgcg ggggcgtgga cacagccgca gctccggccg gtggagctcc cccagcgcac 120  
 gcgccagggtc cgggcagaga cgccgcgtct gccgcagggg gtcacgaatg cggccgcaca 180  
 tattcaccct cagcgtgcct ttcccgaccc ccttggaggc ggaaatcgcc catgggtccc 240  
 tggcaccaga tgccgagccc caccaaaggg tggttgggaa ggatctcaca gtgagtggca 300  
 ggatcctggg cgtccgctgg aaagctgaag actgtcgcct gctccgaatt tccgtcatca 360  
 actttcttga ccagctttcc ctgggtgggtgc ggaccatgca gcgctttggg cccccgttt 420  
 cccgctaagc ctggcctggg caaatggagc gaggtcccac ttgctgtctc cttgtaggca 480  
 gtgcgtccat ccttccttag ggcaggaatt cccacagttg ctactttcct gggagggcct 540  
 catgttttat ctggttctta aatgtttgtt actacagaaa ataaaactga ggtattatt 599

<210> 21  
 <211> 890  
 <212> DNA  
 <213> Homo Sapiens

<400> 21  
 ggcggaccga agaacgcagg aagggggccg gggggacccg cccccggccg gccgcagcca 60  
 tgaactccaa cgtggagaac ctacccccgc acatcatccg cctgggtgtac aaggaggtga 120  
 cgacactgac cgcagaccca cccgatggca tcaaggtctt tccaacgag gaggacctca 180  
 ccgacctcca ggtcaccatc gagggccctg aggggacccc atatgctgga ggtctgttcc 240  
 gcatgaaact cctgctgggg aaggacttcc ctgcctcccc acccaagggc tacttcctga 300  
 ccaagatctt ccacccgaac gtgggcgcca atggcgagat ctgctcaac gtgctcaaga 360  
 gggactggac ggctgagctg ggcatccgac acgtactgct gaccatcaag tgctgctga 420  
 tccaccctaa ccccgagtct gcactcaacg aggaggcggg ccgctgtctc ttggagaact 480  
 acgaggagta tgccgctcgg gcccgctctgc tcacagagat ccacgggggc gccggcgggc 540  
 ccagcggcag ggccgaagcc ggtcggggcc tggccagtgg cactgaagct tcctccaccg 600  
 accctggggc cccagggggc ccgggagggg ctgaggggtcc catggccaag aagcatgctg 660  
 gcgagcgcga taagaagctg gcggccaaga aaaagacgga caagaagcgg gcgctgcggg 720  
 cgctgcggcg gctgtagtgg gctctcttcc tccttcacc gtgaccccaa cctctcctgt 780

-23-

cccctccctc caactctgtc tctaagttat ttaaattatg gctgggggtcg gggaggggtac 840  
 aggggggcact gggacctgga ttgttttttc taaataaagt tggaaaagca 890

<210> 22  
 <211> 1449  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> Unsure  
 <222> (1316)..(1316)  
 <223> n = a, c, g, or t

<220>  
 <221> Unsure  
 <222> (1360)..(1360)  
 <223> n = a, c, g, or t

<220>  
 <221> Unsure  
 <222> (1366)..(1367)  
 <223> n = a, c, g, or t

<220>  
 <221> Unsure  
 <222> (1369)..(1369)  
 <223> n = a, c, g, or t

<400> 22  
 agccgaaact gagagggggc ggactcacag tgatgtgcac ctctcccgt ccaggtgggg 60  
 cctgcctggg gaaagcttgt ggccggaaga gaaaatgagc ttctaggac ccctgactca 120  
 cgacctcatc aacgttggtg ctactgcttg gtggagaatg taaacccttt gtaaccccat 180  
 cccatgcccc tccgactccc caccacagga ggggaacgggc aggccgggcg gccttgacaga 240  
 tccacagggc aaggaaacaa gaggggagcg gccaaagtgc ccgaccagga ggccccctac 300  
 tttagaggca agggccatgt ggtcctggcc cccacccca tcccttccca cctaggagct 360  
 cccctccac acagcctcca tctccagggg aacttggtgc tacacgctgg tgccttatac 420  
 ttcttggggg gagggaggag ggaagggtgg cccctcgggg aacccctac ctggggctcc 480  
 tctaaagatg gtgcagacac ttcttgggca gtcccagctc cccctgcca ccaggacca 540  
 ccgttggtg ccatccagtt ggtaccaag cacctgaagc ctcaaagctg gattcgctct 600  
 agcatccctc ctctcctggg tccacttggc cgtctcctcc ccaccgatcg ctgttcccca 660  
 catctggggc gcttttgggt tggaaaacca cccacactg ggaatagcca ccttgcccct 720  
 tgtagaatcc atccgcgcac ccgtccatc atccatcggt ccgtccatcc atgtccccag 780

-24-

```

ttgaccgccc ggcaccatta gctggctggg tgcaccacc atcaacctgg ttgacctgtc      840
atggccgcct gtgccctgcc tccaccccca tcctacactc cccagggcg tgcggggctg      900
tgcagactgg ggtgccaggc atctcctccc caccgggggt gtcccacat gcagtactgt      960
atacccccca tcctccctc ggtccactga acttcagagc agttcccatt cctgccccgc     1020
ccatcttttt gtgtctcgct gtgatagatc aataaatatt ttattttttg tcctggatat     1080
ttggggatta tttttgattg ttgatattct cttttggttt tattgttgtg gttcattgaa     1140
aaaaaaagat aatttttttt tctgatccgg ggagctgtat cccagtaga aaaaacattt     1200
taatcactct aatataactc tggatgaaac acaccttttt ttttaataag aaaagagaat     1260
taactgcttc agaaatgact aataaatgaa aaccctttaa aggaaactgt gtcttngctt     1320
ccttggtatg atttaatctg ccttcaactg ttggcctggn tggggnnang ggctctgctt     1380
cagggaaact ccaccacca aattgtatth gagaggttgc ccaacaaaa gccctgctg      1440
cctggcttc                                     1449

```

```

<210> 23
<211> 736
<212> DNA
<213> Homo Sapiens

```

```

<400> 23
cgagctggag aggtggctcg agaagtagga acctcctgcc gggctcgtgg cggcttctgt      60
ccgctccgcg gagggaagcg cttccccac aggacatcaa tgcaagcttg aataagaaaa     120
acaaattctt cctcctaagc catggcatat cagttataca gaaatactac tttgggaaac     180
agtcttcagg agagcctaga tgagctcata cagtctcaac agatcacccc ccaacttgcc     240
cttcaagtth tacttcagth tgataaggct ataaatgcag cactggctca gagggtcagg     300
aacagagtca atttcagggg ctctctaaat acgtacagat tctgcgataa tgtgtggact     360
tttgtactga atgatgttga attcagagag gtgacagaac ttattaaagt ggataaagtg     420
aaaattgtag cctgtgatgg taaaaatact ggctccaata ctacagaatg aatagaaaaa     480
atatgactth ttacaccat cttctgttat tcattgctth tgaagagaag catagaagag     540
actttttatt tattctagaa ttgcagaaat gactacactg tgctatacca gagaattcca     600
gtagaaagaa acttgtaact ctgtagcctc ttacatcacc tttattatac agcatgaaaa     660
accataactt ttttttaagg aaaaagttg ttgccttcct aagaacctc ttttaataaac     720
tcatttttaa actctg                                     736

```

```

<210> 24

```

-25-

&lt;211&gt; 2212

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 24

tgccgggtgc	tcctcgacca	ggcctccttc	tcaacctcag	cccgcggcgc	cgacccttcc	60
ggcaccctcc	cgccccgtct	cgtactgtcg	cogtcaccgc	cgcggtccg	gccttggccc	120
cgatggctct	gtgcaacgga	gactccaagc	tggagaatgc	tggaggagac	cttaaggatg	180
gccaccacca	ctatgaagga	gctgttgtca	ttctggatgc	tggtgctcag	tacgggaaag	240
tcatagaccg	aagagtgagg	gaactgttcg	tgcagtctga	aattttcccc	ttggaaacac	300
cagcatttgc	tataaaggaa	caaggattcc	gtgctattat	catctctgga	ggacctaat	360
ctgtgtatgc	tgaagatgct	ccctggtttg	atccagcaat	attcactatt	ggcaagcctg	420
ttcttggaat	ttgctatggt	atgcagatga	tgaataaggt	atctggaggt	actgtgcaca	480
aaaaaagtgt	cagagaagat	ggagttttca	acattagtgt	ggataatata	tgttcattat	540
tcaggggcct	tcagaaggaa	gaagtgtgtt	tgcttacaca	tggagatagt	gtagacaaag	600
tagctgatgg	attcaagggt	gtggcacggt	ctggaaacat	agtagcaggc	atagcaaatg	660
aatctaaaaa	gttatatgga	gcacagttcc	accctgaagt	tggccttaca	gaaaatggaa	720
aagtaatact	gaagaatttc	ctttatgata	tagctggatg	cagtgggaacc	ttcacctgtc	780
agaacagaga	acttgagtgt	attcgagaga	tcaaagagag	agtaggcacg	tcaaaagtgt	840
tggttttact	cagtgggtga	gtagactcaa	cagtttgtac	agctttgcta	aatcgtgctt	900
tgaaccaaga	acaagtcatt	gctgtgcaca	ttgataatgg	ctttatgaga	aaacgagaaa	960
gccagtctgt	tgaagaggcc	ctcaaaaagc	ttggaattca	ggtcaaagtg	ataaatgctg	1020
ctcattcttt	ctacaatgga	acaacaaccc	taccaatatc	agatgaagat	agaacccccc	1080
ggaaaagaat	tagcaaaacg	ttaaatatga	ccacaagtcc	tgaagagaaa	agaaaaatca	1140
ttggggatac	ttttgttaag	attgccaatg	aagtaattgg	agaaatgaac	ttgaaaccag	1200
aggaggtttt	ccttgcccaa	ggtactttac	ggcctgatct	aattgaaagt	gcatcccttg	1260
ttgcaagtgg	caaagctgaa	ctcatcaaaa	cccatcacaa	tgacacagag	ctcatcagaa	1320
agttgagaga	ggagggaaaa	gtaatagaac	ctctgaaaga	ttttcataaa	gatgaagtga	1380
gaatthttggg	cagagaactt	ggacttccag	aagagttagt	ttccaggcat	ccatttccag	1440
gtcctggcct	ggcaatcaga	gtaatatgtg	ctgaagaacc	ttatatattg	aaggactttc	1500
ctgaaaccaa	caatattttg	aaaatagtag	ctgatttttc	tgcaagtgtt	aaaaagccac	1560
ataccctatt	acagagagtc	aaagcctgca	caacagaaga	ggatcaggag	aagctgatgc	1620
aaattaccag	tctgcattca	ctgaatgcct	tcttgctgcc	aattaaaact	gtaggtgtgc	1680

-26-

```

agggtgactg tcgttcctac agttacgtgt gtggaatctc cagtaaagat gaacctgact 1740
gggaatcact tatTTTTctg gctaggctta tacctcgcat gtgtcacaac gttaacagag 1800
ttgtttatat atttggccca ccagttaaag aacctcctac agatgttact ccacttttct 1860
tgacaacagg ggtgctcagt actttacgcc aagctgattt tgaggcccat aacattctca 1920
gggagtctgg gtatgctggg aaaatcagcc agatgccggt gatTTtgaca ccattacatt 1980
ttgatcggga ccacttcaa aagcagcctt catgccagag atctgtgggt attcgaacct 2040
ttattactag tgacttcatg actggtatac ctgcaacacc tggcaatgag atccctgtag 2100
aggTggTatt aaagatggTc actgagatta agaagattcc TggTatttct cgaattatgt 2160
atgacttaac atcaaagccc ccaggaacta ctgagtggga gtaataaact tc 2212

```

```

<210> 25
<211> 1585
<212> DNA
<213> Homo Sapiens

```

```

<400> 25
acagcagtta cactgcggcg ggcgtctgtt ctagtgTTtg agccgtcgtg cttcaccggt 60
ctacctcgct agcatgtcgg gccgcggcaa gactggcggc aaggcccgcg ccaaggccaa 120
gtcgcgctcg tcgcgcgccg gcctccagtt ccagtgggc cgtgtacacc ggctgctgcg 180
gaagggccac tacgccgagc gcgttggcgc cggcgcgcca gtgtacctgg cggcagtgct 240
ggagtacctc accgctgaga tcctggagct ggcgggcaat gcggcccgcg acaacaagaa 300
gacgcgaatc atccccgcc acctgcagct ggccatccgc aacgacgagg agctcaacaa 360
gctgctgggc ggctgacga tcgcccaggg aggcgtcctg cccaacatcc aggcctgct 420
gctgcccag aagaccagcg ccaccgtggg gccgaaggcg ccctcgggcg gcaagaaggc 480
caccagggcc tcccaggagt actaagaggg cccgcgccgc ggccggccgc ccagctccc 540
catgccacca caaaggccct tttaagggcc accaccgcc tcattgaaag agctgagccg 600
cttcagactg cggggcaagc gggccgcggc tcccttccc tcccctccc tcgcccgcct 660
tcgcgcgccg gcctcgagtc ccgcgccgc cccgtcccc tccgcaccg cctgccgcgt 720
cggcctcggg cctgccctgt ccgcgctccg ccctccggtg gggttcgggc cttccggatg 780
cggcttgggc gctcttcggg gacctccgtg gcgcggaaga cccgagcctg cgggggggag 840
gccggcggcg ccgcacctgc ccgcctcggc gtctgtgact cagccgcccc atcccagtc 900
gctaaggggc tcgggggagg ccgcagcacc ttctggaaga cttggccttc cgctctgacg 960
cagggccgag gtgggcagtc caggccgaga gccggcggcc ctgaaggtga gtgaggccct 1020

```

-27-

cggcagctgc agccggggtg tctggtaccc ccccggcgtg gtgcttagcc caggactttc 1080  
 agacggccgc tggccgggag gctttggtgg gagagacgcg atcgccgatt tcggtctggc 1140  
 gcccttctg cggccgggac ccaggccttt cacatcagct ctccctccat cttcattcat 1200  
 aggtctgcgc tggggccggg acgaagcact tggtaacagg cacatcttcc tcccagagtga 1260  
 ctgcctccta ggaggacatt taggggaggg cagaggcctg cagtttggct tcacggctgg 1320  
 ctatgtggac agcaagagtc gttttgcgga acgcgactgg cagccaggcc tgtcggggcc 1380  
 ccgacgccgc ccatttccc ttccagcaaa ctcaactcgg caatccaagc acctagatac 1440  
 cagcacaagt cggttaatcc ctgtctggac tgagcctccg ttggcttctg aactggaatt 1500  
 ctgcagctaa ccctccacg actagaacct taggcattgg ggagttttag atggactaat 1560  
 tttattaaag gattgttttt ttttt 1585

<210> 26  
 <211> 847  
 <212> DNA  
 <213> Homo Sapiens

<400> 26  
 agtggcttcc taacagcaga agaactaaca atccactgaa taaagaaaaa gaatgggctc 60  
 gatggaggaa taagaagcta gttatagtca tcggtagaat tgtgaaaggc gcaatttgat 120  
 tggttaaaat tgttctttga cgagccaacc aattagaaaag gaaataaggc gaaggctatt 180  
 ttacatgtat gcgtcactga cacattgccc aatcagagct ggatattttg aattctttat 240  
 ttgcatgaaa ggcctataaa aggagagact ctagacacga gcttttattt aagtgcgttc 300  
 attctcactg ctgttattgt tttctgacag catgcctgaa ccagctaagt cagctcctgc 360  
 tccgaagaag ggttccaaga aggctgtgac caaggcgagc aagaaggatg gcaagaagcg 420  
 caagcgcagt cgtaaggaga gctactccgt gtatgtgtac aagggtgctaa aacaggttca 480  
 ccccgatact ggcattctcat ccaaggccat gggcatcatg aattccttcg ttaacgacat 540  
 cttcgaacgc atcgaggcg aggcttcccg tctggccac tacaacaagc gctcgaccat 600  
 tacctccagg gagatccaga ccgccgtgcg tctgtgtgtt cccggagagc tggccaagca 660  
 cgcagtgtcc gaaggtacca aggctgtcac caagtataca agctccaagt aaatgtgtgc 720  
 ttaggtgctt taaaactcaa aggctctttt cagagccact caagtctcac ataaagagct 780  
 ttaatattga atttcaccgt tttctagggg ataagggaat ttttcgattt tgtaatccca 840  
 gcacttt 847

<210> 27  
 <211> 2808



-28-

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 27

cggcacatgaga	ggccagcctg	ccaggggaaat	ccaggaatct	gcaacaaaaa	cgatgacagt	60
ctgaaataact	ctctggtgcc	aacctccaaa	ttctcgtctg	tcacttcaga	ccccactag	120
ttgacagagc	agcagaatat	caactccagt	agacttgaat	gtgcctctgg	gcaaagaagc	180
agagctaacg	aggaaagga	tttaaagagt	ttttcttggg	tgtttgtcaa	acttttattc	240
cctgtctgtg	tgagagggg	attcaacttc	aattttctgc	agtggctctg	ggccagccc	300
cttacttaaa	gatctggaaa	gcatgaagac	tgggcctttt	ttcctatgtc	tcttgggaac	360
tgagctgca	atcccgacaa	atgcaagatt	attatctgat	cattccaaac	caactgctga	420
aacggtagca	cctgacaaca	ctgcaatccc	cagtttatgg	gctgaagctg	aagaaaatga	480
aaaagaaaca	gcagtatcca	cagaagacga	ttcccacat	aaggctgaaa	aatcatcagt	540
actaaagtca	aaagaggaaa	gccatgaaca	gtcagcagaa	cagggcaaga	gttctagcca	600
agagctggga	ttgaaggatc	aagaggacag	tgatgggtcac	ttaagtgtga	atttgaggta	660
tgacccaact	gaaggtacat	tgacataaaa	agaagatatg	attgagcctc	aggagaaaaa	720
actctcagag	aacactgatt	ttttggctcc	tggtgttagt	tccttcacag	attctaacca	780
acaagaaagt	atcacaaaga	gagaggaaaa	ccaagaacaa	cctagaaatt	attcacatca	840
tcagttgaac	aggagcagta	aacatagcca	aggcctaagg	gatcaaggaa	accaagagca	900
ggatccaaat	atttccaatg	gagaagagga	agaagaaaaa	gagccaggtg	aagttggtac	960
ccacaatgat	aaccaagaaa	gaaagacaga	attgcccagg	gagcatgcta	acagcaagca	1020
ggagggaagac	aatacccaat	ctgatgatat	tttgggaagag	tctgatcaac	caactcaagt	1080
aagcaagatg	caggaggatg	aatttgatca	gggtaaccaa	gaacaagaag	ataactccaa	1140
tgagaaaatg	gaagaggaaa	atgcatcgaa	cgtcaataag	cacattcaag	aaactgaatg	1200
gcagagtcaa	gagggtaaaa	ctggcctaga	agctatcagc	aaccacaaag	agacagaaga	1260
aaagactgtt	tctgaggctc	tgctcatgga	acctactgat	gatggtaata	ccacgcccag	1320
aatcatgga	gttgatgatg	atggcgatga	tgatggcgat	gatggcgcca	ctgatggccc	1380
caggcacagt	gcaagtgatg	actacttcat	ccaagccag	gcctttctgg	aggccgagag	1440
agctcaatcc	attgcctatc	acctcaaaat	tgaggagcaa	agagaaaaag	tacatgaaaa	1500
tgaaaatata	ggtaccactg	agcctggaga	gcaccaagag	gccaagaaag	cagagaactc	1560
atcaaatgag	gaggaaacgt	caagtgaagg	caacatgagg	gtgcatgctg	tggattcttg	1620
catgagcttc	cagtgtaaaa	gaggccacat	ctgtaaggca	gaccaacagg	gaaaacctca	1680

-29-

ctgtgtctgc caggatccag tgacttgtcc tccaacaaaa ccccttgatc aagtttgtgg 1740  
 cactgacaat cagacctatg ctagttcctg tcatctattc gctactaaat gcagactgga 1800  
 ggggaccaaaa aagggggcatc aactccagct ggattatttt ggagcctgca aatctattcc 1860  
 tacttgtacg gactttgaag tgattcagtt tctctacgg atgagagact ggctcaagaa 1920  
 tatcctcatg cagctttatg aagccaactc tgaacatgct ggttatctaa atgagaagca 1980  
 gagaaataaa gtcaagaaaa tttaacctgga tgaaaagagg cttttggctg gggaccatcc 2040  
 cattgatctt ctcttaaggg actttaagaa aaactaccac atgtatgtgt atcctgtgca 2100  
 ctggcagttt agtgaacttg accaacaccc tatggataga gtcttgacac attctgaact 2160  
 tgctcctctg cgagcatctc tgggtgcccac ggaacactgc ataaccggtt tctttgagga 2220  
 gtgtgacccc aacaaggata agcacatcac cctgaaggag tggggccact gctttggaat 2280  
 taaagaagag gacatagatg aaaatctctt gttttgaacg aagattttta agaactcaac 2340  
 tttccagcat cctcctctgt tctaaccact tcagaaatat atgcagctgt gatacttgta 2400  
 gatttatatt tagcaaaatg ttagcatgta tgacaagaca atgagagtaa ttgcttgaca 2460  
 acaacctatg caccaggtat ttaacattaa ctttggaac aaaaatgtac aattaagtaa 2520  
 agtcaacata tgcaaaatac tgtacattgt gaacagaagt ttaattcata gtaatttcac 2580  
 tctctgcatt gacttatgag ataattaatg attaaactat taatgataaa aataatgcat 2640  
 ttgtattggt cataatatca tgtgcacttc aagaaaatgg aatgctactc ttttgtgggt 2700  
 tacgtgtatt attttcaata tcttaatacc ctaataaaga gtccataaaa atccaaaaaa 2760  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 2808

&lt;210&gt; 28

&lt;211&gt; 2220

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 28

ggaaaattac ccggtatcgt tagagctaca ccaaaattgc attgagccaa acttgccacc 60  
 aagagcccaa caatcaccat gatgctgagc acggaaggca gggaggggtt cgtgggtgaag 120  
 gtcagggggc taccctgggc ctgctcagcc gatgaagtga tgcgcttctt ctctgattgc 180  
 aagatccaaa atggcacatc aggtattcgt ttcattctaca ccagagaagg cagaccaagt 240  
 ggtgaagcat ttgttgaact tgaatctgaa gaggaagtga aattggcttt gaagaaggac 300  
 agagaaacca tgggacacag atacgttgaa gtattcaagt ctaacagtgt tgaaatggat 360  
 tgggtgttga agcatacagg tccgaatagc cctgatactg ccaacgatgg cttcgtccgg 420  
 cttagaggac tcccatttgg ctgtagcaag gaagagattg ttcagttctt ttcaggggtg 480

-30-

gaaattgtgc	caaattgggat	gacactgccca	gtggacttttc	aggggcgaag	cacagggggaa	540
gcctttgtgc	agtttgcttc	acaggagata	gctgagaagg	ccttaaagaa	acacaaggaa	600
agaatagggc	acaggtacat	tgagatcttc	aagagtagcc	gagctgaagt	tcgaaccac	660
tatgatcccc	ctcgaaagct	catggctatg	cagcggccag	gtccctatga	taggccgggg	720
gctggcagag	ggtataatag	cattggcaga	ggagctgggt	ttgaaaggat	gaggcgtggt	780
gcctatggtg	gagggtatgg	aggctatgat	gactatggtg	gctataatga	tggatatggc	840
tttgggtctg	atagatttgg	aagagacctc	aattactgtt	tttcaggaat	gtctgatcat	900
agatacggag	atggtgggtc	cagtttccag	agcaccacag	ggcactgtgt	acacatgagg	960
gggttacctt	acagagccac	tgagaatgat	atttataatt	tcttctcacc	tcttaatccc	1020
atgagagtac	atattgaaat	tggacccgat	ggcagagtta	ccggtgaggc	agatgttgaa	1080
tttgctactc	atgaagatgc	tgtggcagct	atggcaaaag	aaaagctaa	tatgcaacac	1140
agatatgtgg	agctcttctt	aaattctact	gcaggaacaa	gtgggggtgc	ttacgatcac	1200
agctatgtag	aacttttttt	gaattctaca	gcaggggcaa	gtggtggcgc	ttatggtagc	1260
caaatgatgg	gagggatggg	cttatccaac	cagtctagtt	atggaggtcc	tgctagccag	1320
cagctgagtg	gtggttatgg	aggtgggttat	ggtggtcaga	gcagtatgag	tggatatgac	1380
caagttctgc	aggaaaactc	cagtgactat	cagtcaaacc	ttgcttaggt	agagaaggag	1440
cactaaatag	ctactccaga	tataaaagct	gtacatttgt	gggagttgaa	tagaatggga	1500
gggatgttta	gtatatccag	tatgattggt	aaatgggaaa	tataattgat	tctgatcact	1560
cttggtcagc	ttctctttct	ttatctttct	gtctcctttt	ttaagaaaac	gagttaagtt	1620
taacagtttt	gcattacagg	cttgtgattc	atgcttactg	taaagtggaa	gttgagatta	1680
ttttaaaact	tcaagctcag	taattttgaa	ccactgaaac	attcatctag	gacataataa	1740
caaagttcag	tattgaccat	aactgttaaa	acaattttta	gctttcctca	agttagttat	1800
gttgtaggag	tgtacctaa	cagtaagcgt	atttaggtta	atgcagtttc	acttatgtta	1860
aatgttgctc	ttataccaca	aatacattga	aaacttcgga	tgcattgtga	gaaacatgcc	1920
tttctgtaaa	actcaaatat	aggagctgtg	tctacgattc	aaagtgaaaa	catttggtcat	1980
gtttgttaat	tctagctttt	tggtttaata	tcctgtaagg	cacgtgagtg	tacacttttt	2040
ttttttttta	ggatacggga	caattttaag	atgtaatacc	aatacttttag	aagtttggtc	2100
gtgtcgtttg	tatgaaaatc	tgaggctttg	gtttaaatct	ttccttgat	tgtgatttcc	2160
atttagatgt	attgtactaa	gtgaaacttg	ttaaataaat	cttcctttta	aaaactggaa	2220

-31-

<210> 29  
 <211> 2203  
 <212> DNA  
 <213> Homo Sapiens

<400> 29  
 cggcgggccgc gccctggttg ggtccccact gctctcgggg gcgccatgga cgaggccgtg 60  
 ggcgacctga agcaggcgct tccctgtgtg gccgagtcgc caacgggtcca cgtggagggtg 120  
 catcagcgcg gcagcagcac tgcaaagaaa gaagacataa acctgagtgt tagaaagcta 180  
 ctcaacagac ataatatgtt gtttggtgat tacacatgga ctgagtttga tgaacctttt 240  
 ttgaccagaa atgtgcagtc tgtgtctatt attgacacag aattaaaggt taaagactca 300  
 cagcccatcg atttgagtgc atgcactggt gcacttcaca ttttccagct gaatgaagat 360  
 ggccccagca gtgaaaatct ggaggaagag acagaaaaca taattgcagc aaatcactgg 420  
 gttctacctg cagctgaatt ccatgggctt tgggacagct tggatatacga tgtggaagtc 480  
 aaatcccatc tcctcgatta tgtgatgaca actttactgt tttcagacaa gaacgtcaac 540  
 agcaacctca tcacctggaa ccgggtggtg ctgctccacg gtccctcctgg cactggaaaa 600  
 acatccctgt gtaaagcggt agcccagaaa ttgacaatta gactttcaag caggtaccga 660  
 tatggccaat taattgaaat aaacagccac agcctctttt ctaagtgggtt ttcggaaagt 720  
 ggcaagctgg taaccaagat gtttcagaag attcaggatt tgattgatga taaagacgcc 780  
 ctggtgttcg tgctgattga tgaggtggag agtctcacag ccgcccga aa tgccctgcagg 840  
 gcgggcaccg agccatcaga tgccatccgc gtggtcaatg ctgtcttgac ccaaattgat 900  
 cagattaataa ggcattccaa tgttgtgatt ctgaccactt ctaacatcac cgagaagatc 960  
 gacgtggcct tcgtggacag ggctgacatc aagcagtaca ttggggccacc ctctgcagca 1020  
 gccatcttca aaatctacct ctcttgtttg gaagaactga tgaagtgtca gatcatatac 1080  
 cctcgccagc agctgctgac cctccgagag ctagagatga ttggcttcat tgaaaacaac 1140  
 gtgtcaaaat tgagccttct tttgaatgac atttcaagga agagcgaggg cctcagcggc 1200  
 cgggtcctga gaaaactccc ctttctggct catgcgctgt atgtccaggc cccaccgtc 1260  
 accatagagg ggttcctcca ggcctgtct ctggcagtg acaagcagtt tgaagagaga 1320  
 aagaagcttg cagcttacat ctgacccctg gcttccccat ctggtgcttt tcccatggag 1380  
 aacacacaac cagtaagtga ggttgcccca cacagccgtc tcccagggaa tcccttctgc 1440  
 aaaccaaacg ttacttagac tgcaagctag aaagccacca aggccaggct ttgttaaaag 1500  
 aagtgtattc tatttatgtt gttttaaaat gcatactgag agacaaacat cttgtcattt 1560  
 tcactgtttg taaaagataa ttcagattgt ttgtctcctt gtgaagaacc atcgaaacct 1620

- 32 -

```

gtttgttccc agcccacccc cagtggatgg gatgcataat gccagcaagt tttgtttaac 1680
agcaaaaaag gaagattaat gcagggtgta tagaagccag aagagaaact gtgtcacccct 1740
aaagaagcat ataatcatag cattaataat gcacacatta ctccagggtg aaggtggcaa 1800
ttgctttctg atatcagctc gtttgattta gtgcaaaaat gttttcaaga ctatttaatg 1860
gatgtaaaaa agcctatttc tacattatac caactgagaa aaaaatggtc ggtaaagtgt 1920
tctttcataa taaataatca agacatggtc ccatttgcag gaaaagtgca gactctgagt 1980
gttccaggga aacacatgct ggacatccct tgtaaccggg tatgggcgcc cctgcattgc 2040
tgggatgttt ctgcccacgg ttttgtttgt gcaataacgt tatcacattt ctaatgagga 2100
ttcacattaa tataatataa aataaatagg tcagttactg gtctctttct gccgaatggt 2160
atgttttgct tttatctcac agtaaaataa atataattaa aaa 2203

```

```

<210> 30
<211> 2155
<212> DNA
<213> Homo Sapiens

```

```

<400> 30
gtcacatggg gtgcgcgccc agactccgac ccggaggcgg aaccggcagt gcagcccga 60
gccccgcagt ccccgagcac gcgtggccat gcgtcccctg cgcgcccgcg ccgcgtgct 120
ggcgtccttg gcctcgctcc tggccgcgccc cccggtggcc ccggccgagg ccccgcacct 180
gggtgcagggtg gacgcggccc gcgcgtgtg gccctgcgg cgcttctgga ggagcacagg 240
cttctgcccc ccgtgccac acagccaggc tgaccagtac gtcctcagct gggaccagca 300
gctcaacctc gcctatgtgg gcgccgtccc tcaccgcggc atcaagcagg tccggacca 360
ctggctgctg gagcttgtca ccaccagggg gtccactgga cggggcctga gctacaactt 420
caccacactg gacgggtact tggaccttct cagggagaac cagctcctcc cagggtttga 480
gctgatgggc agcgctcgg gccacttcac tgactttgag gacaagcagc aggtgtttga 540
gtggaaggac ttggtctcca gcctggccag gagatacatc ggtaggtacg gactggcgca 600
tgtttccaag tggaacttcg agacgtggaa tgagccagac caccacgact ttgacaacgt 660
ctccatgacc atgcaaggct tcctgaacta ctacgatgcc tgctcggagg gtctgcgcgc 720
cgccagcccc gccctgcggc tgggaggccc cggcgactcc ttccacaccc caccgcgatc 780
cccgtgagc tggggcctcc tgcgccactg ccacgacggt accaacttct tctactgggga 840
ggcgggctgt cggctggact acatctccct ccacaggaag ggtgcgcgca gctccatctc 900
catcctggag caggagaagg tcgtcgcgca gcagatccgg cagctcttcc ccaagttcgc 960
ggacaccccc atttacaacg acgaggcgga cccgctggtg ggctgggtccc tgccacagcc 1020

```

-33-

```

gtggagggcg gacgtgacct acgcggccat ggtggtgaag gtcacgcgc agcatcagaa 1080
cctgctactg gccaacacca cctcgcctt cccctacgcg ctctgagca acgacaatgc 1140
cttcctgagc taccacccgc accccttcgc gcagcgacg ctaccgcgc gcttccaggt 1200
caacaacacc cgcccgcgc acgtgcagct gttgcgcaag ccggtgctca cggccatggg 1260
gctgctggcg ctgctggatg aggagcagct ctgggccgaa gtgtcgcagg ccgggaccgt 1320
cctggacagc aaccacacgg tgggcgtcct ggccagcgcc caccgcccc agggcccggc 1380
cgacgcctgg cgcgccgcgg tgctgatcta cgcgagcgac gacaccgcg cccaccccaa 1440
ccgcagcgtc gcggtgacct tgcggtgcg cggggtgccc cccggcccg gcctggtcta 1500
cgtcacgcgc tacctggaca acgggtcttg cagccccgac ggcgagtggc ggcgctggg 1560
ccggcccgtc tccccacgg cagagcagtt ccggcgcatg cgcgcggctg aggaccgggt 1620
ggccgcggcg ccccgccct taccgcggc cggccgctg accctgcgc ccgcgtgcg 1680
gctgccgtcg cttttgctgg tgcacgtgtg tgcgcgccc gagaagccgc ccgggcaggt 1740
cacgcggctc cgcgccctgc ccctgacca agggcagctg gttctggtct ggtcggatga 1800
acacgtgggc tccaagtgc tgtggacata cgagatccag ttctctcagg acggtaaggc 1860
gtacaccccg gtcagcagga agccatcgac cttcaacctc tttgtgttca gccagacac 1920
agggtgctgc tctggctcct accgagttcg agccctggac tactgggccc gaccaggccc 1980
cttctcggac cctgtgccgt acctggaggt ccctgtgcca agagggcccc catccccggg 2040
caatccatga gcctgtgctg agccccagtg ggttgacct ccaccggcag tcagcgagct 2100
ggggctgcac tgtgcccatg ctgccctccc atcaccacct ttgcaatata ttttt 2155

```

&lt;210&gt; 31

&lt;211&gt; 7260

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 31

```

tcaactgtcac tgctaaattc agagcagatt agagcctgcg caatggaata aagtcctcaa 60
aattgaaatg tgacattgct ctcaacatct cccatctctc tggatttcct tttgcttcat 120
tattcctgct aaccaattca ttttcagact ttgtacttca gaagcaatgg gaaaaatcag 180
cagtcttcca acccaattat ttaagtgtg cttttgtgat ttcttgaagg tgaagatgca 240
caccatgtcc tcctcgcac tcttctacct ggcgctgtgc ctgctcacct tcaccagctc 300
tgccacggct ggaccggaga cgctctgcgg ggctgagctg gtggatgctc ttcagttcgt 360
gtgtggagac aggggctttt atttcaacaa gccacaggg tatggctcca gcagtcggag 420

```

- 34 -

ggcgccctcag	acaggcatcg	tggatgagtg	ctgcttccgg	agctgtgatc	taaggaggct	480
ggagatgtat	tgcgaccccc	tcaagcctgc	caagtcagct	cgctctgtcc	gtgcccagcg	540
ccacaccgac	atgcccaga	cccagaagga	agtacatttg	aagaacgcaa	gtagagggag	600
tgcaggaaac	aagaactaca	ggatgtagga	agaccctcct	gaggagtga	gagtgcacatg	660
ccaccgcagg	atcctttgct	ctgcacgagt	tacctgttaa	actttggaac	acctaccaa	720
aaataagttt	gataacattt	aaaagatggg	cgtttcccc	aatgaaatac	acaagtaa	780
attccaacat	tgtctttagg	agtgatttgc	accttgcaa	aatggctctg	gagttggtag	840
attgctgttg	atcttttatc	aataatgttc	tatagaaaag	aaaaaaaaat	atatatatat	900
atatatctta	gtccctgcct	ctcaagagcc	acaaatgcat	gggtgttgta	tagatccagt	960
tgcactaaat	tcctctctga	atcttggtcg	ctggagccat	tcattcagca	accttgtcta	1020
agtggtttat	gaattgtttc	cttatttgca	cttctttcta	cacaactcgg	gctgtttgtt	1080
ttacagtgtc	tgataatctt	gttagtctat	accaccacc	tccttcata	acctttatat	1140
ttgccgaatt	tggcctcctc	aaaagcagca	gcaagtcgtc	aagaagcaca	ccaattctaa	1200
cccacaagat	tccatctgtg	gcatttgtac	caaataaag	ttggatgcat	tttatttttag	1260
acacaaagct	ttatttttcc	acatcatgct	tacaaaaaag	aataatgcaa	atagttgcaa	1320
ctttgaggcc	aatcattttt	aggcatatgt	tttaaacata	gaaagtttct	tcaactcaaa	1380
agagttcctt	caaataatga	gttaatgtgc	aacctaat	gtaactttcc	tctttttatt	1440
ttttccatat	agagcactat	gtaaatttag	catatcaatt	atacaggata	tatcaaacag	1500
tatgtaaaac	tctgtttttt	agtataatgg	tgctattttg	tagtttgta	tatgaaagag	1560
tctggccaaa	acggtaatac	gtgaaagcaa	aacaataggg	gaagcctgga	gccaaagatg	1620
acacaagggg	aagggtactg	aaaacaccat	ccatttggga	aagaaggcaa	agtcccccca	1680
gttatgcctt	ccaagaggaa	cttcagacac	aaaagtccac	tgatgcaa	tggactggcg	1740
agtccagaga	ggaaactgtg	gaatggaaaa	agcagaaggc	taggaatttt	agcagtcctg	1800
gtttcttttt	ctcatggaag	aaatgaacat	ctgccagctg	tgtcatggac	tcaccaactgt	1860
gtgaccttgg	gcaagtcact	tcacctctct	gtgcctcagt	ttcctcatct	gcaaaatggg	1920
ggcaatatgt	catctaccta	cctcaaaggg	gtggtataag	gtttaaaaag	ataaagattc	1980
agattttttt	accctgggtt	gctgtaaggg	tgcaacatca	ggcgcttga	gttgctgaga	2040
tgcaaggaat	tctataaata	accattcat	agcatagcta	gagattgggtg	aattgaatgc	2100
tcctgacatc	tcagttcttg	tcagtgaagc	tatccaaata	actggccaac	tagttgttaa	2160
aagctaacag	ctcaatctct	taaaacactt	ttcaaaatat	gtgggaagca	tttgattttc	2220

-35-

aatttgat	ttt	tgaattctgc	atttggtttt	atgaatacaa	agataagtga	aaagagagaa	2280
aggaaaagaa	aaaggagaaa	aacaaagaga	tttctaccag	tgaaagggga	attaattact		2340
ctttgttagc	actcactgac	tcttctatgc	agttactaca	tatctagtaa	aaccttgttt		2400
aatactataa	ataatattct	attcattttg	aaaaacacaa	tgattccttc	ttttctaggc		2460
aatataagga	aagtgatcca	aaatttgaaa	tattaaaata	atatctaata	aaaagtcaca		2520
aagttatctt	ctttaacaaa	ctttactctt	attcttagct	gtatatacat	ttttttaaaa		2580
agtttggttaa	aatatgcttg	actagagttt	cagttgaaag	gcaaaaactt	ccatcacaaac		2640
aagaaatttc	ccatgcctgc	tcagaagggt	agcccctagc	tctctgtgaa	tgtgttttat		2700
ccattcaact	gaaaattggg	atcaagaaag	tccactgggt	agtgtactag	tccatcatag		2760
cctagaaaat	gatccctatc	tcagatcaa	gattttctca	ttagaacaat	gaattatcca		2820
gcattcagat	ctttctagtc	accttagaac	tttttggtta	aaagtaccca	ggcttgatta		2880
tttcatgcaa	attctatatt	ttacattctt	ggaaagtcta	tatgaaaaac	aaaaataaca		2940
tcttcagttt	ttctcccact	gggtcacctc	aaggatcaga	ggccaggaaa	aaaaaaaaag		3000
actccctgga	tctctgaata	tatgcaaaaa	gaaggcccca	tttagtggag	ccagcaatcc		3060
tggttcagtca	acaagtattt	taactctcag	tccaacatta	tttgaattga	gcacctcaag		3120
catgcttagc	aatgttctaa	tcactatgga	cagatgtaaa	agaaactata	catcatTTTT		3180
gccctctgcc	tgTTTTccag	acatacaggt	tctgtggaat	aagatactgg	actcctcttc		3240
ccaagatggc	acttctTTTT	atttcttgtc	cccagtgtgt	accttttaaa	attattccct		3300
ctcaacaaaa	ctttataggc	agtcttctgc	agacttaaca	tgTTTTctgt	catagttaga		3360
tgtgataatt	ctaagagtgt	ctatgactta	tttcttccac	ttaattctat	ccacagtcaa		3420
aaatcccca	aggaggaaag	ctgaaagatg	caactgccaa	tattatcttt	cttaactttt		3480
tccaacacat	aatcctctcc	aactggatta	taaataaatt	gaaaataact	cattatacca		3540
attcactatt	ttatttttta	atgaattaaa	actagaaaac	aaattgatgc	aaaccctgga		3600
agtcagttga	ttactatata	ctacagcaga	atgactcaga	tttcatagaa	aggagcaacc		3660
aaaatgtcac	aacaaaaact	ttacaagctt	tgcttcagaa	ttagattgct	ttataattct		3720
tgaatgaggc	aatttcaaga	tatttgtaaa	agaacagtaa	acattggtaa	gaatgagctt		3780
tcaactcata	ggcttatttc	caatttaatt	gaccatactg	gatacttagg	tcaaatttct		3840
gttctctctt	gcccaaataa	tattaaagta	ttatttgaac	tttttaagat	gaggcagttc		3900
ccctgaaaaa	gttaatgcag	ctctccatca	gaatccactc	ttctagggat	atgaaaatct		3960
cttaacaccc	accctacata	cacagacaca	cacacacaca	cacacacaca	cacacacaca		4020



-36-

cacacattca	ccctaaggat	ccaatggaat	actgaaaaga	aatcacttcc	ttgaaaatTT	4080
tattaaaaaa	caaacaaca	aacaaaaagc	ctgtccaccc	ttgagaatcc	ttcctctcct	4140
tggaacgtca	atgttttgtt	agatgaaacc	atctcatgct	ctgtggctcc	agggtttctg	4200
ttactatTTT	atgcacttgg	gagaaggctt	agaataaaag	atgtagcaca	ttttgctttc	4260
ccatttattg	tttggccagc	tatgccaatg	tggtgctatt	gtttctttta	gaaagtactt	4320
gactaaaaaa	aaaagaaaaa	aagaaaaaaa	agaaagcata	gacatatTTT	tttaaagtat	4380
aaaaacaaca	attctataga	tagatggctt	aataaaatag	cattaggtct	atctagccac	4440
caccaccttt	caacttttta	tcactcaca	gtagtgtact	gttcaccaa	ttgtgaatTT	4500
gggggtgcag	gggcaggagt	tggaaatTTT	ttaaagttag	aaggctccat	tgTTTTgttg	4560
gctctcaaac	ttagcaaaat	tagcaatata	ttatccaatc	ttctgaactt	gatcaagagc	4620
atggagaata	aacgcgggaa	aaaagatctt	ataggcaaat	agaagaatTT	aaaagataag	4680
taagttcctt	attgatTTTT	gtgcactctg	ctctaaaaca	gatattcagc	aagtggagaa	4740
aataagaaca	aagagaaaaa	atacatagat	ttacctgcaa	aaaatagctt	ctgccaaatc	4800
ccccttgggt	attctttggc	atttactggg	ttatagaaga	cattctccct	tcaccagac	4860
atctcaaaga	gcagtagctc	tcatgaaaag	caatcactga	tctcatttgg	gaaatgttgg	4920
aaagtatTTc	cttatgagat	gggggttatc	tactgataaa	gaaagaatTT	atgagaaatt	4980
gttgaaagag	atggctaaca	atctgtgaag	atTTTTgtt	tcttggTTTT	gtTTTTTTTT	5040
TTTTTTTTac	tttatacagt	ctttatgaat	ttcttaatgt	tcaaaatgac	ttggttcttt	5100
tcttctTTTT	tttatatcag	aatgaggaat	aataagttaa	accacatag	actctttaa	5160
actatagggt	agatagaaat	gtatgtttga	cttgttgaag	ctataatcag	actatTTtaa	5220
atgttttgct	atTTTtaatc	ttaaaagatt	gtgctaattt	attagagcag	aacctgtttg	5280
gctctcctca	gaagaaagaa	tctttccatt	caaatcacat	ggctttccac	caatatTTTc	5340
aaaagataaa	tctgatTTtat	gcaatggcat	catttatTTT	aaaacagaag	aattgtgaaa	5400
gtttatgccc	ctcccttgca	aagaccataa	agtccagatc	tggtaggggg	gcaacaacaa	5460
aaggaaaatg	ttgttgattc	ttggTTTTtg	atTTTgtTTT	gttttcaatg	ctagtgtTTa	5520
atcctgtagt	acatatTTgc	ttattgctat	tttaatatTT	tataagacct	tcctgttagg	5580
tattagaaag	tgatacatag	atatctTTTT	tgtgtaattt	ctatTTtaaa	aagagagaag	5640
actgtcagaa	gctTTtaagt	catatggtac	aggataaaga	tatcaattta	aataaccaat	5700
tcctatctgg	aacaatgctt	ttgtTTTTta	aagaaacctc	tcacagataa	gacagaggcc	5760
caggggatTT	ttgaagctgt	ctttattctg	cccccatccc	aaccagccc	ttattatTTT	5820

-37-

```

agtatctgcc tcagaat ttt atagagggct gaccaagctg aaactctaga attaaaggaa 5880
cctcactgaa aacatatatt tcacgtgttc cctctctttt ttttcctttt tgtgagatgg 5940
ggctctcgac tgtccccag gctggagtgc agtggcatga tctcggtca ctgcaacctc 6000
cacctcctgg gttaagcga ttctcctgcc tcagcctcct gagtagctgg gattacaggc 6060
accaccact atgcccggt aatttttttg atttttaata gagacggggg tttaccatgt 6120
tgggcagggt ggactcaaac tcctgacctt gtgatttgcc cgcctcagcc tcccaaattg 6180
ctgggattac aggcattgag caccacaccc tgcccatgtg ttccctctta atgtatgatt 6240
acatggatct taaacatgat cttctctctc tcattcttca actatctttg atgggggtctt 6300
tcaaggggaa aaaaatccaa gcttttttaa agtaaaaaaa aaaaaagaga ggacacaaaa 6360
ccaatgtta ctgctcaact gaaatatgag ttaagatgga gacagagttt ctctaataa 6420
ccggagctga attacctttc actttcaaaa acatgacctt ccacaatcct tagaatctgc 6480
ctttttttat attactgagg cctaaaagta aacattactc attttatttt gcccaaatg 6540
cactgatgta aagtaggaaa aataaaaaa gagctctaaa atccctttca agccacccat 6600
tgacccact caccaactca tagcaaagtc acttctgtta atcccttaat ctgattttgt 6660
ttggatatatt atcttgtacc cgctgctaaa cacactgcag gagggactct gaaacctcaa 6720
gctgtctact tacatctttt atctgtgtct gtgtatcatg aaaatgtcta ttcaaatat 6780
caaaccttt caaatatcac gcagcttata ttcagtttac ataaaggccc caaataccat 6840
gtcagatctt tttggtaaaa gagttaatga actatgagaa ttgggattac atcatgtatt 6900
ttgcctcatg tattttttat acacttatag gccaaagtgt ataaataaac ttacagacac 6960
tgaattaatt tcccctgcta ctttgaaacc agaaaataat gactggccat tcgttacatc 7020
tgtcttagtt gaaaagcata ttttttatta aattaattct gattgtattt gaaattatta 7080
ttcaattcac ttatggcaga ggaatatcaa tcctaatgac ttctaaaaat gtaactaatt 7140
gaatcattat cttacattta ctgtttaata agcatatttt gaaaatgtat ggctagagtg 7200
tcataataaa atggtatatc tttcttttagt aattacaaaa aaaaaaaaaa aaaaaaaaaa 7260

```

```

<210> 32
<211> 5767
<212> DNA
<213> Homo Sapiens

```

```

<400> 32
gagggaggag agttcacttt tacttcagtg tcagcgcgcg gcggccgtgg ctggctctgg 60
cgagagagca ccgagggagt gggtcgcaga tcttcggggc gctaggggaa atcggcgaga 120
ggcgggatcc gagcgcgcgc gcggggcgca gagcccgcca gcctggccag cgagggtagc 180

```

-38-

cgcgggggggc	gcgccccggg	cgggcccccg	gagacgcgca	ggatgccaca	cgaagagctg	240
ccgtcgctgc	agagaccccc	ctatggctct	attgtggacg	atgaaaggct	ctctgcagag	300
gagatggatg	agaggaggcg	gcagaacatt	gcttatgaat	atctgtgcca	cttagaggaa	360
gccaaaagggt	ggatggaagt	ttgcttagtt	gaagaattgc	caccaaccac	tgaattggaa	420
gaagggctcc	ggaatggagt	ttaccttgca	aagttagcca	agttctttgc	cccgaaaatg	480
gtatcagaga	aaaagatcta	tgatgtggaa	caaacacgtt	ataagaagtc	tggccttcat	540
tttcgacaca	cagataatac	cgtccagtgg	ttaagagcga	tggagtctat	tgggtctacc	600
aagatatttt	atccagaaac	aacagatgtc	tatgatcgga	aaaacatacc	aagaatgata	660
tattgcattc	acgcactgag	tttgtatctg	ttcaaactag	gaatagcacc	ccagatccag	720
gatttggttg	gcaaagtaga	cttcacagag	gaggaaatca	gtaatatgag	aaaagaactt	780
gagaaatatg	gaatacagat	gccatctttc	agcaaaaatag	gtggtattct	ggccaatgaa	840
ctgtccgtgg	atgaagctgc	attacatgct	gcagttatag	ccattaatga	agcagttgaa	900
aaaggaatag	cagagcaaac	cgttgtaaca	ctaagaaacc	caaatgcggt	tttaacttta	960
gtggatgaca	accttgcacc	agaatatcag	aaagaactct	gggatgccaa	aaagaaaaaa	1020
gaggaaaatg	caagactgaa	gaatagctgt	atttcagaag	aagaaagaga	tgcttatgaa	1080
gaactgctga	cacaagcaga	aatccaaggc	aatattaata	aagtcaacag	gcaggctgca	1140
gtggaccata	tcaatgctgt	cattccggaa	ggtgaccccg	agaatacgct	gcttgcactg	1200
aagaaaccag	aggcccagct	gcctgctggt	tatccctttg	ctgctgccat	gtatcagaac	1260
gaacttttca	acctccagaa	acagaacacc	atgaactact	tggcccacga	ggagcttttg	1320
attgctgtgg	aaatgttgct	tgctgttgct	ttactaaacc	aggccttgga	aagcaacgat	1380
cttgtgtctg	tgcagaatca	actcagaagc	cccgcaatag	gcttaaacia	tctggacaag	1440
gcatatgtgg	aacgttatgc	aaacacacta	ctctctgtta	aactagaagt	tttatcccaa	1500
gggcaagata	acttaagctg	gaatgaaatt	cagaattgta	ttgatatggt	taatgctcaa	1560
attcaagaag	aaaatgaccg	agttgtagct	gtagggtaca	tcaatgaagc	tattgatgaa	1620
gggaatcctt	tgaggacttt	agaaactttg	ctcctaccta	ctgcgaatat	tagtgatgtg	1680
gaccagccc	atgcccagca	ctaccaggat	gttttatacc	atgctaaatc	acagaaactc	1740
ggagactctg	agagtgtttc	caaagtgcct	tggctggatg	agatacagca	agccgtcgat	1800
gaggccaacg	tggacgagga	cagagcaaaa	caatgggtta	ctctgggtgg	tgatgttaat	1860
cagtgtttgg	aaggaaaaaa	atcaagtgat	attttgtctg	tattgaagtc	ttccacttct	1920
aatgcaaagt	acataatccc	ggagtgtgct	gacaaatact	atgatgccct	tgtgaaggca	1980

aaagagctca	aatctgaaag	agtgtctagt	gacggttcat	ggctcaaact	caacctgcac	2040
aaaaaatatg	actactatta	caacactgat	tcaaaagaga	gttcctgggt	cacacctgaa	2100
tcatgcttct	ataaagaatc	atggctcaca	ggaaaagaaa	tcgaggacat	tattgaggaa	2160
gtcacagtag	gttacattcg	tgagaatata	tggtctgctt	cagaagagtt	gcttcttcgc	2220
tttcaagcca	caagctcagg	acccatcctt	aggggaagagt	ttgaagctag	aaaatcattt	2280
ttgcatgaac	aagaagagaa	tgtgggtcaaa	atacaggctt	tttggaagg	atataaacia	2340
cgggaaggagt	atatgcacag	gcggaacacg	ttcattgata	atactgattc	tgttgatgaag	2400
attcagtcct	ggttccgaat	ggcaactgca	agaaagagct	atctttcaag	actacagtat	2460
ttcagagatc	ataataatga	aattgtgaaa	atacagtcac	tgttgagagc	gaacaaagct	2520
agagatgact	acaaaacatt	ggttggctct	gaaaaccac	cattaacagt	aattcgcaaa	2580
tttgtatacc	tgctggacca	aagtgatttg	gatttccagg	aggaactaga	ggttgcacga	2640
ttaagggag	aagtagtgac	caagatcagg	gccaatcaac	agctggaaaa	agacctgaac	2700
ctgatggaca	tcaagattgg	actgctgggtg	aagaacagga	tcacactaga	ggatgtaatt	2760
tcacacagta	aaaagctgaa	caagaaaaaa	ggaggagaaa	tggaaatact	gaataacacc	2820
gacaaccaag	gaataaaaag	tttgagtaag	gagaggagaa	aaacactaga	aacatatcag	2880
cagctgtttt	accttttaca	gaccaacctt	ttatacttgg	ctaagctgat	tttccagatg	2940
ccacagaaca	agtcactaa	atztatggat	actgttattt	tcacactata	taattatgcc	3000
tctaatacagc	gagaagaata	tctacttctc	aagcttttta	aaactgctct	ggaggaagaa	3060
ataaaatcaa	aagtggacca	ggtacaggac	atagttactg	gtaaccctac	agtcatacaag	3120
atggctgtca	gcttcaatag	aggtgccccg	ggacagaaca	ccctgcgcca	actcctggct	3180
ccagtggtaa	aagagatcat	cgacgacaag	tcgctgatta	tcaacacaaa	ccctgtagag	3240
gtgtacaagg	cttgggtgaa	ccaactagaa	acacagactg	gagaggccag	caagttgcct	3300
tatgatgtga	ccacagaaca	agctctaaca	taccagaag	tgaaaaataa	actggaggct	3360
tccattgaga	acctgagaag	ggtcaccgac	aaagtcctga	attctatcat	ttcttccctt	3420
gatctactgc	cttatggatt	gaggtatata	gccaaagtac	tgaagaattc	gatccatgag	3480
aaattccccg	atgcaacaga	agatgagcta	ttaaagattg	ttggaaacct	cctgtactat	3540
cgggtacatga	atccagccat	tgtagctcca	gatggctttg	atatcatcga	catgacagct	3600
ggagggtcaga	taaattctga	ccaaaggaga	aacttaggat	cagtggccaa	ggttcttcag	3660
cacgcagcct	ccaacaagct	gtttgaagga	gaaaatgagc	atctctcatc	tatgaacaat	3720
tatttatcag	agacgtatca	ggaattcagg	aaatatttca	aagaagcatg	taatgtccct	3780

-40-

gagccagaag	agaagtttaa	tatggacaaa	tacacagacc	tggtgacagt	cagcaaacca	3840
gtcatttata	tttcaattga	agaaatcatc	agcacacact	cactcctggt	ggaacaccag	3900
gatgcaattg	cccctgagaa	aaatgactta	ctgagtgaat	tgctgggggc	gctgggagag	3960
gtgccaaaccg	tggaatcttt	tcttggggaa	ggagcagttg	acccaatga	ccctaacaag	4020
gcaaatacac	taagtcagct	ttcaaagacc	gagatttctc	ttgtcttgac	aagcaaatat	4080
gacatagagg	acggtgaagc	tatagatagc	cgaagcctca	tgataaagac	caagaagctg	4140
ataattgatg	tgatccggaa	ccagccaggg	aacacattga	cagaaatctt	agagacacca	4200
gcaactgctc	aacaggaggt	agaccatgcc	acggacatgg	tgagccgtgc	aatgatagat	4260
tccaggactc	cagaagaaat	gaagcatagc	caatctatga	ttgaagatgc	acagctgcct	4320
cttgagcaga	agaagaggaa	aatccagagg	aatcttcgga	cgttggaaca	gactggacac	4380
gtgtcatccg	aaaataaata	ccaagacatt	ctcaatgaga	ttgccaaagg	tattcgaaat	4440
caaagaatct	atcgtaagct	tcgaaaagct	gaattggcaa	aacttcagca	gaccctgaat	4500
gcacttaaca	agaaggcagc	attttatgaa	gagcaaatac	attattatga	cacctacata	4560
aagacttggt	tagacaactt	aaaaagaaaa	aatactcgga	gatcaattaa	actagatgga	4620
aaaggagaac	ccaaaggggc	gaagagagcg	aagccagtga	agtacactgc	agcaaagctg	4680
catgagaaaag	gtgtcctgct	agatatagat	gatcttcaaa	caaaccagtt	taagaatggt	4740
acatttgata	tcatagctac	tgaagatgta	ggcattttcg	atgtaagatc	aaaattcctt	4800
ggtgttgaga	tggaagaggt	gcaactcaat	attcaggatt	tacttcagat	gcaatatgaa	4860
ggagtagctg	taatgaaaat	gtttgataag	gttaaagtga	atgtaaacct	tctcatatac	4920
ctgctgaaca	agaagttcta	tggaagtgta	agtgcctaca	gaaatttctt	ggattctgta	4980
tcatctggat	taggaaatga	atgtgtttta	tatttttggt	tttaaactatg	attgaaatca	5040
ctgcttataa	atgtgtgatt	ttttttaaat	gacaaaaact	gttctgaaga	atgtaccag	5100
gtgccttttt	gctaatttga	tactataata	gaatgagaca	taaaatgaat	taatggaaac	5160
atatccacac	tgtactgtga	tataggtact	ctgattttaa	actttggaca	tctgtgatc	5220
tgtttttaaag	ttgggggggtg	ggaaatttag	ctgactaggg	acaacatgt	aaacctat	5280
tcttatgaaa	aaagttttta	atgtccact	tgaataacgt	aattcttcat	agttttttta	5340
atctatggat	aaatggaaac	ctaattat	gtaatgaatt	atttagacag	ttctaagccc	5400
tgtcttctgg	gagttatcaa	ttttaaagag	aacttttgtg	caattcaa	gaagttttta	5460
taagtaattg	aaaatgacaa	cacaataaca	ctttctgtat	aaaagtatat	attttatgtg	5520
atttattcct	actaaatgaa	agtgactac	tgctcatgt	aaagactctt	gcacgcagag	5580

-41-

cctttaagtg actaaggaac aacatagata gtgagcatag tccccacctc cccccctcac 5640  
 aatttatattg aatacttcaa ttgtgcctct caattttttg taatgctaaa aaatcagtat 5700  
 ctagatgggtt tttaaatgta ttctctggaa attgtttttat gtaaaataaa tgttacttaa 5760  
 ttccatt 5767

<210> 33  
 <211> 634  
 <212> DNA  
 <213> Homo Sapiens

<400> 33  
 cggctgagag gcagcgaact catctttgcc agtacaggag cttgtgccgt ggcccacagc 60  
 ccacagccca cagccatggg ctgggacctg acggtgaaga tgctggcggg caacgaattc 120  
 caggtgtccc tgagcagctc catgtcgggtg tcagagctga aggcgcagat caccagaag 180  
 attggcgtgc acgccttcca gcagcgtctg gctgtccacc cgagcgggtg ggcgctgcag 240  
 gacaggggtcc cccttgccag ccagggcctg ggccctggca gcacggtcct gctgggtgggtg 300  
 gacaaatgcg acgaacctct gagcatcctg gtgaggaata acaagggccg cagcagcacc 360  
 tacgaggtcc ggctgacgca gaccgtggcc cacctgaagc agcaagtgag cgggctggag 420  
 ggtgtgcagg acgacctgtt ctggctgacc ttcgagggga agcccctgga ggaccagctc 480  
 ccgctggggg agtacggcct caagcccctg agcaccgtgt tcatgaatct gcgcctgcgg 540  
 ggaggcggca cagagcctgg cgggcggagc taagggcctc caccagcatc cgagcaggat 600  
 caagggcccg aaataaaggc tgttgtaaga gaat 634

<210> 34  
 <211> 4855  
 <212> DNA  
 <213> Homo Sapiens

<400> 34  
 gaattcccct cccccctttt tccatgcagc tgatctaaaa gggaataaaa ggctgcgcat 60  
 aatcataata ataaaaagaag gggagcgcga gagaaggaaa gaaagccggg aggtggaaga 120  
 ggaggggggag cgtctcaaag aagcgatcag aataataaaa ggaggccggg ctctttgcct 180  
 tctggaacgg gccgctcttg aaagggtttt tgaaaagtgg tgttgttttc cagtcgtgca 240  
 tgctccaatc ggcggagtat attagagccg ggacgcggcc gcaggggcag cggcgacggc 300  
 agcaccggcg gcagcaccag cggaacagc agcggcggcg tcccagtgct ccgcggcggc 360  
 gcgcgcagcg atgcgttccc cacggacacg cggccggtcc gggcgcccc taagcctcct 420  
 gctcgccctg ctctgtgccc tgcgagccaa ggtgtgtggg gcctcgggtc agttcgagtt 480

-42-

ggagatcctg	tccatgcaga	acgtgaacgg	ggagctgcag	aacgggaact	gctgcggcgg	540
cgcccggaac	ccgggagacc	gcaagtgcac	ccgcgacgag	tgtgacacat	acttcaaagt	600
gtgcctcaag	gagtatcagt	ccgcgctcac	ggccgggggg	ccctgcagct	tcggctcagg	660
gtccacgcct	gtcatcgggg	gcaacacctt	caacctcaag	gccagccgcg	gcaacgaccc	720
gaaccgcac	gtgctgcctt	tcagtttcgc	ctggccgagg	tcctatacgt	tgcttgtgga	780
ggcgtgggat	tccagtaatg	acaccgttca	acctgacagt	attattgaaa	aggcttctca	840
ctcgggcatg	atcaacccca	gccggcagtg	gcagacgctg	aagcagaaca	cgggcgttgc	900
ccactttgag	tatcagatcc	gcgtgacctg	tgatgactac	tactatggct	ttggctgtaa	960
taagttctgc	cgccccagag	atgacttctt	tggacactat	gcctgtgacc	agaatggcaa	1020
caaaacttgc	atggaaggct	ggatggggcc	cgaatgtaac	agagctattt	gccgacaagg	1080
ctgcagtcct	aagcatgggt	cttgcaaaact	cccaggtgac	tgcaggtgcc	agtacggctg	1140
gcaaggcctg	tactgtgata	agtgcacccc	acaccgggga	tgcgtccacg	gcacctgtaa	1200
tgagccctgg	cagtgcctct	gtgagaccaa	ctggggcggc	cagctctgtg	acaaagatct	1260
caattactgt	gggactcatc	agcctgtgtc	caacggggga	acttgtagca	acacaggccc	1320
tgacaaaatat	cagtgttcct	gccctgaggg	gtattcagga	cccaactgtg	aaattgctga	1380
gcacgcctgc	ctctctgac	cctgtcacaa	cagaggcagc	tgtaaggaga	cctccctggg	1440
ctttgagtgt	gagtgttccc	caggctggac	cggccccaca	tgctctacaa	acattgatga	1500
ctgttctcct	aataactgtt	cccacggggg	cacctgccag	gacctgggta	acggatttaa	1560
gtgtgtgtgc	ccccacagt	ggactgggaa	aacgtgccag	ttagatgcaa	atgaatgtga	1620
ggccaaacct	tgtgtaaacg	ccaaatcctg	taagaatctc	attgccagct	actactgcga	1680
ctgtcttccc	ggctggatgg	gtcagaattg	tgacataaat	attaatgact	gccttggcca	1740
gtgtcagaat	gacgcctcct	gtcgggattt	ggttaatggg	tatcgctgta	tctgtccacc	1800
tggctatgca	ggcgatcact	gtgagagaga	catcgatgaa	tgtgccagca	accctgtttt	1860
gaatgggggt	cactgtcaga	atgaaatcaa	cagattccag	tgtctgtgtc	ccactgggtt	1920
ctctggaaac	ctctgtcagc	tggacatcga	ttattgtgag	cctaatacct	gccagaacgg	1980
tgcccagtg	tacaaccgtg	ccagtgacta	tttctgcaag	tgccccgagg	actatgaggg	2040
caagaactgc	tcacacctga	aagaccactg	ccgcacgacc	ccctgtgaag	tgattgacag	2100
ctgcacagt	gccatggctt	ccaacgacac	acctgaaggg	gtgcggtata	tttcctccaa	2160
cgtctgtggg	cctcacggga	agtgcgaag	tcagtcggga	ggcaaattca	cctgtgactg	2220
taacaaaggc	ttcacgggaa	catactgcca	tgaaaatatt	aatgactgtg	agagcaaccc	2280

-43-

ttgtagaaac ggtggcactt gcatcgatgg tgtcaactcc tacaagtgca tctgtagtga	2340
cggctgggag ggggcctact gtgaaaccaa tattaatgac tgcagccaga acccctgcc	2400
caatgggggc acgtgtcgcg acctgggtcaa tgactttctac tgtgactgta aaaatgggtg	2460
gaaaggaaaag acctgccact cacgtgacag tcagtgtgat gaggccacgt gcaacaacgg	2520
tggcacctgc tatgatgagg gggatgcttt taagtgcattg tgcctggcg gctgggaagg	2580
aacaacctgt aacatagccc gaaacagtag ctgcctgcc aaccctgcc ataattggggg	2640
cacatgtgtg gtcaacggcg agtcctttac gtgcgtctgc aaggaaggct gggaggggcc	2700
catctgtgct cagaatacca atgactgcag ccctcatccc tgttacaaca gggcacctg	2760
tgtggatgga gacaactggg accggtgcga atgtgccccg ggttttgctg ggcccgactg	2820
cagaataaac atcaatgaat gccagtcttc acctgtgccc tttggagcga cctgtgtgga	2880
tgagatcaat ggctaccggg gtgtctgccc tccagggcac agtgggtgcca agtgccagga	2940
agtttcaggg agaccttgca tcaccatggg gagtgtgata ccagatgggg ccaaattggga	3000
tgatgactgt aatacctgcc agtgccctgaa tggacggatc gcctgctcaa aggtctgggtg	3060
tggccctcga ccttgccctgc tccacaaagg gcacagcgag tgccccagcg ggcagagctg	3120
catccccatc ctggacgacc agtgcttcgt ccaccctgc actgggtgtgg gcgagtgtcg	3180
gtcttccagt ctccagccgg tgaagacaaa gtgcacctct gactcctatt accaggataa	3240
ctgtgcgaac atcacattta cctttaacaa ggagatgatg tcaccaggtc ttactacgga	3300
gcacatttgc agtgaattga ggaatttgaa tattttgaag aatgtttccg ctgaatattc	3360
aatctacatc gcttgcgagc cttccccttc agcgaacaat gaaatacatg tggccatttc	3420
tgtgaagat atacgggatg atgggaaccc gatcaaggaa atcactgaca aaataatcga	3480
tcttgtagt aaacgtgatg gaaacagctc gctgattgct gccgttgagc aagtaagagt	3540
tcagaggcgg cctctgaaga acagaacaga tttccttggt cccttgctga gctctgtctt	3600
aactgtggct tggatctgtt gcttggtgac ggccttctac tggtgccctgc ggaagcggcg	3660
gaagccgggc agccacacac actcagcctc tgaggacaac accaccaaca acgtgcggga	3720
gcagctgaac cagatcaaaa acccattga gaaacatggg gccaacacgg tccccatcaa	3780
ggattacgag aacaagaact ccaaaatgtc taaaataagg acacacaatt ctgaagtaga	3840
agaggacgac atggacaaac accagcagaa agcccgggtt gccaaagcagc cggcgtagac	3900
gctggtagac agagaagaga agcccccaa cggcacgccg aaaaaacacc caaactggac	3960
aaacaaacag gacaacagag acttggaag tgcccagagc ttaaaccgaa tggagtacat	4020
cgtatagcag accgcgggca ctgccgccgc taggtagagt ctgagggctt gtagttcttt	4080



-44-

```

aaactgtcgt gtcatactcg agtctgagggc cgttgctgac ttagaatccc tgtgttaatt 4140
tagtttgaca agctggctta cactggcaat ggtagttctg tggttggctg ggaaatcgag 4200
tggcgcatct cacagctatg caaaaagcta gtcaacagta cccttggttg tgtgtcccct 4260
tgcagccgac acggtctcgg atcagggtcc caggagctgc ccagccccct ggtactttga 4320
gctcccactt ctgccagatg tctaattggtg atgcagtctt agatcatagt tttattttata 4380
tttatttgact cttgagttgt ttttgtatat tggttttatg atgacgtaca agtagttctg 4440
tatttgaaag tgcctttgca gctcagaacc acagcaacga tcacaaatga ctttattatt 4500
tattttttttt aattgtattt ttgttggttg gggaggggag actttgatgt cagcagttgc 4560
tggtaaaatg aagaatttaa agaaaaaatg tccaaaagta gaactttgta tagttatgta 4620
aataattctt ttttattaat cactgtgtat atttgattta ttaacttaat aatcaagagc 4680
cttaaaacat cattcctttt tatttatatg tatgtgttta gaattgaagg tttttgatag 4740
cattgtaagc gtatggcttt atttttttga actcttctca ttacttggtg cctataagcc 4800
aaaaaggaaa ggggtgttttg aaaatagttt attttaaaac aataggatgg gctac 4855

```

```

<210> 35
<211> 9534
<212> DNA
<213> Homo Sapiens

```

```

<400> 35
cagcgactcc tctggctccc gagaagtgga tccggtcgcg gccactacga tgccggggagc 60
cgccgggggtc ctctccttc tgctgctctc cggaggcctc gggggcgtag aggcgcagcg 120
gccgcagcag cagcggcagt cacaggcaca tcagcaaaga ggttttattcc ctgctgtcct 180
gaatcttgct tctaattgctc ttatcacgac caatgcaaca tgtggagaaa aaggacctga 240
aatgtactgc aaattggtag aacatgtccc tgggcagcct gtgaggaacc cgcagtgtcg 300
aatctgcaat caaaacagca gcaatccaaa ccagagacac ccgattacaa atgctattga 360
tggaagaagc acttggtggc agagtcccag tattaagaat ggaatcgaat accattatgt 420
gacaattaca ctggatttac agcaggtggt ccagatcgcg tatgtgattg tgaaggcagc 480
taactcccc cggcctggaa actggatttt ggaacgctct cttgatgatg ttgaatacaa 540
gccctggcag tatcatgctg tgacagacac ggagtgccta acgctttaca atatttatcc 600
ccgcactggg ccaccgtcat atgccaaaga tgatgaggtc atctgcactt cattttactc 660
caagatacac cccttagaaa atggagagat tcacatctct ttaatcaatg ggagaccaag 720
tgccgatgat ccttctccag aactgctaga atttacctcc gctcgctata ttcgcctgag 780

```

-45-

atttcagagg atccgcacac tgaatgctga cttgatgatg tttgctcaca aagacccaag	840
agaaattgac cccattgtca ccagaagata ttactactcg gtcaaggata tttcagttgg	900
agggatgtgc atctgctatg gtcattgccag ggcttgtcca cttgatccag cgacaaataa	960
atctcgctgt gagtgtgagc ataacacatg tggcgatagc tgtgatcagt gctgtccagg	1020
attccatcag aaaccctgga gagctggaac ttttctaact aaaactgaat gtgaagcatg	1080
caattgtcat ggaaaagctg aagaatgcta ttatgatgaa aatgttgcca gaagaaatct	1140
gagtttgaat atacgtggaa agtacattgg agggggtgtc tgcattaatt gtacccaaaa	1200
cactgctggg ataaactgag agacatgtac agatggcttc ttcagacca aaggggtatc	1260
tccaaattat ccaaggccat gccagccatg tcattgcatg ccaattgggt ccttaaataa	1320
agtctgtgtc aaggatgaga aacatgctcg acgaggtttg gcacctggat cctgtcattg	1380
caaaactggg tttggagggt tgagctgtga tcgggtgtgc aggggctaca ctggctaccc	1440
ggactgcaaa gcctgtactt gcagtgggtt agggagcaaa aatgaggatc cttgttttgg	1500
cccctgtatc tgcaaggaaa atgttgaagg aggagactgt agtcgttgca aatccggctt	1560
cttcaatttg caagaggata attggaaagg ctgcgatgag tgtttctgtt caggggtttc	1620
aaacagatgt cagagttcct actggacctt tggcaaaata caagatatga gtggctggta	1680
tctgactgac cttcctggcc gcattcgagt ggctccccag caggacgact tggactcacc	1740
tcagcagatc agcatcagta acgcggaggc ccggcaagcc ctgccgcaca gctactactg	1800
gagcgcgcgc gctccctatc tgggaaacaa actcccagca gtaggaggac agttgacatt	1860
taccatatca tatgacctg aagaagagga agaagataca gaacgtgttc tccagcttat	1920
gattatctta gagggtaatt acttgagcat cagcacagcc caagatgagg tgtacctgca	1980
cccatctgaa gaacatacta atgtattgtt acttaaagaa gaatcattta ccatacatgg	2040
cacacatttt ccagtccgta gaaaggaatt tatgacagtg cttgcgaatt tgaagagagt	2100
cctcctacaa atcacataca gctttgggat ggatgccatc ttcagggtga gctctgttaa	2160
ccttgaatcc gctgtctcct atcctactga tggaaagcatt gcagcagctg tagaagtgtg	2220
tcagtgccca ccagggtata ctggctcctc ttgtgaatct tgttggccta ggcacaggcg	2280
agttaacggc actatTTTTT gtggcatctg tgagccatgt cagtgccttg gtcattgcga	2340
gtcctgtgat gacgtcactg gagaatgcct gaactgtaag gatcacacag gtggcccata	2400
ttgtgataaa tgtcttcctg gtttctatgg cgagcctact aaaggaacct ctgaagactg	2460
tcaacctgtg gcctgtccac tcaatatccc atccaataac tttagcccaa cgtgccatTT	2520
agaccggagt cttggattga tctgtgatgg atgccctgtc gggtacacag gaccacgctg	2580

-46-

tgagaggtgt	gcagaaggct	atTTtggaca	accctctgta	cctggaggat	catgtcagcc	2640
atgccaatgc	aatgacaacc	ttgacttctc	catccctggc	agctgtgaca	gcttgtctgg	2700
ctcctgtctg	atatgtaaac	caggtacaac	aggccggtac	tgtgagctct	gtgctgatgg	2760
atatttttga	gatgcagttg	atgcgaagaa	ctgtcagccc	tgtcgctgta	atgccggtgg	2820
ctctttctct	gaggtttgcc	acagtcaaac	tggacagtgt	gagtgcagag	ccaacgttca	2880
gggtcagaga	tgtgacaaat	gcaaggctgg	gacctttggc	ctacaatcag	caaggggctg	2940
tgttccctgc	aactgcaatt	cttttgggtc	taagtcatte	gactgtgaag	agagtggaca	3000
atgttggtgc	caacctggag	tcacagggaa	gaaatgtgac	cgctgtgccc	acggctatTT	3060
caacttccaa	gaaggaggct	gcacagcttg	tgaatgttct	catctgggta	ataattgtga	3120
cccaaagact	gggcgatgca	tttgcccacc	caataccatt	ggagagaaat	gttctaaatg	3180
tgcacccaat	acctggggcc	acagcattac	cactggttgt	aaggcttgta	actgcagcac	3240
agtgggatcc	ttggatttcc	aatgcaatgt	aaatacaggc	caatgcaact	gtcatccaaa	3300
attctctggt	gcaaaatgta	cagagtgcag	tcgaggtcac	tggaaactacc	ctcgctgcaa	3360
tctctgtgac	tgcttctctc	ctgggacaga	tgccacaacc	tgtgattcag	agactaaaaa	3420
atgctcctgt	agtgatcaaa	ctgggcagtg	cacttgtaag	gtgaatgtgg	aaggcatcca	3480
ctgtgacaga	tgccggcctg	gcaaattcgg	actcgatgcc	aagaatccac	ttggctgcag	3540
cagctgctat	tgcttcggca	ctactaccca	gtgctctgaa	gcaaaaggac	tgatccggac	3600
gtgggtgact	ctgaaggctg	agcagaccat	tctacccttg	gtagatgagg	ctctgcagca	3660
cacgaccacc	aagggcattg	tttttcaaca	tccagagatt	gttgcccaca	tggacctgat	3720
gagagaagat	ctccatttgg	aaccttttta	ttggaaaactt	ccagaacaat	ttgaaggaaa	3780
gaagttgatg	gcctatgggg	gcaaactcaa	gtatgcaatc	tatttcgagg	ctcggaaga	3840
aacagggtttc	tctacatata	atcctcaagt	gatcattcga	ggtgggacac	ctactcatgc	3900
tagaattatc	gtcaggcata	tggctgctcc	tctgattggc	caattgacaa	ggcatgaaat	3960
tgaaatgaca	gagaaagaat	ggaaatatta	tggggatgat	cctcgagtcc	atagaactgt	4020
gacccgagaa	gacttcttgg	atatactata	tgatattcat	tacattctta	tcaaagctac	4080
ttatggaaat	ttcatgcgac	aaagcaggat	ttctgaaatc	tcaatggagg	tagctgaaca	4140
aggacgtgga	acaacaatga	ctcctccagc	tgacttgatt	gaaaaatgtg	attgtcccct	4200
gggctattct	ggcctgtcct	gtgaggcatg	cttgccggga	ttttatcgac	tgcgttctca	4260
accagggtggc	cgcacccctg	gaccaaccct	gggcacctgt	gttccatgtc	aatgtaatgg	4320
acacagcagc	ctgtgtgacc	ctgaaacatc	gatatgccag	aattgtcaac	atcacactgc	4380

-47-

tggtgacttc	tgtgaacgat	gtgctcttgg	atactatgga	attgtcaagg	gattgccaaa	4440
tgactgtcag	caatgtgcct	gccctctgat	ttcttccagt	aacaatttca	gcccctcttg	4500
tgctgcagaa	ggacttgacg	actaccgctg	cacggcttgt	ccacggggat	atgaaggcca	4560
gtactgtgaa	aggtgtgccc	ctggctatac	tggcagtcca	ggcaaccctg	gaggctcctg	4620
ccaagaatgt	gagtgtgatc	cctatggctc	actgcctgtg	ccctgtgacc	ctgtcacagg	4680
attctgcacg	tgccgacctg	gagccacggg	aaggaagtgt	gacggctgca	agcactggca	4740
tgcacgcgag	ggctgggagt	gtgttttttg	tggagatgag	tgcactggcc	ttcttctcgg	4800
tgacttggct	cgcttgagc	agatggtcac	gagcatcaac	ctcactggtc	cgctgcctgc	4860
gccatataaa	atgctgtatg	gtcttgaaaa	tatgactcag	gagctaaagc	acttgcctgc	4920
acctcagcgg	gcccagaga	ggcttattca	gctggcagag	ggcaatctga	atacactcgt	4980
gaccgaaatg	aacgagctgc	tgaccagggc	taccaaagtg	acagcagatg	gcgagcagac	5040
cggacaggat	gctgagagga	ccaacacaag	agcaaagtcc	ctggggagaat	tcattaagga	5100
gcttgcccgg	gatgcagaag	ctgtaaatga	aaaagctata	aaactaaatg	aaactctagg	5160
aaactcgagac	gaggcctttg	agagaaatth	ggaagggtct	cagaaagaga	ttgaccagat	5220
gattaaagaa	ctgaggagga	aaaatctaga	gacacaaaag	gaaattgctg	aagatgagtt	5280
ggtagctgca	gaagcccttc	tgaaaaaagt	gaagaagctg	tttgagagat	cccggggggg	5340
aatgaagaa	atggagaagg	atctccggga	aaaactggct	gactacaaaa	acaaagttga	5400
tgatgcttgg	gaccttttga	gagaagccac	agataaaatc	agagaagcta	atcgcttatt	5460
tgcagtaaat	cagaaaaaca	tgactgcatt	ggagaaaaag	aaggaggctg	ttgagagcgg	5520
caaacgacaa	attgagaaca	ctttaaaaga	aggcaatgac	atactcgatg	aagccaaccg	5580
tcttgcagat	gaaatcaact	ccatcataga	ctatgttgaa	gacatccaaa	ctaaattgcc	5640
acctatgtct	gaggagctta	atgataaaat	agatgacctc	tccaagaaa	taaaggacag	5700
gaagcttgct	gagaagggtg	cccaggctga	gagccacgca	gctcagttga	atgactcatc	5760
tgctgtcctt	gatggaatcc	ttgatgaggc	taaaaacatc	tccttcaatg	ccactgcagc	5820
cttcaaagct	tacagcaata	ttaaggacta	tattgatgaa	gctgagaaag	ttgccaagaa	5880
agccaaagat	cttgacatg	aagctacaaa	actggcaaca	ggtcctcggg	gtttattaaa	5940
ggaagatgcc	aaaggctgtc	ttcagaaaag	cttcaggatt	cttaacgaag	ccaagaagtt	6000
agcaaagatg	gtaaaagaaa	atgaagacca	tctaaatggc	ttaaaaacca	ggatagaaaa	6060
tgctgatgct	agaaatgggg	atctcttgag	aacttttgaat	gacacttttg	gaaagttatc	6120
agctattcca	aatgatacag	ctgctaaact	gcaagctgtt	aaggacaaag	ccagacaagc	6180

-48-

caacgacaca gctaaagatg tactggcaca gattacagag ctccaccaga acctcgatgg	6240
cctgaagaag aattacaata aactagcaga cagcgtcgcc aaaacgaatg ctgtgggttaa	6300
agatccttcc aagaacaaaa tcattgccga tgcagatgcc actgtcaaaa atttagaaca	6360
ggaagctgac cggctaataag ataaactcaa acccatcaag gaacttgagg ataacctaaa	6420
gaaaaacatc tctgagataa aggaattgat aaaccaagct cggaaacaag ccaattctat	6480
caaagtatct gtgtcttcag gaggtgactg cattcgaaca taaaaccag aaatcaagaa	6540
aggaagttac aataatattg ttgtcaacgt aaagacagct gttgctgata acctcctctt	6600
ttatcttggga agtgccaaat ttattgactt tctggctata gaaatgcgta aaggcaaagt	6660
cagcttcctc tgggatgttg gatctggagt tggacgtgta gagtaccag atttgactat	6720
tgatgactca tattggtacc gtatcgtagc atcaagaact gggagaaatg gaactatttc	6780
tgtgagagcc ctggatggac ccaaagccag catttgtgcc agcacacacc attcgacgtc	6840
tcctccaggg tacacgattc tagatgtgga tgcaaatgca atgctgtttg ttggtggcct	6900
gactgggaaa ttaaagaagg ctgatgctgt acgtgtgatt acattcactg gctgcatggg	6960
agaaacatac tttgacaaca aacctatagg tttgtggaat ttccgagaaa aagaagggtga	7020
ctgcaaagga tgcactgtca gtcctcaggt ggaagatagt gaggggacta ttcaatttga	7080
tggagaaggt tatgcattgg tcagccgtcc cattcgctgg taccacaaca tctccactgt	7140
catgttcaag ttcagaacat tttcttcgag tgctcttctg atgtatcttg ccacacgaga	7200
cctgagagat ttcattgagtg tggagctcac tgatgggcac ataaaagtca gttacgatct	7260
gggctcagga atggcttccg ttgtcagcaa tcaaaaccat aatgatggga aatggaaatc	7320
attcactctg tcaagaattc aaaaacaagc caatatatca attgtagata tagatactaa	7380
tcaggaggag aatatagcaa cttcgtcttc tggaaacaac tttggtcttg acttgaaagc	7440
agatgacaaa atatatcttg gtggcctgcc aacgctgaga aacttgagta tgaaagcaag	7500
gccagaagta aatctgaaga aatattccgg ctgcctcaaa gatattgaaa tttcaagaac	7560
tccgtacaat atactcagta gtcccgatta tgttggtgtt accaaaggat gttccctgga	7620
gaatgtttac acagttagct ttcctaagcc tgggtttgtg gagctctccc ctgtgccaat	7680
tgatgtagga acagaaatca acctgtcatt cagcaccaag aatgagtccg gcattcattct	7740
tttgggaagt ggaggacac cagcaccacc taggagaaaa cgaaggcaga ctggacaggc	7800
ctattatgta atactcctca acaggggccc tctggaagtg catctctcca caggggcacg	7860
aacaatgagg aaaattgtca tcagaccaga gccgaatctg tttcatgatg gaagagaaca	7920
ttccgttcat gtagagcgaa ctagaggcat ctttacagtt caagtggatg aaaacagaag	7980

-49-

atacatgcaa aacctgacag ttgaacagcc tatcgaagtt aaaaagcttt tcgttggggg	8040
tgctccacct gaatttcaac cttccccact cagaaatatt cctccttttg aaggctgcat	8100
atggaatctt gttattaact ctgtcccat ggactttgca aggcctgtgt cttcaaaaa	8160
tgctgacatt ggtcgctgtg cccatcagaa actccgtgaa gatgaagatg gagcagctcc	8220
agctgaaata gttatccagc ctgagccagt tcccaccca gcctttccta cgcccccccc	8280
agttctgaca catggtcctt gtgctgcaga atcagaacca gctcttttga tagggagcaa	8340
gcagttcggg ctttcaagaa acagtcacat tgcaattgca tttgatgaca ccaaagttaa	8400
aaaccgtctc acaattgagt tggaagtaag aaccgaagct gaatccggct tgctttttta	8460
catggctgcg atcaatcatg ctgattttgc aacagttcag ctgagaaatg gattgcccta	8520
cttcagctat gacttgggga gtggggacac ccacaccatg atccccacca aaatcaatga	8580
tggccagtgg cacaagatta agataatgag aagtaagcaa gaaggaattc tttatgtaga	8640
tggggcttcc aacagaacca tcagtcccaa aaaagccgac atcctggatg tcgtgggaat	8700
gctgtatgtt ggtgggttac ccatcaacta cactaccga agaattggtc cagtgccta	8760
tagcattgat ggctgcgtca ggaatctcca catggcagag gccctgccg atctggaaca	8820
acccacctcc agcttccatg ttgggacatg ttttgcaa at gctcagagggaacataattt	8880
tgacggaacc ggttttgcc aagcagttgg tggattcaaa gtgggattgg accttcttgt	8940
agaatttgaa ttcgcgacaa ctacaacgac tggagttctt ctggggatca gtagtcaaaa	9000
aatggatgga atgggtattg aaatgattga tgaaaagttg atgtttcatg tggacaatgg	9060
tgcgggcaga ttcactgctg tctatgatgc tggggttcca gggcatttgt gtgatggaca	9120
atggcataaa gtcactgcc acaagatcaa acaccgcatt gagctcacag tcgatgggaa	9180
ccagggtgga gcccaaagcc caaaccagc atctacatca gctgacacaa atgaccctgt	9240
gtttgttga ggcttcccag atgacctcaa gcagtttggc ctaacaacca gtattccgtt	9300
ccgaggttgc atcagatccc tgaagctcac caaaggcaca gcaagccact ggaggttaat	9360
tttgccaagg ccctggaact gaggggcgtt caacctgtat catgccagc caactaataa	9420
aaataagtgt aaccccagga agagtctgtc aaaacaagta tatcaagtaa aacaaacaaa	9480
tatattttac ctatatatgt taattaaact aatttgtgca tgtacataga attc	9534

<210> 36  
 <211> 5683  
 <212> DNA  
 <213> Homo Sapiens

<400> 36  
 ccgcccgggtg ttgcgctcct tcccagaatc cgctccggcc tttccttctt gccgcgattc 60

- 50 -

ccaactttgc tcaaagtcgc cggactctaa gctgtcggag ggaccgctgg acagacctgg	120
gaactgacag agggcctgga gggaaatagg ccaaagaccc acaggatgga gctgacctca	180
accgaaagag ggaggggaca gcctctgccc tgggaacttc gactgcccct actgctaagc	240
gtgctggctg ccacactggc acaggccccct gccccggatg tccctggctg ttccagggga	300
agctgctacc ccgccacggc cgacctgctg gtgggcccag ctgacagact gactgcctca	360
tccacttgctg gcctgaatgg ccgccagccc tactgcatcg tcagtcacct gcaggacgaa	420
aagaagtgtc tcctttgtga ctcccggcgc cccttctctg ctagagacaa cccacacacc	480
catcgcatcc agaattgtagt caccagcttt gcaccacagc ggcgggcagc ttggtggcag	540
tcacagaatg gtatccctgc ggtcaccatc cagctggacc tggaggctga gtttcatttc	600
acacacctca ttatgacctt caagacattt cgccctgctg ccatgctggc cgaacgctca	660
gcagactttg gccgcacctg gcatgtgtac cgatatctct cctatcactg tggggctgac	720
ttcccaggag tcccactagc acccccacgg cactgggatg atgtagtctg tgagtccgc	780
tactcagaga ttgagccatc cactgaaggc gaggtcatct atcgtgtgct ggaccctgcc	840
atccctatcc cagacccta cagctcacgg attcagaacc tgttgaagat caccaacct	900
cgggtgaacc tgactcgtct acacacgttg ggagacaacc tactcgacc acggaggag	960
atccgagaga agtactacta tgccctctat gagctgggtg tacgtggcaa ctgcttctgc	1020
tacggacacg cctcagagtg tgcaccgcgc ccaggggcac cagcccatgc tgagggcatg	1080
gtgcacggag cttgcatctg caaacacaac acacgtggcc tcaactgcga gcagtgtcag	1140
gatttctatc gtgacctgcc ctggcgctcc gctgaggacg gccatagtca tgctgtagg	1200
aagtgtgate ggcattggga caccacagc tgccacttcg acatggccgt atacctcgga	1260
tctggcaatg tgagtggagg tgtgtgtgat ggatgtcagc ataacacagc gtggcgccac	1320
tgtgagctct gtcggccctt cttctaccgt gacccaacca aggacctgcg ggatccggct	1380
gtgtgccgct cctgtgattg tgaccccatg ggttctcaag acggtggctg ctgtgattcc	1440
catgatgacc ctgcactggg actggtctcc ggccagtgtc gctgcaaaga acacgtgggtg	1500
ggcactcgct gccagcaatg ccgtgatggc ttctttgggc tcagcatcag tgaccctct	1560
gggtgccggc gatgtcaatg taatgcacgg ggcacagtgc ctgggagcac tccttgtgac	1620
cccaacagtg gatcctgtta ctgcaaactg ctagtactg gacgtggatg tgaccgctgc	1680
ctgcctggcc actggggcct gagcctcgac ctgctcggt gccgccctg tgactgcgac	1740
gtgggtgggtg ctttggtacc ccagtgtgat gagggcacag gtcaatgcca ctgccgccag	1800
cacatgggtg ggcgacgctg tgagcagggt caacctggct acttccggcc cttcctggac	1860

- 51 -

cacctaattt	gggaggctga	gaacaccoga	gggcagggtgc	tcgatgtggt	ggagcgcctg	1920
gtgacccccg	gggaaactcc	atcctggact	ggctcaggct	tcgtgcgact	acaggaaggt	1980
cagaccctgg	agttcctggt	ggcctctgtg	ccgaacgcga	tggactatga	cctgctgctg	2040
cgttagagc	cccagggtccc	tgagcaatgg	gcagagtgtg	aactgattgt	gcagcgtcca	2100
gggcctgtgc	ctgcccacag	cctgtgtggg	catttggtgc	ccagggatga	tcgcatccaa	2160
gggactctgc	aaccacatgc	caggtaactt	atatttccta	atcctgtctg	ccttgagcct	2220
ggtatctcct	acaagctgca	tctgaagctg	gtacggacag	ggggaagtgc	ccagcctgag	2280
actccctact	ctggacctgg	cctgctcatt	gactcgctgg	tgctgctgcc	ccgtgtcctg	2340
gtgctagaga	tgtttagtgg	gggtgatget	gctgccctgg	agcgccaggc	cacctttgaa	2400
cgtaccaat	gccatgagga	gggtctggtg	cccagcaaga	cttctccctc	tgaggcctgc	2460
gcacccctcc	tcatcagcct	gtccaccctc	atctacaatg	gtgccctgcc	atgtcagtgc	2520
aaccctcaag	gttcactgag	ttctgagtgc	aaccctcatg	gtggtcagtg	cctgtgcaag	2580
cctggagtgg	ttgggcgccg	ctgtgacaag	tgtgcccttg	gctactatgg	ctttggcccc	2640
acaggctgtc	aagcctgcca	gtgcagccca	cgaggggcac	tcagcagtct	ctgtgaaagg	2700
accagtgggc	aatgtctctg	tcgaactggg	gcctttgggg	ttcgctgtga	cgctgccag	2760
cgtggccagt	ggggattccc	tagctgccgg	ccatgtgtct	gcaatgggca	tgcagatgag	2820
tgcaacaccc	acacaggcgc	ttgcctgggc	tgccgtgatc	tcacaggggg	tgagcactgt	2880
gaaagggtgca	ttgctggttt	ccacggggac	ccacggctgc	catatggggc	gcagtgccgg	2940
ccctgtccct	gtcctgaagg	ccctgggagc	caacggcact	ttgctacttc	ttgccaccag	3000
gatgaatatt	cccagcagat	tgtgtgccac	tgccggggcag	gctatacggg	gctgcatgt	3060
gaagcttgtg	cccctgggca	gtttggggac	ccatcaaggc	caggtggccg	gtgccaactg	3120
tgtgagtgca	gtgggaacat	tgacccaatg	gatcctgatg	cctgtgaccc	acacccggg	3180
caatgcctgc	gctgtttaca	ccacacagag	ggtccacact	gtgcccactc	gaagcctggc	3240
ttccatggcc	aggctgcccg	gcagagctgt	caccgctgca	catgcaacct	gctgggcaca	3300
aatccgcagc	agtgcccatc	tcctgaccag	tgccactgtg	atccaagcag	tgggcagtgc	3360
ccatgcctcc	ccaatgtcca	ggccctagct	gtagaccgct	gtgcccccaa	cttctggaac	3420
ctcaccagtg	gccatggttg	ccagccttgt	gcctgcctcc	caagcccgga	agaaggcccc	3480
acctgcaacg	agttcacagg	gcagtgccac	tgccctgtgcg	gctttggagg	gcggacttgt	3540
tctgagtgcc	aagagctcca	ctggggagac	cctgggttgc	agtgccatgc	ctgtgattgt	3600
gactctcgtg	gaatagatac	acctcagtgt	caccgcttca	caggtcactg	cacgtgccgc	3660



- 52 -

ccaggggtgt	ctggtgtgcg	ctgtgaccag	tgtgcccgtg	gcttctcagg	aatctttcct	3720
gcctgccatc	cctgccatgc	atgcttcggg	gattgggacc	gagtgggtgca	ggacttggca	3780
gcccgtacac	agcgcctaga	gcagcgggcg	caggagttgc	aacagacggg	tgtgctgggt	3840
gcctttgaga	gcagcttctg	gcacatgcag	gagaagctgg	gcattgtgca	gggcatcgta	3900
ggtgcccgc	acacctcagc	cgctccact	gcacagcttg	tggaggccac	agaggagctg	3960
cggcgtgaaa	ttggggaggc	cactgagcac	ctgactcagc	tcgaggcaga	cctgacagat	4020
gtgcaagatg	agaacttcaa	tgccaacccat	gcactaagtg	gtctggagcg	agataggctt	4080
gcacttaatc	tcacactgcg	gcagctcgac	cagcatcttg	acttgctcaa	acattcaaac	4140
ttcctgggtg	cctatgacag	catccggcat	gcccatagcc	agtctgcaga	ggcagaacgt	4200
cgtgccata	cctcagccct	ggcagtacct	agccctgtga	gcaactcggc	aagtgtcggg	4260
catcggacag	aggcactgat	ggatgctcag	aaggaggact	tcaacagcaa	acacatggcc	4320
aaccagcggg	cacttggcaa	gctctctgcc	catacccaca	ccctgagcct	gacagacata	4380
aatgagctgg	tgtgtggggc	ccagggattg	catcatgatc	gtacaagccc	ttgtgggggt	4440
gccggctgtc	gagatgagga	tgggcagccg	cgctgtgggg	gcctcagctg	caatggggca	4500
gcggctacag	cagacctagc	actggggccg	gcccggcaca	cacaggcaga	gctgcagcgg	4560
gcactggcag	aagggtgtag	catcctcagc	agagtggctg	agactcgtcg	gcaggcaagc	4620
gaggcacagc	agcgggcccc	ggcagccctg	gacaaggcta	atgcttccag	gggacagggt	4680
gaacaggcca	accaggaact	tcaagaactt	atccagagtg	tgaaggactt	cctcaaccag	4740
gagggggctg	atcctgatag	cattgaaatg	gtggccacac	gggtgctaga	gctctccatc	4800
ccagcttcag	ctgagcagat	ccagcacctg	gcgggcgcga	ttgcagagcg	agtccggagc	4860
ctggcagatg	tggatgcat	cctggcacgt	actgtaggag	atgtgcgtcg	tgccgagcag	4920
ctactgcagg	atgcacggcg	ggcaaggagc	tgggctgagg	atgagaaaca	gaaggcagag	4980
acagtacagg	cagcactgga	ggaggcccag	cgggcacagg	gtattgcccc	gggtgccatc	5040
cggggggcag	tggctgacac	acgggacaca	gagcagaccc	tgtaccaggt	acaggagagg	5100
atggcagggtg	cagagcgggc	actgagctct	gcagggtgaaa	gggctcggca	gttggtatgct	5160
ctcctggagg	ctctgaaatt	gaaacgggca	ggaaatagtc	tggcagcctc	tacagcagaa	5220
gaaacggcag	gcagtgcccc	gggtcgtgcc	caggaggctg	agcagctgct	acgcggtcct	5280
ctgggtgatc	agtaccagac	ggtgaaggcc	ctagctgagc	gcaaggcccc	aggtgtgctg	5340
gctgcacagg	caagggcaga	acaactgccg	gatgaggctc	gggacctgtt	gcaagccgct	5400
caggacaagc	tgcagcggct	acaggaattg	gaaggcacct	atgaggaaaa	tgagcgggca	5460

-53-

```

ctggagagta aggcagccca gttggacggg ttggaggcca ggatgcgcag cgtgcttcaa 5520
gccatcaact tgcagggtgca gatctacaac acctgccagt gacctctgcc caaggcctac 5580
cccagttcct agcactgccc cacatgcatg tctgcctatg cactgaagag ctcttggccc 5640
ggcagggccc ccaataaacc agtgtgaacc cccaaaaaaa aaa 5683

```

&lt;210&gt; 37

&lt;211&gt; 3714

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 37

```

ccgggttgct gtgcgactat tctccgggag ccgttcgtgt caccgccgga acctggcgca 60
ggttaattat agaaaatgcc aagtaggaaa tttgccgatg gtgaagtggc aagaggctga 120
tggcctggga gttcacttta ttatgaagta gaaattctga gccacgacag cacctcccag 180
ctttacactg tgaagtataa agatggaaca gagcttgaat tgaaagagaa tgatattaag 240
cctttaactt cctttaggca aaggaaaggt ggctcaactt ccagttcccc ttccagacgc 300
cgagggagtc gatcaaggtc acgctcccgga tcccctggtc gaccacctaa aagtgcccg 360
cgatctgctt ctgcttccca ccaggccgac attaaggaag caaggaggga agtggaagtt 420
aaattgactc cgctgattct gaagccattt ggaaatagca tcagcagata taatggggag 480
cctgagcata ttgagagaaa tgacgcacct cataaaaaata cacaggaaaa attcagtttg 540
tcacaagaaa gcagttacat agcaacacag tatagccttc gtccaagaag agaagaagtc 600
aaattaaaag aaatagattc taaggaagaa aaatacgttg caaaagaact ggcagtgaga 660
acctttgaag tgacccccat ccgggcaaag gacttgaggt ttggaggagt acctggtgtg 720
tttctcatca tgtttggcct gcctgtgttc ctcttcctgt tgctgttgat gtgtaaacag 780
aaagatccca gtcttctgaa tttccctcct cctttgccag ctttgtatga gttatgggaa 840
accagagtat ttgggggtcta cctcctgtgg tttttgattc aagtcctgtt ctacctactg 900
ccaattggaa aggttgtaga aggaacgcct cttattgatg gaagaagact caagtataga 960
ttaaatggat tctatccttt tctcctgaca tctgcagtca tcggaacatc tctcttccag 1020
ggcgtagagt ttcattacgt gtacagtcac tttcttcagt ttgcacttgc ggccactgtt 1080
ttttgtgtgg tcttgagtgt gtatctctac atgcgctctt tgaaagcgcc ccggaatgac 1140
ctgtcgcttg ccagctctgg aaatgctgtc tatgatttct tcattggccg tgaattaaac 1200
cctcgaattg gtacttttga tctcaaatac ttttgtgaat tgcgccccgg attgattgga 1260
tgggtgggta ttaacttggg gatgcttttg gctgaaatga aaatacagga ccgcgctgtt 1320

```

-54-

ccatccttgg	ccatgatttt	agttaatagt	ttccagcttc	tctatgtggt	ggatgctctc	1380
tggaaatgagg	aagcgttggt	gacgaccatg	gacatcatcc	acgatggatt	tggattcatg	1440
ctggccttttg	gagacttggt	gtgggttccc	tttatttaca	gcttccaagc	cttttattta	1500
gtcagtcatc	caaatgaagt	gtcttggcca	atggcttctc	taattattgt	tctgaaactt	1560
tgtggttatg	taatcttccg	aggtgcaa	at	tctcagaaaa	atgcattccg	1620
agtgatccaa	agcttgcaca	tttaaaaaacc	attcatactt	caagtggaaa	aaatcttcta	1680
gtttctggat	ggtggggctt	tgttcgccac	cccaattact	tgggtgatct	catcatggcc	1740
ttggcgtggt	ccctcccatg	tggttttaac	cacattctgc	cttatttcta	cataatttat	1800
ttcaccatgt	tgcttgtcca	ccgagaagct	cgtgacgagt	accactgtaa	gaagaaatac	1860
ggcgtggctt	gggaaaagta	ctgtcagcgt	gtgccctacc	gtatatttcc	atacatctac	1920
taatgctctt	ctggccttttc	tacaaaaatac	tcttgcaatt	ccagctgcca	tttgcaaaaa	1980
caggaaaaaa	atccgaaact	ttcttttggt	gcactgacag	ggtctgtact	tttttttttc	2040
tttttgagtc	aggactatgg	agccgagtag	ttgatctttt	aatatagccg	tgtttacttg	2100
tattaactta	cagttaacat	aggaaaaata	caagtaagga	tgtgagaatt	tgcattttta	2160
tgggaaaattt	tcaaccctta	atctgaaaac	agaagacagt	cttaataata	atgtactgtg	2220
aagaatgcta	ttgatgttta	tggtttctga	ttacttttca	aattttgatg	tttttttgcc	2280
agttggcttt	tcttaaatga	aaacactggt	ccattttaaag	tacatttatg	ttttattcag	2340
taagagaata	gaattttcat	ttgtttttct	ttaaatcctt	tactaattat	ataatttgaa	2400
agcaaaaaga	agggcctata	ttaaatgctg	aaagtgaaaa	gtgatgacat	tattagcaga	2460
cactgcttaa	aggagaccat	ttgtagcagt	tggcttaacc	tcaacttcta	aaactacatt	2520
gaaaatgtaa	atacatagct	tagttttttg	taatatatgg	tgacttcaga	tttttttgta	2580
cagtattttg	aatgtgagat	gattgtcagg	actaactgtc	tttttaacaa	aacattttca	2640
gtatttttaa	taaaattttg	taaagtaatg	tgaattaaaa	attttggaac	aattagaatt	2700
cattcactat	tgtatagaag	atgctgttaa	aacataggaa	gggtattttt	cttgatccaa	2760
agtttgtgaa	tttggctttg	ctacctcaat	tgcaggtggt	tgtttgcctt	tataaactgt	2820
tgcaaataga	aaaaaaatag	aataagtata	tattttttgga	gtaacatcaa	tatttaaaca	2880
tttttacaca	gatcgggtgt	tgaaaatttg	ccatttcagg	ctaataattt	tatatatttt	2940
tgacttttta	aaagttcatc	agtgtttttg	ctactgttaa	gcttatgcag	tttatactgt	3000
attttttatg	tatcctttat	atttaccaa	cctgactccc	tgtaaaggag	tgctgtctta	3060
aaaacaactg	aaggggttaa	agtcgtttct	tttagtttaa	tagatgtgca	taaggtagct	3120

-55-

```

ttagcaatta aattctagtg aagttgatat agtctcattt ttaattgtcc tgtaatggaa 3180
cagtagcaaaa ttactaaac ttttgtgttc agagttaa at tttctcagt actttcaatg 3240
taggggaatg taataaacat agtgtgtatg tttgggtttt aattacacat tttatatatg 3300
agccatttag atatgcagtg ttaattctat actgcatttg aagtgtatgt aacttagctt 3360
atgttaatgc agtcatgaag ttggtttgct ccagcatccg gtagtcttta aacattcttt 3420
tagtgaaatt gtcattgttt tatcagtgtc aatgtgtgca agcagttttt ttattttgct 3480
tttctcctgg catcagaaag tgggtggcgtt ttctgtactg gattgcacca aggaagcttt 3540
tggggaggaa ggaaggacat taaattcttt ccctggtaat gaaaagagcc ctttatcaat 3600
acagtgtgc aatttctgga tatcagctac actttgtttt taagtttggt tttgacatgt 3660
ttatttggca aattttataa tgaagtttta agttgaaaat aaaatgtagc aaca 3714

```

```

<210> 38
<211> 911
<212> DNA
<213> Homo Sapiens

```

```

<400> 38
tctatcccag gtcacagcta cttcttcaag ggtgcctatt acctgaagct ggagaaccaa 60
agtctgaaga gcgtgaagtt tggaagcatc aaatccgact ggctaggctg ctgagctggc 120
cctggctccc acaggccctt cctctccact gccttcgata caccgggcct ggagaactag 180
agaaggaccc ggaggggcct ggcagccgtg ccttcagctc tacagctaat cagcattctc 240
actcctacct ggtaatttaa gattccagag agtggctcct cccggtgccc aagaatagat 300
gctgactgta ctctcccag gcgccccttc cccctccaat ccaccaacc ctgagagcca 360
cccctaaaga gatcctttga tattttcaac gcagccctgc tttgggctgc cctgggtgtg 420
ccacacttca ggctcttctc ctttcacaac cttctgtggc tcacagaacc cttggagcca 480
atggagactg tctcaagagg gcactggtgg cccgacagcc tggcacaggg cagtgggaca 540
gggcatggcc aggtggccac tccagacccc tggcttttca ctgctggctg ccttagaacc 600
tttcttacat tagcagtttg ctttgtatgc actttgtttt tttctttggg tcttgttttt 660
tttttccact tagaaattgc atttcttgac agaaggactc aggttgtctg aagtcactgc 720
acagtgcac tcagcccaca tagtgatggg tcccctgttc actctactta gcatgtccct 780
accgagtctc ttctccactg gatggaggaa aaccaagccg tggcttcccg ctgagccctc 840
cctgcccctc ctttcaacca ttccccatgg gaaatgtcaa caagtatgaa taaagacacc 900
tactgagtgg c 911

```

-56-

<210> 39  
 <211> 1423  
 <212> DNA  
 <213> Homo Sapiens

<400> 39  
 ctccgctatc aacaacttat taaagaaaac ttgaaagaaa ttgccaagtt aatcacattg 60  
 gaacaaggga agaccctagc tgatgctgaa ggagatgtat ttcgaggcct tcaggtgggtt 120  
 gagcatgcct gtagtgtgac atccctcatg atgggagaga ccatgccatc catcaccaaa 180  
 gacatggacc tttattccta ccgtctgcct ctggggagtgt gtgcaggcat tgctccattc 240  
 aattttcctg ccatgatccc cctttggatg tttcccatgg ccatgggtgtg tggaaatacc 300  
 ttcctaataga aaccatctga gcgagtccct ggagcaacta tgcttcttgc taagttgctc 360  
 caggattctg gtgccctga tggaaacatta aacatcatcc atggacagca tgaagctgta 420  
 aattttatctt gcgatcatcc ggacatcaaa gcaatcagct ttgtgggato caacaaggca 480  
 ggagagtata tcttcgagag aggatcaaga catggcaaga gggttcaagc caatatggga 540  
 gccaagaacc atggggtagt catgccagat gccaataagg aaaataccct gaaccagctg 600  
 gttggggcag cattttggagc tgctgggtcag cgctgcatgg ctctttcaac agcagtcctt 660  
 gtgggagaag ccaagaagtg gctgccagag ctgggtggagc atgccaaaaa cctgagagtc 720  
 aatgcaggag atcagcctgg agctgatctt ggccctctga tcactcccca ggccaaagag 780  
 cgagtctgta atctgattga tagtggaaca aaggaggagg cttccatcct tcttgatgga 840  
 cgaaaaatta aagtgaagg ctatgaaaat ggcaactttg ttggaccaac catcatctcg 900  
 aatgtcaagc caaatatgac ctgttacaaa gaggagattt ttgggtccagt tcttggtggtt 960  
 ctggagacag aaacattgga tgaagccatc cagattgtaa ataacaacc atatggaaat 1020  
 ggaactgcca tcttcaccac caatggagcc actgctcgga aatatgcca cttggtggat 1080  
 gttggacagg tgggagtga tgtccccatt ccagtgcctt tgccaatggt ctcatcacc 1140  
 ggctctcgat cctccttcag gggagacacc aattttctatg gcaaacaggg catccaattc 1200  
 tacactcagt taaagaccat tactttctcag tggaaagaag aagatgctac tctttcctca 1260  
 cctgctgttg tcatgcctac catggggcgt tagaaacaag tttgtttaag actgactcca 1320  
 tctgagtaa tctcccttta tttttgacca gcttcatttg tcagctttgc tcagatcaga 1380  
 tcgatgggat tggaaatacat tgtaactaaa atcttaaaaa aaa 1423

<210> 40  
 <211> 5574  
 <212> DNA  
 <213> Homo Sapiens

-57-

<400> 40  
acgtactctg gcctcttctg cgtggtggtc aaccctata aacacctgcc catctactcg 60  
gagaagatcg tcgacatgta caagggcaag aagaggcacg agatgccgcc tcacatctac 120  
gccatcgcag acacggccta ccggagcatg cttcaagatc gggaggacca gtccattcta 180  
tgcacaggcg agtctggagc cgggaaaacc gaaaacacca agaaggcatc tcagtacctg 240  
gccgtggtgg cctcctccca caagggcaag aaagacacaa gtatcacggg agagctggaa 300  
aagcagcttc tacaagcaaa cccgattctg gaggctttcg gcaacgcaa aacagtgaag 360  
aacgacaact cctcacgatt cggcaaattc atccgcatca acttcgacgt cacgggttac 420  
atcgtgggag ccaacattga gacctatctg ctagaaaaat cacgggcaat tcgccaagcc 480  
agagacgaga ggacattcca catcttttac tacatgattg ctggagccaa ggagaagatg 540  
agaagtgact tgcttttggg gggcttcaac aactacacct tcctctccaa tggctttgtg 600  
cccatcccag cagcccagga tgatgagatg ttccaggaaa ccgtggaggc catggcaatc 660  
atgggtttca gcgaggagga gcagctatcc atattgaagg tggatcatc ggtcctgcag 720  
cttggaata tcgtcttcaa gaaggaaaga aacacagacc aggcgtccat gccagataac 780  
acagctgctc agaaagtttg ccacctcatg ggaattaatg tgacagattt caccagatcc 840  
atcctcactc ctcgtatcaa ggttgggcga gatgtggtac agaaagctca gacaaaagaa 900  
caggctgact ttgctgtaga ggctttggcc aaggcaacat atgagcgcct tttccgctgg 960  
atactcaccg gcgtgaacaa agccctggac aagacccatc ggcaaggggc ttccttcctg 1020  
gggatcctgg atatagctgg atttgagatc tttgaggtga actccttcga gcagctgtgc 1080  
atcaactaca ccaacgagaa gctgcagcag ctcttcaacc acaccatgtt catcctggag 1140  
caggaggagt accagcgcga gggcatcgag tggaaacttca tcgactttgg gctggacctc 1200  
cagccctgca tcgagctcat cgagcgaccg aacaaccctc caggtgtgct ggcctgctg 1260  
gacgaggaat gctggttccc caaagccacg gacaagtctt tcgtggagaa gctgtgcacg 1320  
gagcagggca gccaccccaa gttccagaag cccaagcagc tcaaggacaa gactgagttc 1380  
tccatcatcc attatgctgg gaaggtggac tataatgcga gtgcctggct gaccaagaat 1440  
atggacccgc tgaatgacaa cgtgacttcc ctgctcaatg cctcctccga caagtttgtg 1500  
gccgacctgt ggaaggacgt ggaccgcac gtgggcctgg accagatggc caagatgacg 1560  
gagagctcgc tgcccagcgc ctccaagacc aagaagggca tgttccgcac agtggggcag 1620  
ctgtacaagg agcagctggg caagctgatg accacgctac gcaacaccac gcccaacttc 1680  
gtgcgctgca tcatcccaaa ccacgagaag aggtccggca agctggatgc gttcctggtg 1740  
ctggagcagc tcggtgcaa tggggtgctg gaaggcattc gcctctgccg gcagggttc 1800

- 58 -

cccaaccgga	tcgtcttcca	ggagttccgc	caacgctacg	agatcctggc	ggcgaatgcc	1860
atccccaaaag	gcttcatgga	cgggaagcag	gcctgcattc	tcatgatcaa	agccctggaa	1920
cttgaccccca	acttatacag	gatagggcag	agcaaaatct	tcttccgaac	tggcgtcctg	1980
gcccacctag	aggaggagcg	agatttgaag	atcacccgatg	tcatcatggc	cttccaggcg	2040
atgtgtcgtg	gctacttggc	cagaaaggct	tttgccaaga	ggcagcagca	gctgaccgcc	2100
atgaagggtga	ttcagaggaa	ctgcgccgcc	tacctcaagc	tgcggaactg	gcagtgggtgg	2160
aggctttttca	ccaaagtga	gccactgctg	caggtgacac	ggcaggagga	ggagatgcag	2220
gccaaaggagg	atgaactgca	gaagaccaag	gagcggcagc	agaaggcaga	gaatgagctt	2280
aaggagctgg	aacagaagca	ctcgcagctg	accgaggaga	agaacctgct	acaggaacag	2340
ctgcaggcag	agacagagct	gtatgcagag	gctgaggaga	tgcgggtgcg	gctggcggcc	2400
aagaagcagg	agctggagga	gatactgcat	gagatggagg	ccgcctgga	ggaggaggaa	2460
gacagggggcc	agcagctaca	ggctgaaagg	aagaagatgg	cccagcagat	gctggacctt	2520
gaagaacagc	tggaggagga	ggaagctgcc	aggcagaagc	tgcaacttga	gaaggtcacg	2580
gctgaggcca	agatcaagaa	actggaggat	gagatcctgg	tcatggatga	tcagaacaat	2640
aaactatcaa	aagaacgaaa	actccttgag	gagaggatta	gtgacttaac	gacaaatctt	2700
gcagaagagg	aagaaaaggc	caagaatctt	accaagctga	aaaacaagca	tgaatctatg	2760
atttcagaac	tggaagtgcg	gctaaagaag	gaagagaaga	gccgacagga	gctggagaag	2820
ctgaaacgga	agctggaggg	tgatgccagc	gacttccacg	agcagatcgc	tgacctccag	2880
gcgcagatcg	cagagctcaa	gatgcagctg	gccaagaagg	aggaggagct	gcaggcggcc	2940
ctggccaggc	ttgacgatga	aatcgctcag	aagaacaatg	ccctgaagaa	gatccgggag	3000
ctggaggggcc	acatctcaga	cctccaggag	gacctggact	cagagcgggc	cgccaggaac	3060
aaggctgaaa	agcagaagcg	agacctcggc	gaggagctgg	aggccctaaa	gacagagctg	3120
gaagacacac	tggacagcac	agccactcag	caggagctca	gggccaagag	ggagcaggag	3180
gtgacggtgc	tgaagaaggc	cctggatgaa	gagacgcggt	cccatgaggc	tcaggtccag	3240
gagatgaggc	agaaacacgc	acaggcggtg	gaggagctca	cagagcagct	tgagcagttc	3300
aagaggggcca	aggcgaacct	agacaagaat	aagcagacgc	tggagaaaga	gaacgcagac	3360
ctggccggggg	agctgcgggt	cctgggccag	gccaagcagg	aggtggaaca	taagaagaag	3420
aagctggagg	cgcaggtgca	ggagctgcag	tccaagtgca	gcgatgggga	gcgggcccgg	3480
gcggagctca	atgacaaagt	ccacaagctg	cagaatgaag	ttgagagcgt	cacagggatg	3540
cttaacgagg	ccgaggggaa	ggccattaag	ctggccaagg	acgtggcgtc	cctcagttcc	3600

- 59 -

cagctccagg	acaccagga	gctgcttcaa	gaagaaaccc	ggcagaagct	caacgtgtct	3660
acgaagctgc	gccagctgga	ggaggagcgg	aacagcctgc	aagaccagct	ggacgaggag	3720
atggaggcca	agcagaacct	ggagcgccac	atctccactc	tcaacatcca	gctctccgac	3780
tccaagaaga	agctgcagga	ctttgccagc	accgtggaag	ctctggaaga	ggggaagaag	3840
aggttccaga	aggagatcga	gaacctcacc	cagcagtacg	aggagaaggc	ggccgcttat	3900
gataaactgg	aaaagaccaa	gaacaggctt	cagcaggagc	tggacgacct	ggttggtgat	3960
ttggacaacc	agcggcaact	cgtgtccaac	ctggaaaaga	agcagaggaa	atttgatcag	4020
ttgttagccg	aggagaaaaa	catctcttcc	aaatacgcgg	atgagaggga	cagagctgag	4080
gcagaagcca	gggagaagga	aaccaaggcc	ctgtccctgg	ctcgggccct	tgaagaggcc	4140
ttggaagcca	aagaggaact	cgagcggacc	aacaaaatgc	tcaaagccga	aatggaagac	4200
ctggtcagct	ccaaggatga	cgtgggcaag	aacgtccatg	agctggagaa	gtccaagcgg	4260
gccctggaga	cccagatgga	ggagatgaag	acgcagctgg	aagagctgga	ggacgagctg	4320
caagccacgg	aggacgcaa	actgcggctg	gaagtcaaca	tgcaggcgct	caagggccag	4380
ttcgaaaggg	atctccaagc	ccgggacgag	cagaatgagg	agaagaggag	gcaactgcag	4440
agacagcttc	acgagtatga	gacggaactg	gaagacgagc	gaaagcaacg	tgccctggca	4500
gctgcagcaa	agaagaagct	ggaaggggac	ctgaaagacc	tggagcttca	ggccgactct	4560
gccatcaagg	ggaggaggga	agccatcaag	cagctacgca	aactgcaggc	tcagatgaag	4620
gactttcaaa	gagagctgga	agatgcccg	gcctccagag	atgagatctt	tgccacagcc	4680
aaagagaatg	agaagaaagc	caagagcttg	gaagcagacc	tcatgcagct	acaagaggac	4740
ctcgccgccc	ctgagagggc	tgcgaaacaa	gcggacctcg	agaaggagga	actggcagag	4800
gagctggcca	gtagcctgtc	gggaaggaac	gcactccagg	acgagaagcg	ccgcctggag	4860
gcccggatcg	cccagctgga	ggaggagctg	gaggaggagc	agggcaacat	ggaggccatg	4920
agcgaccggg	tccgcaaagc	cacacagcag	gccgagcagc	tcagcaacga	gctggccaca	4980
gagcgagca	cggcccagaa	gaatgagagt	gcccggcagc	agctcgagcg	gcagaacaag	5040
gagctccgga	gcaagctcca	cgagatggag	ggggccgtca	agtccaagtt	caagtccacc	5100
atcgcgggcg	tggaggccaa	gattgcacag	ctggaggagc	aggtcgagca	ggaggccaga	5160
gagaaacagg	cggccaccaa	gtcgctgaag	cagaaagaca	agaagctgaa	ggaaatcttg	5220
ctgcaggtgg	aggacgagcg	caagatggcc	gagcagtaca	aggagcaggc	agagaaaggc	5280
aatgccaggg	tcaagcagct	caagaggcag	ctggaggagg	cagaggagga	gtcccagcgc	5340
atcaacgcca	accgcaggaa	gctgcagcgg	gagctggatg	aggccacgga	gagcaacgag	5400



- 60 -

gccatggggcc gcgaggtgaa cgcactcaag agcaagctca ggcgaggaaa cgagacctct 5460  
 ttcggttcctt ctagaaggctc tggaggacgt agagttattg aaaatgcaga tggttctgag 5520  
 gaggaaacgg acactcgaga cgcagacttc aatggaacca aggccagtga ataa 5574

<210> 41  
 <211> 5926  
 <212> DNA  
 <213> Homo Sapiens

<400> 41  
 ccggctgcct ctgctgcagt tcagagcaac ttcaggagct tcccagccga gagcttcagg 60  
 acgcctttcc tgtccactg gccagttgc cacaacaaac aacagagaag acggtgacca 120  
 tgggggatgt gaagctgggt gcctcgtcac acatttccaa aacctccctc agtgtggatc 180  
 cctcaagagt tgactccatg cccctgacag aggccccctgc tttcattttg ccccctcgga 240  
 acctctgcat caaagaagga gccaccgcca agttcgaagg gcgggtccgg gggtacccag 300  
 agccccaggt gacatggcac agaaacgggc aaccatcac cagcgggggc cgcttcctgc 360  
 tggattgcgg catccggggg actttcagcc ttgtgattca tgctgtccat gaggaggaca 420  
 ggggaaagta tacctgtgaa gccaccaatg gcagtgggtg tcgccaggtg acagtggagt 480  
 tgacagtaga aggaagtttt gcgaagcagc ttgggtcagcc tgttgtttcc aaaaccttag 540  
 gggatagatt ttcagcttca gcagtggaga cccgtcctag catctggggg gagtgcaccac 600  
 caaagtttgc taccaagctg ggccgagttg tgggtcaaaga aggacagatg ggacgattct 660  
 cctgcaagat cactggccgg ccccaaccgc aggtcacctg gctcaaggga aatgttccac 720  
 tgcagccgag tgcccgtgtg tctgtgtctg agaagaacgg catgcagggt ctggaaatcc 780  
 atggagtcaa ccaagatgac gtgggagtg acacgtgcct ggtggtgaac gggtcgggga 840  
 aggctcgat gtcagctgaa ctttccatcc aagggttga cagtgccaat aggtcatttg 900  
 tgagagaaac aaaagccacc aattcagatg tcaggaaaga ggtgaccaat gtaatctcaa 960  
 aggagtcgaa gctggacagt ctggaggctg cagccaaaag caagaactgc tccagcccc 1020  
 agagaggtgg ctccccaccc tgggctgcaa acagccagcc tcagccccca agggagtcca 1080  
 agctggagtc atgcaaggac tcgcccagaa cggccccgca gaccccggtc cttcagaaga 1140  
 cttccagctc catcaccctg caggccgcaa gagttcagcc ggaaccaaga gcaccaggcc 1200  
 tgggggtcct atcaccttct ggagaagaga ggaagaggcc agtcctccc cgtccagcca 1260  
 ccttccccac caggcagcct ggctgggga gccaatgtg tgtgagcaag gctgctaaca 1320  
 ggagaatccc catggagggc cagagggatt cagcattccc caaatgtgag agcaagcccc 1380

- 61 -

aaagccagga	ggtcaaggaa	aatcaaactg	tcaagttcag	atgtgaagtt	tccgggattc	1440
caaagcctga	agtggcctgg	ttcctggaag	gcacccccgt	gaggagacag	gaaggcagca	1500
ttgaggttta	tgaagatgct	ggctccatt	acctctgcct	gctgaaagcc	cggaccaggg	1560
acagtgggac	atacagctgc	actgcttcca	acgccaagg	ccaggtgtcc	tgtagctgga	1620
ccctccaagt	ggaaaggctt	gccgtgatgg	aggtggcccc	ctccttctcc	agtgtcctga	1680
aggactgcgc	tgttattgag	ggccaggatt	ttgtgctgca	gtgctccgta	cgggggaccc	1740
cagtgccccg	gatcacttgg	ctgctgaatg	ggcagcccat	ccagtacgct	cgtccacact	1800
gcgaggccgg	cgtggctgag	ctccacatcc	aggatgccct	gccggaggac	catggcacct	1860
acacctgcct	agctgagaat	gccttggggc	aggtgtcctg	cagcgcctgg	gtcacctgcc	1920
atgaaaagaa	gagtagcagg	aagagtgagt	accttctgcc	tgtggctccc	agcaagccca	1980
ctgcacccat	cttcctgcag	ggcctctctg	atctcaaagt	catggatgga	agccagggtca	2040
ctatgactgt	ccaagtgtca	gggaatccac	cccctgaagt	catctggctg	cacaatggga	2100
atgagatcca	agagtcagag	gacttccact	ttgaacagag	aggaactcag	cacagccttt	2160
ggatccagga	agtgttcccc	gaggacacgg	gcacgtacac	ctgcgaggcc	tggaacagcg	2220
ctggagaggt	ccgcacccag	gccgtgctca	cggtacaaga	gcctcacgat	ggcaccacgc	2280
cctggttcat	cagtaagcct	cgctcagtga	cagcctccct	gggccagagt	gtcctcatct	2340
cctgcgccat	agctggtgac	ccctttccta	ccgtgcactg	gctcagagat	ggcaaagccc	2400
tctgcaaaga	cactggccac	ttcgaggtgc	ttcagaatga	ggacgtgttc	accctgggtc	2460
taaagaaggt	gcagccctgg	catgccggcc	agtatgagat	cctgctcaag	aaccgggttg	2520
gcgaatgcag	ttgccaggtg	tactgatgac	tacagaacag	ctctgccaga	gcccttccac	2580
gggggagggg	gcctgccagc	tgcgaggacc	tctgtggtgg	aggagtgggt	gctgatgggtg	2640
gtggtagtga	ccgctatggg	tccctgaggg	ctggctggcc	agcaagaggg	caggggtggc	2700
tagaggagga	agacggcgag	gacgtgcgag	gggtgctgaa	gaggcgctg	gagacgaggc	2760
agcacactga	ggaggcgatc	cgccagcagg	aggtggagca	gctggacttc	cgagacctcc	2820
tggggaagaa	ggtgagtaca	aagaccctat	cggaagacga	cctgaaggag	atcccggccg	2880
agcagatgga	tttccgtgcc	aacctgcagc	ggcaagtga	gccaaagact	gtgtctgagg	2940
aagagaggaa	ggtgcacagc	ccccagcagg	tcgattttcg	ctctgtcctg	gccaagaagg	3000
ggacttccaa	gacccccgtg	cctgagaagg	tgccaccgcc	aaaacctgcc	accccggtt	3060
ttcgctcagt	gctgggtggc	aagaagaaat	taccagcaga	gaatggcagc	agcagtgccg	3120
agaccctgaa	tgccaaggca	gtggagagtt	ccaagcccct	gagcaatgca	cagccttcag	3180

- 62 -

ggcccttgaa	acccgtgggc	aacgccaagc	ctgctgagac	cctgaagcca	atgggcaacg	3240
ccaagcctgc	cgagaccctg	aagcccatgg	gcaatgcca	gcctgatgag	aacctgaaat	3300
ccgctagcaa	agaagaactc	aagaaagacg	ttaagaatga	tgtgaactgc	aagagaggcc	3360
atgcagggac	cacagataat	gaaaagagat	cagagagcca	ggggacagcc	ccagccttca	3420
agcagaagct	gcaagatggt	catgtggcag	agggcaagaa	gctgctgctc	cagtgccagg	3480
tgtcttctga	ccccccagcc	accatcatct	ggacgctgaa	tggaaagacc	ctcaagacca	3540
ccaagttcat	catcctctcc	caggaaggct	cactctgctc	cgctctccatc	gagaaggcac	3600
tgccctgagga	cagaggctta	tacaagtgtg	tagccaagaa	tgacgctggc	caggcgaggt	3660
gctcctgcca	agtcaccgtg	gatgatgctc	cagccagtga	gaacaccaag	gccccagaga	3720
tgaaatcccg	gaggcccaag	agctctcttc	ctcccgtgct	aggaactgag	agtgatgcga	3780
ctgtgaaaaa	gaaacctgcc	cccaagacac	ctccgaaggc	agcaatgcc	cctcagatca	3840
tccagttccc	tgaggaccag	aaggtacgcg	caggagagtc	agtggagctg	tttggcaaag	3900
tgacaggcac	tcagcccatc	acctgtacct	ggatgaagtt	ccgaaagcag	atccaggaaa	3960
gcgagcacat	gaaggtggag	aacagcgaga	atggcagcaa	gctcaccatc	ctggccgcgc	4020
gccaggagca	ctgcggctgc	tacacactgc	tggtggagaa	caagctgggc	agcaggcagg	4080
cccagggtcaa	cctcactgtc	gtggataagc	cagaccccc	agctggcaca	ccttgtgcct	4140
ctgacattcg	gagctcctca	ctgaccctgt	cctggtatgg	ctcctcatat	gatgggggca	4200
gtgctgtaca	gtcctacagc	atcgagatct	gggactcagc	caacaagacg	tggaaggaac	4260
tagccacatg	ccgcagcacc	tctttcaacg	tccaggacct	gctgcctgac	cacgaatata	4320
agttccgtgt	acgtgcaatc	aacgtgtatg	gaaccagtga	gccaagccag	gagtctgaac	4380
tcacaacggt	aggagagaaa	cctgaagagc	cgaaggatga	agtggaggtg	tcagatgatg	4440
atgagaagga	gcccagaggt	gattaccgga	cagtgacaat	caatactgaa	caaaaagtat	4500
ctgacttcta	cgacattgag	gagagattag	gatctgggaa	atttgacag	gtctttcgac	4560
ttgtagaaaa	gaaaactcga	aaagtctggg	cagggaagtt	cttcaaggca	tattcagcaa	4620
aagagaaaga	gaatatccgg	caggagatta	gcatcatgaa	ctgcctccac	caccctaagc	4680
tggtccagtg	tgtggatgcc	tttgaagaaa	aggccaacat	cgatcatggc	ctggagatcg	4740
tgtcaggagg	ggagctgttt	gagcgcacat	ttgacgagga	ctttgagctg	acggagcgtg	4800
agtgcacaa	gtacatgcgg	cagatctcgg	agggagtggg	gtacatccac	aagcagggca	4860
tcgtgcacct	ggacctcaag	ccggagaaca	tcatgtgtgt	caacaagacg	ggcaccagga	4920
tcaagctcat	cgactttggg	ctggccagga	ggctggagaa	tgcggggtct	ctgaagggtcc	4980

-63-

tctttggcac cccagaattt gtggctcctg aagtgatcaa ctatgagccc atcggtctacg 5040  
 ccacagacat gtggagcatc ggggtcatct gctacatcct agtcagtggc ctttccccct 5100  
 tcatgggaga caacgataac gaaaccttgg ccaacgttac ctcagccacc tgggacttcg 5160  
 acgacgaggc attcgatgag atctccgacg atgccaagga tttcatcagc aatctgctga 5220  
 agaaagatat gaaaaaccgc ctggactgca cgcagtgcct tcagcatcca tggctaataga 5280  
 aagataccaa gaacatggag gccaaagaaac tctccaagga ccggatgaag aagtacatgg 5340  
 caagaaggaa atggcagaaa acgggcaatg ctgtgagagc cattggaaga ctgtcctcta 5400  
 tggcaatgat ctcagggctc agtggcagga aatcctcaac agggtcacca accagcccgc 5460  
 tcaatgcaga aaaactagaa tctgaagaag atgtgtccca agctttcctt gaggctgttg 5520  
 ctgaggaaaa gcctcatgta aaacctatt tctctaagac cattcgcgat ttagaagttg 5580  
 tggaggggaag tgctgctaga tttgactgca agattgaagg ataccagac cccgagggtg 5640  
 tctggttcaa agatgaccag tcaatcaggg agtcccgcga cttccagata gactacgatg 5700  
 aggacgggaa ctgctcttta attattagtg atgtttgcgg ggatgacgat gccaaagtaca 5760  
 cctgcaaggc tgtcaacagt cttggagaag ccacctgcac agcagagctc attgtggaaa 5820  
 cgatggagga aggtgaaggg gaaggggaag aggaagaaga gtgaaacaaa gccagagaaa 5880  
 agcagtttct aagtcattt aaaaggacta tttctctcaa aatcca 5926

<210> 42  
 <211> 3705  
 <212> DNA  
 <213> Homo Sapiens

<400> 42  
 ggaattcccc gccgggcgca cccgcggggc cctgggctcg ctggcttgcg cgcagctgag 60  
 cggggtgtag gttggaaggg ccagggcccc tggggcgcaa gtgggggccc gcgccatgga 120  
 acccccgacc gtcccctcgg aaaggagcct gtctctgtca ctgcccgggc cccgggaggg 180  
 ccaggccacc ctgaagcctc cccgcagca cctgtggcgg cagcctcgga ccccatccg 240  
 tatccagcag cgcggtact ccgacagcgc ggagcgcgcc gagcgggagc ggcagccgca 300  
 ccggcccata gagcgcgccg atgccatgga caccagcgac cggcccggcc tgcgcacgac 360  
 ccgcatgtcc tggccctcgt ccttccatgg cactggcacc ggcagcggcg gcgcgggcgg 420  
 aggcagcagc aggcgcttcg aggcagagaa tgggccgaca ccatctcctg gccgcagccc 480  
 cctggactcg caggcgagcc caggactcgt gctgcacgcc ggggcggcca ccagccagcg 540  
 ccgggagtc ttcctgtacc gctcagacag cgactatgac atgtcaccca agaccatgtc 600  
 ccggaactca tcggtcacca gcgaggcgca cgctgaagac ctcacgttaa caccatttgc 660

-64-

tcaggtgctg gccagcctcc ggagcgctcc tagcaacttc tcactcctga ccaatgtgcc	720
cgttcccagt aacaagcggc ccccgctggg cggccccacc cctgtctgca aggccacgct	780
gtcagaagaa acgtgtcagc agttggcccg ggagactctg gaggagctgg actggtgtct	840
ggagcagctg gagaccatgc agacctatcg ctctgtcagc gagatggcct cgcacaagtt	900
caaaaggatg ttgaaccgtg agctcacaca cctgtcagaa atgagcaggt ccggaaacca	960
ggtctcagag tacatttcca caacattcct ggacaaacag aatgaagtgg agatcccatc	1020
acccacgatg aaggaacgag aaaaacagca agcgccgcga ccaagaccct ccagccgcc	1080
cccgccccct gtaccacact tacagcccat gtcccaaatac acaggggtga aaaagttgat	1140
gcatagtaac agcctgaaca actctaacaat tccccgattt ggggtgaaga ccgatcaaga	1200
agagctcctg gcccaagaac tggagaacct gaacaagtgg ggctgaaca tcttttgct	1260
gtcggattac gctggaggcc gctcactcac ctgcatcatg tacatgatat tccaggagcg	1320
ggacctgctg aagaaattcc gcatcccggt ggacacgatg gtgacataca tgctgacgct	1380
ggaggatcac taccacgctg acgtggccta ccataacagc ctgcacgcag ctgacgtgct	1440
gcagtccacc cacgtactgc tggccacgcc tgcactagat gcagtgttca cggacctgga	1500
gattctcgcc gccctcttcg cggtgccaat ccacgatgtg gatcacctg ggggtctcaa	1560
ccagttcctc atcaacacca attcggagct ggcgctcatg tacaacgatg agtcggtgct	1620
cgagaatcac cacctggccg tgggcttcaa gctgctgcag gaggacaact gcgacatctt	1680
ccagaacctc agcaagcgcc agcggcagag cctacgcaag atggctcatg acatggtgct	1740
ggccacggac atgtccaagc acatgaccct cctggctgac ctgaagacca tggaggagac	1800
caagaaagtg accagctcag gggctcctct gctagataac tactccgacc gcatccaggt	1860
cctccggaac atggtgcact gtgccgacct cagcaacccc accaagccgc tggagctgta	1920
ccgccagtgg acagaccgca tcatggccga gttcttccag cagggtgacc gagagcgca	1980
gcgtggcatg gaaatcagcc ccatgtgtga caagcacact gcctccgtgg agaagtctca	2040
ggtgggtttt attgactaca ttgtgcaccc attgtgggag acctgggagg accttgcca	2100
cccagatgcc caggagatct tggacacttt ggaggacaac cgggactggt actacagcgc	2160
catccggcag agcccatctc cgccaccgga ggaggagtca agggggccag gccaccacc	2220
cctgcctgac aagttccagt ttgagctgac gctggaggag gaagaggagg aagaaatata	2280
aatggcccag ataccgtgca cagcccaaga ggcattgact gcgcagggat tgtcaggagt	2340
cgaggaagct ctggatgcaa ccatagcctg ggaggcatcc ccggcccagg agtcgttggg	2400
agttatggca caggaagcat ccctggaggc cgagctggag gcagtgtatt tgacacagca	2460

- 65 -

```

ggcacagtcc acaggcagtg cacctgtggc tccggatgag ttctcgtccc gggaggaatt 2520
cgtggttgct gtaagccaca gcagccctc tgccttggct cttcaaagcc cctttctccc 2580
tgcttggagg accctgtctg tttcagagca tgccccgggc ctcccgggccc tcccctccac 2640
ggcggccgag gtggaggccc aacgagagca ccaggctgcc aagagggcctt gcagtgcctg 2700
cgcagggaca tttggggagg acacatccgc actcccagct cctggtggcg gggggtcagg 2760
tgagagacct acctgatccc cagacctctg tccctgttcc cctccactcc tcccctcact 2820
cccctgctcc cccgaccacc tctcctctctg cctcaaagac tcttgtcctc ttgtccctcc 2880
tgagaaaaaa gaaaacgaaa agtgggggttt ttttctgttt tctttttttc ccctttcccc 2940
ctgccccccac ccacggggcc ttttttttga ggtgggggct ggggaatgag gggctgaggt 3000
cccgaagga ttttatTTTT ttgaatttta attgtaacat ttttagaaaa agaacaaaaa 3060
aagaaaaaaa aaagaaagaa acacagcaac tgtagatgct cctgttcctg gttcccgcctt 3120
tccacttcca aatccctccc ctacacctcc cccactgcc cccaagttcc aggctcagtc 3180
ttccagccgc ctggggagtc tctacctggg cccaagcagg tgtggggcct ccttctgggc 3240
ttttcttctg aatttagagg atttctagaa cgtggtcagg aatagccatt ctaggcgggg 3300
ctggggccag ggtggggggc agtcactgtg ggagggtcca gctccagccc cctcttggtt 3360
tgctgcctcc tctcccctct aaaaaagtct tccgcttgat tttgcacaat cccggcgata 3420
ctcctggcga tactgactag aagtcaggga gctgggggag ctgttcactt taggatacgg 3480
ggggatggaa gggagcgttc acaccgccag cctcgggcct gggatttgag gagggcccta 3540
gacctcctcc actctccatc ccctttccct tccactttgg gttcactttg aattttctcc 3600
gttttttggg gcagtggctc tgatccactc accccccgc cccgtaagtt atagccactg 3660
tggaagtag tatgaaagtt cctcaagaaa ctaaaaatgg aattc 3705

```

```

<210> 43
<211> 3151
<212> DNA
<213> Homo Sapiens

```

```

<400> 43
ccggccagcg ggcgggctcc ccagccaggc cgctgcacct gtcaggggaa caagctggag 60
gagcaggacc ctagacctct gcagcccata ccaggctctca tggaggggaa caagctggag 120
gagcaggact ctagccctcc acagtccact ccagggtctca tgaaggggaa caagcgtgag 180
gagcaggggc tgggccccga acctgcgggc cccagcagc ccacggcgga ggaggaggcc 240
ctgatcgagt tccaccgctc ctaccgagag ctcttcgagt tcttctgcaa caacaccacc 300

```

- 66 -

atccacggcg	ccatccgcct	ggtgtgctcc	cagcacaacc	gcatgaagac	ggccttctgg	360
gcagtgtgt	ggctctgcac	ctttggcatg	atgtactggc	aattcggcct	gcttttcgga	420
gagtacttca	gctaccccg	cagcctcaac	atcaacctca	actcggacaa	gctcgtcttc	480
cccgcagtga	ccatctgcac	cctcaatccc	tacagggtacc	cggaaattaa	agaggagctg	540
gaggagctgg	accgcatcac	agagcagacg	ctctttgacc	tgtacaaata	cagctccttc	600
accactctcg	tggccggctc	ccgcagccgt	cgcgacctgc	gggggactct	gccgcacccc	660
ttgcagcgcc	tgagggctcc	gccccgcct	cacggggccc	gtcgagcccc	tagcgtggcc	720
tccagcttgc	gggacaacaa	cccccaggtg	gactggaagg	actggaagat	cggcttccag	780
ctgtgcaacc	agaacaaatc	ggactgcttc	taccagacat	actcatcagg	ggtggatgcg	840
gtgagggagt	ggtaccgctt	ccactacatc	aacatcctgt	cgaggctgcc	agagactctg	900
ccatccctgg	aggaggacac	gctgggcaac	ttcatcttcg	cctgccgctt	caaccaggtc	960
tcttgcaacc	aggcgaatta	ctctcacttc	caccacccga	tgtatggaaa	ctgctatact	1020
ttcaatgaca	agaacaactc	caacctctgg	atgtcttcca	tgcttggaat	caacaacggg	1080
ctgtccctga	tgctgcgcgc	agagcagaat	gacttcattc	ccctgctgtc	cacagtgact	1140
ggggcccggg	taatggtgca	cgggcaggat	gaacctgcct	ttatggatga	tgggtggcttt	1200
aacttgccgg	ctggcgtgga	gacctccatc	agcatgagga	aggaaaccct	ggacagactt	1260
gggggcgatt	atggcgactg	caccaagaat	ggcagtgatg	ttcctgttga	gaacctttac	1320
ccttcaaagt	acacacagca	ggtgtgtatt	cactcctgct	tccaggagag	catgatcaag	1380
gagtgtggct	gtgcctacat	cttctatccg	cggccccaga	acgtggagta	ctgtgactac	1440
agaaagcaca	gttcctgggg	gtactgctac	tataagctcc	aggttgactt	ctcctcagac	1500
cacctgggct	gtttcaccaa	gtgccggaag	ccatgcagcg	tgaccagcta	ccagctctct	1560
gctggttact	cacgatggcc	ctcggtgaca	tcccaggaat	gggtcttcca	gatgctatcg	1620
cgacagaaca	attacaccgt	caacaacaag	agaaatggag	tggccaaagt	caacatcttc	1680
ttcaaggagc	tgaactacaa	aaccaattct	gagtctccct	ctgtcacgat	ggtcaccctc	1740
ctgtccaacc	tgggcagcca	gtggagcctg	tggttcggct	cctcgggtgt	gtctgtggtg	1800
gagatggctg	agctcgtctt	tgacctgctg	gtcatcatgt	tcctcatgct	gctccgaagg	1860
ttccgaagcc	gatactggtc	tccaggccga	gggggcaggg	gtgctcagga	ggtagcctcc	1920
accctggcat	cctcccctcc	ttcccacttc	tgccccacc	ccatgtctct	gtccttgtcc	1980
cagccaggcc	ctgctccctc	tccagccttg	acagcccctc	cccctgccta	tgccaccctg	2040
ggcccccgcc	catctccagg	gggctctgca	ggggccagtt	cctccacctg	tcctctgggg	2100

-67-

```

gggccctgag agggaaggag aggtttctca caccaaggca gatgctcctc tgggtgggagg 2160
gtgctggccc tggcaagatt gaaggatgtg cagggcttcc tctcagagcc gcccaaactg 2220
ccgttgatgt gtggagggga agcaagatgg gtaagggctc aggaagttgc tccaagaaca 2280
gtagctgatg aagctgcccc gaagtgcctt ggctccagcc ctgtaccctt tgggtactgcc 2340
tctgaacact ctggtttccc caccctaactg cggctaagtc tctttttccc ttggatcagc 2400
caagcgaaac ttggagcttt gacaaggaac tttcctaaga aaccgctgat aaccaggaca 2460
aaacacaacc aagggtacac gcaggcatgc acgggtttcc tgcccagcga cggcttaagc 2520
cagcccccca ctggcctggc cactctgctc tccagtagca cagatgtctg ctctctctct 2580
tgaacttggg tgggaaaccc caccctaaag cccctttgt tacttaggca attccccttc 2640
cctgactccc gagggctagg gctagagcag acccgggtaa gttaaaggcag acccagggt 2700
cctctagcct cataccctg cctcacaga gccatgcccc ggcacctctg cctgtgtct 2760
ttcatacctc tacatgtctg cttgagatat ttctcagcc tgaaagtct cccaaccatc 2820
tgccagagaa ctctatgca tcccttagaa ccctgctcag acaccattac ttttgtgaac 2880
gcttctgcca catcttgtct tccccaaat tgatcactcc gccttctcct gggctcccgt 2940
agcacactat aacatctgct ggagtgttgc tgttgcaacca tactttcttg tacatttgtg 3000
tctcccttcc caactagact gtaagtgcct tgoggtcagg gactgaatct tgcccgttta 3060
tgtatgctcc atgtctagcc catcatcctg cttggagcaa gtaggcagga gctcaataaa 3120
tgtttgttgc atgaaaaaaaa aaaaaaaaaa a 3151

```

```

<210> 44
<211> 1172
<212> DNA
<213> Homo Sapiens

```

```

<400> 44
gagacattcc tcaattgctt agacatattc tgagcctaca gcagaggaac ctccagtctc 60
agcaccatga atcaaactgc gattctgatt tgctgcctta tctttctgac tctaagtggc 120
attcaaggag tacctctctc tagaaccgta cgctgtacct gcatcagcat tagtaatcaa 180
cctgttaatc caaggtcttt agaaaaactt gaaattattc ctgcaagcca attttgtcca 240
cgtgttgaga tcattgctac aatgaaaaag aagggtgaga agagatgtct gaatccagaa 300
tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctcct 360
taaaaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg 420
cctctcccat cacttcccta catggagtat atgtcaagcc ataattgttc ttagtttgca 480
gttacactaa aagggtgacca atgatggtca ccaaatacagc tgctactact cctgtaggaa 540

```



-68-

```

ggttaatgtt catcatccta agctattcag taataactct accctggcac tataatgtaa 600
gctctactga ggtgctatgt tcttagtgga tgttctgacc ctgcttcaaa tatttccctc 660
acctttccca tcttccaagg gtactaagga atctttctgc tttggggttt atcagaattc 720
tcagaatctc aaataactaa aaggatatgca atcaaactctg ctttttaaag aatgctcttt 780
acttcatgga cttccactgc catcctccca aggggcccac attctttcag tggtaccta 840
catacaattc caaacacata caggaaggta gaaatatctg aaaatgtatg tgtaagtatt 900
cttattttaat gaaagactgt acaaagtata agtcttagat gtatatattt cctatatattg 960
tttcagtgtg catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa 1020
ttttaaaaaat acagatagat atatgctctg catgttacat aagataaatg tgctgaatgg 1080
ttttcaaata aaaatgaggt actctcctgg aaatattaag aaagactatc taaatgttga 1140
aagatcaaaa ggttaataaa gtaattataa ct 1172

```

```

<210> 45
<211> 1044
<212> DNA
<213> Homo Sapiens

```

```

<400> 45
gaattccctg aggaggcgaa tccggcgggt atcagagcca tcagaaccgc caccatgacg 60
gtgggcaaga gcagcaagat gctgcagcat attgattaca ggatgaggtg catcctgcag 120
gacggccgga tcttcattgg caccttcaag gcttttgaca agcacatgaa tttgatcctc 180
tgtgactgtg atgagttcag aaagatcaag ccaaagaact ccaaacaagc agaaagggaa 240
gagaagcgag tcctcggctt ggtgctgctg cgaggggaga atctgggtctc aatgacagta 300
gagggacctc ctcccaaaga tactggtatt gctcgagttc cacttgctgg agctgccggg 360
ggcccaggga tcggcagggc tgctggcaga ggaatcccag ctgggggttc catgccccag 420
gctcctgcag gacttgctgg gccagtcctg ggggttggcg ggccatccca acaggtgatg 480
accccacaag gaagaggtac tgttgcagcc gctgcagctg ctgccacagc cagtattgcc 540
ggggctccaa ccagtagacc acctggcctg ggggttcctc cccacctat gggccgagga 600
gcacccccctc caggcatgat gggcccacct cctggtatga gacctcctat ggggtcccca 660
atggggatcc ccctggaag agggactcca atgggcatgc ccctccggg aatgcggcct 720
cctccccctg ggatgcgagg ccttctttga cccttgcca cagagtatgg aagtagctcc 780
gcagaggcgt gggctcgatt cctcagggcc acgttaccac agacctgttt gtttcttatg 840
ctgttgttcg tggagtctca tgggattgtc tggtttccct tacagggccc cctcccccg 900

```

-69-

gaatgcgccc	accaaggccc	tagactcatc	ttggccctcc	tcagctccct	gcctgtttcc	960
cgtaaggctg	tacatagtcc	ttttatctcc	ttgtggccta	tgaaactggg	ttataataaa	1020
ctcttaagag	aacattataa	ttgc				1044

<210> 46  
 <211> 2607  
 <212> DNA  
 <213> Homo Sapiens

<400> 46						
attaaacctc	tcgccgagcc	cctccgcaga	ctctgcgccc	gaaagtttca	tttgctgtat	60
gccatcctcg	agagctgtct	aggttaacgt	tcgcactctg	tgtatataac	ctcgacagtc	120
ttggcaccta	acgtgctgtg	cgtagctgct	cctttgggtg	aatccccagg	cccttggttg	180
ggcacaaggt	ggcaggatgt	ctcagtggta	cgaacttcag	cagcttgact	caaaattcct	240
ggagcaggtt	caccagcttt	atgatgacag	ttttcccatg	gaaatcagac	agtacctggc	300
acagtgggta	gaaaagcaag	actgggagca	cgctgccaat	gatgtttcat	ttgccaccat	360
ccgttttcat	gacctcctgt	cacagctgga	tgatcaatat	agtcgctttt	ccttgagaaa	420
taacttcttg	ctacagcata	acataaggaa	aagcaagcgt	aatcttcagg	ataattttca	480
ggaagaccca	atccagatgt	ctatgatcat	ttacagctgt	ctgaaggaag	aaaggaaaat	540
tctggaaaac	gccagagat	ttaatcaggc	tcagtcgggg	aatattcaga	gcacagtgat	600
gttagacaaa	cagaaagagc	ttgacagtaa	agtcagaaat	gtgaaggaca	aggttatgtg	660
tatagagcat	gaaatcaaga	gcctggaaga	tttacaagat	gaatatgact	tcaaattgcaa	720
aaccttgtag	aacagagaac	acgagaccaa	tggtgtggca	aagagtgatc	agaaacaaga	780
acagctgtta	ctcaagaaga	tgtattttaat	gcttgacaat	aagagaaagg	aagtagttca	840
caaaataata	gagttgctga	atgtcactga	acttaccag	aatgccctga	ttaatgatga	900
actagtggag	tggaagcgga	gacagcagag	cgctgtatt	ggggggccgc	ccaatgcttg	960
cttgtagcag	ctgcagaact	ggttcactat	agttgcggag	agtctgcagc	aagttcggca	1020
gcagcttaaa	aagttggagg	aattggaaca	gaaatacacc	tacgaacatg	accctatcac	1080
aaaaaataaa	caagtgttat	gggaccgcac	cttcagtctt	ttccagcagc	tcattcagag	1140
ctcgtttgtg	gtggaaagac	agccctgcat	gccaacgcac	cctcagaggg	cgctggtctt	1200
gaagacaggg	gtccagttca	ctgtgaagtt	gagactgttg	gtgaaattgc	aagagctgaa	1260
ttataatttg	aaagtcaaag	tcttatttga	taaagatgtg	aatgagagaa	atacagtaaa	1320
aggatttagg	aagttcaaca	ttttgggcac	gcacacaaaa	gtgatgaaca	tggaggagtc	1380
caccaatggc	agtctggcgg	ctgaatttcg	gcacctgcaa	ttgaaagaac	agaaaaatgc	1440

-70-

tggcaccaga	acgaatgagg	gtcctctcat	cgttactgaa	gagcttcact	cccttagttt	1500
tgaaacccaa	ttgtgccagc	ctggtttggg	aattgacctc	gagacgacct	ctctgcccgt	1560
tgtggtgatc	tccaacgtca	gccagctccc	gagcggttgg	gcctccatcc	tttggtacaa	1620
catgctgggtg	gcggaaccca	ggaatctgtc	cttcttctctg	actccaccat	gtgcacgatg	1680
ggctcagctt	tcagaagtgc	tgagttggca	gttttcttct	gtcaccaaaa	gaggtctcaa	1740
tgtggaccag	ctgaacatgt	tgggagagaa	gcttcttggg	cctaacgcca	gccccgatgg	1800
tctcattccg	tggacgaggt	tttgtaagga	aaatataaat	gataaaaatt	ttcccttctg	1860
gctttggatt	gaaagcatcc	tagaactcat	taaaaaacac	ctgctccctc	tctggaatga	1920
tgggtgcatc	atgggcttca	tcagcaagga	gcgagagcgt	gccctggtga	aggaccagca	1980
gccggggacc	ttcctgctgc	ggttcagtga	gagctcccgg	gaagggggcca	tcacattcac	2040
atgggtggag	cgggtcccaga	acggaggcga	acctgacttc	catgcggttg	aaccctacac	2100
gaagaaagaa	ctttctgctg	ttactttccc	tgacatcatt	cgcaattaca	aagtcattggc	2160
tgctgagaat	attcctgaga	atcccctgaa	gtatctgtat	ccaaatattg	acaaagacca	2220
tgcccttgga	aagtattact	ccaggccaaa	ggaagcacca	gagccaatgg	aacttgatgg	2280
ccctaaagga	actggatata	tcaagactga	gttgatttct	gtgtctgaag	tgtaagtga	2340
cacagaagag	tgacatgttt	acaaacctca	agccagcctt	gctcctgggt	ggggcctggt	2400
gaagatgctt	gtattttact	tttccattgt	aattgctatc	gccatcacag	ctgaacttgt	2460
tgagatcccc	gtgttactgc	ctatcagcat	tttactactt	taaaaaaaaa	aaaaaaagcc	2520
aaaaacccaa	tttgtattta	aggtatataa	attttcccaa	aactgatacc	ctttgaaaaa	2580
gtataaataa	aatgagcaaa	agttgaa				2607

&lt;210&gt; 47

&lt;211&gt; 5257

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 47

gaattccttt	tttttttgag	ctttaaataa	agcatttatt	catgagcgga	agcttacagt	60
ttgcatagat	tcttcatacc	ttatctggaa	gggcgatgga	aacccaagg	cactagagag	120
catcagaaga	aatcagtgac	atgatttgag	tagggctggg	ggactgggtc	cctgcacccc	180
agccacatcc	tatgggcctt	aggcccatat	tcggagaacg	agtccattgg	acaaagaaca	240
tggtgagag	accttctggg	ggccttgaag	aggccgcctc	cttgggtctcc	tcaaccccag	300
tgtaagtctg	gggaggccca	aggtgagggt	catgtatcgg	gatgaatgta	agaagcactt	360

- 71 -

ggcaggccttg	ggggcctttgg	ggctgggag	cctgatcact	gaactcacgg	caaatgaaga	420
attgaccggg	actgacgggtg	ccttggtaaa	tgatgaagg	tgggttagga	gtacagaaga	480
tgctgtggac	tattcagaca	tcaatgaggt	ggcagaagat	gaaagccgaa	gataccagca	540
gacgatgggg	agcttgacgc	ccctttgcc	ctcagattat	gatgaagatg	actatgatgc	600
tgattgtgaa	gacattgatt	gcaagttgat	gcctcctcca	cctccacccc	cgggaccaat	660
gaagaaggat	aaggaccagg	attctattac	tggtgagaaa	gtggacttca	gtagtctctc	720
tgactcagaa	tctgagatgg	gacctcagga	agcaacacag	gcagaatctg	aagatggaaa	780
gctgaccctt	ccattggctg	ggattatgca	gcatgatgcc	accaagctgt	tgccaagtgt	840
cacagaactt	tttccagaat	ttcgacctgg	aaagggtgta	cgttttctac	gtcttttttg	900
accaggggag	aatgtcccat	ctgtttggcg	gagtgtctcg	agaaagagga	agaagaagca	960
ccgtgagctg	atacaggaag	agcagatcca	ggaggtggag	tgctcagtag	aatcagaagt	1020
cagccagaag	tctttgtgga	actacgacta	cgctccacca	ccacctccag	agcagtgtct	1080
ctctgatgat	gaaatcacga	tgatggctcc	tgtggagtcc	aaattttccc	aatcaactgg	1140
agatatagat	aaagtgcag	ataccaaacc	aagagtggct	gagtggcggt	atgggcctgc	1200
ccgactgtgg	tatgatatgc	tgggtgtccc	tgaagatggc	agtgggtttg	actatggctt	1260
caaactgaga	aagacagaac	atgaacctgt	gataaaatct	agaatgatag	aggaatttag	1320
gaaacttgag	gaaaacaatg	gcactgatct	tctggctgat	gaaaacttcc	tgatgggtgac	1380
acagctgcat	tgggaggatg	atatcatctg	ggatggggag	gatgtcaaac	acaaagggac	1440
aaaacctcag	cgtgcaagcc	tggcaggctg	gcttccttct	agcatgacta	ggaatgcat	1500
ggcttacaat	gttcagcaag	gttttgcagc	cactcttgat	gatgacaaac	cttgggtactc	1560
catttttccc	attgacaatg	aggatctggg	atatggacgc	tgggaggaca	atatcatttg	1620
ggatgctcag	gccatgcccc	ggctgttgga	acctcctgtt	ttgacacttg	atcccaatga	1680
tgagaacctc	atttttgaaa	ttcctgatga	gaaggaagag	gccacctcta	actccccctc	1740
caaggagagt	aagaaggaat	catctctgaa	gaagagtcga	attctcttag	ggaaaacagg	1800
agtcatacaag	gaggaaccac	agcagaacat	gtctcagcca	gaagtgaag	atccatggaa	1860
tctctccaat	gatgagtatt	attatcccaa	gcaacagggt	cttcgaggca	cctttggagg	1920
gaatattatc	cagcattcaa	ttcctgctgt	ggaattacgg	cagcccttct	ttcccaccca	1980
catggggccc	atcaaactcc	ggcagttcca	tcgcccacct	ctgaaaaagt	actcatttgg	2040
tgcactttct	cagccagggtc	cccactcagt	ccaacctttg	ctaaagcaca	tcaaaaaaaaa	2100
ggccaagatg	agagaacaag	agaggcaagc	ttcagggtgg	ggagagatgt	tttttatgcg	2160

- 72 -

cacacctcag	gacctcacag	gcaaagatgg	tgatcttatt	cttgcagaat	atagtgagga	2220
aaatggaccc	ttaatgatgc	aggttggcat	ggcaaccaag	ataaagaact	attataaacg	2280
gaaacctgga	aaagatcctg	gagcaccaga	ttgtaaatat	ggggaaactg	tttactgcc	2340
tacatctcct	ttcctgggtt	ctctccatcc	tggccaattg	ctgcaagcat	ttgagaacaa	2400
cctttttcgt	gctccaattt	atcttcataa	gatgccagaa	actgatttct	tgatcattcg	2460
gacaagacag	ggttactata	ttcgggaatt	agtggatatt	tttgtgggtg	gccagcagtg	2520
tcccttgttt	gaagttcctg	ggcctaactc	caaaagggcc	aatacgcata	ttcgagactt	2580
tctacagggt	tttatttacc	gccttttctg	gaaaagtaaa	gatcggccac	ggaggatacg	2640
aatggaagat	ataaaaaaag	cctttccttc	ccattcagaa	agcagcatcc	ggaagaggct	2700
aaagctctgc	gctgacttca	aacgcacagg	gatggactca	aactgggtggg	tgcttaagtc	2760
tgattttcgt	ttaccaacgg	aagaagagat	cagagctatg	gtgtcaccag	agcagtgtg	2820
tgcttattat	agcatgatag	ctgcagagca	acgactgaag	gatgctggct	atggtgagaa	2880
atcctttttt	gctccagaag	aagaaaatga	ggaagatttc	cagatgaaga	ttgatgatga	2940
agttcgcact	gccccttgg	acaccacaag	ggccttcatt	gctgccatga	agggcaagtg	3000
tctgctagag	gtgactgggg	tggcagatcc	cacgggggtg	ggtgaaggat	tctcctatgt	3060
gaagattcca	aacaaaccaa	cacagcagaa	ggatgataaa	gaaccgcagc	cagtgaagaa	3120
gacagtgaca	ggaacagatg	cagaccttcg	tcgcctttcc	ctgaaaaatg	ccaagcaact	3180
tctacgtaaa	tttggtgtgc	ctgaggaaga	gattaaaaag	ttgtcccgt	gggaagtgat	3240
tgatgtgggtg	cgcacaatgt	caacagaaca	ggctcgttct	ggagaggggc	ccatgagtaa	3300
atgtgccgt	ggatcaaggt	tttctgtggc	tgagcatcaa	gagcgttaca	aagaggaatg	3360
tcagcgcata	tttgacctac	agaacaaggt	tctgtcatca	actgaagtct	tatcaactga	3420
cacagacagc	agctcagctg	aagatagtga	ctttgaagaa	atgggaaaga	acattgagaa	3480
catgttgcag	aacaagaaaa	ccagctctca	gctttcacgt	gaacgggagg	aacaggagcg	3540
gaaggaacta	cagcgaatgc	tactggcagc	aggctcagca	gcatccggaa	acaatcacag	3600
agatgatgac	acagcttccg	tgactagcct	taactcttct	gccactggac	gctgtctcaa	3660
gatttatcgc	acgtttcag	atgaagaggg	gaaagagtat	gttcgctgtg	agacagtccg	3720
aaaaccagct	gtcattgatg	cctatgtgcg	catacggact	acaaaagatg	aggaattcat	3780
tcgaaaattt	gcccctttttg	atgaacaaca	tcgggaagag	atgcgaaaag	aacggcggag	3840
gattcaagag	caactgaggc	ggcttaagag	gaaccaggaa	aaggagaagc	ttaaggggtcc	3900
tcctgagaag	aagcccaaga	aatgaagga	gcgtcctgac	ctaaaactga	aatgtggggc	3960

-73-

atgtggtgcc attggacaca tgaggactaa caaattctgc cccctctatt atcaaacaaa 4020  
 tgcgccacct tccaaccctg ttgccatgac agaagaacag gaggaggagt tggaaaagac 4080  
 agtcattcat aatgataatg aagaacttat caagggtgaa gggaccacaaa ttgtcttggg 4140  
 gaaacagcta attgagagtg cggatgaggt tcgcagaaaa tctctggttc tcaagtttcc 4200  
 taaacagcag cttcctccaa agaagaaacg gcgagttgga accactgttc actgtgacta 4260  
 tttgaataga cctcataagt ccatccaccg gcgccgcaca gaccctatgg tgacgctgtc 4320  
 gtccatcttg gagtctatca tcaatgacat gagagatctt ccaaatacat accctttcca 4380  
 cactccagtc aatgcaaagg ttgtaaagga ctactacaaa atcatcactc ggccaatgga 4440  
 cctacaaaaca ctccgcgaaa acgtgcgtaa acgcctctac ccatctcggg aagagttcag 4500  
 agagcatctg gagctaattg tgaaaaatag tgcaacctac aatgggcca aacactcatt 4560  
 gactcagatc tctcaatcca tgctggatct ctgtgatgaa aaactcaaag agaaagaaga 4620  
 caaattagct cgcttagaga aagctatcaa ccccttgctg gatgatgatg accaagtggc 4680  
 gttttctttc attctggaca acattgtcac ccagaaaatg atggcagttc cagattcttg 4740  
 gccatttcat caccagtta ataagaaatt tgttccagat tattacaaag tgattgtcaa 4800  
 tccaatggat ttagagacca tacgtaagaa catctccaag cacaagtatc agagtccgga 4860  
 gagctttctg gatgatgtaa accttattct ggccaacagt gttaagtata atgacaatga 4920  
 gtgttcatct aaagcaaagtg acatagtttg cctaattccag tactgtagtt cacagataga 4980  
 agaattaaga ttttaatggg acggtgattt gccagcagtc cctactgaat ttcttaatta 5040  
 agatttgtgc ccaactgtcc tgggtctctaa actggtgtca tgtttcctcc ttattccatc 5100  
 atgtccctga tcatagcctg ccaatctgga tgtagaactc tctgctgctc tcctggaatg 5160  
 atgtctacct gcatgctgcc atgcctcca ccatgacaat aattgactga agctctgaac 5220  
 tgtaaggcag cccaattaa atgctttcct ttatag 5257

<210> 48  
 <211> 1174  
 <212> DNA  
 <213> Homo Sapiens

<400> 48  
 gcctgtccac catctcccta ttaccctttg gtogagaggg aaagcagaag aagtctgctg 60  
 gtcacacggg ggcacctcga ggagaggacg actaggagca cacggcccgg aaaggtccag 120  
 gtcaggggaag ggaataactg tgcttgaaga agaaaattcc caacatggac aaaccacgca 180  
 aagaaaatga agaagagccg cagagccgcc caagaccgat gaggagaggc ctccggtgga 240  
 gcactctccc gaaaagcagt cccccgagga gcagtcttcg gaggagcagt cctcggagga 300

-74-

```

ggagttcttt cctgaggagc tcttgccctga gctcctgcct gagatgctcc tctcggagga 360
ctccctccgc aggtctttcc aggaaggacc tgtttgaggt tcgccctccc atggagcagc 420
ctccttgttg agtaggaaaa cataaccttg aagaaggaat ctttaaagaa aggttggctc 480
gttctcgcgc gcaattttaga ggggacatac atggcagaaa tttaagcaat gaggagatga 540
tacaggcagc agatgagcta gaagagatga aaagagtaag aaacaaactg atgataatgc 600
actggagggc aaaacggggc ggtccttata ctatttaatg tgttcggcct ttaattctgt 660
tttgccctgt atagtattgc cattgccacc tggactttct gtttgcattt tcttaatgcc 720
ttttccctat ttctgaattt taactttttg tgaggcttta ttttagatgt ttagcatgta 780
actcgcttaa agttgaggtt tccccctaaa atctacaagt ttccctcttt cagtcatgag 840
ccctacacat ttgcatgaaa gatgtacata tatattgtga acgaaaaaag caattttcaa 900
atggtatata tgtatcccat tttgtaaaaa atgtatatta tatattaata tgcaaagaaa 960
aagctaaaag tatagacttc aaaggcataa cagtggttgt gtggaagat ataggtgatt 1020
ttttaaattt ttgttttata tgaatttctc attttttcag gacaaacgtt ttacttgtgt 1080
tgcaaaaata tataatgaaa aaatcacaca attttgaaga aaactgtcaa tcagcttata 1140
acgacaatgt ggcacttaat aaatacttgt cagg 1174

```

```

<210> 49
<211> 1569
<212> DNA
<213> Homo Sapiens

```

```

<400> 49
caaaatctca accatgatct tgagatggca aaggttttta atacgttttg gaaatatact 60
cattggtata tttcttttga gaaggctgaa atgtagctgg ggacagcagg ttgatcacia 120
gggacgatga tatgaggtaa gcacacaaga gctatggaca agacaaggtc taaaggattt 180
tgaatacaaa gcagaaatat ttcgaccttc tcatttctgg ggtgggagtg gggagtgttc 240
attaagtaca tatgacaaga gggagtgtgg ggagaagggtg aaacagtaga ctacatttat 300
ggattaagta gggaatgtga acaaagatgt taaagtcatg gcgatccggt agacagatta 360
cacagaaggg gaccgaagat gaactggaca aatactctga ggctctcaa gatgccagg 420
agaagctgga gctggcagag aaaaaggcca ccgatgctga agccgacgta gcttctctga 480
acagacgcat ccagctggtt gaggaagagt tggatcgtgc ccaggagcgt ctggcaacag 540
ctttgcagaa gctggaggaa gctgagaagg cagcagatga gagtgagaga ggcatgaaag 600
tcattgagag tcgagcccaa aaagatgaag aaaaaatgga aattcaggag atccaactga 660

```

-75-

```

aagaggccaa gcacattgct gaagatgccg accgcaaata tgaagaggtg gcccgtaagc 720
tggtcatcat tgagagcgac ctggaacgtg cagaggagcg ggctgagctc tcagaaggcc 780
aagtccgaca gctggaagaa caattaagaa taatggatca gaccttgaaa gcattaatgg 840
ctgcagagga taagtactcg cagaaggaag acagatatga ggaagagatc aaggtccttt 900
ccgacaagct gaaggaggct gagactcggg ctgagtttgc ggagaggtca gtaactaaat 960
tggagaaaag cattgatgac ttagaagaga aagtgctcat gccaaagaag aaaaccttag 1020
tatgcatcag atgctggatc agactttact ggagttaaac aacatgtgaa aacctcctta 1080
gctgcgacca cattctttca ttttggtttg ttttggtttg tttttaaaca cctgcttacc 1140
ccttaaatgc aatttattta cttttaccac tgtcacagaa acatccacaa gataccagct 1200
aggtcagggg gtggggaaaa cacatacaaa aagcaagccc atgtcagggc gatcctgggt 1260
caaatgtgcc atttcccggg ttgatgctgc cacactttgt agagagttta gcaacacagt 1320
gtgcttagtc agtgtaggaa tcctcactaa agcagaagaa gttccattcc tttctgattg 1380
gcacacgtgc agctcatgac aatctgtagg ataacaatca gtgtggattt ccactctttt 1440
cagtccttca tgtaaagat ttagacacca catacaactg gtaaaggacg ttttcttgag 1500
agttttaact atatgtaaac attgtataat gatatggaat aaaatgcaca ttttaggaca 1560
ttttctaaa 1569

```

```

<210> 50
<211> 1081
<212> DNA
<213> Homo Sapiens

```

```

<400> 50
gctgcccgtc ctggcgagcc ggcgctacgc ggcccctgcc ccaggccagg ccctgcagcg 60
agtgggcata gttgggggtc aggaggcccc caggagcaag tggccctggc aggtgagcct 120
gagagtccgc gaccgatact ggatgcactt ctgcgggggc tccctcatcc acccccagtg 180
ggtgctgacc gcagcgact gcgtgggacc ggacgtcaag gatctggccg ccctcagggt 240
gcaactgcgg gagcagcacc tctactacca ggaccagctg ctgccggtca gcaggatcat 300
cgtgcaccca cagttctaca ccgcccagat cggagcggac atcgccctgc tggagctgga 360
ggagccgggtg aaggtctcca gccacgtcca cacggtcacc ctgccccctg cctcagagac 420
cttccccccg gggatgccgt gctgggtcac tggctggggc gatgtggaca atgatgagcg 480
cctcccaccg ccatttcctc tgaagcaggt gaagggtccc ataatggaaa accacatttg 540
tgacgcaaaa taccaccttg ggcgctacac gggagacgac gtccgcatcg tccgtgacga 600
catgctgtgt gccgggaaca cccggagggg ctcattgccag ggcgactccg gagggcccct 660

```



-76-

```

gggtgtgcaag gtgaatggca cctgggtgca ggcgggctg gtcagctggg gcgagggctg 720
tgcccagccc aaccggcctg gcctctacac ccgtgtcacc tactacttgg actggatcca 780
ccactatgtc cccaaaaagc cgtgagtcag gcctgggggtg tccacctggg tccactggagg 840
accagcccct cctgtccaaa acaccactgc ttccctacca ggcggcgact gccccccaca 900
ccttccctgc cccgtcctga gtgccccttc ctgtcctaag cccctgctc tcttctgagc 960
cccttccctc gtctgagga cccttcccca tctgagccc ccttccctgt cctaagcctg 1020
acgcctgcac cgggccctcc ggccctcccc tgcccaggca gctgggtggg ggcgctaatac 1080
c 1081

```

```

<210> 51
<211> 783
<212> DNA
<213> Homo Sapiens

```

```

<400> 51
ggcacgagcg agttcctgtc tctctgccaa cgccgcccgg atggcttccc aaaaccgcca 60
cccagccgcc actagcgtcg ccgccgcccg taaaggagct gagccgagcg ggggcgcccgc 120
ccgggggtccg gtgggcaaaa ggctacagca ggagctgatg accctcatga tgtctggcga 180
taaagggatt tctgccttcc ctgaatcaga caaccttttc aaatgggtag ggaccatcca 240
tggagcagct ggaacagtat atgaagacct gaggtataag ctctcgctag agttccccag 300
tggtaccct tacaatgcgc ccacagtga gttcctcacg ccctgctatc accccaacgt 360
ggacaccag ggtaacatat gcctggacat cctgaaggaa aagtgggtctg ccctgtatga 420
tgtcaggacc attctgtctc ccatccagag ccttctagga gaaccaaca ttgatagtcc 480
cttgaacaca catgctgccg agctctggaa aaaccccaca gcttttaaga agtacctgca 540
agaaacctac tcaaagcagg tcaccagcca ggagccctga ccaggctgc ccagcctgtc 600
cttgtgtcgt ctttttaatt ttcccttaga tggctctgtc tttttgtgat ttctgtatag 660
gactctttat cttgagctgt ggtatTTTTTg ttttgttttt gtcttttaaa ttaagcctcg 720
gttgagccct tgtatattaa ataaatgcat ttttgtcctt ttttaaaaaa aaaaaaaaaa 780
aaa 783

```

```

<210> 52
<211> 808
<212> PRT
<213> Homo Sapiens

```

```

<400> 52

```

-77-

Met Ala Glu Leu Leu Ala Ser Ala Gly Ser Ala Cys Ser Trp Asp Phe  
 1 5 10 15  
 Pro Arg Ala Pro Pro Ser Phe Pro Pro Pro Ala Ala Ser Arg Gly Gly  
 20 25 30  
 Leu Gly Gly Thr Arg Ser Phe Arg Pro His Arg Gly Ala Glu Ser Pro  
 35 40 45  
 Arg Pro Gly Arg Asp Arg Asp Gly Val Arg Val Pro Met Ala Ser Ser  
 50 55 60  
 Arg Cys Pro Ala Pro Arg Gly Cys Arg Cys Leu Pro Gly Ala Ser Leu  
 65 70 75 80  
 Ala Trp Leu Gly Thr Val Leu Leu Leu Leu Ala Asp Trp Val Leu Leu  
 85 90 95  
 Arg Thr Ala Leu Pro Arg Ile Phe Ser Leu Leu Val Pro Thr Ala Leu  
 100 105 110  
 Pro Leu Leu Arg Val Trp Ala Val Gly Leu Ser Arg Trp Ala Val Leu  
 115 120 125  
 Trp Leu Gly Ala Cys Gly Val Leu Arg Ala Thr Val Gly Ser Lys Ser  
 130 135 140  
 Glu Asn Ala Gly Ala Gln Gly Trp Leu Ala Ala Leu Lys Pro Leu Ala  
 145 150 155 160  
 Ala Ala Leu Gly Leu Ala Leu Pro Gly Leu Ala Leu Phe Arg Glu Leu  
 165 170 175  
 Ile Ser Trp Gly Ala Pro Gly Ser Ala Asp Ser Thr Arg Leu Leu His  
 180 185 190  
 Trp Gly Ser His Pro Thr Ala Phe Val Val Ser Tyr Ala Ala Ala Leu  
 195 200 205  
 Pro Ala Ala Ala Leu Trp His Lys Leu Gly Ser Leu Trp Val Pro Gly  
 210 215 220  
 Gly Gln Gly Gly Ser Gly Asn Pro Val Arg Arg Leu Leu Gly Cys Leu  
 225 230 235 240  
 Gly Ser Glu Thr Arg Arg Leu Ser Leu Phe Leu Val Leu Val Val Leu  
 245 250 255  
 Ser Ser Leu Gly Glu Met Ala Ile Pro Phe Phe Thr Gly Arg Leu Thr  
 260 265 270  
 Asp Trp Ile Leu Gln Asp Gly Ser Ala Asp Thr Phe Thr Arg Asn Leu  
 275 280 285  
 Thr Leu Met Ser Ile Leu Thr Ile Ala Ser Ala Val Leu Glu Phe Val  
 290 295 300  
 Gly Asp Gly Ile Tyr Asn Asn Thr Met Gly His Val His Ser His Leu  
 305 310 315 320

-78-

Gln Gly Glu Val Phe Gly Ala Val Leu Arg Gln Glu Thr Glu Phe Phe  
 325 330 335  
 Gln Gln Asn Gln Thr Gly Asn Ile Met Ser Arg Val Thr Glu Asp Thr  
 340 345 350  
 Ser Thr Leu Ser Asp Ser Leu Ser Glu Asn Leu Ser Leu Phe Leu Trp  
 355 360 365  
 Tyr Leu Val Arg Gly Leu Cys Leu Leu Gly Ile Met Leu Trp Gly Ser  
 370 375 380  
 Val Ser Leu Thr Met Val Thr Leu Ile Thr Leu Pro Leu Leu Phe Leu  
 385 390 395 400  
 Leu Pro Lys Lys Val Gly Lys Trp Tyr Gln Leu Leu Glu Val Gln Val  
 405 410 415  
 Arg Glu Ser Leu Ala Lys Ser Ser Gln Val Ala Ile Glu Ala Leu Ser  
 420 425 430  
 Ala Met Pro Thr Val Arg Ser Phe Ala Asn Glu Glu Gly Glu Ala Gln  
 435 440 445  
 Lys Phe Arg Glu Lys Leu Gln Glu Ile Lys Thr Leu Asn Gln Lys Glu  
 450 455 460  
 Ala Val Ala Tyr Ala Val Asn Ser Trp Thr Thr Ser Ile Ser Gly Met  
 465 470 475 480  
 Leu Leu Lys Val Gly Ile Leu Tyr Ile Gly Gly Gln Leu Val Thr Ser  
 485 490 495  
 Gly Ala Val Ser Ser Gly Asn Leu Val Thr Phe Val Leu Tyr Gln Met  
 500 505 510  
 Gln Phe Thr Gln Ala Val Glu Val Leu Leu Ser Ile Tyr Pro Arg Val  
 515 520 525  
 Gln Lys Ala Val Gly Ser Ser Glu Lys Ile Phe Glu Tyr Leu Asp Arg  
 530 535 540  
 Thr Pro Arg Cys Pro Pro Ser Gly Leu Leu Thr Pro Leu His Leu Glu  
 545 550 555 560  
 Gly Leu Val Gln Phe Gln Asp Val Ser Phe Ala Tyr Pro Asn Arg Pro  
 565 570 575  
 Asp Val Leu Val Leu Gln Gly Leu Thr Phe Thr Leu Arg Pro Gly Glu  
 580 585 590  
 Val Thr Ala Leu Val Gly Pro Asn Gly Ser Gly Lys Ser Thr Val Ala  
 595 600 605  
 Ala Leu Leu Gln Asn Leu Tyr Gln Pro Thr Gly Gly Gln Leu Leu Leu  
 610 615 620  
 Asp Gly Lys Pro Leu Pro Gln Tyr Glu His Arg Tyr Leu His Arg Gln  
 625 630 635 640

-79-

Val Ala Ala Val Gly Gln Glu Pro Gln Val Phe Gly Arg Ser Leu Gln  
 645 650 655  
 Glu Asn Ile Ala Tyr Gly Leu Thr Gln Lys Pro Thr Met Glu Glu Ile  
 660 665 670  
 Thr Ala Ala Ala Val Lys Ser Gly Ala His Ser Phe Ile Ser Gly Leu  
 675 680 685  
 Pro Gln Gly Tyr Asp Thr Glu Val Asp Glu Ala Gly Ser Gln Leu Ser  
 690 695 700  
 Gly Gly Gln Arg Gln Ala Val Ala Leu Ala Arg Ala Leu Ile Arg Lys  
 705 710 715 720  
 Pro Cys Val Leu Ile Leu Asp Asp Ala Thr Ser Ala Leu Asp Ala Asn  
 725 730 735  
 Ser Gln Leu Gln Val Glu Gln Leu Leu Tyr Glu Ser Pro Glu Arg Tyr  
 740 745 750  
 Ser Arg Ser Val Leu Leu Ile Thr Gln His Leu Ser Leu Val Glu Gln  
 755 760 765  
 Ala Asp His Ile Leu Phe Leu Glu Gly Gly Ala Ile Arg Glu Gly Gly  
 770 775 780  
 Thr His Gln Gln Leu Met Glu Lys Lys Gly Cys Tyr Trp Ala Met Val  
 785 790 795 800  
 Gln Ala Pro Ala Asp Ala Pro Glu  
 805  
 <210> 53  
 <211> 377  
 <212> PRT  
 <213> Homo Sapiens  
 <400> 53  
 Met Cys Glu Glu Glu Asp Ser Thr Ala Leu Val Cys Asp Asn Gly Ser  
 1 5 10 15  
 Gly Leu Cys Lys Ala Gly Phe Ala Gly Asp Asp Ala Pro Arg Ala Val  
 20 25 30  
 Phe Pro Ser Ile Val Gly Arg Pro Arg His Gln Gly Val Met Val Gly  
 35 40 45  
 Met Gly Gln Lys Asp Ser Tyr Val Gly Asp Glu Ala Gln Ser Lys Arg  
 50 55 60  
 Gly Ile Leu Thr Leu Lys Tyr Pro Ile Glu His Gly Ile Ile Thr Asn  
 65 70 75 80  
 Trp Asp Asp Met Glu Lys Ile Trp His His Ser Phe Tyr Asn Glu Leu  
 85 90 95  
 Arg Val Ala Pro Glu Glu His Pro Thr Leu Leu Thr Glu Ala Pro Leu  
 100 105 110

-80-

Asn Pro Lys Ala Asn Arg Glu Lys Met Thr Gln Ile Met Phe Glu Thr  
 115 120 125  
 Phe Asn Val Pro Ala Met Tyr Val Ala Ile Gln Ala Val Leu Ser Leu  
 130 135 140  
 Tyr Ala Ser Gly Arg Thr Thr Gly Ile Val Leu Asp Ser Gly Asp Gly  
 145 150 155 160  
 Val Thr His Asn Val Pro Ile Tyr Glu Gly Tyr Ala Leu Pro His Ala  
 165 170 175  
 Ile Met Arg Leu Asp Leu Ala Gly Arg Asp Leu Thr Asp Tyr Leu Met  
 180 185 190  
 Lys Ile Leu Thr Glu Arg Gly Tyr Ser Phe Val Thr Thr Ala Glu Arg  
 195 200 205  
 Glu Ile Val Arg Asp Ile Lys Glu Lys Leu Cys Tyr Val Ala Leu Asp  
 210 215 220  
 Phe Glu Asn Glu Met Ala Thr Ala Ala Ser Ser Ser Ser Leu Glu Lys  
 225 230 235 240  
 Ser Tyr Glu Leu Pro Asp Gly Gln Val Ile Thr Ile Gly Asn Glu Arg  
 245 250 255  
 Phe Arg Cys Pro Glu Thr Leu Phe Gln Pro Ser Phe Ile Gly Met Glu  
 260 265 270  
 Ser Ala Gly Ile His Glu Thr Thr Tyr Asn Ser Ile Met Lys Cys Asp  
 275 280 285  
 Ile Asp Ile Arg Lys Asp Leu Tyr Ala Asn Asn Val Leu Ser Gly Gly  
 290 295 300  
 Thr Thr Met Tyr Pro Gly Ile Ala Asp Arg Met Gln Lys Glu Ile Thr  
 305 310 315 320  
 Ala Leu Ala Pro Ser Thr Met Lys Ile Lys Ile Ile Ala Pro Pro Glu  
 325 330 335  
 Arg Lys Tyr Ser Val Trp Ile Gly Gly Ser Ile Leu Ala Ser Leu Ser  
 340 345 350  
 Thr Phe Gln Gln Met Trp Ile Ser Lys Gln Glu Tyr Asp Glu Ala Gly  
 355 360 365  
 Pro Ser Ile Val His Arg Lys Cys Phe  
 370 375

<210> 54  
 <211> 334  
 <212> PRT  
 <213> Homo Sapiens

<400> 54

Met Glu Ala Ala His Phe Phe Glu Gly Thr Glu Lys Leu Leu Glu Val

-81-

1	5	10	15
Trp Phe Ser Arg Gln Gln Pro Asp Ala Asn Gln Gly Ser Gly Asp Leu	20	25	30
Arg Thr Ile Pro Arg Ser Glu Trp Asp Ile Leu Leu Lys Asp Val Gln	35	40	45
Cys Ser Ile Ile Ser Val Thr Lys Thr Asp Lys Gln Glu Ala Tyr Val	50	55	60
Leu Ser Glu Ser Ser Met Phe Val Ser Lys Arg Arg Phe Ile Leu Lys	65	70	75
Thr Cys Gly Thr Thr Leu Leu Leu Lys Ala Leu Val Pro Leu Leu Lys	85	90	95
Leu Ala Arg Asp Tyr Ser Gly Phe Asp Ser Ile Gln Ser Phe Phe Tyr	100	105	110
Ser Arg Lys Asn Phe Met Lys Pro Ser His Gln Gly Tyr Pro His Arg	115	120	125
Asn Phe Gln Glu Glu Ile Glu Phe Leu Asn Ala Ile Phe Pro Asn Gly	130	135	140
Ala Gly Tyr Cys Met Gly Arg Met Asn Ser Asp Cys Trp Tyr Leu Tyr	145	150	155
Thr Leu Asp Phe Pro Glu Ser Arg Val Ile Ser Gln Pro Asp Gln Thr	165	170	175
Leu Glu Ile Leu Met Ser Glu Leu Asp Pro Ala Val Met Asp Gln Phe	180	185	190
Tyr Met Lys Asp Gly Val Thr Ala Lys Asp Val Thr Arg Glu Ser Gly	195	200	205
Ile Arg Asp Leu Ile Pro Gly Ser Val Ile Asp Ala Thr Met Phe Asn	210	215	220
Pro Cys Gly Tyr Ser Met Asn Gly Met Lys Ser Asp Gly Thr Tyr Trp	225	230	235
Thr Ile His Ile Thr Pro Glu Pro Glu Phe Ser Tyr Val Ser Phe Glu	245	250	255
Thr Asn Leu Ser Gln Thr Ser Tyr Asp Asp Leu Ile Arg Lys Val Val	260	265	270
Glu Val Phe Lys Pro Gly Lys Phe Val Thr Thr Leu Phe Val Asn Gln	275	280	285
Ser Ser Lys Cys Arg Thr Val Leu Ala Ser Pro Gln Lys Ile Glu Gly	290	295	300
Phe Lys Arg Leu Asp Cys Gln Ser Ala Met Phe Asn Asp Tyr Asn Phe	305	310	315
Val Phe Thr Ser Phe Ala Lys Lys Gln Gln Gln Gln Gln Ser			

-82-

325

330

<210> 55  
 <211> 76  
 <212> PRT  
 <213> Homo Sapiens

<400> 55

Met	Ala	Ser	Lys	Gly	Leu	Gln	Asp	Leu	Lys	Gln	Gln	Val	Glu	Gly	Thr
1				5					10					15	
Ala	Gln	Glu	Ala	Val	Ser	Ala	Ala	Gly	Ala	Ala	Ala	Gln	Gln	Val	Val
			20					25					30		
Asp	Gln	Ala	Thr	Glu	Ala	Gly	Gln	Lys	Ala	Met	Asp	Gln	Leu	Ala	Lys
		35					40					45			
Thr	Thr	Gln	Glu	Thr	Ile	Asp	Lys	Thr	Ala	Asn	Gln	Ala	Ser	Asp	Thr
	50					55					60				
Phe	Ser	Gly	Ile	Gly	Lys	Lys	Phe	Gly	Leu	Leu	Lys				
65					70					75					

<210> 56  
 <211> 395  
 <212> PRT  
 <213> Homo Sapiens

<400> 56

Met	Pro	Gly	Arg	Ser	Cys	Val	Ala	Leu	Val	Leu	Leu	Ala	Ala	Ala	Val
1				5					10					15	
Ser	Cys	Ala	Val	Ala	Gln	His	Ala	Pro	Pro	Trp	Thr	Glu	Asp	Cys	Arg
			20					25					30		
Lys	Ser	Thr	Tyr	Pro	Pro	Ser	Gly	Pro	Thr	Tyr	Arg	Gly	Ala	Val	Pro
		35					40					45			
Trp	Tyr	Thr	Ile	Asn	Leu	Asp	Leu	Pro	Pro	Tyr	Lys	Arg	Trp	His	Glu
	50					55					60				
Leu	Met	Leu	Asp	Lys	Ala	Pro	Met	Leu	Lys	Val	Ile	Val	Asn	Ser	Leu
65					70					75					80
Lys	Asn	Met	Ile	Asn	Thr	Phe	Val	Pro	Ser	Gly	Lys	Val	Met	Gln	Val
			85						90					95	
Val	Asp	Glu	Lys	Leu	Pro	Gly	Leu	Leu	Gly	Asn	Phe	Pro	Gly	Pro	Phe
			100					105					110		
Glu	Glu	Glu	Met	Lys	Gly	Ile	Ala	Ala	Val	Thr	Asp	Ile	Pro	Leu	Gly
		115					120					125			
Glu	Ile	Ile	Ser	Phe	Asn	Ile	Phe	Tyr	Glu	Leu	Phe	Thr	Ile	Cys	Thr
	130					135					140				
Ser	Ile	Val	Ala	Glu	Asp	Lys	Lys	Gly	His	Leu	Ile	His	Gly	Arg	Asn
145					150					155					160

-83-

Met Asp Phe Gly Val Phe Leu Gly Trp Asn Ile Asn Asn Asp Thr Trp  
165 170 175

Val Ile Thr Glu Gln Leu Lys Pro Leu Thr Val Asn Leu Asp Phe Gln  
180 185 190

Arg Asn Asn Lys Thr Val Phe Lys Ala Ser Ser Phe Ala Gly Tyr Val  
195 200 205

Gly Met Leu Thr Gly Phe Lys Pro Gly Leu Phe Ser Leu Thr Leu Asn  
210 215 220

Glu Arg Phe Ser Ile Asn Gly Gly Tyr Leu Gly Ile Leu Glu Trp Ile  
225 230 235 240

Leu Gly Lys Lys Asp Ala Met Trp Ile Gly Phe Leu Thr Arg Thr Val  
245 250 255

Leu Glu Asn Ser Thr Ser Tyr Glu Glu Ala Lys Asn Leu Leu Thr Lys  
260 265 270

Thr Lys Ile Leu Ala Pro Ala Tyr Phe Ile Leu Gly Gly Asn Gln Ser  
275 280 285

Gly Glu Gly Cys Val Ile Thr Arg Asp Arg Lys Glu Ser Leu Asp Val  
290 295 300

Tyr Glu Leu Asp Ala Lys Gln Gly Arg Trp Tyr Val Val Gln Thr Asn  
305 310 315 320

Tyr Asp Arg Trp Lys His Pro Phe Phe Leu Asp Asp Arg Arg Thr Pro  
325 330 335

Ala Lys Met Cys Leu Asn Arg Thr Ser Gln Glu Asn Ile Ser Phe Glu  
340 345 350

Thr Met Tyr Asp Val Leu Ser Thr Lys Pro Val Leu Asn Lys Leu Thr  
355 360 365

Val Tyr Thr Thr Leu Ile Asp Val Thr Lys Gly Gln Phe Glu Thr Tyr  
370 375 380

Leu Arg Asp Cys Pro Asp Pro Cys Ile Gly Trp  
385 390 395

<210> 57  
<211> 777  
<212> PRT  
<213> Homo Sapiens

<400> 57

Met Pro Asp Asn Arg Gln Pro Arg Asn Arg Gln Pro Arg Ile Arg Ser  
1 5 10 15

Gly Asn Glu Pro Arg Ser Ala Pro Ala Met Glu Pro Asp Gly Arg Gly  
20 25 30

Ala Trp Ala His Ser Arg Ala Ala Leu Asp Arg Leu Glu Lys Leu Leu



-84-

35					40					45					
Arg	Cys	Ser	Arg	Cys	Thr	Asn	Ile	Leu	Arg	Glu	Pro	Val	Cys	Leu	Gly
50						55					60				
Gly	Cys	Glu	His	Ile	Phe	Cys	Ser	Asn	Cys	Val	Ser	Asp	Cys	Ile	Gly
65					70					75					80
Thr	Gly	Cys	Pro	Val	Cys	Tyr	Thr	Pro	Ala	Trp	Ile	Gln	Asp	Leu	Lys
				85					90					95	
Ile	Asn	Arg	Gln	Leu	Asp	Ser	Met	Ile	Gln	Leu	Cys	Ser	Lys	Leu	Arg
			100					105					110		
Asn	Leu	Leu	His	Asp	Asn	Glu	Leu	Ser	Asp	Leu	Lys	Glu	Asp	Lys	Pro
		115					120					125			
Arg	Lys	Ser	Leu	Phe	Asn	Asp	Ala	Gly	Asn	Lys	Lys	Asn	Ser	Ile	Lys
	130					135					140				
Met	Trp	Phe	Ser	Pro	Arg	Ser	Lys	Lys	Val	Arg	Tyr	Val	Val	Ser	Lys
145					150					155					160
Ala	Ser	Val	Gln	Thr	Gln	Pro	Ala	Ile	Lys	Lys	Asp	Ala	Ser	Ala	Gln
				165					170					175	
Gln	Asp	Ser	Tyr	Glu	Phe	Val	Ser	Pro	Ser	Pro	Pro	Ala	Asp	Val	Ser
			180					185					190		
Glu	Arg	Ala	Lys	Lys	Ala	Ser	Ala	Arg	Ser	Gly	Lys	Lys	Gln	Lys	Lys
		195					200					205			
Lys	Thr	Leu	Ala	Glu	Ile	Asn	Gln	Lys	Trp	Asn	Leu	Glu	Ala	Glu	Lys
	210					215					220				
Glu	Asp	Gly	Glu	Phe	Asp	Ser	Lys	Glu	Glu	Ser	Lys	Gln	Lys	Leu	Val
225					230					235					240
Ser	Phe	Cys	Ser	Gln	Pro	Ser	Val	Ile	Ser	Ser	Pro	Gln	Ile	Asn	Gly
				245					250					255	
Glu	Ile	Asp	Leu	Leu	Ala	Ser	Gly	Ser	Leu	Thr	Glu	Ser	Glu	Cys	Phe
			260					265					270		
Gly	Ser	Leu	Thr	Glu	Val	Ser	Leu	Pro	Leu	Ala	Glu	Gln	Ile	Glu	Ser
		275					280					285			
Pro	Asp	Thr	Lys	Ser	Arg	Asn	Glu	Val	Val	Thr	Pro	Glu	Lys	Val	Cys
	290					295					300				
Lys	Asn	Tyr	Leu	Thr	Ser	Lys	Lys	Ser	Leu	Pro	Leu	Glu	Asn	Asn	Gly
305					310					315					320
Lys	Arg	Gly	His	His	Asn	Arg	Leu	Ser	Ser	Pro	Ile	Ser	Lys	Arg	Cys
				325					330					335	
Arg	Thr	Ser	Ile	Leu	Ser	Thr	Ser	Gly	Asp	Phe	Val	Lys	Gln	Thr	Val
			340					345					350		
Pro	Ser	Glu	Asn	Ile	Pro	Leu	Pro	Glu	Cys	Ser	Ser	Pro	Pro	Ser	Cys

-85-

355					360					365					
Lys	Arg	Lys	Val	Gly	Gly	Thr	Ser	Gly	Arg	Lys	Asn	Ser	Asn	Met	Ser
370						375					380				
Asp	Glu	Phe	Ile	Ser	Leu	Ser	Pro	Gly	Thr	Pro	Pro	Ser	Thr	Leu	Ser
385					390					395					400
Ser	Ser	Ser	Tyr	Arg	Gln	Val	Met	Ser	Ser	Pro	Ser	Ala	Met	Lys	Leu
				405					410					415	
Leu	Pro	Asn	Met	Ala	Val	Lys	Arg	Asn	His	Arg	Gly	Glu	Thr	Leu	Leu
			420					425					430		
His	Ile	Ala	Ser	Ile	Lys	Gly	Asp	Ile	Pro	Ser	Val	Glu	Tyr	Leu	Leu
		435					440					445			
Gln	Asn	Gly	Ser	Asp	Pro	Asn	Val	Lys	Asp	His	Ala	Gly	Trp	Thr	Pro
	450					455					460				
Leu	His	Glu	Ala	Cys	Asn	His	Gly	His	Leu	Lys	Val	Val	Glu	Leu	Leu
465					470					475					480
Leu	Gln	His	Lys	Ala	Leu	Val	Asn	Thr	Thr	Gly	Tyr	Gln	Asn	Asp	Ser
				485					490					495	
Pro	Leu	His	Asp	Ala	Ala	Lys	Asn	Gly	His	Val	Asp	Ile	Val	Lys	Leu
			500					505					510		
Leu	Leu	Ser	Tyr	Gly	Ala	Ser	Arg	Asn	Ala	Val	Asn	Ile	Phe	Gly	Leu
		515					520					525			
Arg	Pro	Val	Asp	Tyr	Thr	Asp	Asp	Glu	Ser	Met	Lys	Ser	Leu	Leu	Leu
	530					535					540				
Leu	Pro	Glu	Lys	Asn	Glu	Ser	Ser	Ser	Ala	Ser	His	Cys	Ser	Val	Met
545					550					555					560
Asn	Thr	Gly	Gln	Arg	Arg	Asp	Gly	Pro	Leu	Val	Leu	Ile	Gly	Ser	Gly
				565					570					575	
Leu	Ser	Ser	Glu	Gln	Gln	Lys	Met	Leu	Ser	Glu	Leu	Ala	Val	Ile	Leu
			580					585					590		
Lys	Ala	Lys	Lys	Tyr	Thr	Glu	Phe	Asp	Ser	Thr	Val	Thr	His	Val	Val
		595					600					605			
Val	Pro	Gly	Asp	Ala	Val	Gln	Ser	Thr	Leu	Lys	Cys	Met	Leu	Gly	Ile
	610					615					620				
Leu	Asn	Gly	Cys	Trp	Ile	Leu	Lys	Phe	Glu	Trp	Val	Lys	Ala	Cys	Leu
625					630					635					640
Arg	Arg	Lys	Val	Cys	Glu	Gln	Glu	Glu	Lys	Tyr	Glu	Ile	Pro	Glu	Gly
				645					650					655	
Pro	Arg	Arg	Ser	Arg	Leu	Asn	Arg	Glu	Gln	Leu	Leu	Pro	Lys	Leu	Phe
			660					665					670		
Asp	Gly	Cys	Tyr	Phe	Tyr	Leu	Trp	Gly	Thr	Phe	Lys	His	His	Pro	Lys

-86-

675	680	685
Asp Asn Leu Ile Lys Leu Val Thr Ala Gly Gly Gly Gln Ile Leu Ser		
690	695	700
Arg Lys Pro Lys Pro Asp Ser Asp Val Thr Gln Thr Ile Asn Thr Val		
705	710	715
Ala Tyr His Ala Arg Pro Asp Ser Asp Gln Arg Phe Cys Thr Gln Tyr		
	725	730
		735
Ile Ile Tyr Glu Asp Leu Cys Asn Tyr His Pro Glu Arg Val Arg Gln		
	740	745
		750
Gly Lys Val Trp Lys Ala Pro Ser Ser Trp Phe Ile Asp Cys Val Met		
	755	760
		765
Ser Phe Glu Leu Leu Pro Leu Asp Ser		
770	775	
<210> 58		
<211> 323		
<212> PRT		
<213> Homo Sapiens		
<400> 58		
Met Tyr His Asn Ser Ser Gln Lys Arg His Trp Thr Phe Ser Ser Glu		
1	5	10
		15
Glu Gln Leu Ala Arg Leu Arg Ala Asp Ala Asn Arg Lys Phe Arg Cys		
	20	25
		30
Lys Ala Val Ala Asn Gly Lys Val Leu Pro Asn Asp Pro Val Phe Leu		
	35	40
		45
Glu Pro His Glu Glu Met Thr Leu Cys Lys Tyr Tyr Glu Lys Arg Leu		
	50	55
		60
Leu Glu Phe Cys Ser Val Phe Lys Pro Ala Met Pro Arg Ser Val Val		
65	70	75
		80
Gly Thr Ala Cys Met Tyr Phe Lys Arg Phe Tyr Leu Asn Asn Ser Val		
	85	90
		95
Met Glu Tyr His Pro Arg Ile Ile Met Leu Thr Cys Ala Phe Leu Ala		
	100	105
		110
Cys Lys Val Asp Glu Phe Asn Val Ser Ser Pro Gln Phe Val Gly Asn		
	115	120
		125
Leu Arg Glu Ser Pro Leu Gly Gln Glu Lys Ala Leu Glu Gln Ile Leu		
	130	135
		140
Glu Tyr Glu Leu Leu Leu Ile Gln Gln Leu Asn Phe His Leu Ile Val		
145	150	155
		160
His Asn Pro Tyr Arg Pro Phe Glu Gly Phe Leu Ile Asp Leu Lys Thr		
	165	170
		175

-87-

Arg Tyr Pro Ile Leu Glu Asn Pro Glu Ile Leu Arg Lys Thr Ala Asp  
 180 185 190  
 Asp Phe Leu Asn Arg Ile Ala Leu Thr Asp Ala Tyr Leu Leu Tyr Thr  
 195 200 205  
 Pro Ser Gln Ile Ala Leu Thr Ala Ile Leu Ser Ser Ala Ser Arg Ala  
 210 215 220  
 Gly Ile Thr Met Glu Ser Tyr Leu Ser Glu Ser Leu Met Leu Lys Glu  
 225 230 235 240  
 Asn Arg Thr Cys Leu Ser Gln Leu Leu Asp Ile Met Lys Ser Met Arg  
 245 250 255  
 Asn Leu Val Lys Lys Tyr Glu Pro Pro Arg Ser Glu Glu Val Ala Val  
 260 265 270  
 Leu Lys Gln Lys Leu Glu Arg Cys His Ser Ala Glu Leu Ala Leu Asn  
 275 280 285  
 Val Ile Thr Lys Lys Arg Lys Gly Tyr Glu Asp Asp Asp Tyr Val Ser  
 290 295 300  
 Lys Lys Ser Lys His Glu Glu Glu Glu Trp Thr Asp Asp Asp Leu Val  
 305 310 315 320  
 Glu Ser Leu

<210> 59  
 <211> 217  
 <212> PRT  
 <213> Homo Sapiens

<400> 59

Met Ala Ser Leu Ser Leu Ala Pro Val Asn Ile Phe Lys Ala Gly Ala  
 1 5 10 15  
 Asp Glu Glu Arg Ala Glu Thr Ala Arg Leu Thr Ser Phe Ile Gly Ala  
 20 25 30  
 Ile Ala Ile Gly Asp Leu Val Lys Ser Thr Leu Gly Pro Lys Gly Met  
 35 40 45  
 Asp Lys Ile Leu Leu Ser Ser Gly Arg Asp Ala Ser Leu Met Val Thr  
 50 55 60  
 Asn Asp Gly Ala Thr Ile Leu Lys Asn Ile Gly Val Asp Asn Pro Ala  
 65 70 75 80  
 Ala Lys Val Leu Val Asp Met Ser Arg Val Gln Asp Asp Glu Val Gly  
 85 90 95  
 Asp Gly Thr Thr Ser Val Thr Val Leu Ala Ala Glu Leu Leu Arg Glu  
 100 105 110  
 Ala Glu Ser Leu Ile Ala Lys Lys Ile His Pro Gln Thr Ile Ile Ala  
 115 120 125

-88-

Gly Trp Arg Glu Ala Thr Lys Ala Ala Arg Glu Ala Leu Leu Ser Ser  
 130 135 140

Ala Val Asp His Gly Ser Asp Glu Val Lys Phe Arg Gln Asp Leu Met  
 145 150 155 160

Asn Ile Ala Gly Thr Thr Leu Ser Ser Lys Leu Leu Thr His His Lys  
 165 170 175

Asp His Phe Thr Lys Leu Ala Val Glu Ala Val Leu Arg Leu Lys Gly  
 180 185 190

Ser Gly Asn Leu Glu Ala Ile His Ile Ile Lys Lys Leu Gly Gly Ser  
 195 200 205

Leu Ala Asp Ser Tyr Leu Asp Glu Gly  
 210 215

<210> 60  
 <211> 499  
 <212> PRT  
 <213> Homo Sapiens

<400> 60

Met Ala Gln Phe Ala Phe Glu Ser Asp Leu His Ser Leu Leu Gln Leu  
 1 5 10 15

Asp Ala Pro Ile Pro Asn Ala Pro Pro Ala Arg Trp Gln Arg Lys Ala  
 20 25 30

Lys Glu Ala Ala Gly Pro Ala Pro Ser Pro Met Arg Ala Ala Asn Arg  
 35 40 45

Ser His Ser Ala Gly Arg Thr Pro Gly Arg Thr Pro Gly Lys Ser Ser  
 50 55 60

Ser Lys Val Gln Thr Thr Pro Ser Lys Pro Gly Gly Asp Arg Tyr Ile  
 65 70 75 80

Pro His Arg Ser Ala Ala Gln Met Glu Val Ala Ser Phe Leu Leu Ser  
 85 90 95

Lys Glu Asn Gln Ser Glu Asn Ser Gln Thr Pro Thr Lys Lys Glu His  
 100 105 110

Gln Lys Ala Trp Ala Leu Asn Leu Asn Gly Phe Asp Val Glu Glu Ala  
 115 120 125

Lys Ile Leu Arg Leu Ser Gly Lys Pro Gln Asn Ala Pro Glu Gly Tyr  
 130 135 140

Gln Asn Arg Leu Lys Val Leu Tyr Ser Gln Lys Ala Thr Pro Gly Ser  
 145 150 155 160

Ser Arg Lys Thr Cys Arg Tyr Ile Pro Ser Leu Pro Asp Arg Ile Leu  
 165 170 175

Asp Ala Pro Glu Ile Arg Asn Asp Tyr Tyr Leu Asn Leu Val Asp Trp

- 89 -

180							185					190			
Ser	Ser	Gly	Asn	Val	Leu	Ala	Val	Ala	Leu	Asp	Asn	Ser	Val	Tyr	Leu
		195					200					205			
Trp	Ser	Ala	Ser	Ser	Gly	Asp	Ile	Leu	Gln	Leu	Leu	Gln	Met	Glu	Gln
	210					215					220				
Pro	Gly	Glu	Tyr	Ile	Ser	Ser	Val	Ala	Trp	Ile	Lys	Glu	Gly	Asn	Tyr
225					230					235					240
Leu	Ala	Val	Gly	Thr	Ser	Ser	Ala	Glu	Val	Gln	Leu	Trp	Asp	Val	Gln
				245					250					255	
Gln	Gln	Lys	Arg	Leu	Arg	Asn	Met	Thr	Ser	His	Ser	Ala	Arg	Val	Gly
			260					265					270		
Ser	Leu	Ser	Trp	Asn	Ser	Tyr	Ile	Leu	Ser	Ser	Gly	Ser	Arg	Ser	Gly
		275					280					285			
His	Ile	His	His	His	Asp	Val	Arg	Val	Ala	Glu	His	His	Val	Ala	Thr
	290					295					300				
Leu	Ser	Gly	His	Ser	Gln	Glu	Val	Cys	Gly	Leu	Arg	Trp	Ala	Pro	Asp
305					310					315					320
Gly	Arg	His	Leu	Ala	Ser	Gly	Gly	Asn	Asp	Asn	Leu	Val	Asn	Val	Trp
				325					330					335	
Pro	Ser	Ala	Pro	Gly	Glu	Gly	Gly	Trp	Val	Pro	Leu	Gln	Thr	Phe	Thr
			340					345					350		
Gln	His	Gln	Gly	Ala	Val	Lys	Ala	Val	Ala	Trp	Cys	Pro	Trp	Gln	Ser
		355					360					365			
Asn	Val	Leu	Ala	Thr	Gly	Gly	Gly	Thr	Ser	Asp	Arg	His	Ile	Arg	Ile
	370					375					380				
Trp	Asn	Val	Cys	Ser	Gly	Ala	Cys	Leu	Ser	Ala	Val	Asp	Ala	His	Ser
385					390					395					400
Gln	Val	Cys	Ser	Ile	Leu	Trp	Ser	Pro	His	Tyr	Lys	Glu	Leu	Ile	Ser
				405					410					415	
Gly	His	Gly	Phe	Ala	Gln	Asn	Gln	Leu	Val	Ile	Trp	Lys	Tyr	Pro	Thr
			420					425					430		
Met	Ala	Lys	Val	Ala	Glu	Leu	Lys	Gly	His	Thr	Ser	Arg	Val	Leu	Ser
		435					440					445			
Leu	Thr	Met	Ser	Pro	Asp	Gly	Ala	Thr	Val	Ala	Ser	Ala	Ala	Ala	Asp
	450					455					460				
Glu	Thr	Leu	Arg	Leu	Trp	Arg	Cys	Phe	Glu	Leu	Asp	Pro	Ala	Arg	Arg
465					470					475					480
Arg	Glu	Arg	Glu	Lys	Ala	Ser	Ala	Ala	Lys	Ser	Ser	Leu	Ile	His	Gln
				485					490					495	
Gly	Ile	Arg													

-90-

&lt;210&gt; 61

&lt;211&gt; 298

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 61

Ile Ala Ala Ala Pro Glu Leu Leu Glu Arg Ser Gly Ser Pro Gly Gly  
 1 5 10 15

Gly Gly Gly Ala Glu Glu Glu Ala Gly Gly Gly Pro Gly Gly Ser Pro  
 20 25 30

Pro Asp Gly Ala Arg Pro Gly Pro Ser Arg Glu Leu Ala Val Val Ala  
 35 40 45

Arg Pro Arg Ala Ala Pro Thr Pro Gly Pro Ser Ala Ala Ala Met Ala  
 50 55 60

Arg Pro Leu Val Pro Ser Ser Gln Lys Ala Leu Leu Leu Glu Leu Lys  
 65 70 75 80

Gly Leu Gln Glu Glu Pro Val Glu Gly Phe Arg Val Thr Leu Val Asp  
 85 90 95

Glu Gly Asp Leu Tyr Asn Trp Glu Val Ala Ile Phe Gly Pro Pro Asn  
 100 105 110

Thr Tyr Tyr Glu Gly Gly Tyr Phe Lys Ala Arg Leu Lys Phe Pro Ile  
 115 120 125

Asp Tyr Pro Tyr Ser Pro Pro Ala Phe Arg Phe Leu Thr Lys Met Trp  
 130 135 140

His Pro Asn Ile Tyr Glu Thr Gly Asp Val Cys Ile Ser Ile Leu His  
 145 150 155 160

Pro Pro Val Asp Asp Pro Gln Ser Gly Glu Leu Pro Ser Glu Arg Trp  
 165 170 175

Asn Pro Thr Gln Asn Val Arg Thr Ile Leu Leu Ser Val Ile Ser Leu  
 180 185 190

Leu Asn Glu Pro Asn Thr Phe Ser Pro Ala Asn Val Asp Ala Ser Val  
 195 200 205

Met Tyr Arg Lys Trp Lys Glu Ser Lys Gly Lys Asp Arg Glu Tyr Thr  
 210 215 220

Asp Ile Ile Arg Lys Gln Val Leu Gly Thr Lys Val Asp Ala Glu Arg  
 225 230 235 240

Asp Gly Val Lys Val Pro Thr Thr Leu Ala Glu Tyr Cys Val Lys Thr  
 245 250 255

Lys Ala Pro Ala Pro Asp Glu Gly Ser Asp Leu Phe Tyr Asp Asp Tyr  
 260 265 270

-91-

Tyr Glu Asp Gly Glu Val Glu Glu Glu Ala Asp Ser Cys Phe Gly Asp  
           275                                  280                                  285

Asp Glu Asp Asp Ser Gly Thr Glu Glu Ser  
       290                                  295

<210> 62  
 <211> 212  
 <212> PRT  
 <213> Homo Sapiens

<400> 62

Met Glu Pro Pro Ser Ser Ile Gln Thr Ser Glu Phe Asp Ser Ser Asp  
 1                                  5                                  10                                  15

Glu Glu Pro Ile Glu Asp Glu Gln Thr Pro Ile His Ile Ser Trp Leu  
           20                                  25                                  30

Ser Leu Ser Arg Val Asn Cys Ser Gln Phe Leu Gly Leu Cys Ala Leu  
           35                                  40                                  45

Pro Gly Cys Lys Phe Lys Asp Val Arg Arg Asn Val Gln Lys Asp Thr  
       50                                  55                                  60

Glu Glu Leu Lys Ser Cys Gly Ile Gln Asp Ile Phe Val Phe Cys Thr  
 65                                  70                                  75                                  80

Arg Gly Glu Leu Ser Lys Tyr Arg Val Pro Asn Leu Leu Asp Leu Tyr  
           85                                  90                                  95

Gln Gln Cys Gly Ile Ile Thr His His His Pro Ile Ala Asp Gly Gly  
           100                                  105                                  110

Thr Pro Asp Ile Ala Ser Cys Cys Glu Ile Met Glu Glu Leu Thr Thr  
       115                                  120                                  125

Cys Leu Lys Asn Tyr Arg Lys Thr Leu Ile His Cys Tyr Gly Gly Leu  
       130                                  135                                  140

Gly Arg Ser Cys Leu Val Ala Ala Cys Leu Leu Leu Tyr Leu Ser Asp  
 145                                  150                                  155                                  160

Thr Ile Ser Pro Glu Gln Ala Ile Asp Ser Leu Arg Asp Leu Arg Gly  
           165                                  170                                  175

Ser Gly Ala Ile Gln Thr Ile Lys Gln Tyr Asn Tyr Leu His Glu Phe  
           180                                  185                                  190

Arg Asp Lys Leu Ala Ala His Leu Ser Ser Arg Asp Ser Gln Ser Arg  
       195                                  200                                  205

Ser Val Ser Arg  
       210

<210> 63  
 <211> 79  
 <212> PRT  
 <213> Homo Sapiens



-92-

&lt;400&gt; 63

Met Ser His Lys Gln Ile Tyr Tyr Ser Asp Lys Tyr Asp Asp Glu Glu  
 1 5 10 15  
 Phe Glu Tyr Arg His Val Met Leu Pro Lys Asp Ile Ala Lys Leu Val  
 20 25 30  
 Pro Lys Thr His Leu Met Ser Glu Ser Glu Trp Arg Asn Leu Gly Val  
 35 40 45  
 Gln Gln Ser Gln Gly Trp Val His Tyr Met Ile His Glu Pro Glu Pro  
 50 55 60  
 His Ile Leu Leu Phe Arg Arg Pro Leu Pro Lys Lys Pro Lys Lys  
 65 70 75

&lt;210&gt; 64

&lt;211&gt; 79

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 64

Met Ala His Lys Gln Ile Tyr Tyr Ser Asp Lys Tyr Phe Asp Glu His  
 1 5 10 15  
 Tyr Glu Tyr Arg His Val Met Leu Pro Arg Glu Leu Ser Lys Gln Val  
 20 25 30  
 Pro Lys Thr His Leu Met Ser Glu Glu Glu Trp Arg Arg Leu Gly Val  
 35 40 45  
 Gln Gln Ser Leu Gly Trp Val His Tyr Met Ile His Glu Pro Glu Pro  
 50 55 60  
 His Ile Leu Leu Phe Arg Arg Pro Leu Pro Lys Asp Gln Gln Lys  
 65 70 75

&lt;210&gt; 65

&lt;211&gt; 79

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 65

Met Gln Ala Leu Arg Val Ser Gln Ala Leu Ile Arg Ser Phe Ser Ser  
 1 5 10 15  
 Thr Ala Arg Asn Arg Phe Gln Asn Arg Val Arg Glu Lys Gln Lys Leu  
 20 25 30  
 Phe Gln Glu Asp Asn Asp Ile Pro Leu Tyr Leu Lys Gly Gly Ile Val  
 35 40 45  
 Asp Asn Ile Leu Tyr Arg Val Thr Met Thr Leu Cys Leu Gly Gly Thr  
 50 55 60  
 Val Tyr Ser Leu Tyr Ser Leu Gly Trp Ala Ser Phe Pro Arg Asn  
 65 70 75

-93-

&lt;210&gt; 66

&lt;211&gt; 417

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 66

```

Met Arg Leu Ile Leu Pro Val Gly Leu Ile Ala Thr Thr Leu Ala Ile
1          5          10          15

Ala Pro Val Arg Phe Asp Arg Glu Lys Val Phe Arg Val Lys Pro Gln
          20          25          30

Asp Glu Lys Gln Ala Asp Ile Ile Lys Asp Leu Ala Lys Thr Asn Glu
          35          40          45

Leu Asp Phe Trp Tyr Pro Gly Ala Thr His His Val Ala Ala Asn Met
          50          55          60

Met Val Asp Phe Arg Val Ser Glu Lys Glu Ser Gln Ala Ile Gln Ser
65          70          75          80

Ala Leu Asp Gln Asn Lys Met His Tyr Glu Ile Leu Ile His Asp Leu
          85          90          95

Gln Glu Glu Ile Glu Lys Gln Phe Asp Val Lys Glu Asp Ile Pro Gly
          100          105          110

Arg His Ser Tyr Ala Lys Tyr Asn Asn Trp Glu Lys Ile Val Ala Trp
          115          120          125

Thr Glu Lys Met Met Asp Lys Tyr Pro Glu Met Val Ser Arg Ile Lys
          130          135          140

Ile Gly Ser Thr Val Glu Asp Asn Pro Leu Tyr Val Leu Lys Ile Gly
145          150          155          160

Glu Lys Asn Glu Arg Arg Lys Ala Ile Phe Met Asp Cys Gly Ile His
          165          170          175

Ala Arg Glu Trp Val Ser Pro Ala Phe Cys Gln Trp Phe Val Tyr Gln
          180          185          190

Ala Thr Lys Thr Tyr Gly Arg Asn Lys Ile Met Thr Lys Leu Leu Asp
          195          200          205

Arg Met Asn Phe Tyr Ile Leu Pro Val Phe Asn Val Asp Gly Tyr Ile
          210          215          220

Trp Ser Trp Thr Lys Asn Arg Met Trp Arg Lys Asn Arg Ser Lys Asn
225          230          235          240

Gln Asn Ser Lys Cys Ile Gly Thr Asp Leu Asn Arg Asn Phe Asn Ala
          245          250          255

Ser Trp Asn Ser Ile Pro Asn Thr Asn Asp Pro Cys Ala Asp Asn Tyr
          260          265          270

Arg Gly Ser Ala Pro Glu Ser Glu Lys Glu Thr Lys Ala Val Thr Asn

```

-94-

275	280	285
Phe Ile Arg Ser His Leu Asn Glu Ile Lys Val Tyr Ile Thr Phe His		
290	295	300
Ser Tyr Ser Gln Met Leu Leu Phe Pro Tyr Gly Tyr Thr Ser Lys Leu		
305	310	315 320
Pro Pro Asn His Glu Asp Leu Ala Lys Val Ala Lys Ile Gly Thr Asp		
	325	330 335
Val Leu Ser Thr Arg Tyr Glu Thr Arg Tyr Ile Tyr Gly Pro Ile Glu		
	340	345 350
Ser Thr Ile Tyr Pro Ile Ser Gly Ser Ser Leu Asp Trp Ala Tyr Asp		
	355	360 365
Leu Gly Ile Lys His Thr Phe Ala Phe Glu Leu Arg Asp Lys Gly Lys		
	370	375 380
Phe Gly Phe Leu Leu Pro Glu Ser Arg Ile Lys Pro Thr Cys Arg Glu		
385	390	395 400
Thr Met Leu Ala Val Lys Phe Ile Ala Lys Tyr Ile Leu Lys His Thr		
	405	410 415
Ser		

<210> 67  
 <211> 476  
 <212> PRT  
 <213> Homo Sapiens

<400> 67

Met Ala Gly Arg Gly Gly Ser Ala Leu Leu Ala Leu Cys Gly Ala Leu	
1	5 10 15
Ala Ala Cys Gly Trp Leu Leu Gly Ala Glu Ala Gln Glu Pro Gly Ala	
	20 25 30
Pro Ala Ala Gly Met Arg Arg Arg Arg Leu Gln Gln Glu Asp Gly	
	35 40 45
Ile Ser Phe Glu Tyr His Arg Tyr Pro Glu Leu Arg Glu Ala Leu Val	
	50 55 60
Ser Val Trp Leu Gln Cys Thr Ala Ile Ser Arg Ile Tyr Thr Val Gly	
65	70 75 80
Arg Ser Phe Glu Gly Arg Glu Leu Leu Val Ile Glu Leu Ser Asp Asn	
	85 90 95
Pro Gly Val His Glu Pro Gly Glu Pro Glu Phe Lys Tyr Ile Gly Asn	
	100 105 110
Met His Gly Asn Glu Ala Val Gly Arg Glu Leu Leu Ile Phe Leu Ala	
	115 120 125

-95-

Gln	Tyr	Leu	Cys	Asn	Glu	Tyr	Gln	Lys	Gly	Asn	Glu	Thr	Ile	Val	Asn		
130						135					140						
Leu	Ile	His	Ser	Thr	Arg	Ile	His	Ile	Met	Pro	Ser	Leu	Asn	Pro	Asp		
145					150					155					160		
Gly	Phe	Glu	Lys	Ala	Ala	Ser	Gln	Pro	Gly	Glu	Leu	Lys	Asp	Trp	Phe		
				165					170					175			
Val	Gly	Arg	Ser	Asn	Ala	Gln	Gly	Ile	Asp	Leu	Asn	Arg	Asn	Phe	Pro		
			180				185						190				
Asp	Leu	Asp	Arg	Ile	Val	Tyr	Val	Asn	Glu	Lys	Glu	Gly	Gly	Pro	Asn		
		195					200						205				
Asn	His	Leu	Leu	Lys	Asn	Met	Lys	Lys	Ile	Val	Asp	Gln	Asn	Thr	Lys		
	210					215					220						
Leu	Ala	Pro	Glu	Thr	Lys	Ala	Val	Ile	His	Trp	Ile	Met	Asp	Ile	Pro		
225					230					235					240		
Phe	Val	Leu	Ser	Ala	Asn	Leu	His	Gly	Gly	Asp	Leu	Val	Ala	Asn	Tyr		
				245					250					255			
Pro	Tyr	Asp	Glu	Thr	Arg	Ser	Gly	Ser	Ala	His	Glu	Tyr	Ser	Ser	Ser		
			260					265					270				
Pro	Asp	Asp	Ala	Ile	Phe	Gln	Ser	Leu	Ala	Arg	Ala	Tyr	Ser	Ser	Phe		
		275					280					285					
Asn	Pro	Ala	Met	Ser	Asp	Pro	Asn	Arg	Pro	Pro	Cys	Arg	Lys	Asn	Asp		
	290					295					300						
Asp	Asp	Ser	Ser	Phe	Val	Asp	Gly	Thr	Thr	Asn	Gly	Gly	Ala	Trp	Tyr		
305					310					315					320		
Ser	Val	Pro	Gly	Gly	Met	Gln	Asp	Phe	Asn	Tyr	Leu	Ser	Ser	Asn	Cys		
				325					330					335			
Phe	Glu	Ile	Thr	Val	Glu	Leu	Ser	Cys	Glu	Lys	Phe	Pro	Pro	Glu	Glu		
			340					345					350				
Thr	Leu	Lys	Thr	Tyr	Trp	Glu	Asp	Asn	Lys	Asn	Ser	Leu	Ile	Ser	Tyr		
		355					360					365					
Leu	Glu	Gln	Ile	His	Arg	Gly	Val	Lys	Gly	Phe	Val	Arg	Asp	Leu	Gln		
	370					375					380						
Gly	Asn	Pro	Ile	Ala	Asn	Ala	Thr	Ile	Ser	Val	Glu	Gly	Ile	Asp	His		
385					390					395					400		
Asp	Val	Thr	Ser	Ala	Lys	Asp	Gly	Asp	Tyr	Trp	Arg	Leu	Leu	Ile	Pro		
				405					410					415			
Gly	Asn	Tyr	Lys	Leu	Thr	Ala	Ser	Ala	Pro	Gly	Tyr	Leu	Ala	Ile	Thr		
			420					425					430				
Lys	Lys	Val	Ala	Val	Pro	Tyr	Ser	Pro	Ala	Ala	Gly	Val	Asp	Phe	Glu		
		435					440					445					

-96-

Leu Glu Ser Phe Ser Glu Arg Lys Glu Glu Glu Lys Glu Glu Leu Met  
 450 455 460

Glu Trp Trp Lys Met Met Ser Glu Thr Leu Asn Phe  
 465 470 475

<210> 68

<211> 355

<212> PRT

<213> Homo Sapiens

<400> 68

Met Asp Gln Phe Pro Glu Ser Val Thr Glu Asn Phe Glu Tyr Asp Asp  
 1 5 10 15

Leu Ala Glu Ala Cys Tyr Ile Gly Asp Ile Val Val Phe Gly Thr Val  
 20 25 30

Phe Leu Ser Ile Phe Tyr Ser Val Ile Phe Ala Ile Gly Leu Val Gly  
 35 40 45

Asn Leu Leu Val Val Phe Ala Leu Thr Asn Ser Lys Lys Pro Lys Ser  
 50 55 60

Val Thr Asp Ile Tyr Leu Leu Asn Leu Ala Leu Ser Asp Leu Leu Phe  
 65 70 75 80

Val Ala Thr Leu Pro Phe Trp Thr His Tyr Leu Ile Asn Glu Lys Gly  
 85 90 95

Leu His Asn Ala Met Cys Lys Phe Thr Thr Ala Phe Phe Phe Ile Gly  
 100 105 110

Phe Phe Gly Ser Ile Phe Phe Ile Thr Val Ile Ser Ile Asp Arg Tyr  
 115 120 125

Leu Ala Ile Val Leu Ala Ala Asn Ser Met Asn Asn Arg Thr Val Gln  
 130 135 140

His Gly Val Thr Ile Ser Leu Gly Val Trp Ala Ala Ala Ile Leu Val  
 145 150 155 160

Ala Ala Pro Gln Phe Met Phe Thr Lys Gln Lys Glu Asn Glu Cys Leu  
 165 170 175

Gly Asp Tyr Pro Glu Val Leu Gln Glu Ile Trp Pro Val Leu Arg Asn  
 180 185 190

Val Glu Thr Asn Phe Leu Gly Phe Leu Leu Pro Leu Leu Ile Met Ser  
 195 200 205

Tyr Cys Tyr Phe Arg Ile Ile Gln Thr Leu Phe Ser Cys Lys Asn His  
 210 215 220

Lys Lys Ala Lys Ala Ile Lys Leu Ile Leu Leu Val Val Ile Val Phe  
 225 230 235 240

Phe Leu Phe Trp Thr Pro Tyr Asn Val Met Ile Phe Leu Glu Thr Leu  
 245 250 255

-97-

Lys Leu Tyr Asp Phe Phe Pro Ser Cys Asp Met Arg Lys Asp Leu Arg  
 260 265 270  
 Leu Ala Leu Ser Val Thr Glu Thr Val Ala Phe Ser His Cys Cys Leu  
 275 280 285  
 Asn Pro Leu Ile Tyr Ala Phe Ala Gly Glu Lys Phe Arg Arg Tyr Leu  
 290 295 300  
 Tyr His Leu Tyr Gly Lys Cys Leu Ala Val Leu Cys Gly Arg Ser Val  
 305 310 315 320  
 His Val Asp Phe Ser Ser Ser Glu Ser Gln Arg Ser Arg His Gly Ser  
 325 330 335  
 Val Leu Ser Ser Asn Phe Thr Tyr His Thr Ser Asp Gly Asp Ala Leu  
 340 345 350  
 Leu Leu Leu  
 355  
 <210> 69  
 <211> 767  
 <212> PRT  
 <213> Homo Sapiens  
 <400> 69  
 Met Ser Gln Arg Pro Arg Ala Pro Arg Ser Ala Leu Trp Leu Leu Ala  
 1 5 10 15  
 Pro Pro Leu Leu Arg Trp Ala Pro Pro Leu Leu Thr Val Leu His Ser  
 20 25 30  
 Asp Leu Phe Gln Ala Leu Leu Asp Ile Leu Asp Tyr Tyr Glu Ala Ser  
 35 40 45  
 Leu Ser Glu Ser Gln Lys Tyr Arg Tyr Gln Asp Glu Asp Thr Pro Pro  
 50 55 60  
 Leu Glu His Ser Pro Ala His Leu Pro Asn Gln Ala Asn Ser Pro Pro  
 65 70 75 80  
 Val Ile Val Asn Thr Asp Thr Leu Glu Ala Pro Gly Tyr Glu Leu Gln  
 85 90 95  
 Val Asn Gly Thr Glu Gly Glu Met Glu Tyr Glu Glu Ile Thr Leu Glu  
 100 105 110  
 Arg Gly Asn Ser Gly Leu Gly Phe Ser Ile Ala Gly Gly Thr Asp Asn  
 115 120 125  
 Pro His Ile Gly Asp Asp Pro Ser Ile Phe Ile Thr Lys Ile Ile Pro  
 130 135 140  
 Gly Gly Ala Ala Ala Gln Asp Gly Arg Leu Arg Val Asn Asp Ser Ile  
 145 150 155 160  
 Leu Phe Val Asn Glu Val Asp Val Arg Glu Val Thr His Ser Ala Ala

-98-

165										170					175				
Val	Glu	Ala	Leu	Lys	Glu	Ala	Gly	Ser	Ile	Val	Arg	Leu	Tyr	Val	Met				
			180					185					190						
Arg	Arg	Lys	Pro	Pro	Ala	Glu	Lys	Val	Met	Glu	Ile	Lys	Leu	Ile	Lys				
		195					200					205							
Gly	Pro	Lys	Gly	Leu	Gly	Phe	Ser	Ile	Ala	Gly	Gly	Val	Gly	Asn	Gln				
	210					215					220								
His	Ile	Pro	Gly	Asp	Asn	Ser	Ile	Tyr	Val	Thr	Lys	Ile	Ile	Glu	Gly				
225					230					235					240				
Gly	Ala	Ala	His	Lys	Asp	Gly	Arg	Leu	Gln	Ile	Gly	Asp	Lys	Ile	Leu				
			245						250					255					
Ala	Val	Asn	Ser	Val	Gly	Leu	Glu	Asp	Val	Met	His	Glu	Asp	Ala	Val				
			260					265					270						
Ala	Ala	Leu	Lys	Asn	Thr	Tyr	Asp	Val	Val	Tyr	Leu	Lys	Val	Ala	Lys				
		275					280					285							
Pro	Ser	Asn	Ala	Tyr	Leu	Ser	Asp	Ser	Tyr	Ala	Pro	Pro	Asp	Ile	Thr				
	290					295					300								
Thr	Ser	Tyr	Ser	Gln	His	Leu	Asp	Asn	Glu	Ile	Ser	His	Ser	Ser	Tyr				
305				310						315					320				
Leu	Gly	Thr	Asp	Tyr	Pro	Thr	Ala	Met	Thr	Pro	Thr	Ser	Pro	Arg	Arg				
			325						330					335					
Tyr	Ser	Pro	Val	Ala	Lys	Asp	Leu	Leu	Gly	Glu	Glu	Asp	Ile	Pro	Arg				
			340					345					350						
Glu	Pro	Arg	Arg	Ile	Val	Ile	His	Arg	Gly	Ser	Thr	Gly	Leu	Gly	Phe				
	355						360					365							
Asn	Ile	Val	Gly	Gly	Glu	Asp	Gly	Glu	Gly	Ile	Phe	Ile	Ser	Phe	Ile				
	370					375					380								
Leu	Ala	Gly	Gly	Pro	Ala	Asp	Leu	Ser	Gly	Glu	Leu	Arg	Lys	Gly	Asp				
385				390						395					400				
Gln	Ile	Leu	Ser	Val	Asn	Gly	Val	Asp	Leu	Arg	Asn	Ala	Ser	His	Glu				
			405						410					415					
Gln	Ala	Ala	Ile	Ala	Leu	Lys	Asn	Ala	Gly	Gln	Thr	Val	Thr	Ile	Ile				
			420					425					430						
Ala	Gln	Tyr	Lys	Pro	Glu	Glu	Tyr	Ser	Arg	Phe	Glu	Ala	Lys	Ile	His				
		435					440					445							
Asp	Leu	Arg	Glu	Gln	Leu	Met	Asn	Ser	Ser	Leu	Gly	Ser	Gly	Thr	Ala				
	450					455					460								
Ser	Leu	Arg	Ser	Asn	Pro	Lys	Arg	Gly	Phe	Tyr	Ile	Arg	Ala	Leu	Phe				
465				470						475					480				
Asp	Tyr	Asp	Lys	Thr	Lys	Asp	Cys	Gly	Phe	Leu	Ser	Gln	Ala	Leu	Ser				

-99-

485										490					495				
Phe	Arg	Phe	Gly	Asp	Val	Leu	His	Val	Ile	Asp	Ala	Ser	Asp	Glu	Glu				
			500					505						510					
Trp	Trp	Gln	Ala	Arg	Arg	Val	His	Ser	Asp	Ser	Glu	Thr	Asp	Asp	Ile				
		515					520					525							
Gly	Phe	Ile	Pro	Ser	Lys	Arg	Arg	Val	Glu	Arg	Arg	Glu	Trp	Ser	Arg				
	530					535					540								
Leu	Lys	Ala	Lys	Asp	Trp	Gly	Ser	Ser	Ser	Gly	Ser	Gln	Gly	Arg	Glu				
545					550					555						560			
Asp	Ser	Val	Leu	Ser	Tyr	Glu	Thr	Val	Thr	Gln	Met	Glu	Val	His	Tyr				
				565					570					575					
Ala	Arg	Pro	Ile	Ile	Ile	Leu	Gly	Pro	Thr	Lys	Asp	Arg	Ala	Asn	Asp				
			580					585						590					
Asp	Leu	Leu	Ser	Glu	Phe	Pro	Asp	Lys	Phe	Gly	Ser	Cys	Val	Pro	His				
		595					600					605							
Thr	Thr	Arg	Pro	Lys	Arg	Glu	Tyr	Glu	Ile	Asp	Gly	Arg	Asp	Tyr	His				
	610					615					620								
Phe	Val	Ser	Ser	Arg	Glu	Lys	Met	Glu	Lys	Asp	Ile	Gln	Ala	His	Lys				
625					630					635					640				
Phe	Ile	Glu	Ala	Gly	Gln	Tyr	Asn	Ser	His	Leu	Tyr	Gly	Thr	Ser	Val				
				645					650					655					
Gln	Ser	Val	Arg	Glu	Val	Ala	Glu	Gln	Gly	Lys	His	Cys	Ile	Leu	Asp				
			660					665					670						
Val	Ser	Ala	Asn	Ala	Val	Arg	Arg	Leu	Gln	Ala	Ala	His	Leu	His	Pro				
		675					680					685							
Ile	Ala	Ile	Phe	Ile	Arg	Pro	Arg	Ser	Leu	Glu	Asn	Val	Leu	Glu	Ile				
	690					695					700								
Asn	Lys	Arg	Ile	Thr	Glu	Glu	Gln	Ala	Arg	Lys	Ala	Phe	Asp	Arg	Ala				
705					710					715					720				
Thr	Lys	Leu	Glu	Gln	Glu	Phe	Thr	Glu	Cys	Phe	Ser	Ala	Ile	Val	Glu				
				725					730					735					
Gly	Asp	Ser	Phe	Glu	Glu	Ile	Tyr	His	Lys	Val	Lys	Arg	Val	Ile	Glu				
			740					745					750						
Asp	Leu	Ser	Gly	Pro	Tyr	Ile	Trp	Val	Pro	Ala	Arg	Glu	Arg	Leu					
		755					760					765							

<210> 70  
 <211> 752  
 <212> PRT  
 <213> Homo Sapiens

<400> 70



-100-

Met Val Val Asp Glu Gln Gln Arg Leu Thr Ala Gln Leu Thr Leu Gln  
 1 5 10 15  
 Arg Gln Lys Ile Gln Glu Leu Thr Thr Asn Ala Lys Glu Thr His Thr  
 20 25 30  
 Lys Leu Ala Leu Ala Glu Ala Arg Val Gln Glu Glu Glu Gln Lys Ala  
 35 40 45  
 Thr Arg Leu Glu Lys Glu Leu Gln Thr Gln Thr Thr Lys Phe His Gln  
 50 55 60  
 Asp Gln Asp Thr Ile Met Ala Lys Leu Thr Asn Glu Asp Ser Gln Asn  
 65 70 75 80  
 Arg Gln Leu Gln Gln Lys Leu Ala Ala Leu Ser Arg Gln Ile Asp Glu  
 85 90 95  
 Leu Glu Glu Thr Asn Arg Ser Leu Arg Lys Ala Glu Glu Glu Leu Gln  
 100 105 110  
 Asp Ile Lys Glu Lys Ile Ser Lys Gly Glu Tyr Gly Asn Ala Gly Ile  
 115 120 125  
 Met Ala Glu Val Glu Glu Leu Ile Lys Met Glu Glu Gln Cys Arg Asp  
 130 135 140  
 Leu Asn Lys Arg Leu Glu Arg Glu Thr Leu Gln Ser Lys Asp Phe Lys  
 145 150 155 160  
 Leu Glu Val Glu Lys Leu Ser Lys Arg Ile Met Ala Leu Glu Lys Leu  
 165 170 175  
 Glu Asp Ala Phe Asn Lys Ser Lys Gln Glu Cys Tyr Ser Leu Lys Cys  
 180 185 190  
 Asn Leu Glu Lys Glu Arg Met Thr Thr Lys Gln Leu Ser Gln Glu Leu  
 195 200 205  
 Glu Ser Leu Lys Val Arg Ile Lys Glu Leu Glu Ala Ile Glu Ser Arg  
 210 215 220  
 Leu Glu Lys Thr Glu Phe Thr Leu Lys Glu Asp Leu Thr Lys Leu Lys  
 225 230 235 240  
 Thr Leu Thr Val Met Phe Val Asp Glu Arg Lys Thr Met Ser Glu Lys  
 245 250 255  
 Leu Lys Lys Thr Glu Asp Lys Leu Gln Ala Ala Ser Ser Gln Leu Gln  
 260 265 270  
 Val Glu Gln Asn Lys Val Thr Thr Val Thr Glu Lys Leu Ile Glu Glu  
 275 280 285  
 Thr Lys Arg Ala Leu Lys Ser Lys Thr Asp Val Glu Glu Lys Met Tyr  
 290 295 300  
 Ser Val Thr Lys Glu Arg Asp Asp Leu Lys Asn Lys Leu Lys Ala Glu  
 305 310 315 320

-101-

Glu Glu Lys Gly Asn Asp Leu Leu Ser Arg Val Asn Met Leu Lys Asn  
 325 330 335  
 Arg Leu Gln Ser Leu Glu Ala Ile Glu Lys Asp Phe Leu Lys Asn Lys  
 340 345 350  
 Leu Asn Gln Asp Ser Gly Lys Ser Thr Thr Ala Leu His Gln Glu Asn  
 355 360 365  
 Asn Lys Ile Lys Glu Leu Ser Gln Glu Val Glu Arg Leu Lys Leu Lys  
 370 375 380  
 Leu Lys Asp Met Lys Ala Ile Glu Asp Asp Leu Met Lys Thr Glu Asp  
 385 390 395 400  
 Glu Tyr Glu Thr Leu Glu Arg Arg Tyr Ala Asn Glu Arg Asp Lys Ala  
 405 410 415  
 Gln Phe Leu Ser Lys Glu Leu Glu His Val Lys Met Glu Leu Ala Lys  
 420 425 430  
 Tyr Lys Leu Ala Glu Lys Thr Glu Thr Ser His Glu Gln Trp Leu Phe  
 435 440 445  
 Lys Arg Leu Gln Glu Glu Glu Ala Lys Ser Gly His Leu Ser Arg Glu  
 450 455 460  
 Val Asp Ala Leu Lys Glu Lys Ile His Glu Tyr Met Ala Thr Glu Asp  
 465 470 475 480  
 Leu Ile Cys His Leu Gln Gly Asp His Ser Val Cys Lys Lys Lys Leu  
 485 490 495  
 Asn Gln Gln Glu Asn Arg Asn Arg Asp Leu Gly Arg Glu Ile Glu Asn  
 500 505 510  
 Leu Thr Lys Glu Leu Glu Arg Tyr Arg His Phe Ser Lys Ser Leu Arg  
 515 520 525  
 Pro Ser Leu Asn Gly Arg Arg Ile Ser Asp Pro Gln Val Phe Ser Lys  
 530 535 540  
 Glu Val Gln Thr Glu Ala Val Asp Asn Glu Pro Pro Asp Tyr Lys Ser  
 545 550 555 560  
 Leu Ile Pro Leu Glu Arg Ala Val Ile Asn Gly Gln Leu Tyr Glu Glu  
 565 570 575  
 Ser Glu Asn Gln Asp Glu Asp Pro Asn Asp Glu Gly Ser Val Leu Ser  
 580 585 590  
 Phe Lys Cys Ser Gln Ser Thr Pro Cys Pro Val Asn Arg Lys Leu Trp  
 595 600 605  
 Ile Pro Trp Met Lys Ser Lys Glu Gly His Leu Gln Asn Gly Lys Met  
 610 615 620  
 Gln Thr Lys Pro Asn Ala Asn Phe Val Gln Pro Gly Asp Leu Val Leu  
 625 630 635 640

-102-

Ser His Thr Pro Gly Gln Pro Leu His Ile Lys Val Thr Pro Asp His  
645 650 655

Val Gln Asn Thr Ala Thr Leu Glu Ile Thr Ser Pro Thr Thr Glu Ser  
660 665 670

Pro His Ser Tyr Thr Ser Thr Ala Val Ile Pro Asn Cys Gly Thr Pro  
675 680 685

Lys Gln Arg Ile Thr Ile Leu Gln Asn Ala Ser Ile Thr Pro Val Lys  
690 695 700

Ser Lys Thr Ser Thr Glu Asp Leu Met Asn Leu Glu Gln Gly Met Ser  
705 710 715 720

Pro Ile Thr Met Ala Thr Phe Ala Arg Ala Gln Thr Pro Glu Ser Cys  
725 730 735

Gly Ser Leu Thr Pro Glu Arg Thr Met Ser Leu Phe Arg Phe Trp Leu  
740 745 750

<210> 71  
<211> 105  
<212> PRT  
<213> Homo Sapiens

<400> 71

Met Gln Thr Gln Ala Glu Ala Leu Thr Ala Gly Met Ala Gly Val Ala  
1 5 10 15

Thr Ala Ala Ala Gly Ala Trp Thr Gln Pro Gln Leu Arg Pro Val Glu  
20 25 30

Leu Pro Gln Arg Thr Arg Gln Val Arg Ala Glu Thr Pro Arg Leu Pro  
35 40 45

Gln Gly Val Thr Asn Ala Ala Ala His Ile His Pro Gln Arg Ala Phe  
50 55 60

Pro Asp Pro Leu Gly Gly Gly Asn Arg Pro Trp Val Pro Gly Thr Arg  
65 70 75 80

Cys Arg Ala Pro Pro Lys Gly Gly Trp Glu Gly Ser His Ser Glu Trp  
85 90 95

Gln Asp Pro Gly Arg Pro Leu Glu Ser  
100 105

<210> 72  
<211> 225  
<212> PRT  
<213> Homo Sapiens

<400> 72

Met Asn Ser Asn Val Glu Asn Leu Pro Pro His Ile Ile Arg Leu Val  
1 5 10 15

Tyr Lys Glu Val Thr Thr Leu Thr Ala Asp Pro Pro Asp Gly Ile Lys

-103-

20					25					30					
Val	Phe	Pro	Asn	Glu	Glu	Asp	Leu	Thr	Asp	Leu	Gln	Val	Thr	Ile	Glu
	35						40					45			
Gly	Pro	Glu	Gly	Thr	Pro	Tyr	Ala	Gly	Gly	Leu	Phe	Arg	Met	Lys	Leu
	50					55					60				
Leu	Leu	Gly	Lys	Asp	Phe	Pro	Ala	Ser	Pro	Pro	Lys	Gly	Tyr	Phe	Leu
65					70					75					80
Thr	Lys	Ile	Phe	His	Pro	Asn	Val	Gly	Ala	Asn	Gly	Glu	Ile	Cys	Val
				85					90					95	
Asn	Val	Leu	Lys	Arg	Asp	Trp	Thr	Ala	Glu	Leu	Gly	Ile	Arg	His	Val
			100					105					110		
Leu	Leu	Thr	Ile	Lys	Cys	Leu	Leu	Ile	His	Pro	Asn	Pro	Glu	Ser	Ala
			115					120				125			
Leu	Asn	Glu	Glu	Ala	Gly	Arg	Leu	Leu	Leu	Glu	Asn	Tyr	Glu	Glu	Tyr
	130					135					140				
Ala	Ala	Arg	Ala	Arg	Leu	Leu	Thr	Glu	Ile	His	Gly	Gly	Ala	Gly	Gly
145						150					155				160
Pro	Ser	Gly	Arg	Ala	Glu	Ala	Gly	Arg	Ala	Leu	Ala	Ser	Gly	Thr	Glu
				165					170					175	
Ala	Ser	Ser	Thr	Asp	Pro	Gly	Ala	Pro	Gly	Gly	Pro	Gly	Gly	Ala	Glu
			180					185					190		
Gly	Pro	Met	Ala	Lys	Lys	His	Ala	Gly	Glu	Arg	Asp	Lys	Lys	Leu	Ala
	195						200					205			
Ala	Lys	Lys	Lys	Thr	Asp	Lys	Lys	Arg	Ala	Leu	Arg	Ala	Leu	Arg	Arg
	210					215					220				

Leu  
225

<210> 73  
 <211> 208  
 <212> PRT  
 <213> Homo Sapiens

<400> 73

Pro	His	Pro	Met	Pro	Leu	Arg	Leu	Pro	Thr	Pro	Gly	Gly	Asn	Gly	Gln
1				5					10					15	
Ala	Gly	Arg	Pro	Cys	Arg	Ser	Thr	Gly	Gln	Gly	Asn	Lys	Arg	Gly	Ala
			20					25					30		
Ala	Lys	Cys	Pro	Asp	Gln	Glu	Ala	Pro	Tyr	Phe	Arg	Gly	Lys	Gly	His
		35					40					45			
Val	Val	Leu	Ala	Pro	His	Pro	Ile	Pro	Ser	His	Leu	Gly	Ala	Pro	Pro
	50					55					60				

-104-

Pro His Ser Leu His Leu Gln Gly Asn Leu Val Leu His Ala Gly Ala  
 65 70 75 80  
 Leu Ile Phe Leu Gly Gly Gly Arg Arg Glu Gly Trp Pro Leu Gly Glu  
 85 90 95  
 Pro Pro Thr Trp Gly Ser Ser Lys Asp Gly Ala Asp Thr Ser Trp Ala  
 100 105 110  
 Val Pro Ala Pro Pro Ala His Gln Asp Pro Pro Leu Ala Ala Ile Gln  
 115 120 125  
 Leu Val Pro Lys His Leu Lys Pro Gln Ser Trp Ile Arg Ser Ser Ile  
 130 135 140  
 Pro Pro Leu Leu Gly Pro Leu Gly Arg Leu Leu Pro Thr Asp Arg Cys  
 145 150 155 160  
 Ser Pro His Leu Gly Arg Phe Trp Val Gly Lys Pro Pro His Thr Gly  
 165 170 175  
 Asn Ser His Leu Ala Pro Cys Arg Ile His Pro Arg Ile Arg Pro Phe  
 180 185 190  
 Ile His Arg Ser Val His Pro Cys Pro Gln Leu Thr Ala Arg His His  
 195 200 205

<210> 74  
 <211> 109  
 <212> PRT  
 <213> Homo Sapiens

<400> 74

Met Ala Tyr Gln Leu Tyr Arg Asn Thr Thr Leu Gly Asn Ser Leu Gln  
 1 5 10 15  
 Glu Ser Leu Asp Glu Leu Ile Gln Ser Gln Gln Ile Thr Pro Gln Leu  
 20 25 30  
 Ala Leu Gln Val Leu Leu Gln Phe Asp Lys Ala Ile Asn Ala Ala Leu  
 35 40 45  
 Ala Gln Arg Val Arg Asn Arg Val Asn Phe Arg Gly Ser Leu Asn Thr  
 50 55 60  
 Tyr Arg Phe Cys Asp Asn Val Trp Thr Phe Val Leu Asn Asp Val Glu  
 65 70 75 80  
 Phe Arg Glu Val Thr Glu Leu Ile Lys Val Asp Lys Val Lys Ile Val  
 85 90 95  
 Ala Cys Asp Gly Lys Asn Thr Gly Ser Asn Thr Thr Glu  
 100 105

<210> 75  
 <211> 693  
 <212> PRT  
 <213> Homo Sapiens

-105-

&lt;400&gt; 75

```

Met Ala Leu Cys Asn Gly Asp Ser Lys Leu Glu Asn Ala Gly Gly Asp
1          5          10          15
Leu Lys Asp Gly His His His Tyr Glu Gly Ala Val Val Ile Leu Asp
          20          25          30
Ala Gly Ala Gln Tyr Gly Lys Val Ile Asp Arg Arg Val Arg Glu Leu
          35          40          45
Phe Val Gln Ser Glu Ile Phe Pro Leu Glu Thr Pro Ala Phe Ala Ile
          50          55          60
Lys Glu Gln Gly Phe Arg Ala Ile Ile Ile Ser Gly Gly Pro Asn Ser
65          70          75          80
Val Tyr Ala Glu Asp Ala Pro Trp Phe Asp Pro Ala Ile Phe Thr Ile
          85          90          95
Gly Lys Pro Val Leu Gly Ile Cys Tyr Gly Met Gln Met Met Asn Lys
          100          105          110
Val Phe Gly Gly Thr Val His Lys Lys Ser Val Arg Glu Asp Gly Val
          115          120          125
Phe Asn Ile Ser Val Asp Asn Thr Cys Ser Leu Phe Arg Gly Leu Gln
          130          135          140
Lys Glu Glu Val Val Leu Leu Thr His Gly Asp Ser Val Asp Lys Val
145          150          155          160
Ala Asp Gly Phe Lys Val Val Ala Arg Ser Gly Asn Ile Val Ala Gly
          165          170          175
Ile Ala Asn Glu Ser Lys Lys Leu Tyr Gly Ala Gln Phe His Pro Glu
          180          185          190
Val Gly Leu Thr Glu Asn Gly Lys Val Ile Leu Lys Asn Phe Leu Tyr
          195          200          205
Asp Ile Ala Gly Cys Ser Gly Thr Phe Thr Val Gln Asn Arg Glu Leu
210          215          220
Glu Cys Ile Arg Glu Ile Lys Glu Arg Val Gly Thr Ser Lys Val Leu
225          230          235          240
Val Leu Leu Ser Gly Gly Val Asp Ser Thr Val Cys Thr Ala Leu Leu
          245          250          255
Asn Arg Ala Leu Asn Gln Glu Gln Val Ile Ala Val His Ile Asp Asn
          260          265          270
Gly Phe Met Arg Lys Arg Glu Ser Gln Ser Val Glu Glu Ala Leu Lys
          275          280          285
Lys Leu Gly Ile Gln Val Lys Val Ile Asn Ala Ala His Ser Phe Tyr
          290          295          300
Asn Gly Thr Thr Thr Leu Pro Ile Ser Asp Glu Asp Arg Thr Pro Arg

```

-106-

305		310		315		320
Lys Arg Ile Ser	Lys Thr Leu Asn Met Thr Thr Ser Pro Glu Glu Lys					
	325			330		335
Arg Lys Ile Ile	Gly Asp Thr Phe Val Lys Ile Ala Asn Glu Val Ile					
	340		345			350
Gly Glu Met Asn Leu Lys Pro Glu Glu Val Phe Leu Ala Gln Gly Thr						
	355		360			365
Leu Arg Pro Asp Leu Ile Glu Ser Ala Ser Leu Val Ala Ser Gly Lys						
	370		375			380
Ala Glu Leu Ile Lys Thr His His Asn Asp Thr Glu Leu Ile Arg Lys						
	385		390			395
Leu Arg Glu Glu Gly Lys Val Ile Glu Pro Leu Lys Asp Phe His Lys						
		405		410		415
Asp Glu Val Arg Ile Leu Gly Arg Glu Leu Gly Leu Pro Glu Glu Leu						
	420		425			430
Val Ser Arg His Pro Phe Pro Gly Pro Gly Leu Ala Ile Arg Val Ile						
	435		440			445
Cys Ala Glu Glu Pro Tyr Ile Cys Lys Asp Phe Pro Glu Thr Asn Asn						
	450		455			460
Ile Leu Lys Ile Val Ala Asp Phe Ser Ala Ser Val Lys Lys Pro His						
	465		470			475
Thr Leu Leu Gln Arg Val Lys Ala Cys Thr Thr Glu Glu Asp Gln Glu						
	485		490			495
Lys Leu Met Gln Ile Thr Ser Leu His Ser Leu Asn Ala Phe Leu Leu						
	500		505			510
Pro Ile Lys Thr Val Gly Val Gln Gly Asp Cys Arg Ser Tyr Ser Tyr						
	515		520			525
Val Cys Gly Ile Ser Ser Lys Asp Glu Pro Asp Trp Glu Ser Leu Ile						
	530		535			540
Phe Leu Ala Arg Leu Ile Pro Arg Met Cys His Asn Val Asn Arg Val						
	545		550			555
Val Tyr Ile Phe Gly Pro Pro Val Lys Glu Pro Pro Thr Asp Val Thr						
	565		570			575
Pro Thr Phe Leu Thr Thr Gly Val Leu Ser Thr Leu Arg Gln Ala Asp						
	580		585			590
Phe Glu Ala His Asn Ile Leu Arg Glu Ser Gly Tyr Ala Gly Lys Ile						
	595		600			605
Ser Gln Met Pro Val Ile Leu Thr Pro Leu His Phe Asp Arg Asp Pro						
	610		615			620
Leu Gln Lys Gln Pro Ser Cys Gln Arg Ser Val Val Ile Arg Thr Phe						

-107-

[illegible]

<210>	76
<211>	143
<212>	PRT
<213>	Homo Sapiens

<400> 76

Met Ser Gly Arg Gly Lys Thr Gly Gly Lys Ala Arg Ala Lys Ala Lys  
1 5 10 15

Ser Arg Ser Ser Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val His  
20 25 30

Arg Leu Leu Arg Lys Gly His Tyr Ala Glu Arg Val Gly Ala Gly Ala  
35 40 45

Pro Val Tyr Leu Ala Ala Val Leu Glu Tyr Leu Thr Ala Glu Ile Leu  
50 55 60

Glu Leu Ala Gly Asn Ala Ala Arg Asp Asn Lys Lys Thr Arg Ile Ile  
65 70 75 80

Pro Arg His Leu Gln Leu Ala Ile Arg Asn Asp Glu Glu Leu Asn Lys  
85 90 95

Leu Leu Gly Gly Val Thr Ile Ala Gln Gly Gly Val Leu Pro Asn Ile  
100 105 110

Gln Ala Val Leu Leu Pro Lys Lys Thr Ser Ala Thr Val Gly Pro Lys  
115 120 125

Ala Pro Ser Gly Gly Lys Lys Ala Thr Gln Ala Ser Gln Glu Tyr  
130 135 140

<210>	77
<211>	126
<212>	PRT
<213>	Homo Sapiens

<400> 77

Met Pro Glu Pro Ala Lys Ser Ala Pro Ala Pro Lys Lys Gly Ser Lys  
1 5 10 15

Lys Ala Val Thr Lys Ala Gln Lys Lys Asp Gly Lys Lys Arg Lys Arg  
20 25 30



-108-

Ser Arg Lys Glu Ser Tyr Ser Val Tyr Val Tyr Lys Val Leu Lys Gln  
 35 40 45  
 Val His Pro Asp Thr Gly Ile Ser Ser Lys Ala Met Gly Ile Met Asn  
 50 55 60  
 Ser Phe Val Asn Asp Ile Phe Glu Arg Ile Ala Gly Glu Ala Ser Arg  
 65 70 75 80  
 Leu Ala His Tyr Asn Lys Arg Ser Thr Ile Thr Ser Arg Glu Ile Gln  
 85 90 95  
 Thr Ala Val Arg Leu Leu Leu Pro Gly Glu Leu Ala Lys His Ala Val  
 100 105 110  
 Ser Glu Gly Thr Lys Ala Val Thr Lys Tyr Thr Ser Ser Lys  
 115 120 125  
 <210> 78  
 <211> 664  
 <212> PRT  
 <213> Homo Sapiens  
 <400> 78  
 Met Lys Thr Gly Pro Phe Phe Leu Cys Leu Leu Gly Thr Ala Ala Ala  
 1 5 10 15  
 Ile Pro Thr Asn Ala Arg Leu Leu Ser Asp His Ser Lys Pro Thr Ala  
 20 25 30  
 Glu Thr Val Ala Pro Asp Asn Thr Ala Ile Pro Ser Leu Trp Ala Glu  
 35 40 45  
 Ala Glu Glu Asn Glu Lys Glu Thr Ala Val Ser Thr Glu Asp Asp Ser  
 50 55 60  
 His His Lys Ala Glu Lys Ser Ser Val Leu Lys Ser Lys Glu Glu Ser  
 65 70 75 80  
 His Glu Gln Ser Ala Glu Gln Gly Lys Ser Ser Ser Gln Glu Leu Gly  
 85 90 95  
 Leu Lys Asp Gln Glu Asp Ser Asp Gly His Leu Ser Val Asn Leu Glu  
 100 105 110  
 Tyr Ala Pro Thr Glu Gly Thr Leu Asp Ile Lys Glu Asp Met Ile Glu  
 115 120 125  
 Pro Gln Glu Lys Lys Leu Ser Glu Asn Thr Asp Phe Leu Ala Pro Gly  
 130 135 140  
 Val Ser Ser Phe Thr Asp Ser Asn Gln Gln Glu Ser Ile Thr Lys Arg  
 145 150 155 160  
 Glu Glu Asn Gln Glu Gln Pro Arg Asn Tyr Ser His His Gln Leu Asn  
 165 170 175  
 Arg Ser Ser Lys His Ser Gln Gly Leu Arg Asp Gln Gly Asn Gln Glu

-109-

180					185					190					
Gln	Asp	Pro	Asn	Ile	Ser	Asn	Gly	Glu	Glu	Glu	Glu	Glu	Lys	Glu	Pro
		195					200					205			
Gly	Glu	Val	Gly	Thr	His	Asn	Asp	Asn	Gln	Glu	Arg	Lys	Thr	Glu	Leu
		210					215					220			
Pro	Arg	Glu	His	Ala	Asn	Ser	Lys	Gln	Glu	Glu	Asp	Asn	Thr	Gln	Ser
		225					230					235			240
Asp	Asp	Ile	Leu	Glu	Glu	Ser	Asp	Gln	Pro	Thr	Gln	Val	Ser	Lys	Met
				245					250					255	
Gln	Glu	Asp	Glu	Phe	Asp	Gln	Gly	Asn	Gln	Glu	Gln	Glu	Asp	Asn	Ser
				260					265					270	
Asn	Ala	Glu	Met	Glu	Glu	Glu	Asn	Ala	Ser	Asn	Val	Asn	Lys	His	Ile
				275					280					285	
Gln	Glu	Thr	Glu	Trp	Gln	Ser	Gln	Glu	Gly	Lys	Thr	Gly	Leu	Glu	Ala
				290					295					300	
Ile	Ser	Asn	His	Lys	Glu	Thr	Glu	Glu	Lys	Thr	Val	Ser	Glu	Ala	Leu
				305					310					315	320
Leu	Met	Glu	Pro	Thr	Asp	Asp	Gly	Asn	Thr	Thr	Pro	Arg	Asn	His	Gly
				325					330					335	
Val	Asp	Asp	Asp	Gly	Asp	Asp	Asp	Gly	Asp	Asp	Gly	Gly	Thr	Asp	Gly
				340					345					350	
Pro	Arg	His	Ser	Ala	Ser	Asp	Asp	Tyr	Phe	Ile	Pro	Ser	Gln	Ala	Phe
				355					360					365	
Leu	Glu	Ala	Glu	Arg	Ala	Gln	Ser	Ile	Ala	Tyr	His	Leu	Lys	Ile	Glu
				370					375					380	
Glu	Gln	Arg	Glu	Lys	Val	His	Glu	Asn	Glu	Asn	Ile	Gly	Thr	Thr	Glu
				385					390					395	400
Pro	Gly	Glu	His	Gln	Glu	Ala	Lys	Lys	Ala	Glu	Asn	Ser	Ser	Asn	Glu
				405					410					415	
Glu	Glu	Thr	Ser	Ser	Glu	Gly	Asn	Met	Arg	Val	His	Ala	Val	Asp	Ser
				420					425					430	
Cys	Met	Ser	Phe	Gln	Cys	Lys	Arg	Gly	His	Ile	Cys	Lys	Ala	Asp	Gln
				435					440					445	
Gln	Gly	Lys	Pro	His	Cys	Val	Cys	Gln	Asp	Pro	Val	Thr	Cys	Pro	Pro
				450					455					460	
Thr	Lys	Pro	Leu	Asp	Gln	Val	Cys	Gly	Thr	Asp	Asn	Gln	Thr	Tyr	Ala
				465					470					475	480
Ser	Ser	Cys	His	Leu	Phe	Ala	Thr	Lys	Cys	Arg	Leu	Glu	Gly	Thr	Lys
				485					490					495	
Lys	Gly	His	Gln	Leu	Gln	Leu	Asp	Tyr	Phe	Gly	Ala	Cys	Lys	Ser	Ile

-110-

500	505	510
Pro Thr Cys Thr Asp Phe Glu Val Ile Gln Phe Pro Leu Arg Met Arg		
515	520	525
Asp Trp Leu Lys Asn Ile Leu Met Gln Leu Tyr Glu Ala Asn Ser Glu		
530	535	540
His Ala Gly Tyr Leu Asn Glu Lys Gln Arg Asn Lys Val Lys Lys Ile		
545	550	555
Tyr Leu Asp Glu Lys Arg Leu Leu Ala Gly Asp His Pro Ile Asp Leu		
565	570	575
Leu Leu Arg Asp Phe Lys Lys Asn Tyr His Met Tyr Val Tyr Pro Val		
580	585	590
His Trp Gln Phe Ser Glu Leu Asp Gln His Pro Met Asp Arg Val Leu		
595	600	605
Thr His Ser Glu Leu Ala Pro Leu Arg Ala Ser Leu Val Pro Met Glu		
610	615	620
His Cys Ile Thr Arg Phe Phe Glu Glu Cys Asp Pro Asn Lys Asp Lys		
625	630	635
His Ile Thr Leu Lys Glu Trp Gly His Cys Phe Gly Ile Lys Glu Glu		
645	650	655
Asp Ile Asp Glu Asn Leu Leu Phe		
660		
<210> 79		
<211> 460		
<212> PRT		
<213> Homo Sapiens		
<400> 79		
Ala Lys Leu Ala Thr Lys Ser Pro Thr Ile Thr Met Met Leu Ser Thr		
1	5	10
Glu Gly Arg Glu Gly Phe Val Val Lys Val Arg Gly Leu Pro Trp Ser		
20	25	30
Cys Ser Ala Asp Glu Val Met Arg Phe Phe Ser Asp Cys Lys Ile Gln		
35	40	45
Asn Gly Thr Ser Gly Ile Arg Phe Ile Tyr Thr Arg Glu Gly Arg Pro		
50	55	60
Ser Gly Glu Ala Phe Val Glu Leu Glu Ser Glu Glu Glu Val Lys Leu		
65	70	75
Ala Leu Lys Lys Asp Arg Glu Thr Met Gly His Arg Tyr Val Glu Val		
85	90	95
Phe Lys Ser Asn Ser Val Glu Met Asp Trp Val Leu Lys His Thr Gly		
100	105	110

Pro	Asn	Ser	Pro	Asp	Thr	Ala	Asn	Asp	Gly	Phe	Val	Arg	Leu	Arg	Gly
		115					120					125			
Leu	Pro	Phe	Gly	Cys	Ser	Lys	Glu	Glu	Ile	Val	Gln	Phe	Phe	Ser	Gly
	130					135					140				
Leu	Glu	Ile	Val	Pro	Asn	Gly	Met	Thr	Leu	Pro	Val	Asp	Phe	Gln	Gly
145					150					155					160
Arg	Ser	Thr	Gly	Glu	Ala	Phe	Val	Gln	Phe	Ala	Ser	Gln	Glu	Ile	Ala
				165					170					175	
Glu	Lys	Ala	Leu	Lys	Lys	His	Lys	Glu	Arg	Ile	Gly	His	Arg	Tyr	Ile
			180					185					190		
Glu	Ile	Phe	Lys	Ser	Ser	Arg	Ala	Glu	Val	Arg	Thr	His	Tyr	Asp	Pro
		195					200					205			
Pro	Arg	Lys	Leu	Met	Ala	Met	Gln	Arg	Pro	Gly	Pro	Tyr	Asp	Arg	Pro
	210					215					220				
Gly	Ala	Gly	Arg	Gly	Tyr	Asn	Ser	Ile	Gly	Arg	Gly	Ala	Gly	Phe	Glu
225					230					235					240
Arg	Met	Arg	Arg	Gly	Ala	Tyr	Gly	Gly	Gly	Tyr	Gly	Gly	Tyr	Asp	Asp
				245					250					255	
Tyr	Gly	Gly	Tyr	Asn	Asp	Gly	Tyr	Gly	Phe	Gly	Ser	Asp	Arg	Phe	Gly
			260					265					270		
Arg	Asp	Leu	Asn	Tyr	Cys	Phe	Ser	Gly	Met	Ser	Asp	His	Arg	Tyr	Gly
		275					280					285			
Asp	Gly	Gly	Ser	Ser	Phe	Gln	Ser	Thr	Thr	Gly	His	Cys	Val	His	Met
	290					295					300				
Arg	Gly	Leu	Pro	Tyr	Arg	Ala	Thr	Glu	Asn	Asp	Ile	Tyr	Asn	Phe	Phe
305					310					315					320
Ser	Pro	Leu	Asn	Pro	Met	Arg	Val	His	Ile	Glu	Ile	Gly	Pro	Asp	Gly
				325					330					335	
Arg	Val	Thr	Gly	Glu	Ala	Asp	Val	Glu	Phe	Ala	Thr	His	Glu	Asp	Ala
			340					345					350		
Val	Ala	Ala	Met	Ala	Lys	Asp	Lys	Ala	Asn	Met	Gln	His	Arg	Tyr	Val
		355					360					365			
Glu	Leu	Phe	Leu	Asn	Ser	Thr	Ala	Gly	Thr	Ser	Gly	Gly	Ala	Tyr	Asp
	370					375					380				
His	Ser	Tyr	Val	Glu	Leu	Phe	Leu	Asn	Ser	Thr	Ala	Gly	Ala	Ser	Gly
385					390					395					400
Gly	Ala	Tyr	Gly	Ser	Gln	Met	Met	Gly	Gly	Met	Gly	Leu	Ser	Asn	Gln
				405					410					415	
Ser	Ser	Tyr	Gly	Gly	Pro	Ala	Ser	Gln	Gln	Leu	Ser	Gly	Gly	Tyr	Gly
			420					425					430		

-112-

Gly Gly Tyr Gly Gly Gln Ser Ser Met Ser Gly Tyr Asp Gln Val Leu  
 435 440 445

Gln Glu Asn Ser Ser Asp Tyr Gln Ser Asn Leu Ala  
 450 455 460

<210> 80

<211> 432

<212> PRT

<213> Homo Sapiens

<400> 80

Met Asp Glu Ala Val Gly Asp Leu Lys Gln Ala Leu Pro Cys Val Ala  
 1 5 10 15

Glu Ser Pro Thr Val His Val Glu Val His Gln Arg Gly Ser Ser Thr  
 20 25 30

Ala Lys Lys Glu Asp Ile Asn Leu Ser Val Arg Lys Leu Leu Asn Arg  
 35 40 45

His Asn Ile Val Phe Gly Asp Tyr Thr Trp Thr Glu Phe Asp Glu Pro  
 50 55 60

Phe Leu Thr Arg Asn Val Gln Ser Val Ser Ile Ile Asp Thr Glu Leu  
 65 70 75 80

Lys Val Lys Asp Ser Gln Pro Ile Asp Leu Ser Ala Cys Thr Val Ala  
 85 90 95

Leu His Ile Phe Gln Leu Asn Glu Asp Gly Pro Ser Ser Glu Asn Leu  
 100 105 110

Glu Glu Glu Thr Glu Asn Ile Ile Ala Ala Asn His Trp Val Leu Pro  
 115 120 125

Ala Ala Glu Phe His Gly Leu Trp Asp Ser Leu Val Tyr Asp Val Glu  
 130 135 140

Val Lys Ser His Leu Leu Asp Tyr Val Met Thr Thr Leu Leu Phe Ser  
 145 150 155 160

Asp Lys Asn Val Asn Ser Asn Leu Ile Thr Trp Asn Arg Val Val Leu  
 165 170 175

Leu His Gly Pro Pro Gly Thr Gly Lys Thr Ser Leu Cys Lys Ala Leu  
 180 185 190

Ala Gln Lys Leu Thr Ile Arg Leu Ser Ser Arg Tyr Arg Tyr Gly Gln  
 195 200 205

Leu Ile Glu Ile Asn Ser His Ser Leu Phe Ser Lys Trp Phe Ser Glu  
 210 215 220

Ser Gly Lys Leu Val Thr Lys Met Phe Gln Lys Ile Gln Asp Leu Ile  
 225 230 235 240

Asp Asp Lys Asp Ala Leu Val Phe Val Leu Ile Asp Glu Val Glu Ser  
 245 250 255

-113-

Leu Thr Ala Ala Arg Asn Ala Cys Arg Ala Gly Thr Glu Pro Ser Asp  
                   260                                  265                                  270  
 Ala Ile Arg Val Val Asn Ala Val Leu Thr Gln Ile Asp Gln Ile Lys  
                   275                                  280                                  285  
 Arg His Ser Asn Val Val Ile Leu Thr Thr Ser Asn Ile Thr Glu Lys  
                   290                                  295                                  300  
 Ile Asp Val Ala Phe Val Asp Arg Ala Asp Ile Lys Gln Tyr Ile Gly  
 305                                  310                                  315                                  320  
 Pro Pro Ser Ala Ala Ala Ile Phe Lys Ile Tyr Leu Ser Cys Leu Glu  
                                   325                                  330                                  335  
 Glu Leu Met Lys Cys Gln Ile Ile Tyr Pro Arg Gln Gln Leu Leu Thr  
                   340                                  345                                  350  
 Leu Arg Glu Leu Glu Met Ile Gly Phe Ile Glu Asn Asn Val Ser Lys  
                   355                                  360                                  365  
 Leu Ser Leu Leu Leu Asn Asp Ile Ser Arg Lys Ser Glu Gly Leu Ser  
                   370                                  375                                  380  
 Gly Arg Val Leu Arg Lys Leu Pro Phe Leu Ala His Ala Leu Tyr Val  
 385                                  390                                  395                                  400  
 Gln Ala Pro Thr Val Thr Ile Glu Gly Phe Leu Gln Ala Leu Ser Leu  
                   405                                  410                                  415  
 Ala Val Asp Lys Gln Phe Glu Glu Arg Lys Lys Leu Ala Ala Tyr Ile  
                   420                                  425                                  430

<210> 81  
 <211> 653  
 <212> PRT  
 <213> Homo Sapiens

<400> 81

Met Arg Pro Leu Arg Pro Arg Ala Ala Leu Leu Ala Leu Leu Ala Ser  
 1                  5                                  10                                  15  
 Leu Leu Ala Ala Pro Pro Val Ala Pro Ala Glu Ala Pro His Leu Val  
                   20                                  25                                  30  
 Gln Val Asp Ala Ala Arg Ala Leu Trp Pro Leu Arg Arg Phe Trp Arg  
                   35                                  40                                  45  
 Ser Thr Gly Phe Cys Pro Pro Leu Pro His Ser Gln Ala Asp Gln Tyr  
                   50                                  55                                  60  
 Val Leu Ser Trp Asp Gln Gln Leu Asn Leu Ala Tyr Val Gly Ala Val  
 65                                  70                                  75                                  80  
 Pro His Arg Gly Ile Lys Gln Val Arg Thr His Trp Leu Leu Glu Leu  
                   85                                  90                                  95  
 Val Thr Thr Arg Gly Ser Thr Gly Arg Gly Leu Ser Tyr Asn Phe Thr

-114-

100					105					110					
His	Leu	Asp	Gly	Tyr	Leu	Asp	Leu	Leu	Arg	Glu	Asn	Gln	Leu	Leu	Pro
	115						120					125			
Gly	Phe	Glu	Leu	Met	Gly	Ser	Ala	Ser	Gly	His	Phe	Thr	Asp	Phe	Glu
	130					135					140				
Asp	Lys	Gln	Gln	Val	Phe	Glu	Trp	Lys	Asp	Leu	Val	Ser	Ser	Leu	Ala
145						150					155				160
Arg	Arg	Tyr	Ile	Gly	Arg	Tyr	Gly	Leu	Ala	His	Val	Ser	Lys	Trp	Asn
				165					170						175
Phe	Glu	Thr	Trp	Asn	Glu	Pro	Asp	His	His	Asp	Phe	Asp	Asn	Val	Ser
			180					185						190	
Met	Thr	Met	Gln	Gly	Phe	Leu	Asn	Tyr	Tyr	Asp	Ala	Cys	Ser	Glu	Gly
		195					200					205			
Leu	Arg	Ala	Ala	Ser	Pro	Ala	Leu	Arg	Leu	Gly	Gly	Pro	Gly	Asp	Ser
	210					215					220				
Phe	His	Thr	Pro	Pro	Arg	Ser	Pro	Leu	Ser	Trp	Gly	Leu	Leu	Arg	His
225						230					235				240
Cys	His	Asp	Gly	Thr	Asn	Phe	Phe	Thr	Gly	Glu	Ala	Gly	Val	Arg	Leu
				245					250					255	
Asp	Tyr	Ile	Ser	Leu	His	Arg	Lys	Gly	Ala	Arg	Ser	Ser	Ile	Ser	Ile
			260					265					270		
Leu	Glu	Gln	Glu	Lys	Val	Val	Ala	Gln	Gln	Ile	Arg	Gln	Leu	Phe	Pro
		275					280					285			
Lys	Phe	Ala	Asp	Thr	Pro	Ile	Tyr	Asn	Asp	Glu	Ala	Asp	Pro	Leu	Val
		290				295					300				
Gly	Trp	Ser	Leu	Pro	Gln	Pro	Trp	Arg	Ala	Asp	Val	Thr	Tyr	Ala	Ala
305						310					315				320
Met	Val	Val	Lys	Val	Ile	Ala	Gln	His	Gln	Asn	Leu	Leu	Leu	Ala	Asn
				325					330					335	
Thr	Thr	Ser	Ala	Phe	Pro	Tyr	Ala	Leu	Leu	Ser	Asn	Asp	Asn	Ala	Phe
			340					345					350		
Leu	Ser	Tyr	His	Pro	His	Pro	Phe	Ala	Gln	Arg	Thr	Leu	Thr	Ala	Arg
		355					360					365			
Phe	Gln	Val	Asn	Asn	Thr	Arg	Pro	Pro	His	Val	Gln	Leu	Leu	Arg	Lys
		370				375					380				
Pro	Val	Leu	Thr	Ala	Met	Gly	Leu	Leu	Ala	Leu	Leu	Asp	Glu	Glu	Gln
385						390					395				400
Leu	Trp	Ala	Glu	Val	Ser	Gln	Ala	Gly	Thr	Val	Leu	Asp	Ser	Asn	His
				405					410					415	
Thr	Val	Gly	Val	Leu	Ala	Ser	Ala	His	Arg	Pro	Gln	Gly	Pro	Ala	Asp

-115-

420					425					430					
Ala	Trp	Arg	Ala	Ala	Val	Leu	Ile	Tyr	Ala	Ser	Asp	Asp	Thr	Arg	Ala
		435					440					445			
His	Pro	Asn	Arg	Ser	Val	Ala	Val	Thr	Leu	Arg	Leu	Arg	Gly	Val	Pro
	450					455					460				
Pro	Gly	Pro	Gly	Leu	Val	Tyr	Val	Thr	Arg	Tyr	Leu	Asp	Asn	Gly	Leu
465					470					475					480
Cys	Ser	Pro	Asp	Gly	Glu	Trp	Arg	Arg	Leu	Gly	Arg	Pro	Val	Phe	Pro
				485					490					495	
Thr	Ala	Glu	Gln	Phe	Arg	Arg	Met	Arg	Ala	Ala	Glu	Asp	Pro	Val	Ala
			500					505					510		
Ala	Ala	Pro	Arg	Pro	Leu	Pro	Ala	Gly	Gly	Arg	Leu	Thr	Leu	Arg	Pro
		515					520					525			
Ala	Leu	Arg	Leu	Pro	Ser	Leu	Leu	Leu	Val	His	Val	Cys	Ala	Arg	Pro
	530					535					540				
Glu	Lys	Pro	Pro	Gly	Gln	Val	Thr	Arg	Leu	Arg	Ala	Leu	Pro	Leu	Thr
545					550				555						560
Gln	Gly	Gln	Leu	Val	Leu	Val	Trp	Ser	Asp	Glu	His	Val	Gly	Ser	Lys
				565					570					575	
Cys	Leu	Trp	Thr	Tyr	Glu	Ile	Gln	Phe	Ser	Gln	Asp	Gly	Lys	Ala	Tyr
			580					585					590		
Thr	Pro	Val	Ser	Arg	Lys	Pro	Ser	Thr	Phe	Asn	Leu	Phe	Val	Phe	Ser
		595					600					605			
Pro	Asp	Thr	Gly	Ala	Val	Ser	Gly	Ser	Tyr	Arg	Val	Arg	Ala	Leu	Asp
	610					615					620				
Tyr	Trp	Ala	Arg	Pro	Gly	Pro	Phe	Ser	Asp	Pro	Val	Pro	Tyr	Leu	Glu
625					630					635					640
Val	Pro	Val	Pro	Arg	Gly	Pro	Pro	Ser	Pro	Gly	Asn	Pro			
				645					650						

<210> 82  
 <211> 153  
 <212> PRT  
 <213> Homo Sapiens

<400> 82

Met	Gly	Lys	Ile	Ser	Ser	Leu	Pro	Thr	Gln	Leu	Phe	Lys	Cys	Cys	Phe
1				5					10					15	
Cys	Asp	Phe	Leu	Lys	Val	Lys	Met	His	Thr	Met	Ser	Ser	Ser	His	Leu
			20					25					30		
Phe	Tyr	Leu	Ala	Leu	Cys	Leu	Leu	Thr	Phe	Thr	Ser	Ser	Ala	Thr	Ala
		35					40					45			



-116-

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe  
 50 55 60  
 Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly  
 65 70 75 80  
 Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys  
 85 90 95  
 Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu  
 100 105 110  
 Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp  
 115 120 125  
 Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Ala Ser Arg Gly  
 130 135 140  
 Ser Ala Gly Asn Lys Asn Tyr Arg Met  
 145 150  
 <210> 83  
 <211> 1575  
 <212> PRT  
 <213> Homo Sapiens  
 <400> 83  
 Met Pro His Glu Glu Leu Pro Ser Leu Gln Arg Pro Arg Tyr Gly Ser  
 1 5 10 15  
 Ile Val Asp Asp Glu Arg Leu Ser Ala Glu Glu Met Asp Glu Arg Arg  
 20 25 30  
 Arg Gln Asn Ile Ala Tyr Glu Tyr Leu Cys His Leu Glu Glu Ala Lys  
 35 40 45  
 Arg Trp Met Glu Val Cys Leu Val Glu Glu Leu Pro Pro Thr Thr Glu  
 50 55 60  
 Leu Glu Glu Gly Leu Arg Asn Gly Val Tyr Leu Ala Lys Leu Ala Lys  
 65 70 75 80  
 Phe Phe Ala Pro Lys Met Val Ser Glu Lys Lys Ile Tyr Asp Val Glu  
 85 90 95  
 Gln Thr Arg Tyr Lys Lys Ser Gly Leu His Phe Arg His Thr Asp Asn  
 100 105 110  
 Thr Val Gln Trp Leu Arg Ala Met Glu Ser Ile Gly Leu Pro Lys Ile  
 115 120 125  
 Phe Tyr Pro Glu Thr Thr Asp Val Tyr Asp Arg Lys Asn Ile Pro Arg  
 130 135 140  
 Met Ile Tyr Cys Ile His Ala Leu Ser Leu Tyr Leu Phe Lys Leu Gly  
 145 150 155 160  
 Ile Ala Pro Gln Ile Gln Asp Leu Leu Gly Lys Val Asp Phe Thr Glu  
 165 170 175

-117-

Glu	Glu	Ile	Ser	Asn	Met	Arg	Lys	Glu	Leu	Glu	Lys	Tyr	Gly	Ile	Gln	180	185	190
Met	Pro	Ser	Phe	Ser	Lys	Ile	Gly	Gly	Ile	Leu	Ala	Asn	Glu	Leu	Ser	195	200	205
Val	Asp	Glu	Ala	Ala	Leu	His	Ala	Ala	Val	Ile	Ala	Ile	Asn	Glu	Ala	210	215	220
Val	Glu	Lys	Gly	Ile	Ala	Glu	Gln	Thr	Val	Val	Thr	Leu	Arg	Asn	Pro	225	230	235
Asn	Ala	Val	Leu	Thr	Leu	Val	Asp	Asp	Asn	Leu	Ala	Pro	Glu	Tyr	Gln	245	250	255
Lys	Glu	Leu	Trp	Asp	Ala	Lys	Lys	Lys	Lys	Glu	Glu	Asn	Ala	Arg	Leu	260	265	270
Lys	Asn	Ser	Cys	Ile	Ser	Glu	Glu	Glu	Arg	Asp	Ala	Tyr	Glu	Glu	Leu	275	280	285
Leu	Thr	Gln	Ala	Glu	Ile	Gln	Gly	Asn	Ile	Asn	Lys	Val	Asn	Arg	Gln	290	295	300
Ala	Ala	Val	Asp	His	Ile	Asn	Ala	Val	Ile	Pro	Glu	Gly	Asp	Pro	Glu	305	310	315
Asn	Thr	Leu	Leu	Ala	Leu	Lys	Lys	Pro	Glu	Ala	Gln	Leu	Pro	Ala	Val	325	330	335
Tyr	Pro	Phe	Ala	Ala	Ala	Met	Tyr	Gln	Asn	Glu	Leu	Phe	Asn	Leu	Gln	340	345	350
Lys	Gln	Asn	Thr	Met	Asn	Tyr	Leu	Ala	His	Glu	Glu	Leu	Leu	Ile	Ala	355	360	365
Val	Glu	Met	Leu	Ser	Ala	Val	Ala	Leu	Leu	Asn	Gln	Ala	Leu	Glu	Ser	370	375	380
Asn	Asp	Leu	Val	Ser	Val	Gln	Asn	Gln	Leu	Arg	Ser	Pro	Ala	Ile	Gly	385	390	395
Leu	Asn	Asn	Leu	Asp	Lys	Ala	Tyr	Val	Glu	Arg	Tyr	Ala	Asn	Thr	Leu	405	410	415
Leu	Ser	Val	Lys	Leu	Glu	Val	Leu	Ser	Gln	Gly	Gln	Asp	Asn	Leu	Ser	420	425	430
Trp	Asn	Glu	Ile	Gln	Asn	Cys	Ile	Asp	Met	Val	Asn	Ala	Gln	Ile	Gln	435	440	445
Glu	Glu	Asn	Asp	Arg	Val	Val	Ala	Val	Gly	Tyr	Ile	Asn	Glu	Ala	Ile	450	455	460
Asp	Glu	Gly	Asn	Pro	Leu	Arg	Thr	Leu	Glu	Thr	Leu	Leu	Leu	Pro	Thr	465	470	475
Ala	Asn	Ile	Ser	Asp	Val	Asp	Pro	Ala	His	Ala	Gln	His	Tyr	Gln	Asp	485	490	495

-118-

Val Leu Tyr His Ala Lys Ser Gln Lys Leu Gly Asp Ser Glu Ser Val  
 500 505 510  
 Ser Lys Val Leu Trp Leu Asp Glu Ile Gln Gln Ala Val Asp Glu Ala  
 515 520 525  
 Asn Val Asp Glu Asp Arg Ala Lys Gln Trp Val Thr Leu Val Val Asp  
 530 535 540  
 Val Asn Gln Cys Leu Glu Gly Lys Lys Ser Ser Asp Ile Leu Ser Val  
 545 550 555 560  
 Leu Lys Ser Ser Thr Ser Asn Ala Asn Asp Ile Ile Pro Glu Cys Ala  
 565 570 575  
 Asp Lys Tyr Tyr Asp Ala Leu Val Lys Ala Lys Glu Leu Lys Ser Glu  
 580 585 590  
 Arg Val Ser Ser Asp Gly Ser Trp Leu Lys Leu Asn Leu His Lys Lys  
 595 600 605  
 Tyr Asp Tyr Tyr Tyr Asn Thr Asp Ser Lys Glu Ser Ser Trp Val Thr  
 610 615 620  
 Pro Glu Ser Cys Phe Tyr Lys Glu Ser Trp Leu Thr Gly Lys Glu Ile  
 625 630 635 640  
 Glu Asp Ile Ile Glu Glu Val Thr Val Gly Tyr Ile Arg Glu Asn Ile  
 645 650 655  
 Trp Ser Ala Ser Glu Glu Leu Leu Leu Arg Phe Gln Ala Thr Ser Ser  
 660 665 670  
 Gly Pro Ile Leu Arg Glu Glu Phe Glu Ala Arg Lys Ser Phe Leu His  
 675 680 685  
 Glu Gln Glu Glu Asn Val Val Lys Ile Gln Ala Phe Trp Lys Gly Tyr  
 690 695 700  
 Lys Gln Arg Lys Glu Tyr Met His Arg Arg Gln Thr Phe Ile Asp Asn  
 705 710 715 720  
 Thr Asp Ser Val Val Lys Ile Gln Ser Trp Phe Arg Met Ala Thr Ala  
 725 730 735  
 Arg Lys Ser Tyr Leu Ser Arg Leu Gln Tyr Phe Arg Asp His Asn Asn  
 740 745 750  
 Glu Ile Val Lys Ile Gln Ser Leu Leu Arg Ala Asn Lys Ala Arg Asp  
 755 760 765  
 Asp Tyr Lys Thr Leu Val Gly Ser Glu Asn Pro Pro Leu Thr Val Ile  
 770 775 780  
 Arg Lys Phe Val Tyr Leu Leu Asp Gln Ser Asp Leu Asp Phe Gln Glu  
 785 790 795 800  
 Glu Leu Glu Val Ala Arg Leu Arg Glu Glu Val Val Thr Lys Ile Arg  
 805 810 815

-119-

Ala Asn Gln Gln Leu Glu Lys Asp Leu Asn Leu Met Asp Ile Lys Ile  
 820 825 830  
 Gly Leu Leu Val Lys Asn Arg Ile Thr Leu Glu Asp Val Ile Ser His  
 835 840 845  
 Ser Lys Lys Leu Asn Lys Lys Lys Gly Gly Glu Met Glu Ile Leu Asn  
 850 855 860  
 Asn Thr Asp Asn Gln Gly Ile Lys Ser Leu Ser Lys Glu Arg Arg Lys  
 865 870 875 880  
 Thr Leu Glu Thr Tyr Gln Gln Leu Phe Tyr Leu Leu Gln Thr Asn Pro  
 885 890 895  
 Leu Tyr Leu Ala Lys Leu Ile Phe Gln Met Pro Gln Asn Lys Ser Thr  
 900 905 910  
 Lys Phe Met Asp Thr Val Ile Phe Thr Leu Tyr Asn Tyr Ala Ser Asn  
 915 920 925  
 Gln Arg Glu Glu Tyr Leu Leu Leu Lys Leu Phe Lys Thr Ala Leu Glu  
 930 935 940  
 Glu Glu Ile Lys Ser Lys Val Asp Gln Val Gln Asp Ile Val Thr Gly  
 945 950 955 960  
 Asn Pro Thr Val Ile Lys Met Val Val Ser Phe Asn Arg Gly Ala Arg  
 965 970 975  
 Gly Gln Asn Thr Leu Arg Gln Leu Leu Ala Pro Val Val Lys Glu Ile  
 980 985 990  
 Ile Asp Asp Lys Ser Leu Ile Ile Asn Thr Asn Pro Val Glu Val Tyr  
 995 1000 1005  
 Lys Ala Trp Val Asn Gln Leu Glu Thr Gln Thr Gly Glu Ala Ser  
 1010 1015 1020  
 Lys Leu Pro Tyr Asp Val Thr Thr Glu Gln Ala Leu Thr Tyr Pro  
 1025 1030 1035  
 Glu Val Lys Asn Lys Leu Glu Ala Ser Ile Glu Asn Leu Arg Arg  
 1040 1045 1050  
 Val Thr Asp Lys Val Leu Asn Ser Ile Ile Ser Ser Leu Asp Leu  
 1055 1060 1065  
 Leu Pro Tyr Gly Leu Arg Tyr Ile Ala Lys Val Leu Lys Asn Ser  
 1070 1075 1080  
 Ile His Glu Lys Phe Pro Asp Ala Thr Glu Asp Glu Leu Leu Lys  
 1085 1090 1095  
 Ile Val Gly Asn Leu Leu Tyr Tyr Arg Tyr Met Asn Pro Ala Ile  
 1100 1105 1110  
 Val Ala Pro Asp Gly Phe Asp Ile Ile Asp Met Thr Ala Gly Gly  
 1115 1120 1125

-120-

Gln Ile	Asn Ser Asp	Gln Arg	Arg Asn Leu Gly	Ser Val Ala Lys
1130		1135		1140
Val Leu	Gln His Ala Ala	Ser Asn Lys Leu Phe	Glu Gly Glu Asn	
1145		1150	1155	
Glu His	Leu Ser Ser Met	Asn Asn Tyr Leu Ser	Glu Thr Tyr Gln	
1160		1165	1170	
Glu Phe	Arg Lys Tyr Phe	Lys Glu Ala Cys Asn	Val Pro Glu Pro	
1175		1180	1185	
Glu Glu	Lys Phe Asn Met	Asp Lys Tyr Thr Asp	Leu Val Thr Val	
1190		1195	1200	
Ser Lys	Pro Val Ile Tyr	Ile Ser Ile Glu Glu	Ile Ile Ser Thr	
1205		1210	1215	
His Ser	Leu Leu Leu Glu	His Gln Asp Ala Ile	Ala Pro Glu Lys	
1220		1225	1230	
Asn Asp	Leu Leu Ser Glu	Leu Leu Gly Ser Leu	Gly Glu Val Pro	
1235		1240	1245	
Thr Val	Glu Ser Phe Leu	Gly Glu Gly Ala Val	Asp Pro Asn Asp	
1250		1255	1260	
Pro Asn	Lys Ala Asn Thr	Leu Ser Gln Leu Ser	Lys Thr Glu Ile	
1265		1270	1275	
Ser Leu	Val Leu Thr Ser	Lys Tyr Asp Ile Glu	Asp Gly Glu Ala	
1280		1285	1290	
Ile Asp	Ser Arg Ser Leu	Met Ile Lys Thr Lys	Lys Leu Ile Ile	
1295		1300	1305	
Asp Val	Ile Arg Asn Gln	Pro Gly Asn Thr Leu	Thr Glu Ile Leu	
1310		1315	1320	
Glu Thr	Pro Ala Thr Ala	Gln Gln Glu Val Asp	His Ala Thr Asp	
1325		1330	1335	
Met Val	Ser Arg Ala Met	Ile Asp Ser Arg Thr	Pro Glu Glu Met	
1340		1345	1350	
Lys His	Ser Gln Ser Met	Ile Glu Asp Ala Gln	Leu Pro Leu Glu	
1355		1360	1365	
Gln Lys	Lys Arg Lys Ile	Gln Arg Asn Leu Arg	Thr Leu Glu Gln	
1370		1375	1380	
Thr Gly	His Val Ser Ser	Glu Asn Lys Tyr Gln	Asp Ile Leu Asn	
1385		1390	1395	
Glu Ile	Ala Lys Asp Ile	Arg Asn Gln Arg Ile	Tyr Arg Lys Leu	
1400		1405	1410	
Arg Lys	Ala Glu Leu Ala	Lys Leu Gln Gln Thr	Leu Asn Ala Leu	
1415		1420	1425	

-121-

Asn Lys Lys Ala Ala Phe Tyr Glu Glu Gln Ile Asn Tyr Tyr Asp  
 1430 1435 1440  
 Thr Tyr Ile Lys Thr Cys Leu Asp Asn Leu Lys Arg Lys Asn Thr  
 1445 1450 1455  
 Arg Arg Ser Ile Lys Leu Asp Gly Lys Gly Glu Pro Lys Gly Ala  
 1460 1465 1470  
 Lys Arg Ala Lys Pro Val Lys Tyr Thr Ala Ala Lys Leu His Glu  
 1475 1480 1485  
 Lys Gly Val Leu Leu Asp Ile Asp Asp Leu Gln Thr Asn Gln Phe  
 1490 1495 1500  
 Lys Asn Val Thr Phe Asp Ile Ile Ala Thr Glu Asp Val Gly Ile  
 1505 1510 1515  
 Phe Asp Val Arg Ser Lys Phe Leu Gly Val Glu Met Glu Lys Val  
 1520 1525 1530  
 Gln Leu Asn Ile Gln Asp Leu Leu Gln Met Gln Tyr Glu Gly Val  
 1535 1540 1545  
 Ala Val Met Lys Met Phe Asp Lys Val Lys Val Asn Val Asn Leu  
 1550 1555 1560  
 Leu Ile Tyr Leu Leu Asn Lys Lys Phe Tyr Gly Lys  
 1565 1570 1575  
 <210> 84  
 <211> 165  
 <212> PRT  
 <213> Homo Sapiens  
 <400> 84  
 Met Gly Trp Asp Leu Thr Val Lys Met Leu Ala Gly Asn Glu Phe Gln  
 1 5 10 15  
 Val Ser Leu Ser Ser Ser Met Ser Val Ser Glu Leu Lys Ala Gln Ile  
 20 25 30  
 Thr Gln Lys Ile Gly Val His Ala Phe Gln Gln Arg Leu Ala Val His  
 35 40 45  
 Pro Ser Gly Val Ala Leu Gln Asp Arg Val Pro Leu Ala Ser Gln Gly  
 50 55 60  
 Leu Gly Pro Gly Ser Thr Val Leu Leu Val Val Asp Lys Cys Asp Glu  
 65 70 75 80  
 Pro Leu Ser Ile Leu Val Arg Asn Asn Lys Gly Arg Ser Ser Thr Tyr  
 85 90 95  
 Glu Val Arg Leu Thr Gln Thr Val Ala His Leu Lys Gln Gln Val Ser  
 100 105 110  
 Gly Leu Glu Gly Val Gln Asp Asp Leu Phe Trp Leu Thr Phe Glu Gly

-122-

115	120	125
Lys Pro Leu Glu Asp Gln Leu Pro Leu Gly Glu Tyr Gly Leu Lys Pro		
130	135	140
Leu Ser Thr Val Phe Met Asn Leu Arg Leu Arg Gly Gly Gly Thr Glu		
145	150	155
Pro Gly Gly Arg Ser		
	165	
<210> 85		
<211> 1218		
<212> PRT		
<213> Homo Sapiens		
<400> 85		
Met Arg Ser Pro Arg Thr Arg Gly Arg Ser Gly Arg Pro Leu Ser Leu		
1	5	10
15		
Leu Leu Ala Leu Leu Cys Ala Leu Arg Ala Lys Val Cys Gly Ala Ser		
20	25	30
Gly Gln Phe Glu Leu Glu Ile Leu Ser Met Gln Asn Val Asn Gly Glu		
35	40	45
Leu Gln Asn Gly Asn Cys Cys Gly Gly Ala Arg Asn Pro Gly Asp Arg		
50	55	60
Lys Cys Thr Arg Asp Glu Cys Asp Thr Tyr Phe Lys Val Cys Leu Lys		
65	70	75
80		
Glu Tyr Gln Ser Arg Val Thr Ala Gly Gly Pro Cys Ser Phe Gly Ser		
85	90	95
Gly Ser Thr Pro Val Ile Gly Gly Asn Thr Phe Asn Leu Lys Ala Ser		
100	105	110
Arg Gly Asn Asp Pro Asn Arg Ile Val Leu Pro Phe Ser Phe Ala Trp		
115	120	125
Pro Arg Ser Tyr Thr Leu Leu Val Glu Ala Trp Asp Ser Ser Asn Asp		
130	135	140
Thr Val Gln Pro Asp Ser Ile Ile Glu Lys Ala Ser His Ser Gly Met		
145	150	155
160		
Ile Asn Pro Ser Arg Gln Trp Gln Thr Leu Lys Gln Asn Thr Gly Val		
165	170	175
Ala His Phe Glu Tyr Gln Ile Arg Val Thr Cys Asp Asp Tyr Tyr Tyr		
180	185	190
Gly Phe Gly Cys Asn Lys Phe Cys Arg Pro Arg Asp Asp Phe Phe Gly		
195	200	205
His Tyr Ala Cys Asp Gln Asn Gly Asn Lys Thr Cys Met Glu Gly Trp		
210	215	220

-123-

Met Gly Pro Glu Cys Asn Arg Ala Ile Cys Arg Gln Gly Cys Ser Pro  
 225 230 235 240  
 Lys His Gly Ser Cys Lys Leu Pro Gly Asp Cys Arg Cys Gln Tyr Gly  
 245 250 255  
 Trp Gln Gly Leu Tyr Cys Asp Lys Cys Ile Pro His Pro Gly Cys Val  
 260 265 270  
 His Gly Ile Cys Asn Glu Pro Trp Gln Cys Leu Cys Glu Thr Asn Trp  
 275 280 285  
 Gly Gly Gln Leu Cys Asp Lys Asp Leu Asn Tyr Cys Gly Thr His Gln  
 290 295 300  
 Pro Cys Leu Asn Gly Gly Thr Cys Ser Asn Thr Gly Pro Asp Lys Tyr  
 305 310 315 320  
 Gln Cys Ser Cys Pro Glu Gly Tyr Ser Gly Pro Asn Cys Glu Ile Ala  
 325 330 335  
 Glu His Ala Cys Leu Ser Asp Pro Cys His Asn Arg Gly Ser Cys Lys  
 340 345 350  
 Glu Thr Ser Leu Gly Phe Glu Cys Glu Cys Ser Pro Gly Trp Thr Gly  
 355 360 365  
 Pro Thr Cys Ser Thr Asn Ile Asp Asp Cys Ser Pro Asn Asn Cys Ser  
 370 375 380  
 His Gly Gly Thr Cys Gln Asp Leu Val Asn Gly Phe Lys Cys Val Cys  
 385 390 395 400  
 Pro Pro Gln Trp Thr Gly Lys Thr Cys Gln Leu Asp Ala Asn Glu Cys  
 405 410 415  
 Glu Ala Lys Pro Cys Val Asn Ala Lys Ser Cys Lys Asn Leu Ile Ala  
 420 425 430  
 Ser Tyr Tyr Cys Asp Cys Leu Pro Gly Trp Met Gly Gln Asn Cys Asp  
 435 440 445  
 Ile Asn Ile Asn Asp Cys Leu Gly Gln Cys Gln Asn Asp Ala Ser Cys  
 450 455 460  
 Arg Asp Leu Val Asn Gly Tyr Arg Cys Ile Cys Pro Pro Gly Tyr Ala  
 465 470 475 480  
 Gly Asp His Cys Glu Arg Asp Ile Asp Glu Cys Ala Ser Asn Pro Cys  
 485 490 495  
 Leu Asn Gly Gly His Cys Gln Asn Glu Ile Asn Arg Phe Gln Cys Leu  
 500 505 510  
 Cys Pro Thr Gly Phe Ser Gly Asn Leu Cys Gln Leu Asp Ile Asp Tyr  
 515 520 525  
 Cys Glu Pro Asn Pro Cys Gln Asn Gly Ala Gln Cys Tyr Asn Arg Ala  
 530 535 540



-124-

Ser Asp Tyr Phe Cys Lys Cys Pro Glu Asp Tyr Glu Gly Lys Asn Cys  
 545 550 555 560  
 Ser His Leu Lys Asp His Cys Arg Thr Thr Pro Cys Glu Val Ile Asp  
 565 570 575  
 Ser Cys Thr Val Ala Met Ala Ser Asn Asp Thr Pro Glu Gly Val Arg  
 580 585 590  
 Tyr Ile Ser Ser Asn Val Cys Gly Pro His Gly Lys Cys Lys Ser Gln  
 595 600 605  
 Ser Gly Gly Lys Phe Thr Cys Asp Cys Asn Lys Gly Phe Thr Gly Thr  
 610 615 620  
 Tyr Cys His Glu Asn Ile Asn Asp Cys Glu Ser Asn Pro Cys Arg Asn  
 625 630 635 640  
 Gly Gly Thr Cys Ile Asp Gly Val Asn Ser Tyr Lys Cys Ile Cys Ser  
 645 650 655  
 Asp Gly Trp Glu Gly Ala Tyr Cys Glu Thr Asn Ile Asn Asp Cys Ser  
 660 665 670  
 Gln Asn Pro Cys His Asn Gly Gly Thr Cys Arg Asp Leu Val Asn Asp  
 675 680 685  
 Phe Tyr Cys Asp Cys Lys Asn Gly Trp Lys Gly Lys Thr Cys His Ser  
 690 695 700  
 Arg Asp Ser Gln Cys Asp Glu Ala Thr Cys Asn Asn Gly Gly Thr Cys  
 705 710 715 720  
 Tyr Asp Glu Gly Asp Ala Phe Lys Cys Met Cys Pro Gly Gly Trp Glu  
 725 730 735  
 Gly Thr Thr Cys Asn Ile Ala Arg Asn Ser Ser Cys Leu Pro Asn Pro  
 740 745 750  
 Cys His Asn Gly Gly Thr Cys Val Val Asn Gly Glu Ser Phe Thr Cys  
 755 760 765  
 Val Cys Lys Glu Gly Trp Glu Gly Pro Ile Cys Ala Gln Asn Thr Asn  
 770 775 780  
 Asp Cys Ser Pro His Pro Cys Tyr Asn Ser Gly Thr Cys Val Asp Gly  
 785 790 795 800  
 Asp Asn Trp Tyr Arg Cys Glu Cys Ala Pro Gly Phe Ala Gly Pro Asp  
 805 810 815  
 Cys Arg Ile Asn Ile Asn Glu Cys Gln Ser Ser Pro Cys Ala Phe Gly  
 820 825 830  
 Ala Thr Cys Val Asp Glu Ile Asn Gly Tyr Arg Cys Val Cys Pro Pro  
 835 840 845  
 Gly His Ser Gly Ala Lys Cys Gln Glu Val Ser Gly Arg Pro Cys Ile  
 850 855 860

-125-

Thr Met Gly Ser Val Ile Pro Asp Gly Ala Lys Trp Asp Asp Asp Cys  
 865 870 875 880  
 Asn Thr Cys Gln Cys Leu Asn Gly Arg Ile Ala Cys Ser Lys Val Trp  
 885 890 895  
 Cys Gly Pro Arg Pro Cys Leu Leu His Lys Gly His Ser Glu Cys Pro  
 900 905 910  
 Ser Gly Gln Ser Cys Ile Pro Ile Leu Asp Asp Gln Cys Phe Val His  
 915 920 925  
 Pro Cys Thr Gly Val Gly Glu Cys Arg Ser Ser Ser Leu Gln Pro Val  
 930 935 940  
 Lys Thr Lys Cys Thr Ser Asp Ser Tyr Tyr Gln Asp Asn Cys Ala Asn  
 945 950 955 960  
 Ile Thr Phe Thr Phe Asn Lys Glu Met Met Ser Pro Gly Leu Thr Thr  
 965 970 975  
 Glu His Ile Cys Ser Glu Leu Arg Asn Leu Asn Ile Leu Lys Asn Val  
 980 985 990  
 Ser Ala Glu Tyr Ser Ile Tyr Ile Ala Cys Glu Pro Ser Pro Ser Ala  
 995 1000 1005  
 Asn Asn Glu Ile His Val Ala Ile Ser Ala Glu Asp Ile Arg Asp  
 1010 1015 1020  
 Asp Gly Asn Pro Ile Lys Glu Ile Thr Asp Lys Ile Ile Asp Leu  
 1025 1030 1035  
 Val Ser Lys Arg Asp Gly Asn Ser Ser Leu Ile Ala Ala Val Ala  
 1040 1045 1050  
 Glu Val Arg Val Gln Arg Arg Pro Leu Lys Asn Arg Thr Asp Phe  
 1055 1060 1065  
 Leu Val Pro Leu Leu Ser Ser Val Leu Thr Val Ala Trp Ile Cys  
 1070 1075 1080  
 Cys Leu Val Thr Ala Phe Tyr Trp Cys Leu Arg Lys Arg Arg Lys  
 1085 1090 1095  
 Pro Gly Ser His Thr His Ser Ala Ser Glu Asp Asn Thr Thr Asn  
 1100 1105 1110  
 Asn Val Arg Glu Gln Leu Asn Gln Ile Lys Asn Pro Ile Glu Lys  
 1115 1120 1125  
 His Gly Ala Asn Thr Val Pro Ile Lys Asp Tyr Glu Asn Lys Asn  
 1130 1135 1140  
 Ser Lys Met Ser Lys Ile Arg Thr His Asn Ser Glu Val Glu Glu  
 1145 1150 1155  
 Asp Asp Met Asp Lys His Gln Gln Lys Ala Arg Phe Ala Lys Gln  
 1160 1165 1170

-126-

Pro Ala Tyr Thr Leu Val Asp Arg Glu Glu Lys Pro Pro Asn Gly  
 1175 1180 1185

Thr Pro Thr Lys His Pro Asn Trp Thr Asn Lys Gln Asp Asn Arg  
 1190 1195 1200

Asp Leu Glu Ser Ala Gln Ser Leu Asn Arg Met Glu Tyr Ile Val  
 1205 1210 1215

<210> 86

<211> 3110

<212> PRT

<213> Homo Sapiens

<400> 86

Met Pro Gly Ala Ala Gly Val Leu Leu Leu Leu Leu Ser Gly Gly  
 1 5 10 15

Leu Gly Gly Val Gln Ala Gln Arg Pro Gln Gln Gln Arg Gln Ser Gln  
 20 25 30

Ala His Gln Gln Arg Gly Leu Phe Pro Ala Val Leu Asn Leu Ala Ser  
 35 40 45

Asn Ala Leu Ile Thr Thr Asn Ala Thr Cys Gly Glu Lys Gly Pro Glu  
 50 55 60

Met Tyr Cys Lys Leu Val Glu His Val Pro Gly Gln Pro Val Arg Asn  
 65 70 75 80

Pro Gln Cys Arg Ile Cys Asn Gln Asn Ser Ser Asn Pro Asn Gln Arg  
 85 90 95

His Pro Ile Thr Asn Ala Ile Asp Gly Lys Asn Thr Trp Trp Gln Ser  
 100 105 110

Pro Ser Ile Lys Asn Gly Ile Glu Tyr His Tyr Val Thr Ile Thr Leu  
 115 120 125

Asp Leu Gln Gln Val Phe Gln Ile Ala Tyr Val Ile Val Lys Ala Ala  
 130 135 140

Asn Ser Pro Arg Pro Gly Asn Trp Ile Leu Glu Arg Ser Leu Asp Asp  
 145 150 155 160

Val Glu Tyr Lys Pro Trp Gln Tyr His Ala Val Thr Asp Thr Glu Cys  
 165 170 175

Leu Thr Leu Tyr Asn Ile Tyr Pro Arg Thr Gly Pro Pro Ser Tyr Ala  
 180 185 190

Lys Asp Asp Glu Val Ile Cys Thr Ser Phe Tyr Ser Lys Ile His Pro  
 195 200 205

Leu Glu Asn Gly Glu Ile His Ile Ser Leu Ile Asn Gly Arg Pro Ser  
 210 215 220

Ala Asp Asp Pro Ser Pro Glu Leu Leu Glu Phe Thr Ser Ala Arg Tyr  
 225 230 235 240

-127-

Ile	Arg	Leu	Arg	Phe	Gln	Arg	Ile	Arg	Thr	Leu	Asn	Ala	Asp	Leu	Met	245	250	255
Met	Phe	Ala	His	Lys	Asp	Pro	Arg	Glu	Ile	Asp	Pro	Ile	Val	Thr	Arg	260	265	270
Arg	Tyr	Tyr	Tyr	Ser	Val	Lys	Asp	Ile	Ser	Val	Gly	Gly	Met	Cys	Ile	275	280	285
Cys	Tyr	Gly	His	Ala	Arg	Ala	Cys	Pro	Leu	Asp	Pro	Ala	Thr	Asn	Lys	290	295	300
Ser	Arg	Cys	Glu	Cys	Glu	His	Asn	Thr	Cys	Gly	Asp	Ser	Cys	Asp	Gln	305	310	315
Cys	Cys	Pro	Gly	Phe	His	Gln	Lys	Pro	Trp	Arg	Ala	Gly	Thr	Phe	Leu	325	330	335
Thr	Lys	Thr	Glu	Cys	Glu	Ala	Cys	Asn	Cys	His	Gly	Lys	Ala	Glu	Glu	340	345	350
Cys	Tyr	Tyr	Asp	Glu	Asn	Val	Ala	Arg	Arg	Asn	Leu	Ser	Leu	Asn	Ile	355	360	365
Arg	Gly	Lys	Tyr	Ile	Gly	Gly	Gly	Val	Cys	Ile	Asn	Cys	Thr	Gln	Asn	370	375	380
Thr	Ala	Gly	Ile	Asn	Cys	Glu	Thr	Cys	Thr	Asp	Gly	Phe	Phe	Arg	Pro	385	390	395
Lys	Gly	Val	Ser	Pro	Asn	Tyr	Pro	Arg	Pro	Cys	Gln	Pro	Cys	His	Cys	405	410	415
Asp	Pro	Ile	Gly	Ser	Leu	Asn	Glu	Val	Cys	Val	Lys	Asp	Glu	Lys	His	420	425	430
Ala	Arg	Arg	Gly	Leu	Ala	Pro	Gly	Ser	Cys	His	Cys	Lys	Thr	Gly	Phe	435	440	445
Gly	Gly	Val	Ser	Cys	Asp	Arg	Cys	Ala	Arg	Gly	Tyr	Thr	Gly	Tyr	Pro	450	455	460
Asp	Cys	Lys	Ala	Cys	Asn	Cys	Ser	Gly	Leu	Gly	Ser	Lys	Asn	Glu	Asp	465	470	475
Pro	Cys	Phe	Gly	Pro	Cys	Ile	Cys	Lys	Glu	Asn	Val	Glu	Gly	Gly	Asp	485	490	495
Cys	Ser	Arg	Cys	Lys	Ser	Gly	Phe	Phe	Asn	Leu	Gln	Glu	Asp	Asn	Trp	500	505	510
Lys	Gly	Cys	Asp	Glu	Cys	Phe	Cys	Ser	Gly	Val	Ser	Asn	Arg	Cys	Gln	515	520	525
Ser	Ser	Tyr	Trp	Thr	Tyr	Gly	Lys	Ile	Gln	Asp	Met	Ser	Gly	Trp	Tyr	530	535	540
Leu	Thr	Asp	Leu	Pro	Gly	Arg	Ile	Arg	Val	Ala	Pro	Gln	Gln	Asp	Asp	545	550	555
																		560

-128-

Leu	Asp	Ser	Pro	Gln	Gln	Ile	Ser	Ile	Ser	Asn	Ala	Glu	Ala	Arg	Gln		
				565					570					575			
Ala	Leu	Pro	His	Ser	Tyr	Tyr	Trp	Ser	Ala	Pro	Ala	Pro	Tyr	Leu	Gly		
			580					585					590				
Asn	Lys	Leu	Pro	Ala	Val	Gly	Gly	Gln	Leu	Thr	Phe	Thr	Ile	Ser	Tyr		
		595					600					605					
Asp	Leu	Glu	Glu	Glu	Glu	Glu	Asp	Thr	Glu	Arg	Val	Leu	Gln	Leu	Met		
	610					615					620						
Ile	Ile	Leu	Glu	Gly	Asn	Asp	Leu	Ser	Ile	Ser	Thr	Ala	Gln	Asp	Glu		
625					630					635					640		
Val	Tyr	Leu	His	Pro	Ser	Glu	Glu	His	Thr	Asn	Val	Leu	Leu	Leu	Lys		
				645					650					655			
Glu	Glu	Ser	Phe	Thr	Ile	His	Gly	Thr	His	Phe	Pro	Val	Arg	Arg	Lys		
			660					665					670				
Glu	Phe	Met	Thr	Val	Leu	Ala	Asn	Leu	Lys	Arg	Val	Leu	Leu	Gln	Ile		
	675						680					685					
Thr	Tyr	Ser	Phe	Gly	Met	Asp	Ala	Ile	Phe	Arg	Leu	Ser	Ser	Val	Asn		
	690					695					700						
Leu	Glu	Ser	Ala	Val	Ser	Tyr	Pro	Thr	Asp	Gly	Ser	Ile	Ala	Ala	Ala		
705					710					715					720		
Val	Glu	Val	Cys	Gln	Cys	Pro	Pro	Gly	Tyr	Thr	Gly	Ser	Ser	Cys	Glu		
			725						730					735			
Ser	Cys	Trp	Pro	Arg	His	Arg	Arg	Val	Asn	Gly	Thr	Ile	Phe	Gly	Gly		
			740					745					750				
Ile	Cys	Glu	Pro	Cys	Gln	Cys	Phe	Gly	His	Ala	Glu	Ser	Cys	Asp	Asp		
	755						760					765					
Val	Thr	Gly	Glu	Cys	Leu	Asn	Cys	Lys	Asp	His	Thr	Gly	Gly	Pro	Tyr		
	770					775					780						
Cys	Asp	Lys	Cys	Leu	Pro	Gly	Phe	Tyr	Gly	Glu	Pro	Thr	Lys	Gly	Thr		
785					790					795					800		
Ser	Glu	Asp	Cys	Gln	Pro	Cys	Ala	Cys	Pro	Leu	Asn	Ile	Pro	Ser	Asn		
			805						810					815			
Asn	Phe	Ser	Pro	Thr	Cys	His	Leu	Asp	Arg	Ser	Leu	Gly	Leu	Ile	Cys		
			820					825					830				
Asp	Gly	Cys	Pro	Val	Gly	Tyr	Thr	Gly	Pro	Arg	Cys	Glu	Arg	Cys	Ala		
	835						840					845					
Glu	Gly	Tyr	Phe	Gly	Gln	Pro	Ser	Val	Pro	Gly	Gly	Ser	Cys	Gln	Pro		
	850					855					860						
Cys	Gln	Cys	Asn	Asp	Asn	Leu	Asp	Phe	Ser	Ile	Pro	Gly	Ser	Cys	Asp		
865					870					875					880		

-129-

Ser Leu Ser Gly Ser Cys Leu Ile Cys Lys Pro Gly Thr Thr Gly Arg  
 885 890 895  
 Tyr Cys Glu Leu Cys Ala Asp Gly Tyr Phe Gly Asp Ala Val Asp Ala  
 900 905 910  
 Lys Asn Cys Gln Pro Cys Arg Cys Asn Ala Gly Gly Ser Phe Ser Glu  
 915 920 925  
 Val Cys His Ser Gln Thr Gly Gln Cys Glu Cys Arg Ala Asn Val Gln  
 930 935 940  
 Gly Gln Arg Cys Asp Lys Cys Lys Ala Gly Thr Phe Gly Leu Gln Ser  
 945 950 955 960  
 Ala Arg Gly Cys Val Pro Cys Asn Cys Asn Ser Phe Gly Ser Lys Ser  
 965 970 975  
 Phe Asp Cys Glu Glu Ser Gly Gln Cys Trp Cys Gln Pro Gly Val Thr  
 980 985 990  
 Gly Lys Lys Cys Asp Arg Cys Ala His Gly Tyr Phe Asn Phe Gln Glu  
 995 1000 1005  
 Gly Gly Cys Thr Ala Cys Glu Cys Ser His Leu Gly Asn Asn Cys  
 1010 1015 1020  
 Asp Pro Lys Thr Gly Arg Cys Ile Cys Pro Pro Asn Thr Ile Gly  
 1025 1030 1035  
 Glu Lys Cys Ser Lys Cys Ala Pro Asn Thr Trp Gly His Ser Ile  
 1040 1045 1050  
 Thr Thr Gly Cys Lys Ala Cys Asn Cys Ser Thr Val Gly Ser Leu  
 1055 1060 1065  
 Asp Phe Gln Cys Asn Val Asn Thr Gly Gln Cys Asn Cys His Pro  
 1070 1075 1080  
 Lys Phe Ser Gly Ala Lys Cys Thr Glu Cys Ser Arg Gly His Trp  
 1085 1090 1095  
 Asn Tyr Pro Arg Cys Asn Leu Cys Asp Cys Phe Leu Pro Gly Thr  
 1100 1105 1110  
 Asp Ala Thr Thr Cys Asp Ser Glu Thr Lys Lys Cys Ser Cys Ser  
 1115 1120 1125  
 Asp Gln Thr Gly Gln Cys Thr Cys Lys Val Asn Val Glu Gly Ile  
 1130 1135 1140  
 His Cys Asp Arg Cys Arg Pro Gly Lys Phe Gly Leu Asp Ala Lys  
 1145 1150 1155  
 Asn Pro Leu Gly Cys Ser Ser Cys Tyr Cys Phe Gly Thr Thr Thr  
 1160 1165 1170  
 Gln Cys Ser Glu Ala Lys Gly Leu Ile Arg Thr Trp Val Thr Leu  
 1175 1180 1185

-130-

Lys	Ala	Glu	Gln	Thr	Ile	Leu	Pro	Leu	Val	Asp	Glu	Ala	Leu	Gln
1190						1195					1200			
His	Thr	Thr	Thr	Lys	Gly	Ile	Val	Phe	Gln	His	Pro	Glu	Ile	Val
1205						1210					1215			
Ala	His	Met	Asp	Leu	Met	Arg	Glu	Asp	Leu	His	Leu	Glu	Pro	Phe
1220						1225					1230			
Tyr	Trp	Lys	Leu	Pro	Glu	Gln	Phe	Glu	Gly	Lys	Lys	Leu	Met	Ala
1235						1240					1245			
Tyr	Gly	Gly	Lys	Leu	Lys	Tyr	Ala	Ile	Tyr	Phe	Glu	Ala	Arg	Glu
1250						1255					1260			
Glu	Thr	Gly	Phe	Ser	Thr	Tyr	Asn	Pro	Gln	Val	Ile	Ile	Arg	Gly
1265						1270					1275			
Gly	Thr	Pro	Thr	His	Ala	Arg	Ile	Ile	Val	Arg	His	Met	Ala	Ala
1280						1285					1290			
Pro	Leu	Ile	Gly	Gln	Leu	Thr	Arg	His	Glu	Ile	Glu	Met	Thr	Glu
1295						1300					1305			
Lys	Glu	Trp	Lys	Tyr	Tyr	Gly	Asp	Asp	Pro	Arg	Val	His	Arg	Thr
1310						1315					1320			
Val	Thr	Arg	Glu	Asp	Phe	Leu	Asp	Ile	Leu	Tyr	Asp	Ile	His	Tyr
1325						1330					1335			
Ile	Leu	Ile	Lys	Ala	Thr	Tyr	Gly	Asn	Phe	Met	Arg	Gln	Ser	Arg
1340						1345					1350			
Ile	Ser	Glu	Ile	Ser	Met	Glu	Val	Ala	Glu	Gln	Gly	Arg	Gly	Thr
1355						1360					1365			
Thr	Met	Thr	Pro	Pro	Ala	Asp	Leu	Ile	Glu	Lys	Cys	Asp	Cys	Pro
1370						1375					1380			
Leu	Gly	Tyr	Ser	Gly	Leu	Ser	Cys	Glu	Ala	Cys	Leu	Pro	Gly	Phe
1385						1390					1395			
Tyr	Arg	Leu	Arg	Ser	Gln	Pro	Gly	Gly	Arg	Thr	Pro	Gly	Pro	Thr
1400						1405					1410			
Leu	Gly	Thr	Cys	Val	Pro	Cys	Gln	Cys	Asn	Gly	His	Ser	Ser	Leu
1415						1420					1425			
Cys	Asp	Pro	Glu	Thr	Ser	Ile	Cys	Gln	Asn	Cys	Gln	His	His	Thr
1430						1435					1440			
Ala	Gly	Asp	Phe	Cys	Glu	Arg	Cys	Ala	Leu	Gly	Tyr	Tyr	Gly	Ile
1445						1450					1455			
Val	Lys	Gly	Leu	Pro	Asn	Asp	Cys	Gln	Gln	Cys	Ala	Cys	Pro	Leu
1460						1465					1470			
Ile	Ser	Ser	Ser	Asn	Asn	Phe	Ser	Pro	Ser	Cys	Val	Ala	Glu	Gly
1475						1480					1485			

-131-

Leu	Asp	Asp	Tyr	Arg	Cys	Thr	Ala	Cys	Pro	Arg	Gly	Tyr	Glu	Gly
1490						1495					1500			
Gln	Tyr	Cys	Glu	Arg	Cys	Ala	Pro	Gly	Tyr	Thr	Gly	Ser	Pro	Gly
1505						1510					1515			
Asn	Pro	Gly	Gly	Ser	Cys	Gln	Glu	Cys	Glu	Cys	Asp	Pro	Tyr	Gly
1520						1525					1530			
Ser	Leu	Pro	Val	Pro	Cys	Asp	Pro	Val	Thr	Gly	Phe	Cys	Thr	Cys
1535						1540					1545			
Arg	Pro	Gly	Ala	Thr	Gly	Arg	Lys	Cys	Asp	Gly	Cys	Lys	His	Trp
1550						1555					1560			
His	Ala	Arg	Glu	Gly	Trp	Glu	Cys	Val	Phe	Cys	Gly	Asp	Glu	Cys
1565						1570					1575			
Thr	Gly	Leu	Leu	Leu	Gly	Asp	Leu	Ala	Arg	Leu	Glu	Gln	Met	Val
1580						1585					1590			
Met	Ser	Ile	Asn	Leu	Thr	Gly	Pro	Leu	Pro	Ala	Pro	Tyr	Lys	Met
1595						1600					1605			
Leu	Tyr	Gly	Leu	Glu	Asn	Met	Thr	Gln	Glu	Leu	Lys	His	Leu	Leu
1610						1615					1620			
Ser	Pro	Gln	Arg	Ala	Pro	Glu	Arg	Leu	Ile	Gln	Leu	Ala	Glu	Gly
1625						1630					1635			
Asn	Leu	Asn	Thr	Leu	Val	Thr	Glu	Met	Asn	Glu	Leu	Leu	Thr	Arg
1640						1645					1650			
Ala	Thr	Lys	Val	Thr	Ala	Asp	Gly	Glu	Gln	Thr	Gly	Gln	Asp	Ala
1655						1660					1665			
Glu	Arg	Thr	Asn	Thr	Arg	Ala	Lys	Ser	Leu	Gly	Glu	Phe	Ile	Lys
1670						1675					1680			
Glu	Leu	Ala	Arg	Asp	Ala	Glu	Ala	Val	Asn	Glu	Lys	Ala	Ile	Lys
1685						1690					1695			
Leu	Asn	Glu	Thr	Leu	Gly	Thr	Arg	Asp	Glu	Ala	Phe	Glu	Arg	Asn
1700						1705					1710			
Leu	Glu	Gly	Leu	Gln	Lys	Glu	Ile	Asp	Gln	Met	Ile	Lys	Glu	Leu
1715						1720					1725			
Arg	Arg	Lys	Asn	Leu	Glu	Thr	Gln	Lys	Glu	Ile	Ala	Glu	Asp	Glu
1730						1735					1740			
Leu	Val	Ala	Ala	Glu	Ala	Leu	Leu	Lys	Lys	Val	Lys	Lys	Leu	Phe
1745						1750					1755			
Gly	Glu	Ser	Arg	Gly	Glu	Asn	Glu	Glu	Met	Glu	Lys	Asp	Leu	Arg
1760						1765					1770			
Glu	Lys	Leu	Ala	Asp	Tyr	Lys	Asn	Lys	Val	Asp	Asp	Ala	Trp	Asp
1775						1780					1785			



-132-

Leu	Leu	Arg	Glu	Ala	Thr	Asp	Lys	Ile	Arg	Glu	Ala	Asn	Arg	Leu
1790						1795					1800			
Phe	Ala	Val	Asn	Gln	Lys	Asn	Met	Thr	Ala	Leu	Glu	Lys	Lys	Lys
1805						1810					1815			
Glu	Ala	Val	Glu	Ser	Gly	Lys	Arg	Gln	Ile	Glu	Asn	Thr	Leu	Lys
1820						1825					1830			
Glu	Gly	Asn	Asp	Ile	Leu	Asp	Glu	Ala	Asn	Arg	Leu	Ala	Asp	Glu
1835						1840					1845			
Ile	Asn	Ser	Ile	Ile	Asp	Tyr	Val	Glu	Asp	Ile	Gln	Thr	Lys	Leu
1850						1855					1860			
Pro	Pro	Met	Ser	Glu	Glu	Leu	Asn	Asp	Lys	Ile	Asp	Asp	Leu	Ser
1865						1870					1875			
Gln	Glu	Ile	Lys	Asp	Arg	Lys	Leu	Ala	Glu	Lys	Val	Ser	Gln	Ala
1880						1885					1890			
Glu	Ser	His	Ala	Ala	Gln	Leu	Asn	Asp	Ser	Ser	Ala	Val	Leu	Asp
1895						1900					1905			
Gly	Ile	Leu	Asp	Glu	Ala	Lys	Asn	Ile	Ser	Phe	Asn	Ala	Thr	Ala
1910						1915					1920			
Ala	Phe	Lys	Ala	Tyr	Ser	Asn	Ile	Lys	Asp	Tyr	Ile	Asp	Glu	Ala
1925						1930					1935			
Glu	Lys	Val	Ala	Lys	Glu	Ala	Lys	Asp	Leu	Ala	His	Glu	Ala	Thr
1940						1945					1950			
Lys	Leu	Ala	Thr	Gly	Pro	Arg	Gly	Leu	Leu	Lys	Glu	Asp	Ala	Lys
1955						1960					1965			
Gly	Cys	Leu	Gln	Lys	Ser	Phe	Arg	Ile	Leu	Asn	Glu	Ala	Lys	Lys
1970						1975					1980			
Leu	Ala	Asn	Asp	Val	Lys	Glu	Asn	Glu	Asp	His	Leu	Asn	Gly	Leu
1985						1990					1995			
Lys	Thr	Arg	Ile	Glu	Asn	Ala	Asp	Ala	Arg	Asn	Gly	Asp	Leu	Leu
2000						2005					2010			
Arg	Thr	Leu	Asn	Asp	Thr	Leu	Gly	Lys	Leu	Ser	Ala	Ile	Pro	Asn
2015						2020					2025			
Asp	Thr	Ala	Ala	Lys	Leu	Gln	Ala	Val	Lys	Asp	Lys	Ala	Arg	Gln
2030						2035					2040			
Ala	Asn	Asp	Thr	Ala	Lys	Asp	Val	Leu	Ala	Gln	Ile	Thr	Glu	Leu
2045						2050					2055			
His	Gln	Asn	Leu	Asp	Gly	Leu	Lys	Lys	Asn	Tyr	Asn	Lys	Leu	Ala
2060						2065					2070			
Asp	Ser	Val	Ala	Lys	Thr	Asn	Ala	Val	Val	Lys	Asp	Pro	Ser	Lys
2075						2080					2085			

-133-

Asn Lys Ile Ile Ala Asp Ala Asp Ala Thr Val Lys Asn Leu Glu 2090 2095 2100
Gln Glu Ala Asp Arg Leu Ile Asp Lys Leu Lys Pro Ile Lys Glu 2105 2110 2115
Leu Glu Asp Asn Leu Lys Lys Asn Ile Ser Glu Ile Lys Glu Leu 2120 2125 2130
Ile Asn Gln Ala Arg Lys Gln Ala Asn Ser Ile Lys Val Ser Val 2135 2140 2145
Ser Ser Gly Gly Asp Cys Ile Arg Thr Tyr Lys Pro Glu Ile Lys 2150 2155 2160
Lys Gly Ser Tyr Asn Asn Ile Val Val Asn Val Lys Thr Ala Val 2165 2170 2175
Ala Asp Asn Leu Leu Phe Tyr Leu Gly Ser Ala Lys Phe Ile Asp 2180 2185 2190
Phe Leu Ala Ile Glu Met Arg Lys Gly Lys Val Ser Phe Leu Trp 2195 2200 2205
Asp Val Gly Ser Gly Val Gly Arg Val Glu Tyr Pro Asp Leu Thr 2210 2215 2220
Ile Asp Asp Ser Tyr Trp Tyr Arg Ile Val Ala Ser Arg Thr Gly 2225 2230 2235
Arg Asn Gly Thr Ile Ser Val Arg Ala Leu Asp Gly Pro Lys Ala 2240 2245 2250
Ser Ile Val Pro Ser Thr His His Ser Thr Ser Pro Pro Gly Tyr 2255 2260 2265
Thr Ile Leu Asp Val Asp Ala Asn Ala Met Leu Phe Val Gly Gly 2270 2275 2280
Leu Thr Gly Lys Leu Lys Lys Ala Asp Ala Val Arg Val Ile Thr 2285 2290 2295
Phe Thr Gly Cys Met Gly Glu Thr Tyr Phe Asp Asn Lys Pro Ile 2300 2305 2310
Gly Leu Trp Asn Phe Arg Glu Lys Glu Gly Asp Cys Lys Gly Cys 2315 2320 2325
Thr Val Ser Pro Gln Val Glu Asp Ser Glu Gly Thr Ile Gln Phe 2330 2335 2340
Asp Gly Glu Gly Tyr Ala Leu Val Ser Arg Pro Ile Arg Trp Tyr 2345 2350 2355
Pro Asn Ile Ser Thr Val Met Phe Lys Phe Arg Thr Phe Ser Ser 2360 2365 2370
Ser Ala Leu Leu Met Tyr Leu Ala Thr Arg Asp Leu Arg Asp Phe 2375 2380 2385

-134-

Met	Ser	Val	Glu	Leu	Thr	Asp	Gly	His	Ile	Lys	Val	Ser	Tyr	Asp
2390						2395					2400			
Leu	Gly	Ser	Gly	Met	Ala	Ser	Val	Val	Ser	Asn	Gln	Asn	His	Asn
2405						2410					2415			
Asp	Gly	Lys	Trp	Lys	Ser	Phe	Thr	Leu	Ser	Arg	Ile	Gln	Lys	Gln
2420						2425					2430			
Ala	Asn	Ile	Ser	Ile	Val	Asp	Ile	Asp	Thr	Asn	Gln	Glu	Glu	Asn
2435						2440					2445			
Ile	Ala	Thr	Ser	Ser	Ser	Gly	Asn	Asn	Phe	Gly	Leu	Asp	Leu	Lys
2450						2455					2460			
Ala	Asp	Asp	Lys	Ile	Tyr	Phe	Gly	Gly	Leu	Pro	Thr	Leu	Arg	Asn
2465						2470					2475			
Leu	Ser	Met	Lys	Ala	Arg	Pro	Glu	Val	Asn	Leu	Lys	Lys	Tyr	Ser
2480						2485					2490			
Gly	Cys	Leu	Lys	Asp	Ile	Glu	Ile	Ser	Arg	Thr	Pro	Tyr	Asn	Ile
2495						2500					2505			
Leu	Ser	Ser	Pro	Asp	Tyr	Val	Gly	Val	Thr	Lys	Gly	Cys	Ser	Leu
2510						2515					2520			
Glu	Asn	Val	Tyr	Thr	Val	Ser	Phe	Pro	Lys	Pro	Gly	Phe	Val	Glu
2525						2530					2535			
Leu	Ser	Pro	Val	Pro	Ile	Asp	Val	Gly	Thr	Glu	Ile	Asn	Leu	Ser
2540						2545					2550			
Phe	Ser	Thr	Lys	Asn	Glu	Ser	Gly	Ile	Ile	Leu	Leu	Gly	Ser	Gly
2555						2560					2565			
Gly	Thr	Pro	Ala	Pro	Pro	Arg	Arg	Lys	Arg	Arg	Gln	Thr	Gly	Gln
2570						2575					2580			
Ala	Tyr	Tyr	Val	Ile	Leu	Leu	Asn	Arg	Gly	Arg	Leu	Glu	Val	His
2585						2590					2595			
Leu	Ser	Thr	Gly	Ala	Arg	Thr	Met	Arg	Lys	Ile	Val	Ile	Arg	Pro
2600						2605					2610			
Glu	Pro	Asn	Leu	Phe	His	Asp	Gly	Arg	Glu	His	Ser	Val	His	Val
2615						2620					2625			
Glu	Arg	Thr	Arg	Gly	Ile	Phe	Thr	Val	Gln	Val	Asp	Glu	Asn	Arg
2630						2635					2640			
Arg	Tyr	Met	Gln	Asn	Leu	Thr	Val	Glu	Gln	Pro	Ile	Glu	Val	Lys
2645						2650					2655			
Lys	Leu	Phe	Val	Gly	Gly	Ala	Pro	Pro	Glu	Phe	Gln	Pro	Ser	Pro
2660						2665					2670			
Leu	Arg	Asn	Ile	Pro	Pro	Phe	Glu	Gly	Cys	Ile	Trp	Asn	Leu	Val
2675						2680					2685			

-135-

Ile	Asn	Ser	Val	Pro	Met	Asp	Phe	Ala	Arg	Pro	Val	Ser	Phe	Lys
2690						2695					2700			
Asn	Ala	Asp	Ile	Gly	Arg	Cys	Ala	His	Gln	Lys	Leu	Arg	Glu	Asp
2705						2710					2715			
Glu	Asp	Gly	Ala	Ala	Pro	Ala	Glu	Ile	Val	Ile	Gln	Pro	Glu	Pro
2720						2725					2730			
Val	Pro	Thr	Pro	Ala	Phe	Pro	Thr	Pro	Thr	Pro	Val	Leu	Thr	His
2735						2740					2745			
Gly	Pro	Cys	Ala	Ala	Glu	Ser	Glu	Pro	Ala	Leu	Leu	Ile	Gly	Ser
2750						2755					2760			
Lys	Gln	Phe	Gly	Leu	Ser	Arg	Asn	Ser	His	Ile	Ala	Ile	Ala	Phe
2765						2770					2775			
Asp	Asp	Thr	Lys	Val	Lys	Asn	Arg	Leu	Thr	Ile	Glu	Leu	Glu	Val
2780						2785					2790			
Arg	Thr	Glu	Ala	Glu	Ser	Gly	Leu	Leu	Phe	Tyr	Met	Ala	Ala	Ile
2795						2800					2805			
Asn	His	Ala	Asp	Phe	Ala	Thr	Val	Gln	Leu	Arg	Asn	Gly	Leu	Pro
2810						2815					2820			
Tyr	Phe	Ser	Tyr	Asp	Leu	Gly	Ser	Gly	Asp	Thr	His	Thr	Met	Ile
2825						2830					2835			
Pro	Thr	Lys	Ile	Asn	Asp	Gly	Gln	Trp	His	Lys	Ile	Lys	Ile	Met
2840						2845					2850			
Arg	Ser	Lys	Gln	Glu	Gly	Ile	Leu	Tyr	Val	Asp	Gly	Ala	Ser	Asn
2855						2860					2865			
Arg	Thr	Ile	Ser	Pro	Lys	Lys	Ala	Asp	Ile	Leu	Asp	Val	Val	Gly
2870						2875					2880			
Met	Leu	Tyr	Val	Gly	Gly	Leu	Pro	Ile	Asn	Tyr	Thr	Thr	Arg	Arg
2885						2890					2895			
Ile	Gly	Pro	Val	Thr	Tyr	Ser	Ile	Asp	Gly	Cys	Val	Arg	Asn	Leu
2900						2905					2910			
His	Met	Ala	Glu	Ala	Pro	Ala	Asp	Leu	Glu	Gln	Pro	Thr	Ser	Ser
2915						2920					2925			
Phe	His	Val	Gly	Thr	Cys	Phe	Ala	Asn	Ala	Gln	Arg	Gly	Thr	Tyr
2930						2935					2940			
Phe	Asp	Gly	Thr	Gly	Phe	Ala	Lys	Ala	Val	Gly	Gly	Phe	Lys	Val
2945						2950					2955			
Gly	Leu	Asp	Leu	Leu	Val	Glu	Phe	Glu	Phe	Ala	Thr	Thr	Thr	Thr
2960						2965					2970			
Thr	Gly	Val	Leu	Leu	Gly	Ile	Ser	Ser	Gln	Lys	Met	Asp	Gly	Met
2975						2980					2985			

-136-

Gly Ile Glu Met Ile Asp Glu Lys Leu Met Phe His Val Asp Asn  
 2990 2995 3000

Gly Ala Gly Arg Phe Thr Ala Val Tyr Asp Ala Gly Val Pro Gly  
 3005 3010 3015

His Leu Cys Asp Gly Gln Trp His Lys Val Thr Ala Asn Lys Ile  
 3020 3025 3030

Lys His Arg Ile Glu Leu Thr Val Asp Gly Asn Gln Val Glu Ala  
 3035 3040 3045

Gln Ser Pro Asn Pro Ala Ser Thr Ser Ala Asp Thr Asn Asp Pro  
 3050 3055 3060

Val Phe Val Gly Gly Phe Pro Asp Asp Leu Lys Gln Phe Gly Leu  
 3065 3070 3075

Thr Thr Ser Ile Pro Phe Arg Gly Cys Ile Arg Ser Leu Lys Leu  
 3080 3085 3090

Thr Lys Gly Thr Ala Ser His Trp Arg Leu Ile Leu Pro Arg Pro  
 3095 3100 3105

Trp Asn  
 3110

<210> 87

<211> 1798

<212> PRT

<213> Homo Sapiens

<400> 87

Met Glu Leu Thr Ser Thr Glu Arg Gly Arg Gly Gln Pro Leu Pro Trp  
 1 5 10 15

Glu Leu Arg Leu Pro Leu Leu Leu Ser Val Leu Ala Ala Thr Leu Ala  
 20 25 30

Gln Ala Pro Ala Pro Asp Val Pro Gly Cys Ser Arg Gly Ser Cys Tyr  
 35 40 45

Pro Ala Thr Ala Asp Leu Leu Val Gly Arg Ala Asp Arg Leu Thr Ala  
 50 55 60

Ser Ser Thr Cys Gly Leu Asn Gly Arg Gln Pro Tyr Cys Ile Val Ser  
 65 70 75 80

His Leu Gln Asp Glu Lys Lys Cys Phe Leu Cys Asp Ser Arg Arg Pro  
 85 90 95

Phe Ser Ala Arg Asp Asn Pro His Thr His Arg Ile Gln Asn Val Val  
 100 105 110

Thr Ser Phe Ala Pro Gln Arg Arg Ala Ala Trp Trp Gln Ser Gln Asn  
 115 120 125

Gly Ile Pro Ala Val Thr Ile Gln Leu Asp Leu Glu Ala Glu Phe His

-137-

130	135	140
Phe Thr His Leu Ile Met Thr Phe Lys Thr Phe Arg Pro Ala Ala Met		
145	150	155 160
Leu Val Glu Arg Ser Ala Asp Phe Gly Arg Thr Trp His Val Tyr Arg		
	165	170 175
Tyr Phe Ser Tyr His Cys Gly Ala Asp Phe Pro Gly Val Pro Leu Ala		
	180	185 190
Pro Pro Arg His Trp Asp Asp Val Val Cys Glu Ser Arg Tyr Ser Glu		
	195	200 205
Ile Glu Pro Ser Thr Glu Gly Glu Val Ile Tyr Arg Val Leu Asp Pro		
	210	215 220
Ala Ile Pro Ile Pro Asp Pro Tyr Ser Ser Arg Ile Gln Asn Leu Leu		
	225	230 235 240
Lys Ile Thr Asn Leu Arg Val Asn Leu Thr Arg Leu His Thr Leu Gly		
	245	250 255
Asp Asn Leu Leu Asp Pro Arg Arg Glu Ile Arg Glu Lys Tyr Tyr Tyr		
	260	265 270
Ala Leu Tyr Glu Leu Val Val Arg Gly Asn Cys Phe Cys Tyr Gly His		
	275	280 285
Ala Ser Glu Cys Ala Pro Ala Pro Gly Ala Pro Ala His Ala Glu Gly		
	290	295 300
Met Val His Gly Ala Cys Ile Cys Lys His Asn Thr Arg Gly Leu Asn		
	305	310 315 320
Cys Glu Gln Cys Gln Asp Phe Tyr Arg Asp Leu Pro Trp Arg Pro Ala		
	325	330 335
Glu Asp Gly His Ser His Ala Cys Arg Lys Cys Asp Arg His Gly His		
	340	345 350
Thr His Ser Cys His Phe Asp Met Ala Val Tyr Leu Gly Ser Gly Asn		
	355	360 365
Val Ser Gly Gly Val Cys Asp Gly Cys Gln His Asn Thr Ala Trp Arg		
	370	375 380
His Cys Glu Leu Cys Arg Pro Phe Phe Tyr Arg Asp Pro Thr Lys Asp		
	385	390 395 400
Leu Arg Asp Pro Ala Val Cys Arg Ser Cys Asp Cys Asp Pro Met Gly		
	405	410 415
Ser Gln Asp Gly Gly Arg Cys Asp Ser His Asp Asp Pro Ala Leu Gly		
	420	425 430
Leu Val Ser Gly Gln Cys Arg Cys Lys Glu His Val Val Gly Thr Arg		
	435	440 445
Cys Gln Gln Cys Arg Asp Gly Phe Phe Gly Leu Ser Ile Ser Asp Pro		

-138-

450		455		460
Ser Gly Cys Arg Arg Cys Gln Cys Asn Ala Arg Gly Thr Val Pro Gly				
465		470	475	480
Ser Thr Pro Cys Asp Pro Asn Ser Gly Ser Cys Tyr Cys Lys Arg Leu				
	485		490	495
Val Thr Gly Arg Gly Cys Asp Arg Cys Leu Pro Gly His Trp Gly Leu				
	500	505		510
Ser Leu Asp Leu Leu Gly Cys Arg Pro Cys Asp Cys Asp Val Gly Gly				
	515	520	525	
Ala Leu Asp Pro Gln Cys Asp Glu Gly Thr Gly Gln Cys His Cys Arg				
	530	535	540	
Gln His Met Val Gly Arg Arg Cys Glu Gln Val Gln Pro Gly Tyr Phe				
545	550	555		560
Arg Pro Phe Leu Asp His Leu Ile Trp Glu Ala Glu Asn Thr Arg Gly				
	565	570		575
Gln Val Leu Asp Val Val Glu Arg Leu Val Thr Pro Gly Glu Thr Pro				
	580	585		590
Ser Trp Thr Gly Ser Gly Phe Val Arg Leu Gln Glu Gly Gln Thr Leu				
	595	600	605	
Glu Phe Leu Val Ala Ser Val Pro Asn Ala Met Asp Tyr Asp Leu Leu				
	610	615	620	
Leu Arg Leu Glu Pro Gln Val Pro Glu Gln Trp Ala Glu Leu Glu Leu				
625	630	635		640
Ile Val Gln Arg Pro Gly Pro Val Pro Ala His Ser Leu Cys Gly His				
	645	650		655
Leu Val Pro Arg Asp Asp Arg Ile Gln Gly Thr Leu Gln Pro His Ala				
	660	665		670
Arg Tyr Leu Ile Phe Pro Asn Pro Val Cys Leu Glu Pro Gly Ile Ser				
	675	680	685	
Tyr Lys Leu His Leu Lys Leu Val Arg Thr Gly Gly Ser Ala Gln Pro				
	690	695	700	
Glu Thr Pro Tyr Ser Gly Pro Gly Leu Leu Ile Asp Ser Leu Val Leu				
705	710	715		720
Leu Pro Arg Val Leu Val Leu Glu Met Phe Ser Gly Gly Asp Ala Ala				
	725	730		735
Ala Leu Glu Arg Gln Ala Thr Phe Glu Arg Tyr Gln Cys His Glu Glu				
	740	745		750
Gly Leu Val Pro Ser Lys Thr Ser Pro Ser Glu Ala Cys Ala Pro Leu				
	755	760	765	
Leu Ile Ser Leu Ser Thr Leu Ile Tyr Asn Gly Ala Leu Pro Cys Gln				

-139-

770		775		780
Cys Asn Pro Gln Gly Ser Leu Ser Ser Glu Cys Asn Pro His Gly Gly				
785		790		795 800
Gln Cys Leu Cys Lys Pro Gly Val Val Gly Arg Arg Cys Asp Thr Cys				
	805		810	815
Ala Pro Gly Tyr Tyr Gly Phe Gly Pro Thr Gly Cys Gln Ala Cys Gln				
	820		825	830
Cys Ser Pro Arg Gly Ala Leu Ser Ser Leu Cys Glu Arg Thr Ser Gly				
	835		840	845
Gln Cys Leu Cys Arg Thr Gly Ala Phe Gly Leu Arg Cys Asp Ala Cys				
	850		855	860
Gln Arg Gly Gln Trp Gly Phe Pro Ser Cys Arg Pro Cys Val Cys Asn				
	865		870	875 880
Gly His Ala Asp Glu Cys Asn Thr His Thr Gly Ala Cys Leu Gly Cys				
	885		890	895
Arg Asp Leu Thr Gly Gly Glu His Cys Glu Arg Cys Ile Ala Gly Phe				
	900		905	910
His Gly Asp Pro Arg Leu Pro Tyr Gly Ala Gln Cys Arg Pro Cys Pro				
	915		920	925
Cys Pro Glu Gly Pro Gly Ser Gln Arg His Phe Ala Thr Ser Cys His				
	930		935	940
Gln Asp Glu Tyr Ser Gln Gln Ile Val Cys His Cys Arg Ala Gly Tyr				
	945		950	955 960
Thr Gly Leu Arg Cys Glu Ala Cys Ala Pro Gly Gln Phe Gly Asp Pro				
	965		970	975
Ser Arg Pro Gly Gly Arg Cys Gln Leu Cys Glu Cys Ser Gly Asn Ile				
	980		985	990
Asp Pro Met Asp Pro Asp Ala Cys Asp Pro His Pro Gly Gln Cys Leu				
	995		1000	1005
Arg Cys Leu His His Thr Glu Gly Pro His Cys Ala His Ser Lys				
	1010		1015	1020
Pro Gly Phe His Gly Gln Ala Ala Arg Gln Ser Cys His Arg Cys				
	1025		1030	1035
Thr Cys Asn Leu Leu Gly Thr Asn Pro Gln Gln Cys Pro Ser Pro				
	1040		1045	1050
Asp Gln Cys His Cys Asp Pro Ser Ser Gly Gln Cys Pro Cys Leu				
	1055		1060	1065
Pro Asn Val Gln Ala Leu Ala Val Asp Arg Cys Ala Pro Asn Phe				
	1070		1075	1080
Trp Asn Leu Thr Ser Gly His Gly Cys Gln Pro Cys Ala Cys Leu				



-140-

1085		1090		1095
Pro Ser	Pro Glu Glu Gly	Pro Thr Cys Asn Glu	Phe Thr Gly Gln	
1100		1105	1110	
Cys His	Cys Leu Cys Gly	Phe Gly Gly Arg Thr	Cys Ser Glu Cys	
1115		1120	1125	
Gln Glu	Leu His Trp Gly	Asp Pro Gly Leu Gln	Cys His Ala Cys	
1130		1135	1140	
Asp Cys	Asp Ser Arg Gly	Ile Asp Thr Pro Gln	Cys His Arg Phe	
1145		1150	1155	
Thr Gly	His Cys Thr Cys	Arg Pro Gly Val Ser	Gly Val Arg Cys	
1160		1165	1170	
Asp Gln	Cys Ala Arg Gly	Phe Ser Gly Ile Phe	Pro Ala Cys His	
1175		1180	1185	
Pro Cys	His Ala Cys Phe	Gly Asp Trp Asp Arg	Val Val Gln Asp	
1190		1195	1200	
Leu Ala	Ala Arg Thr Gln	Arg Leu Glu Gln Arg	Ala Gln Glu Leu	
1205		1210	1215	
Gln Gln	Thr Gly Val Leu	Gly Ala Phe Glu Ser	Ser Phe Trp His	
1220		1225	1230	
Met Gln	Glu Lys Leu Gly	Ile Val Gln Gly Ile	Val Gly Ala Arg	
1235		1240	1245	
Asn Thr	Ser Ala Ala Ser	Thr Ala Gln Leu Val	Glu Ala Thr Glu	
1250		1255	1260	
Glu Leu	Arg Arg Glu Ile	Gly Glu Ala Thr Glu	His Leu Thr Gln	
1265		1270	1275	
Leu Glu	Ala Asp Leu Thr	Asp Val Gln Asp Glu	Asn Phe Asn Ala	
1280		1285	1290	
Asn His	Ala Leu Ser Gly	Leu Glu Arg Asp Arg	Leu Ala Leu Asn	
1295		1300	1305	
Leu Thr	Leu Arg Gln Leu	Asp Gln His Leu Asp	Leu Leu Lys His	
1310		1315	1320	
Ser Asn	Phe Leu Gly Ala	Tyr Asp Ser Ile Arg	His Ala His Ser	
1325		1330	1335	
Gln Ser	Ala Glu Ala Glu	Arg Arg Ala Asn Thr	Ser Ala Leu Ala	
1340		1345	1350	
Val Pro	Ser Pro Val Ser	Asn Ser Ala Ser Ala	Arg His Arg Thr	
1355		1360	1365	
Glu Ala	Leu Met Asp Ala	Gln Lys Glu Asp Phe	Asn Ser Lys His	
1370		1375	1380	
Met Ala	Asn Gln Arg Ala	Leu Gly Lys Leu Ser	Ala His Thr His	

-141-

1385		1390		1395
Thr Leu Ser Leu Thr Asp	Ile Asn Glu Leu Val	Cys Gly Ala Gln		
1400	1405	1410		
Gly Leu His His Asp Arg	Thr Ser Pro Cys Gly	Gly Ala Gly Cys		
1415	1420	1425		
Arg Asp Glu Asp Gly Gln	Pro Arg Cys Gly Gly	Leu Ser Cys Asn		
1430	1435	1440		
Gly Ala Ala Ala Thr Ala	Asp Leu Ala Leu Gly	Arg Ala Arg His		
1445	1450	1455		
Thr Gln Ala Glu Leu Gln	Arg Ala Leu Ala Glu	Gly Gly Ser Ile		
1460	1465	1470		
Leu Ser Arg Val Ala Glu	Thr Arg Arg Gln Ala	Ser Glu Ala Gln		
1475	1480	1485		
Gln Arg Ala Gln Ala Ala	Leu Asp Lys Ala Asn	Ala Ser Arg Gly		
1490	1495	1500		
Gln Val Glu Gln Ala Asn	Gln Glu Leu Gln Glu	Leu Ile Gln Ser		
1505	1510	1515		
Val Lys Asp Phe Leu Asn	Gln Glu Gly Ala Asp	Pro Asp Ser Ile		
1520	1525	1530		
Glu Met Val Ala Thr Arg	Val Leu Glu Leu Ser	Ile Pro Ala Ser		
1535	1540	1545		
Ala Glu Gln Ile Gln His	Leu Ala Gly Ala Ile	Ala Glu Arg Val		
1550	1555	1560		
Arg Ser Leu Ala Asp Val	Asp Ala Ile Leu Ala	Arg Thr Val Gly		
1565	1570	1575		
Asp Val Arg Arg Ala Glu	Gln Leu Leu Gln Asp	Ala Arg Arg Ala		
1580	1585	1590		
Arg Ser Trp Ala Glu Asp	Glu Lys Gln Lys Ala	Glu Thr Val Gln		
1595	1600	1605		
Ala Ala Leu Glu Glu Ala	Gln Arg Ala Gln Gly	Ile Ala Gln Gly		
1610	1615	1620		
Ala Ile Arg Gly Ala Val	Ala Asp Thr Arg Asp	Thr Glu Gln Thr		
1625	1630	1635		
Leu Tyr Gln Val Gln Glu	Arg Met Ala Gly Ala	Glu Arg Ala Leu		
1640	1645	1650		
Ser Ser Ala Gly Glu Arg	Ala Arg Gln Leu Asp	Ala Leu Leu Glu		
1655	1660	1665		
Ala Leu Lys Leu Lys Arg	Ala Gly Asn Ser Leu	Ala Ala Ser Thr		
1670	1675	1680		
Ala Glu Glu Thr Ala Gly	Ser Ala Gln Gly Arg	Ala Gln Glu Ala		

-142-

1685	1690	1695
Glu Gln Leu Leu Arg Gly Pro Leu Gly Asp Gln Tyr Gln Thr Val		
1700	1705	1710
Lys Ala Leu Ala Glu Arg Lys Ala Gln Gly Val Leu Ala Ala Gln		
1715	1720	1725
Ala Arg Ala Glu Gln Leu Pro Asp Glu Ala Arg Asp Leu Leu Gln		
1730	1735	1740
Ala Ala Gln Asp Lys Leu Gln Arg Leu Gln Glu Leu Glu Gly Thr		
1745	1750	1755
Tyr Glu Glu Asn Glu Arg Ala Leu Glu Ser Lys Ala Ala Gln Leu		
1760	1765	1770
Asp Gly Leu Glu Ala Arg Met Arg Ser Val Leu Gln Ala Ile Asn		
1775	1780	1785
Leu Gln Val Gln Ile Tyr Asn Thr Cys Gln		
1790	1795	

<210> 88  
 <211> 615  
 <212> PRT  
 <213> Homo Sapiens

<400> 88

Met Pro Ser Arg Lys Phe Ala Asp Gly Glu Val Val Arg Gly Arg Trp
1 5 10 15
Pro Gly Ser Ser Leu Tyr Tyr Glu Val Glu Ile Leu Ser His Asp Ser
20 25 30
Thr Ser Gln Leu Tyr Thr Val Lys Tyr Lys Asp Gly Thr Glu Leu Glu
35 40 45
Leu Lys Glu Asn Asp Ile Lys Pro Leu Thr Ser Phe Arg Gln Arg Lys
50 55 60
Gly Gly Ser Thr Ser Ser Ser Pro Ser Arg Arg Arg Gly Ser Arg Ser
65 70 75 80
Arg Ser Arg Ser Arg Ser Pro Gly Arg Pro Pro Lys Ser Ala Arg Arg
85 90 95
Ser Ala Ser Ala Ser His Gln Ala Asp Ile Lys Glu Ala Arg Arg Glu
100 105 110
Val Glu Val Lys Leu Thr Pro Leu Ile Leu Lys Pro Phe Gly Asn Ser
115 120 125
Ile Ser Arg Tyr Asn Gly Glu Pro Glu His Ile Glu Arg Asn Asp Ala
130 135 140
Pro His Lys Asn Thr Gln Glu Lys Phe Ser Leu Ser Gln Glu Ser Ser
145 150 155 160

-143-

Tyr Ile Ala Thr Gln Tyr Ser Leu Arg Pro Arg Arg Glu Glu Val Lys  
 165 170 175  
 Leu Lys Glu Ile Asp Ser Lys Glu Glu Lys Tyr Val Ala Lys Glu Leu  
 180 185 190  
 Ala Val Arg Thr Phe Glu Val Thr Pro Ile Arg Ala Lys Asp Leu Glu  
 195 200 205  
 Phe Gly Gly Val Pro Gly Val Phe Leu Ile Met Phe Gly Leu Pro Val  
 210 215 220  
 Phe Leu Phe Leu Leu Leu Leu Met Cys Lys Gln Lys Asp Pro Ser Leu  
 225 230 235 240  
 Leu Asn Phe Pro Pro Pro Leu Pro Ala Leu Tyr Glu Leu Trp Glu Thr  
 245 250 255  
 Arg Val Phe Gly Val Tyr Leu Leu Trp Phe Leu Ile Gln Val Leu Phe  
 260 265 270  
 Tyr Leu Leu Pro Ile Gly Lys Val Val Glu Gly Thr Pro Leu Ile Asp  
 275 280 285  
 Gly Arg Arg Leu Lys Tyr Arg Leu Asn Gly Phe Tyr Pro Phe Ile Leu  
 290 295 300  
 Thr Ser Ala Val Ile Gly Thr Ser Leu Phe Gln Gly Val Glu Phe His  
 305 310 315 320  
 Tyr Val Tyr Ser His Phe Leu Gln Phe Ala Leu Ala Ala Thr Val Phe  
 325 330 335  
 Cys Val Val Leu Ser Val Tyr Leu Tyr Met Arg Ser Leu Lys Ala Pro  
 340 345 350  
 Arg Asn Asp Leu Ser Pro Ala Ser Ser Gly Asn Ala Val Tyr Asp Phe  
 355 360 365  
 Phe Ile Gly Arg Glu Leu Asn Pro Arg Ile Gly Thr Phe Asp Leu Lys  
 370 375 380  
 Tyr Phe Cys Glu Leu Arg Pro Gly Leu Ile Gly Trp Val Val Ile Asn  
 385 390 395 400  
 Leu Val Met Leu Leu Ala Glu Met Lys Ile Gln Asp Arg Ala Val Pro  
 405 410 415  
 Ser Leu Ala Met Ile Leu Val Asn Ser Phe Gln Leu Leu Tyr Val Val  
 420 425 430  
 Asp Ala Leu Trp Asn Glu Glu Ala Leu Leu Thr Thr Met Asp Ile Ile  
 435 440 445  
 His Asp Gly Phe Gly Phe Met Leu Ala Phe Gly Asp Leu Val Trp Val  
 450 455 460  
 Pro Phe Ile Tyr Ser Phe Gln Ala Phe Tyr Leu Val Ser His Pro Asn  
 465 470 475 480

-144-

Glu Val Ser Trp Pro Met Ala Ser Leu Ile Ile Val Leu Lys Leu Cys  
 485 490 495  
 Gly Tyr Val Ile Phe Arg Gly Ala Asn Ser Gln Lys Asn Ala Phe Arg  
 500 505 510  
 Lys Asn Pro Ser Asp Pro Lys Leu Ala His Leu Lys Thr Ile His Thr  
 515 520 525  
 Ser Ser Gly Lys Asn Leu Leu Val Ser Gly Trp Trp Gly Phe Val Arg  
 530 535 540  
 His Pro Asn Tyr Leu Gly Asp Leu Ile Met Ala Leu Ala Trp Ser Leu  
 545 550 555 560  
 Pro Cys Gly Phe Asn His Ile Leu Pro Tyr Phe Tyr Ile Ile Tyr Phe  
 565 570 575  
 Thr Met Leu Leu Val His Arg Glu Ala Arg Asp Glu Tyr His Cys Lys  
 580 585 590  
 Lys Lys Tyr Gly Val Ala Trp Glu Lys Tyr Cys Gln Arg Val Pro Tyr  
 595 600 605  
 Arg Ile Phe Pro Tyr Ile Tyr  
 610 615

<210> 89  
 <211> 660  
 <212> PRT  
 <213> Homo Sapiens

<400> 89

Met Glu Ala Leu Met Ala Arg Gly Ala Leu Thr Gly Pro Leu Arg Ala  
 1 5 10 15  
 Leu Cys Leu Leu Gly Cys Leu Leu Ser His Ala Ala Ala Ala Pro Ser  
 20 25 30  
 Pro Ile Ile Lys Phe Pro Gly Asp Val Ala Pro Lys Thr Asp Lys Glu  
 35 40 45  
 Leu Ala Val Gln Tyr Leu Asn Thr Phe Tyr Gly Cys Pro Lys Glu Ser  
 50 55 60  
 Cys Asn Leu Phe Val Leu Lys Asp Thr Leu Lys Lys Met Gln Lys Phe  
 65 70 75 80  
 Phe Gly Leu Pro Gln Thr Gly Asp Leu Asp Gln Asn Thr Ile Glu Thr  
 85 90 95  
 Met Arg Lys Pro Arg Cys Gly Asn Pro Asp Val Ala Asn Tyr Asn Phe  
 100 105 110  
 Phe Pro Arg Lys Pro Lys Trp Asp Lys Asn Gln Ile Thr Tyr Arg Ile  
 115 120 125  
 Ile Gly Tyr Thr Pro Asp Leu Asp Pro Glu Thr Val Asp Asp Ala Phe  
 130 135 140

-145-

Ala	Arg	Ala	Phe	Gln	Val	Trp	Ser	Asp	Val	Thr	Pro	Leu	Arg	Phe	Ser	145	150	155	160
Arg	Ile	His	Asp	Gly	Glu	Ala	Asp	Ile	Met	Ile	Asn	Phe	Gly	Arg	Trp	165	170	175	
Glu	His	Gly	Asp	Gly	Tyr	Pro	Phe	Asp	Gly	Lys	Asp	Gly	Leu	Leu	Ala	180	185	190	
His	Ala	Phe	Ala	Pro	Gly	Thr	Gly	Val	Gly	Gly	Asp	Ser	His	Phe	Asp	195	200	205	
Asp	Asp	Glu	Leu	Trp	Thr	Leu	Gly	Glu	Gly	Gln	Val	Val	Arg	Val	Lys	210	215	220	
Tyr	Gly	Asn	Ala	Asp	Gly	Glu	Tyr	Cys	Lys	Phe	Pro	Phe	Leu	Phe	Asn	225	230	235	240
Gly	Lys	Glu	Tyr	Asn	Ser	Cys	Thr	Asp	Thr	Gly	Arg	Ser	Asp	Gly	Phe	245	250	255	
Leu	Trp	Cys	Ser	Thr	Thr	Tyr	Asn	Phe	Glu	Lys	Asp	Gly	Lys	Tyr	Gly	260	265	270	
Phe	Cys	Pro	His	Glu	Ala	Leu	Phe	Thr	Met	Gly	Gly	Asn	Ala	Glu	Gly	275	280	285	
Gln	Pro	Cys	Lys	Phe	Pro	Phe	Arg	Phe	Gln	Gly	Thr	Ser	Tyr	Asp	Ser	290	295	300	
Cys	Thr	Thr	Glu	Gly	Arg	Thr	Asp	Gly	Tyr	Arg	Trp	Cys	Gly	Thr	Thr	305	310	315	320
Glu	Asp	Tyr	Asp	Arg	Asp	Lys	Lys	Tyr	Gly	Phe	Cys	Pro	Glu	Thr	Ala	325	330	335	
Met	Ser	Thr	Val	Gly	Gly	Asn	Ser	Glu	Gly	Ala	Pro	Cys	Val	Phe	Pro	340	345	350	
Phe	Thr	Phe	Leu	Gly	Asn	Lys	Tyr	Glu	Ser	Cys	Thr	Ser	Ala	Gly	Arg	355	360	365	
Ser	Asp	Gly	Lys	Met	Trp	Cys	Ala	Thr	Thr	Ala	Asn	Tyr	Asp	Asp	Asp	370	375	380	
Arg	Lys	Trp	Gly	Phe	Cys	Pro	Asp	Gln	Gly	Tyr	Ser	Leu	Phe	Leu	Val	385	390	395	400
Ala	Ala	His	Glu	Phe	Gly	His	Ala	Met	Gly	Leu	Glu	His	Ser	Gln	Asp	405	410	415	
Pro	Gly	Ala	Leu	Met	Ala	Pro	Ile	Tyr	Thr	Tyr	Thr	Lys	Asn	Phe	Arg	420	425	430	
Leu	Ser	Gln	Asp	Asp	Ile	Lys	Gly	Ile	Gln	Glu	Leu	Tyr	Gly	Ala	Ser	435	440	445	
Pro	Asp	Ile	Asp	Leu	Gly	Thr	Gly	Pro	Thr	Pro	Thr	Leu	Gly	Pro	Val	450	455	460	

-146-

Thr Pro Glu Ile Cys Lys Gln Asp Ile Val Phe Asp Gly Ile Ala Gln  
 465 470 475 480  
 Ile Arg Gly Glu Ile Phe Phe Phe Lys Asp Arg Phe Ile Trp Arg Thr  
 485 490 495  
 Val Thr Pro Arg Asp Lys Pro Met Gly Pro Leu Leu Val Ala Thr Phe  
 500 505 510  
 Trp Pro Glu Leu Pro Glu Lys Ile Asp Ala Val Tyr Glu Ala Pro Gln  
 515 520 525  
 Glu Glu Lys Ala Val Phe Phe Ala Gly Asn Glu Tyr Trp Ile Tyr Ser  
 530 535 540  
 Ala Ser Thr Leu Glu Arg Gly Tyr Pro Lys Pro Leu Thr Ser Leu Gly  
 545 550 555 560  
 Leu Pro Pro Asp Val Gln Arg Val Asp Ala Ala Phe Asn Trp Ser Lys  
 565 570 575  
 Asn Lys Lys Thr Tyr Ile Phe Ala Gly Asp Lys Phe Trp Arg Tyr Asn  
 580 585 590  
 Glu Val Lys Lys Lys Met Asp Pro Gly Phe Pro Lys Leu Ile Ala Asp  
 595 600 605  
 Ala Trp Asn Ala Ile Pro Asp Asn Leu Asp Ala Val Val Asp Leu Gln  
 610 615 620  
 Gly Gly Gly His Ser Tyr Phe Phe Lys Gly Ala Tyr Tyr Leu Lys Leu  
 625 630 635 640  
 Glu Asn Gln Ser Leu Lys Ser Val Lys Phe Gly Ser Ile Lys Ser Asp  
 645 650 655  
 Trp Leu Gly Cys  
 660

<210> 90  
 <211> 430  
 <212> PRT  
 <213> Homo Sapiens

<400> 90

Leu Arg Tyr Gln Gln Leu Ile Lys Glu Asn Leu Lys Glu Ile Ala Lys  
 1 5 10 15  
 Leu Ile Thr Leu Glu Gln Gly Lys Thr Leu Ala Asp Ala Glu Gly Asp  
 20 25 30  
 Val Phe Arg Gly Leu Gln Val Val Glu His Ala Cys Ser Val Thr Ser  
 35 40 45  
 Leu Met Met Gly Glu Thr Met Pro Ser Ile Thr Lys Asp Met Asp Leu  
 50 55 60  
 Tyr Ser Tyr Arg Leu Pro Leu Gly Val Cys Ala Gly Ile Ala Pro Phe

-147-

65					70					75					80
Asn	Phe	Pro	Ala	Met	Ile	Pro	Leu	Trp	Met	Phe	Pro	Met	Ala	Met	Val
				85					90					95	
Cys	Gly	Asn	Thr	Phe	Leu	Met	Lys	Pro	Ser	Glu	Arg	Val	Pro	Gly	Ala
			100					105					110		
Thr	Met	Leu	Leu	Ala	Lys	Leu	Leu	Gln	Asp	Ser	Gly	Ala	Pro	Asp	Gly
		115					120					125			
Thr	Leu	Asn	Ile	Ile	His	Gly	Gln	His	Glu	Ala	Val	Asn	Phe	Ile	Cys
	130					135						140			
Asp	His	Pro	Asp	Ile	Lys	Ala	Ile	Ser	Phe	Val	Gly	Ser	Asn	Lys	Ala
145					150					155					160
Gly	Glu	Tyr	Ile	Phe	Glu	Arg	Gly	Ser	Arg	His	Gly	Lys	Arg	Val	Gln
				165					170					175	
Ala	Asn	Met	Gly	Ala	Lys	Asn	His	Gly	Val	Val	Met	Pro	Asp	Ala	Asn
			180					185					190		
Lys	Glu	Asn	Thr	Leu	Asn	Gln	Leu	Val	Gly	Ala	Ala	Phe	Gly	Ala	Ala
		195					200					205			
Gly	Gln	Arg	Cys	Met	Ala	Leu	Ser	Thr	Ala	Val	Leu	Val	Gly	Glu	Ala
	210					215					220				
Lys	Lys	Trp	Leu	Pro	Glu	Leu	Val	Glu	His	Ala	Lys	Asn	Leu	Arg	Val
225					230					235					240
Asn	Ala	Gly	Asp	Gln	Pro	Gly	Ala	Asp	Leu	Gly	Pro	Leu	Ile	Thr	Pro
				245					250					255	
Gln	Ala	Lys	Glu	Arg	Val	Cys	Asn	Leu	Ile	Asp	Ser	Gly	Thr	Lys	Glu
			260					265					270		
Gly	Ala	Ser	Ile	Leu	Leu	Asp	Gly	Arg	Lys	Ile	Lys	Val	Lys	Gly	Tyr
		275					280					285			
Glu	Asn	Gly	Asn	Phe	Val	Gly	Pro	Thr	Ile	Ile	Ser	Asn	Val	Lys	Pro
	290					295					300				
Asn	Met	Thr	Cys	Tyr	Lys	Glu	Glu	Ile	Phe	Gly	Pro	Val	Leu	Val	Val
305					310					315					320
Leu	Glu	Thr	Glu	Thr	Leu	Asp	Glu	Ala	Ile	Gln	Ile	Val	Asn	Asn	Asn
				325					330					335	
Pro	Tyr	Gly	Asn	Gly	Thr	Ala	Ile	Phe	Thr	Thr	Asn	Gly	Ala	Thr	Ala
			340					345					350		
Arg	Lys	Tyr	Ala	His	Leu	Val	Asp	Val	Gly	Gln	Val	Gly	Val	Asn	Val
		355					360					365			
Pro	Ile	Pro	Val	Pro	Leu	Pro	Met	Phe	Ser	Phe	Thr	Gly	Ser	Arg	Ser
	370					375					380				
Ser	Phe	Arg	Gly	Asp	Thr	Asn	Phe	Tyr	Gly	Lys	Gln	Gly	Ile	Gln	Phe



-148-

385                      390                      395                      400  
 Tyr Thr Gln Leu Lys Thr Ile Thr Ser Gln Trp Lys Glu Glu Asp Ala  
                                  405                      410                      415  
 Thr Leu Ser Ser Pro Ala Val Val Met Pro Thr Met Gly Arg  
                                  420                      425                      430  
  
 <210> 91  
 <211> 1857  
 <212> PRT  
 <213> Homo Sapiens  
  
 <400> 91  
  
 Thr Tyr Ser Gly Leu Phe Cys Val Val Val Asn Pro Tyr Lys His Leu  
 1                      5                      10                      15  
 Pro Ile Tyr Ser Glu Lys Ile Val Asp Met Tyr Lys Gly Lys Lys Arg  
                                  20                      25                      30  
 His Glu Met Pro Pro His Ile Tyr Ala Ile Ala Asp Thr Ala Tyr Arg  
                                  35                      40                      45  
 Ser Met Leu Gln Asp Arg Glu Asp Gln Ser Ile Leu Cys Thr Gly Glu  
                                  50                      55                      60  
 Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gln Tyr Leu  
 65                      70                      75                      80  
 Ala Val Val Ala Ser Ser His Lys Gly Lys Lys Asp Thr Ser Ile Thr  
                                  85                      90                      95  
 Gly Glu Leu Glu Lys Gln Leu Leu Gln Ala Asn Pro Ile Leu Glu Ala  
                                  100                      105                      110  
 Phe Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser Arg Phe Gly  
                                  115                      120                      125  
 Lys Phe Ile Arg Ile Asn Phe Asp Val Thr Gly Tyr Ile Val Gly Ala  
                                  130                      135                      140  
 Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Ile Arg Gln Ala  
 145                      150                      155                      160  
 Arg Asp Glu Arg Thr Phe His Ile Phe Tyr Tyr Met Ile Ala Gly Ala  
                                  165                      170                      175  
 Lys Glu Lys Met Arg Ser Asp Leu Leu Leu Glu Gly Phe Asn Asn Tyr  
                                  180                      185                      190  
 Thr Phe Leu Ser Asn Gly Phe Val Pro Ile Pro Ala Ala Gln Asp Asp  
                                  195                      200                      205  
 Glu Met Phe Gln Glu Thr Val Glu Ala Met Ala Ile Met Gly Phe Ser  
                                  210                      215                      220  
 Glu Glu Glu Gln Leu Ser Ile Leu Lys Val Val Ser Ser Val Leu Gln  
 225                      230                      235                      240

-149-

Leu	Gly	Asn	Ile	Val	Phe	Lys	Lys	Glu	Arg	Asn	Thr	Asp	Gln	Ala	Ser		
				245					250					255			
Met	Pro	Asp	Asn	Thr	Ala	Ala	Gln	Lys	Val	Cys	His	Leu	Met	Gly	Ile		
			260					265					270				
Asn	Val	Thr	Asp	Phe	Thr	Arg	Ser	Ile	Leu	Thr	Pro	Arg	Ile	Lys	Val		
		275					280					285					
Gly	Arg	Asp	Val	Val	Gln	Lys	Ala	Gln	Thr	Lys	Glu	Gln	Ala	Asp	Phe		
	290					295					300						
Ala	Val	Glu	Ala	Leu	Ala	Lys	Ala	Thr	Tyr	Glu	Arg	Leu	Phe	Arg	Trp		
305					310					315					320		
Ile	Leu	Thr	Arg	Val	Asn	Lys	Ala	Leu	Asp	Lys	Thr	His	Arg	Gln	Gly		
				325					330					335			
Ala	Ser	Phe	Leu	Gly	Ile	Leu	Asp	Ile	Ala	Gly	Phe	Glu	Ile	Phe	Glu		
			340					345					350				
Val	Asn	Ser	Phe	Glu	Gln	Leu	Cys	Ile	Asn	Tyr	Thr	Asn	Glu	Lys	Leu		
		355					360					365					
Gln	Gln	Leu	Phe	Asn	His	Thr	Met	Phe	Ile	Leu	Glu	Gln	Glu	Glu	Tyr		
	370					375					380						
Gln	Arg	Glu	Gly	Ile	Glu	Trp	Asn	Phe	Ile	Asp	Phe	Gly	Leu	Asp	Leu		
385					390					395					400		
Gln	Pro	Cys	Ile	Glu	Leu	Ile	Glu	Arg	Pro	Asn	Asn	Pro	Pro	Gly	Val		
				405					410					415			
Leu	Ala	Leu	Leu	Asp	Glu	Glu	Cys	Trp	Phe	Pro	Lys	Ala	Thr	Asp	Lys		
				420				425					430				
Ser	Phe	Val	Glu	Lys	Leu	Cys	Thr	Glu	Gln	Gly	Ser	His	Pro	Lys	Phe		
		435					440					445					
Gln	Lys	Pro	Lys	Gln	Leu	Lys	Asp	Lys	Thr	Glu	Phe	Ser	Ile	Ile	His		
	450					455					460						
Tyr	Ala	Gly	Lys	Val	Asp	Tyr	Asn	Ala	Ser	Ala	Trp	Leu	Thr	Lys	Asn		
465					470					475					480		
Met	Asp	Pro	Leu	Asn	Asp	Asn	Val	Thr	Ser	Leu	Leu	Asn	Ala	Ser	Ser		
				485					490					495			
Asp	Lys	Phe	Val	Ala	Asp	Leu	Trp	Lys	Asp	Val	Asp	Arg	Ile	Val	Gly		
			500					505					510				
Leu	Asp	Gln	Met	Ala	Lys	Met	Thr	Glu	Ser	Ser	Leu	Pro	Ser	Ala	Ser		
		515					520					525					
Lys	Thr	Lys	Lys	Gly	Met	Phe	Arg	Thr	Val	Gly	Gln	Leu	Tyr	Lys	Glu		
	530					535					540						
Gln	Leu	Gly	Lys	Leu	Met	Thr	Thr	Leu	Arg	Asn	Thr	Thr	Pro	Asn	Phe		
545					550					555					560		

-150-

Val Arg Cys Ile Ile Pro Asn His Glu Lys Arg Ser Gly Lys Leu Asp  
 565 570 575  
 Ala Phe Leu Val Leu Glu Gln Leu Arg Cys Asn Gly Val Leu Glu Gly  
 580 585 590  
 Ile Arg Ile Cys Arg Gln Gly Phe Pro Asn Arg Ile Val Phe Gln Glu  
 595 600 605  
 Phe Arg Gln Arg Tyr Glu Ile Leu Ala Ala Asn Ala Ile Pro Lys Gly  
 610 615 620  
 Phe Met Asp Gly Lys Gln Ala Cys Ile Leu Met Ile Lys Ala Leu Glu  
 625 630 635 640  
 Leu Asp Pro Asn Leu Tyr Arg Ile Gly Gln Ser Lys Ile Phe Phe Arg  
 645 650 655  
 Thr Gly Val Leu Ala His Leu Glu Glu Glu Arg Asp Leu Lys Ile Thr  
 660 665 670  
 Asp Val Ile Met Ala Phe Gln Ala Met Cys Arg Gly Tyr Leu Ala Arg  
 675 680 685  
 Lys Ala Phe Ala Lys Arg Gln Gln Gln Leu Thr Ala Met Lys Val Ile  
 690 695 700  
 Gln Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg Asn Trp Gln Trp Trp  
 705 710 715 720  
 Arg Leu Phe Thr Lys Val Lys Pro Leu Leu Gln Val Thr Arg Gln Glu  
 725 730 735  
 Glu Glu Met Gln Ala Lys Glu Asp Glu Leu Gln Lys Thr Lys Glu Arg  
 740 745 750  
 Gln Gln Lys Ala Glu Asn Glu Leu Lys Glu Leu Glu Gln Lys His Ser  
 755 760 765  
 Gln Leu Thr Glu Glu Lys Asn Leu Leu Gln Glu Gln Leu Gln Ala Glu  
 770 775 780  
 Thr Glu Leu Tyr Ala Glu Ala Glu Glu Met Arg Val Arg Leu Ala Ala  
 785 790 795 800  
 Lys Lys Gln Glu Leu Glu Glu Ile Leu His Glu Met Glu Ala Arg Leu  
 805 810 815  
 Glu Glu Glu Glu Asp Arg Gly Gln Gln Leu Gln Ala Glu Arg Lys Lys  
 820 825 830  
 Met Ala Gln Gln Met Leu Asp Leu Glu Glu Gln Leu Glu Glu Glu Glu  
 835 840 845  
 Ala Ala Arg Gln Lys Leu Gln Leu Glu Lys Val Thr Ala Glu Ala Lys  
 850 855 860  
 Ile Lys Lys Leu Glu Asp Glu Ile Leu Val Met Asp Asp Gln Asn Asn  
 865 870 875 880

-151-

Lys Leu Ser Lys Glu Arg Lys Leu Leu Glu Glu Arg Ile Ser Asp Leu  
 885 890 895  
 Thr Thr Asn Leu Ala Glu Glu Glu Glu Lys Ala Lys Asn Leu Thr Lys  
 900 905 910  
 Leu Lys Asn Lys His Glu Ser Met Ile Ser Glu Leu Glu Val Arg Leu  
 915 920 925  
 Lys Lys Glu Glu Lys Ser Arg Gln Glu Leu Glu Lys Leu Lys Arg Lys  
 930 935 940  
 Leu Glu Gly Asp Ala Ser Asp Phe His Glu Gln Ile Ala Asp Leu Gln  
 945 950 955 960  
 Ala Gln Ile Ala Glu Leu Lys Met Gln Leu Ala Lys Lys Glu Glu Glu  
 965 970 975  
 Leu Gln Ala Ala Leu Ala Arg Leu Asp Asp Glu Ile Ala Gln Lys Asn  
 980 985 990  
 Asn Ala Leu Lys Lys Ile Arg Glu Leu Glu Gly His Ile Ser Asp Leu  
 995 1000 1005  
 Gln Glu Asp Leu Asp Ser Glu Arg Ala Ala Arg Asn Lys Ala Glu  
 1010 1015 1020  
 Lys Gln Lys Arg Asp Leu Gly Glu Glu Leu Glu Ala Leu Lys Thr  
 1025 1030 1035  
 Glu Leu Glu Asp Thr Leu Asp Ser Thr Ala Thr Gln Gln Glu Leu  
 1040 1045 1050  
 Arg Ala Lys Arg Glu Gln Glu Val Thr Val Leu Lys Lys Ala Leu  
 1055 1060 1065  
 Asp Glu Glu Thr Arg Ser His Glu Ala Gln Val Gln Glu Met Arg  
 1070 1075 1080  
 Gln Lys His Ala Gln Ala Val Glu Glu Leu Thr Glu Gln Leu Glu  
 1085 1090 1095  
 Gln Phe Lys Arg Ala Lys Ala Asn Leu Asp Lys Asn Lys Gln Thr  
 1100 1105 1110  
 Leu Glu Lys Glu Asn Ala Asp Leu Ala Gly Glu Leu Arg Val Leu  
 1115 1120 1125  
 Gly Gln Ala Lys Gln Glu Val Glu His Lys Lys Lys Lys Leu Glu  
 1130 1135 1140  
 Ala Gln Val Gln Glu Leu Gln Ser Lys Cys Ser Asp Gly Glu Arg  
 1145 1150 1155  
 Ala Arg Ala Glu Leu Asn Asp Lys Val His Lys Leu Gln Asn Glu  
 1160 1165 1170  
 Val Glu Ser Val Thr Gly Met Leu Asn Glu Ala Glu Gly Lys Ala  
 1175 1180 1185

Ile	Lys	Leu	Ala	Lys	Asp	Val	Ala	Ser	Leu	Ser	Ser	Gln	Leu	Gln
	1190					1195					1200			
Asp	Thr	Gln	Glu	Leu	Leu	Gln	Glu	Glu	Thr	Arg	Gln	Lys	Leu	Asn
	1205					1210					1215			
Val	Ser	Thr	Lys	Leu	Arg	Gln	Leu	Glu	Glu	Glu	Arg	Asn	Ser	Leu
	1220					1225					1230			
Gln	Asp	Gln	Leu	Asp	Glu	Glu	Met	Glu	Ala	Lys	Gln	Asn	Leu	Glu
	1235					1240					1245			
Arg	His	Ile	Ser	Thr	Leu	Asn	Ile	Gln	Leu	Ser	Asp	Ser	Lys	Lys
	1250					1255					1260			
Lys	Leu	Gln	Asp	Phe	Ala	Ser	Thr	Val	Glu	Ala	Leu	Glu	Glu	Gly
	1265					1270					1275			
Lys	Lys	Arg	Phe	Gln	Lys	Glu	Ile	Glu	Asn	Leu	Thr	Gln	Gln	Tyr
	1280					1285					1290			
Glu	Glu	Lys	Ala	Ala	Ala	Tyr	Asp	Lys	Leu	Glu	Lys	Thr	Lys	Asn
	1295					1300					1305			
Arg	Leu	Gln	Gln	Glu	Leu	Asp	Asp	Leu	Val	Val	Asp	Leu	Asp	Asn
	1310					1315					1320			
Gln	Arg	Gln	Leu	Val	Ser	Asn	Leu	Glu	Lys	Lys	Gln	Arg	Lys	Phe
	1325					1330					1335			
Asp	Gln	Leu	Leu	Ala	Glu	Glu	Lys	Asn	Ile	Ser	Ser	Lys	Tyr	Ala
	1340					1345					1350			
Asp	Glu	Arg	Asp	Arg	Ala	Glu	Ala	Glu	Ala	Arg	Glu	Lys	Glu	Thr
	1355					1360					1365			
Lys	Ala	Leu	Ser	Leu	Ala	Arg	Ala	Leu	Glu	Glu	Ala	Leu	Glu	Ala
	1370					1375					1380			
Lys	Glu	Glu	Leu	Glu	Arg	Thr	Asn	Lys	Met	Leu	Lys	Ala	Glu	Met
	1385					1390					1395			
Glu	Asp	Leu	Val	Ser	Ser	Lys	Asp	Asp	Val	Gly	Lys	Asn	Val	His
	1400					1405					1410			
Glu	Leu	Glu	Lys	Ser	Lys	Arg	Ala	Leu	Glu	Thr	Gln	Met	Glu	Glu
	1415					1420					1425			
Met	Lys	Thr	Gln	Leu	Glu	Glu	Leu	Glu	Asp	Glu	Leu	Gln	Ala	Thr
	1430					1435					1440			
Glu	Asp	Ala	Lys	Leu	Arg	Leu	Glu	Val	Asn	Met	Gln	Ala	Leu	Lys
	1445					1450					1455			
Gly	Gln	Phe	Glu	Arg	Asp	Leu	Gln	Ala	Arg	Asp	Glu	Gln	Asn	Glu
	1460					1465					1470			
Glu	Lys	Arg	Arg	Gln	Leu	Gln	Arg	Gln	Leu	His	Glu	Tyr	Glu	Thr
	1475					1480					1485			

-153-

Glu	Leu	Glu	Asp	Glu	Arg	Lys	Gln	Arg	Ala	Leu	Ala	Ala	Ala	Ala
1490						1495					1500			
Lys	Lys	Lys	Leu	Glu	Gly	Asp	Leu	Lys	Asp	Leu	Glu	Leu	Gln	Ala
1505						1510					1515			
Asp	Ser	Ala	Ile	Lys	Gly	Arg	Glu	Glu	Ala	Ile	Lys	Gln	Leu	Arg
1520						1525					1530			
Lys	Leu	Gln	Ala	Gln	Met	Lys	Asp	Phe	Gln	Arg	Glu	Leu	Glu	Asp
1535						1540					1545			
Ala	Arg	Ala	Ser	Arg	Asp	Glu	Ile	Phe	Ala	Thr	Ala	Lys	Glu	Asn
1550						1555					1560			
Glu	Lys	Lys	Ala	Lys	Ser	Leu	Glu	Ala	Asp	Leu	Met	Gln	Leu	Gln
1565						1570					1575			
Glu	Asp	Leu	Ala	Ala	Ala	Glu	Arg	Ala	Arg	Lys	Gln	Ala	Asp	Leu
1580						1585					1590			
Glu	Lys	Glu	Glu	Leu	Ala	Glu	Glu	Leu	Ala	Ser	Ser	Leu	Ser	Gly
1595						1600					1605			
Arg	Asn	Ala	Leu	Gln	Asp	Glu	Lys	Arg	Arg	Leu	Glu	Ala	Arg	Ile
1610						1615					1620			
Ala	Gln	Leu	Glu	Glu	Glu	Leu	Glu	Glu	Glu	Gln	Gly	Asn	Met	Glu
1625						1630					1635			
Ala	Met	Ser	Asp	Arg	Val	Arg	Lys	Ala	Thr	Gln	Gln	Ala	Glu	Gln
1640						1645					1650			
Leu	Ser	Asn	Glu	Leu	Ala	Thr	Glu	Arg	Ser	Thr	Ala	Gln	Lys	Asn
1655						1660					1665			
Glu	Ser	Ala	Arg	Gln	Gln	Leu	Glu	Arg	Gln	Asn	Lys	Glu	Leu	Arg
1670						1675					1680			
Ser	Lys	Leu	His	Glu	Met	Glu	Gly	Ala	Val	Lys	Ser	Lys	Phe	Lys
1685						1690					1695			
Ser	Thr	Ile	Ala	Ala	Leu	Glu	Ala	Lys	Ile	Ala	Gln	Leu	Glu	Glu
1700						1705					1710			
Gln	Val	Glu	Gln	Glu	Ala	Arg	Glu	Lys	Gln	Ala	Ala	Thr	Lys	Ser
1715						1720					1725			
Leu	Lys	Gln	Lys	Asp	Lys	Lys	Leu	Lys	Glu	Ile	Leu	Leu	Gln	Val
1730						1735					1740			
Glu	Asp	Glu	Arg	Lys	Met	Ala	Glu	Gln	Tyr	Lys	Glu	Gln	Ala	Glu
1745						1750					1755			
Lys	Gly	Asn	Ala	Arg	Val	Lys	Gln	Leu	Lys	Arg	Gln	Leu	Glu	Glu
1760						1765					1770			
Ala	Glu	Glu	Glu	Ser	Gln	Arg	Ile	Asn	Ala	Asn	Arg	Arg	Lys	Leu
1775						1780					1785			

-154-

Gln Arg Glu Leu Asp Glu Ala Thr Glu Ser Asn Glu Ala Met Gly  
 1790 1795 1800  
 Arg Glu Val Asn Ala Leu Lys Ser Lys Leu Arg Arg Gly Asn Glu  
 1805 1810 1815  
 Thr Ser Phe Val Pro Ser Arg Arg Ser Gly Gly Arg Arg Val Ile  
 1820 1825 1830  
 Glu Asn Ala Asp Gly Ser Glu Glu Glu Thr Asp Thr Arg Asp Ala  
 1835 1840 1845  
 Asp Phe Asn Gly Thr Lys Ala Ser Glu  
 1850 1855  
 <210> 92  
 <211> 1953  
 <212> PRT  
 <213> Homo Sapiens  
 <400> 92  
 Gly Cys Leu Cys Cys Ser Ser Glu Gln Leu Gln Glu Leu Pro Ser Arg  
 1 5 10 15  
 Glu Leu Gln Asp Ala Phe Pro Val Pro Leu Ala Gln Leu Pro Gln Gln  
 20 25 30  
 Thr Thr Glu Lys Thr Val Thr Met Gly Asp Val Lys Leu Val Ala Ser  
 35 40 45  
 Ser His Ile Ser Lys Thr Ser Leu Ser Val Asp Pro Ser Arg Val Asp  
 50 55 60  
 Ser Met Pro Leu Thr Glu Ala Pro Ala Phe Ile Leu Pro Pro Arg Asn  
 65 70 75 80  
 Leu Cys Ile Lys Glu Gly Ala Thr Ala Lys Phe Glu Gly Arg Val Arg  
 85 90 95  
 Gly Tyr Pro Glu Pro Gln Val Thr Trp His Arg Asn Gly Gln Pro Ile  
 100 105 110  
 Thr Ser Gly Gly Arg Phe Leu Leu Asp Cys Gly Ile Arg Gly Thr Phe  
 115 120 125  
 Ser Leu Val Ile His Ala Val His Glu Glu Asp Arg Gly Lys Tyr Thr  
 130 135 140  
 Cys Glu Ala Thr Asn Gly Ser Gly Ala Arg Gln Val Thr Val Glu Leu  
 145 150 155 160  
 Thr Val Glu Gly Ser Phe Ala Lys Gln Leu Gly Gln Pro Val Val Ser  
 165 170 175  
 Lys Thr Leu Gly Asp Arg Phe Ser Ala Ser Ala Val Glu Thr Arg Pro  
 180 185 190  
 Ser Ile Trp Gly Glu Cys Pro Pro Lys Phe Ala Thr Lys Leu Gly Arg  
 195 200 205





-156-

Ser	Asn	Ala	Gln	Gly	Gln	Val	Ser	Cys	Ser	Trp	Thr	Leu	Gln	Val	Glu	530	535	540
Arg	Leu	Ala	Val	Met	Glu	Val	Ala	Pro	Ser	Phe	Ser	Ser	Val	Leu	Lys	545	550	555 560
Asp	Cys	Ala	Val	Ile	Glu	Gly	Gln	Asp	Phe	Val	Leu	Gln	Cys	Ser	Val	565	570	575
Arg	Gly	Thr	Pro	Val	Pro	Arg	Ile	Thr	Trp	Leu	Leu	Asn	Gly	Gln	Pro	580	585	590
Ile	Gln	Tyr	Ala	Arg	Ser	Thr	Cys	Glu	Ala	Gly	Val	Ala	Glu	Leu	His	595	600	605
Ile	Gln	Asp	Ala	Leu	Pro	Glu	Asp	His	Gly	Thr	Tyr	Thr	Cys	Leu	Ala	610	615	620
Glu	Asn	Ala	Leu	Gly	Gln	Val	Ser	Cys	Ser	Ala	Trp	Val	Thr	Val	His	625	630	635 640
Glu	Lys	Lys	Ser	Ser	Arg	Lys	Ser	Glu	Tyr	Leu	Leu	Pro	Val	Ala	Pro	645	650	655
Ser	Lys	Pro	Thr	Ala	Pro	Ile	Phe	Leu	Gln	Gly	Leu	Ser	Asp	Leu	Lys	660	665	670
Val	Met	Asp	Gly	Ser	Gln	Val	Thr	Met	Thr	Val	Gln	Val	Ser	Gly	Asn	675	680	685
Pro	Pro	Pro	Glu	Val	Ile	Trp	Leu	His	Asn	Gly	Asn	Glu	Ile	Gln	Glu	690	695	700
Ser	Glu	Asp	Phe	His	Phe	Glu	Gln	Arg	Gly	Thr	Gln	His	Ser	Leu	Trp	705	710	715 720
Ile	Gln	Glu	Val	Phe	Pro	Glu	Asp	Thr	Gly	Thr	Tyr	Thr	Cys	Glu	Ala	725	730	735
Trp	Asn	Ser	Ala	Gly	Glu	Val	Arg	Thr	Gln	Ala	Val	Leu	Thr	Val	Gln	740	745	750
Glu	Pro	His	Asp	Gly	Thr	Gln	Pro	Trp	Phe	Ile	Ser	Lys	Pro	Arg	Ser	755	760	765
Val	Thr	Ala	Ser	Leu	Gly	Gln	Ser	Val	Leu	Ile	Ser	Cys	Ala	Ile	Ala	770	775	780
Gly	Asp	Pro	Phe	Pro	Thr	Val	His	Trp	Leu	Arg	Asp	Gly	Lys	Ala	Leu	785	790	795 800
Cys	Lys	Asp	Thr	Gly	His	Phe	Glu	Val	Leu	Gln	Asn	Glu	Asp	Val	Phe	805	810	815
Thr	Leu	Val	Leu	Lys	Lys	Val	Gln	Pro	Trp	His	Ala	Gly	Gln	Tyr	Glu	820	825	830
Ile	Leu	Leu	Lys	Asn	Arg	Val	Gly	Glu	Cys	Ser	Cys	Gln	Val	Ser	Leu	835	840	845

-157-

Met Leu Gln Asn Ser Ser Ala Arg Ala Leu Pro Arg Gly Arg Glu Pro  
 850 855 860  
 Ala Ser Cys Glu Asp Leu Cys Gly Gly Gly Val Gly Ala Asp Gly Gly  
 865 870 875 880  
 Gly Ser Asp Arg Tyr Gly Ser Leu Arg Pro Gly Trp Pro Ala Arg Gly  
 885 890 895  
 Gln Gly Trp Leu Glu Glu Glu Asp Gly Glu Asp Val Arg Gly Val Leu  
 900 905 910  
 Lys Arg Arg Val Glu Thr Arg Gln His Thr Glu Glu Ala Ile Arg Gln  
 915 920 925  
 Gln Glu Val Glu Gln Leu Asp Phe Arg Asp Leu Leu Gly Lys Lys Val  
 930 935 940  
 Ser Thr Lys Thr Leu Ser Glu Asp Asp Leu Lys Glu Ile Pro Ala Glu  
 945 950 955 960  
 Gln Met Asp Phe Arg Ala Asn Leu Gln Arg Gln Val Lys Pro Lys Thr  
 965 970 975  
 Val Ser Glu Glu Glu Arg Lys Val His Ser Pro Gln Gln Val Asp Phe  
 980 985 990  
 Arg Ser Val Leu Ala Lys Lys Gly Thr Ser Lys Thr Pro Val Pro Glu  
 995 1000 1005  
 Lys Val Pro Pro Pro Lys Pro Ala Thr Pro Asp Phe Arg Ser Val  
 1010 1015 1020  
 Leu Gly Gly Lys Lys Lys Leu Pro Ala Glu Asn Gly Ser Ser Ser  
 1025 1030 1035  
 Ala Glu Thr Leu Asn Ala Lys Ala Val Glu Ser Ser Lys Pro Leu  
 1040 1045 1050  
 Ser Asn Ala Gln Pro Ser Gly Pro Leu Lys Pro Val Gly Asn Ala  
 1055 1060 1065  
 Lys Pro Ala Glu Thr Leu Lys Pro Met Gly Asn Ala Lys Pro Ala  
 1070 1075 1080  
 Glu Thr Leu Lys Pro Met Gly Asn Ala Lys Pro Asp Glu Asn Leu  
 1085 1090 1095  
 Lys Ser Ala Ser Lys Glu Glu Leu Lys Lys Asp Val Lys Asn Asp  
 1100 1105 1110  
 Val Asn Cys Lys Arg Gly His Ala Gly Thr Thr Asp Asn Glu Lys  
 1115 1120 1125  
 Arg Ser Glu Ser Gln Gly Thr Ala Pro Ala Phe Lys Gln Lys Leu  
 1130 1135 1140  
 Gln Asp Val His Val Ala Glu Gly Lys Lys Leu Leu Leu Gln Cys  
 1145 1150 1155

-158-

Gln	Val	Ser	Ser	Asp	Pro	Pro	Ala	Thr	Ile	Ile	Trp	Thr	Leu	Asn
	1160					1165					1170			
Gly	Lys	Thr	Leu	Lys	Thr	Thr	Lys	Phe	Ile	Ile	Leu	Ser	Gln	Glu
	1175					1180					1185			
Gly	Ser	Leu	Cys	Ser	Val	Ser	Ile	Glu	Lys	Ala	Leu	Pro	Glu	Asp
	1190					1195					1200			
Arg	Gly	Leu	Tyr	Lys	Cys	Val	Ala	Lys	Asn	Asp	Ala	Gly	Gln	Ala
	1205					1210					1215			
Glu	Cys	Ser	Cys	Gln	Val	Thr	Val	Asp	Asp	Ala	Pro	Ala	Ser	Glu
	1220					1225					1230			
Asn	Thr	Lys	Ala	Pro	Glu	Met	Lys	Ser	Arg	Arg	Pro	Lys	Ser	Ser
	1235					1240					1245			
Leu	Pro	Pro	Val	Leu	Gly	Thr	Glu	Ser	Asp	Ala	Thr	Val	Lys	Lys
	1250					1255					1260			
Lys	Pro	Ala	Pro	Lys	Thr	Pro	Pro	Lys	Ala	Ala	Met	Pro	Pro	Gln
	1265					1270					1275			
Ile	Ile	Gln	Phe	Pro	Glu	Asp	Gln	Lys	Val	Arg	Ala	Gly	Glu	Ser
	1280					1285					1290			
Val	Glu	Leu	Phe	Gly	Lys	Val	Thr	Gly	Thr	Gln	Pro	Ile	Thr	Cys
	1295					1300					1305			
Thr	Trp	Met	Lys	Phe	Arg	Lys	Gln	Ile	Gln	Glu	Ser	Glu	His	Met
	1310					1315					1320			
Lys	Val	Glu	Asn	Ser	Glu	Asn	Gly	Ser	Lys	Leu	Thr	Ile	Leu	Ala
	1325					1330					1335			
Ala	Arg	Gln	Glu	His	Cys	Gly	Cys	Tyr	Thr	Leu	Leu	Val	Glu	Asn
	1340					1345					1350			
Lys	Leu	Gly	Ser	Arg	Gln	Ala	Gln	Val	Asn	Leu	Thr	Val	Val	Asp
	1355					1360					1365			
Lys	Pro	Asp	Pro	Pro	Ala	Gly	Thr	Pro	Cys	Ala	Ser	Asp	Ile	Arg
	1370					1375					1380			
Ser	Ser	Ser	Leu	Thr	Leu	Ser	Trp	Tyr	Gly	Ser	Ser	Tyr	Asp	Gly
	1385					1390					1395			
Gly	Ser	Ala	Val	Gln	Ser	Tyr	Ser	Ile	Glu	Ile	Trp	Asp	Ser	Ala
	1400					1405					1410			
Asn	Lys	Thr	Trp	Lys	Glu	Leu	Ala	Thr	Cys	Arg	Ser	Thr	Ser	Phe
	1415					1420					1425			
Asn	Val	Gln	Asp	Leu	Leu	Pro	Asp	His	Glu	Tyr	Lys	Phe	Arg	Val
	1430					1435					1440			
Arg	Ala	Ile	Asn	Val	Tyr	Gly	Thr	Ser	Glu	Pro	Ser	Gln	Glu	Ser
	1445					1450					1455			

-159-

Glu	Leu	Thr	Thr	Val	Gly	Glu	Lys	Pro	Glu	Glu	Pro	Lys	Asp	Glu
1460						1465					1470			
Val	Glu	Val	Ser	Asp	Asp	Asp	Glu	Lys	Glu	Pro	Glu	Val	Asp	Tyr
1475						1480					1485			
Arg	Thr	Val	Thr	Ile	Asn	Thr	Glu	Gln	Lys	Val	Ser	Asp	Phe	Tyr
1490						1495					1500			
Asp	Ile	Glu	Glu	Arg	Leu	Gly	Ser	Gly	Lys	Phe	Gly	Gln	Val	Phe
1505						1510					1515			
Arg	Leu	Val	Glu	Lys	Lys	Thr	Arg	Lys	Val	Trp	Ala	Gly	Lys	Phe
1520						1525					1530			
Phe	Lys	Ala	Tyr	Ser	Ala	Lys	Glu	Lys	Glu	Asn	Ile	Arg	Gln	Glu
1535						1540					1545			
Ile	Ser	Ile	Met	Asn	Cys	Leu	His	His	Pro	Lys	Leu	Val	Gln	Cys
1550						1555					1560			
Val	Asp	Ala	Phe	Glu	Glu	Lys	Ala	Asn	Ile	Val	Met	Val	Leu	Glu
1565						1570					1575			
Ile	Val	Ser	Gly	Gly	Glu	Leu	Phe	Glu	Arg	Ile	Ile	Asp	Glu	Asp
1580						1585					1590			
Phe	Glu	Leu	Thr	Glu	Arg	Glu	Cys	Ile	Lys	Tyr	Met	Arg	Gln	Ile
1595						1600					1605			
Ser	Glu	Gly	Val	Glu	Tyr	Ile	His	Lys	Gln	Gly	Ile	Val	His	Leu
1610						1615					1620			
Asp	Leu	Lys	Pro	Glu	Asn	Ile	Met	Cys	Val	Asn	Lys	Thr	Gly	Thr
1625						1630					1635			
Arg	Ile	Lys	Leu	Ile	Asp	Phe	Gly	Leu	Ala	Arg	Arg	Leu	Glu	Asn
1640						1645					1650			
Ala	Gly	Ser	Leu	Lys	Val	Leu	Phe	Gly	Thr	Pro	Glu	Phe	Val	Ala
1655						1660					1665			
Pro	Glu	Val	Ile	Asn	Tyr	Glu	Pro	Ile	Gly	Tyr	Ala	Thr	Asp	Met
1670						1675					1680			
Trp	Ser	Ile	Gly	Val	Ile	Cys	Tyr	Ile	Leu	Val	Ser	Gly	Leu	Ser
1685						1690					1695			
Pro	Phe	Met	Gly	Asp	Asn	Asp	Asn	Glu	Thr	Leu	Ala	Asn	Val	Thr
1700						1705					1710			
Ser	Ala	Thr	Trp	Asp	Phe	Asp	Asp	Glu	Ala	Phe	Asp	Glu	Ile	Ser
1715						1720					1725			
Asp	Asp	Ala	Lys	Asp	Phe	Ile	Ser	Asn	Leu	Leu	Lys	Lys	Asp	Met
1730						1735					1740			
Lys	Asn	Arg	Leu	Asp	Cys	Thr	Gln	Cys	Leu	Gln	His	Pro	Trp	Leu
1745						1750					1755			

-160-

Met Lys Asp Thr Lys Asn Met Glu Ala Lys Lys Leu Ser Lys Asp  
 1760 1765 1770  
 Arg Met Lys Lys Tyr Met Ala Arg Arg Lys Trp Gln Lys Thr Gly  
 1775 1780 1785  
 Asn Ala Val Arg Ala Ile Gly Arg Leu Ser Ser Met Ala Met Ile  
 1790 1795 1800  
 Ser Gly Leu Ser Gly Arg Lys Ser Ser Thr Gly Ser Pro Thr Ser  
 1805 1810 1815  
 Pro Leu Asn Ala Glu Lys Leu Glu Ser Glu Glu Asp Val Ser Gln  
 1820 1825 1830  
 Ala Phe Leu Glu Ala Val Ala Glu Glu Lys Pro His Val Lys Pro  
 1835 1840 1845  
 Tyr Phe Ser Lys Thr Ile Arg Asp Leu Glu Val Val Glu Gly Ser  
 1850 1855 1860  
 Ala Ala Arg Phe Asp Cys Lys Ile Glu Gly Tyr Pro Asp Pro Glu  
 1865 1870 1875  
 Val Val Trp Phe Lys Asp Asp Gln Ser Ile Arg Glu Ser Arg His  
 1880 1885 1890  
 Phe Gln Ile Asp Tyr Asp Glu Asp Gly Asn Cys Ser Leu Ile Ile  
 1895 1900 1905  
 Ser Asp Val Cys Gly Asp Asp Asp Ala Lys Tyr Thr Cys Lys Ala  
 1910 1915 1920  
 Val Asn Ser Leu Gly Glu Ala Thr Cys Thr Ala Glu Leu Ile Val  
 1925 1930 1935  
 Glu Thr Met Glu Glu Gly Glu Gly Glu Gly Glu Glu Glu Glu Glu  
 1940 1945 1950  
 <210> 93  
 <211> 901  
 <212> PRT  
 <213> Homo Sapiens  
 <400> 93  
 Val Gly Arg Ala Arg Ala Pro Gly Ala Gln Val Gly Ala Gly Ala Met  
 1 5 10 15  
 Glu Pro Pro Thr Val Pro Ser Glu Arg Ser Leu Ser Leu Ser Leu Pro  
 20 25 30  
 Gly Pro Arg Glu Gly Gln Ala Thr Leu Lys Pro Pro Pro Gln His Leu  
 35 40 45  
 Trp Arg Gln Pro Arg Thr Pro Ile Arg Ile Gln Gln Arg Gly Tyr Ser  
 50 55 60  
 Asp Ser Ala Glu Arg Ala Glu Arg Glu Arg Gln Pro His Arg Pro Ile

-161-

65					70						75					80
Glu	Arg	Ala	Asp	Ala	Met	Asp	Thr	Ser	Asp	Arg	Pro	Gly	Leu	Arg	Thr	
				85					90					95		
Thr	Arg	Met	Ser	Trp	Pro	Ser	Ser	Phe	His	Gly	Thr	Gly	Thr	Gly	Ser	
			100					105					110			
Gly	Gly	Ala	Gly	Gly	Gly	Ser	Ser	Arg	Arg	Phe	Glu	Ala	Glu	Asn	Gly	
		115					120					125				
Pro	Thr	Pro	Ser	Pro	Gly	Arg	Ser	Pro	Leu	Asp	Ser	Gln	Ala	Ser	Pro	
	130					135					140					
Gly	Leu	Val	Leu	His	Ala	Gly	Ala	Ala	Thr	Ser	Gln	Arg	Arg	Glu	Ser	
145					150					155					160	
Phe	Leu	Tyr	Arg	Ser	Asp	Ser	Asp	Tyr	Asp	Met	Ser	Pro	Lys	Thr	Met	
				165					170					175		
Ser	Arg	Asn	Ser	Ser	Val	Thr	Ser	Glu	Ala	His	Ala	Glu	Asp	Leu	Ile	
			180					185					190			
Val	Thr	Pro	Phe	Ala	Gln	Val	Leu	Ala	Ser	Leu	Arg	Ser	Val	Arg	Ser	
		195					200					205				
Asn	Phe	Ser	Leu	Leu	Thr	Asn	Val	Pro	Val	Pro	Ser	Asn	Lys	Arg	Ser	
	210					215					220					
Pro	Leu	Gly	Gly	Pro	Thr	Pro	Val	Cys	Lys	Ala	Thr	Leu	Ser	Glu	Glu	
225					230					235					240	
Thr	Cys	Gln	Gln	Leu	Ala	Arg	Glu	Thr	Leu	Glu	Glu	Leu	Asp	Trp	Cys	
				245					250					255		
Leu	Glu	Gln	Leu	Glu	Thr	Met	Gln	Thr	Tyr	Arg	Ser	Val	Ser	Glu	Met	
			260					265					270			
Ala	Ser	His	Lys	Phe	Lys	Arg	Met	Leu	Asn	Arg	Glu	Leu	Thr	His	Leu	
		275					280					285				
Ser	Glu	Met	Ser	Arg	Ser	Gly	Asn	Gln	Val	Ser	Glu	Tyr	Ile	Ser	Thr	
	290					295					300					
Thr	Phe	Leu	Asp	Lys	Gln	Asn	Glu	Val	Glu	Ile	Pro	Ser	Pro	Thr	Met	
305					310					315					320	
Lys	Glu	Arg	Glu	Lys	Gln	Gln	Ala	Pro	Arg	Pro	Arg	Pro	Ser	Gln	Pro	
				325					330					335		
Pro	Pro	Pro	Pro	Val	Pro	His	Leu	Gln	Pro	Met	Ser	Gln	Ile	Thr	Gly	
				340				345					350			
Leu	Lys	Lys	Leu	Met	His	Ser	Asn	Ser	Leu	Asn	Asn	Ser	Asn	Ile	Pro	
		355					360					365				
Arg	Phe	Gly	Val	Lys	Thr	Asp	Gln	Glu	Glu	Leu	Leu	Ala	Gln	Glu	Leu	
	370					375					380					
Glu	Asn	Leu	Asn	Lys	Trp	Gly	Leu	Asn	Ile	Phe	Cys	Val	Ser	Asp	Tyr	

-162-

385		390		395		400
Ala Gly Gly Arg Ser Leu Thr Cys Ile Met Tyr Met Ile Phe Gln Glu						
		405		410		415
Arg Asp Leu Leu Lys Lys Phe Arg Ile Pro Val Asp Thr Met Val Thr						
		420		425		430
Tyr Met Leu Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His						
		435		440		445
Asn Ser Leu His Ala Ala Asp Val Leu Gln Ser Thr His Val Leu Leu						
		450		455		460
Ala Thr Pro Ala Leu Asp Ala Val Phe Thr Asp Leu Glu Ile Leu Ala						
		465		470		480
Ala Leu Phe Ala Ala Ala Ile His Asp Val Asp His Pro Gly Val Ser						
		485		490		495
Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn						
		500		505		510
Asp Glu Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu						
		515		520		525
Leu Gln Glu Asp Asn Cys Asp Ile Phe Gln Asn Leu Ser Lys Arg Gln						
		530		535		540
Arg Gln Ser Leu Arg Lys Met Val Ile Asp Met Val Leu Ala Thr Asp						
		545		550		560
Met Ser Lys His Met Thr Leu Leu Ala Asp Leu Lys Thr Met Val Glu						
		565		570		575
Thr Lys Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser						
		580		585		590
Asp Arg Ile Gln Val Leu Arg Asn Met Val His Cys Ala Asp Leu Ser						
		595		600		605
Asn Pro Thr Lys Pro Leu Glu Leu Tyr Arg Gln Trp Thr Asp Arg Ile						
		610		615		620
Met Ala Glu Phe Phe Gln Gln Gly Asp Arg Glu Arg Glu Arg Gly Met						
		625		630		640
Glu Ile Ser Pro Met Cys Asp Lys His Thr Ala Ser Val Glu Lys Ser						
		645		650		655
Gln Val Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp						
		660		665		670
Ala Asp Leu Val His Pro Asp Ala Gln Glu Ile Leu Asp Thr Leu Glu						
		675		680		685
Asp Asn Arg Asp Trp Tyr Tyr Ser Ala Ile Arg Gln Ser Pro Ser Pro						
		690		695		700
Pro Pro Glu Glu Glu Ser Arg Gly Pro Gly His Pro Pro Leu Pro Asp						

705				710				715				720			
Lys	Phe	Gln	Phe	Glu 725	Leu	Thr	Leu	Glu	Glu 730	Glu	Glu	Glu	Glu	Glu 735	Ile
Ser	Met	Ala	Gln	Ile 740	Pro	Cys	Thr	Ala	Gln 745	Glu	Ala	Leu	Thr	Ala	Gln
Gly	Leu	Ser	Gly	Val 755	Glu	Glu	Ala	Leu	Asp 760	Ala	Thr	Ile	Ala	Trp	Glu
Ala	Ser	Pro	Ala	Gln 770	Glu	Ser	Leu	Glu	Val 775	Met	Ala 780	Gln	Glu	Ala	Ser
Leu 785	Glu	Ala	Glu	Leu 790	Glu	Ala	Val	Tyr	Leu 795	Thr	Gln	Gln	Ala	Gln	Ser 800
Thr	Gly	Ser	Ala	Pro 805	Val	Ala	Pro	Asp	Glu 810	Phe	Ser	Ser	Arg	Glu 815	Glu
Phe	Val	Val	Ala	Val 820	Ser	His	Ser	Ser 825	Pro	Ser	Ala	Leu	Ala 830	Leu	Gln
Ser	Pro	Leu	Leu	Pro 835	Ala	Trp	Arg	Thr 840	Leu	Ser	Val	Ser 845	Glu	His	Ala
Pro	Gly	Leu	Pro	Gly 850	Leu	Pro	Ser	Thr 855	Ala	Ala	Glu 860	Val	Glu	Ala	Gln
Arg 865	Glu	His	Gln	Ala 870	Ala	Lys	Arg	Ala	Cys 875	Ser	Ala	Cys	Ala	Gly 880	Thr
Phe	Gly	Glu	Asp	Thr 885	Ser	Ala	Leu	Pro	Ala 890	Pro	Gly	Gly	Gly	Gly 895	Ser
Gly	Gly	Asp	Pro	Thr 900											

<400> 94

Pro	Ala	Ser	Gly	Arg	Ala	Pro	Gln	Pro	Gly	Arg	Cys	Thr	Cys	Gln	Gly
1				5					10					15	
Asn	Lys	Leu	Glu	Glu	Gln	Asp	Pro	Arg	Pro	Leu	Gln	Pro	Ile	Pro	Gly
			20					25					30		
Leu	Met	Glu	Gly	Asn	Lys	Leu	Glu	Glu	Gln	Asp	Ser	Ser	Pro	Pro	Gln
		35					40					45			
Ser	Thr	Pro	Gly	Leu	Met	Lys	Gly	Asn	Lys	Arg	Glu	Glu	Gln	Gly	Leu
	50					55					60				
Gly	Pro	Glu	Pro	Ala	Ala	Pro	Gln	Gln	Pro	Thr	Ala	Glu	Glu	Glu	Ala
65					70					75					80



-164-

Leu	Ile	Glu	Phe	His	Arg	Ser	Tyr	Arg	Glu	Leu	Phe	Glu	Phe	Phe	Cys	85	90	95
Asn	Asn	Thr	Thr	Ile	His	Gly	Ala	Ile	Arg	Leu	Val	Cys	Ser	Gln	His	100	105	110
Asn	Arg	Met	Lys	Thr	Ala	Phe	Trp	Ala	Val	Leu	Trp	Leu	Cys	Thr	Phe	115	120	125
Gly	Met	Met	Tyr	Trp	Gln	Phe	Gly	Leu	Leu	Phe	Gly	Glu	Tyr	Phe	Ser	130	135	140
Tyr	Pro	Val	Ser	Leu	Asn	Ile	Asn	Leu	Asn	Ser	Asp	Lys	Leu	Val	Phe	145	150	155
Pro	Ala	Val	Thr	Ile	Cys	Thr	Leu	Asn	Pro	Tyr	Arg	Tyr	Pro	Glu	Ile	165	170	175
Lys	Glu	Glu	Leu	Glu	Glu	Leu	Asp	Arg	Ile	Thr	Glu	Gln	Thr	Leu	Phe	180	185	190
Asp	Leu	Tyr	Lys	Tyr	Ser	Ser	Phe	Thr	Thr	Leu	Val	Ala	Gly	Ser	Arg	195	200	205
Ser	Arg	Arg	Asp	Leu	Arg	Gly	Thr	Leu	Pro	His	Pro	Leu	Gln	Arg	Leu	210	215	220
Arg	Val	Pro	Pro	Pro	Pro	His	Gly	Ala	Arg	Arg	Ala	Arg	Ser	Val	Ala	225	230	235
Ser	Ser	Leu	Arg	Asp	Asn	Asn	Pro	Gln	Val	Asp	Trp	Lys	Asp	Trp	Lys	245	250	255
Ile	Gly	Phe	Gln	Leu	Cys	Asn	Gln	Asn	Lys	Ser	Asp	Cys	Phe	Tyr	Gln	260	265	270
Thr	Tyr	Ser	Ser	Gly	Val	Asp	Ala	Val	Arg	Glu	Trp	Tyr	Arg	Phe	His	275	280	285
Tyr	Ile	Asn	Ile	Leu	Ser	Arg	Leu	Pro	Glu	Thr	Leu	Pro	Ser	Leu	Glu	290	295	300
Glu	Asp	Thr	Leu	Gly	Asn	Phe	Ile	Phe	Ala	Cys	Arg	Phe	Asn	Gln	Val	305	310	315
Ser	Cys	Asn	Gln	Ala	Asn	Tyr	Ser	His	Phe	His	His	Pro	Met	Tyr	Gly	325	330	335
Asn	Cys	Tyr	Thr	Phe	Asn	Asp	Lys	Asn	Asn	Ser	Asn	Leu	Trp	Met	Ser	340	345	350
Ser	Met	Pro	Gly	Ile	Asn	Asn	Gly	Leu	Ser	Leu	Met	Leu	Arg	Ala	Glu	355	360	365
Gln	Asn	Asp	Phe	Ile	Pro	Leu	Leu	Ser	Thr	Val	Thr	Gly	Ala	Arg	Val	370	375	380
Met	Val	His	Gly	Gln	Asp	Glu	Pro	Ala	Phe	Met	Asp	Asp	Gly	Gly	Phe	385	390	395
																		400

-165-

Asn Leu Arg Pro Gly Val Glu Thr Ser Ile Ser Met Arg Lys Glu Thr  
 405 410 415  
 Leu Asp Arg Leu Gly Gly Asp Tyr Gly Asp Cys Thr Lys Asn Gly Ser  
 420 425 430  
 Asp Val Pro Val Glu Asn Leu Tyr Pro Ser Lys Tyr Thr Gln Gln Val  
 435 440 445  
 Cys Ile His Ser Cys Phe Gln Glu Ser Met Ile Lys Glu Cys Gly Cys  
 450 455 460  
 Ala Tyr Ile Phe Tyr Pro Arg Pro Gln Asn Val Glu Tyr Cys Asp Tyr  
 465 470 475 480  
 Arg Lys His Ser Ser Trp Gly Tyr Cys Tyr Tyr Lys Leu Gln Val Asp  
 485 490 495  
 Phe Ser Ser Asp His Leu Gly Cys Phe Thr Lys Cys Arg Lys Pro Cys  
 500 505 510  
 Ser Val Thr Ser Tyr Gln Leu Ser Ala Gly Tyr Ser Arg Trp Pro Ser  
 515 520 525  
 Val Thr Ser Gln Glu Trp Val Phe Gln Met Leu Ser Arg Gln Asn Asn  
 530 535 540  
 Tyr Thr Val Asn Asn Lys Arg Asn Gly Val Ala Lys Val Asn Ile Phe  
 545 550 555 560  
 Phe Lys Glu Leu Asn Tyr Lys Thr Asn Ser Glu Ser Pro Ser Val Thr  
 565 570 575  
 Met Val Thr Leu Leu Ser Asn Leu Gly Ser Gln Trp Ser Leu Trp Phe  
 580 585 590  
 Gly Ser Ser Val Leu Ser Val Val Glu Met Ala Glu Leu Val Phe Asp  
 595 600 605  
 Leu Leu Val Ile Met Phe Leu Met Leu Leu Arg Arg Phe Arg Ser Arg  
 610 615 620  
 Tyr Trp Ser Pro Gly Arg Gly Gly Arg Gly Ala Gln Glu Val Ala Ser  
 625 630 635 640  
 Thr Leu Ala Ser Ser Pro Pro Ser His Phe Cys Pro His Pro Met Ser  
 645 650 655  
 Leu Ser Leu Ser Gln Pro Gly Pro Ala Pro Ser Pro Ala Leu Thr Ala  
 660 665 670  
 Pro Pro Pro Ala Tyr Ala Thr Leu Gly Pro Arg Pro Ser Pro Gly Gly  
 675 680 685  
 Ser Ala Gly Ala Ser Ser Ser Thr Cys Pro Leu Gly Gly Pro  
 690 695 700

<210> 95  
 <211> 109  
 <212> PRT

-166-

&lt;213&gt; Homo Sapiens

&lt;400&gt; 95

Ala Tyr Ser Arg Gly Thr Ser Ser Leu Ser Thr Met Asn Gln Thr Ala  
 1 5 10 15  
 Ile Leu Ile Cys Cys Leu Ile Phe Leu Thr Leu Ser Gly Ile Gln Gly  
 20 25 30  
 Val Pro Leu Ser Arg Thr Val Arg Cys Thr Cys Ile Ser Ile Ser Asn  
 35 40 45  
 Gln Pro Val Asn Pro Arg Ser Leu Glu Lys Leu Glu Ile Ile Pro Ala  
 50 55 60  
 Ser Gln Phe Cys Pro Arg Val Glu Ile Ile Ala Thr Met Lys Lys Lys  
 65 70 75 80  
 Gly Glu Lys Arg Cys Leu Asn Pro Glu Ser Lys Ala Ile Lys Asn Leu  
 85 90 95  
 Leu Lys Ala Val Ser Lys Glu Met Ser Lys Arg Ser Pro  
 100 105

&lt;210&gt; 96

&lt;211&gt; 249

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 96

Glu Phe Pro Glu Glu Ala Asn Pro Ala Gly Ile Arg Ala Ile Arg Thr  
 1 5 10 15  
 Ala Thr Met Thr Val Gly Lys Ser Ser Lys Met Leu Gln His Ile Asp  
 20 25 30  
 Tyr Arg Met Arg Cys Ile Leu Gln Asp Gly Arg Ile Phe Ile Gly Thr  
 35 40 45  
 Phe Lys Ala Phe Asp Lys His Met Asn Leu Ile Leu Cys Asp Cys Asp  
 50 55 60  
 Glu Phe Arg Lys Ile Lys Pro Lys Asn Ser Lys Gln Ala Glu Arg Glu  
 65 70 75 80  
 Glu Lys Arg Val Leu Gly Leu Val Leu Leu Arg Gly Glu Asn Leu Val  
 85 90 95  
 Ser Met Thr Val Glu Gly Pro Pro Pro Lys Asp Thr Gly Ile Ala Arg  
 100 105 110  
 Val Pro Leu Ala Gly Ala Ala Gly Gly Pro Gly Ile Gly Arg Ala Ala  
 115 120 125  
 Gly Arg Gly Ile Pro Ala Gly Val Pro Met Pro Gln Ala Pro Ala Gly  
 130 135 140  
 Leu Ala Gly Pro Val Arg Gly Val Gly Gly Pro Ser Gln Gln Val Met

-167-

145                      150                      155                      160  
 Thr Pro Gln Gly Arg Gly Thr Val Ala Ala Ala Ala Ala Ala Thr  
                                  165                      170                      175  
 Ala Ser Ile Ala Gly Ala Pro Thr Gln Tyr Pro Pro Gly Arg Gly Gly  
                                  180                      185                      190  
 Pro Pro Pro Pro Met Gly Arg Gly Ala Pro Pro Pro Gly Met Met Gly  
                                  195                      200                      205  
 Pro Pro Pro Gly Met Arg Pro Pro Met Gly Pro Pro Met Gly Ile Pro  
                                  210                      215                      220  
 Pro Gly Arg Gly Thr Pro Met Gly Met Pro Pro Pro Gly Met Arg Pro  
 225                      230                      235                      240  
 Pro Pro Pro Gly Met Arg Gly Leu Leu  
                                  245

<210> 97  
 <211> 729  
 <212> PRT  
 <213> Homo Sapiens

<400> 97

Leu Leu Leu Trp Leu Asn Pro Gln Ala Leu Val Gly Ala Gln Gly Gly  
 1                      5                      10                      15  
 Arg Met Ser Gln Trp Tyr Glu Leu Gln Gln Leu Asp Ser Lys Phe Leu  
                                  20                      25                      30  
 Glu Gln Val His Gln Leu Tyr Asp Asp Ser Phe Pro Met Glu Ile Arg  
                                  35                      40                      45  
 Gln Tyr Leu Ala Gln Trp Leu Glu Lys Gln Asp Trp Glu His Ala Ala  
                                  50                      55                      60  
 Asn Asp Val Ser Phe Ala Thr Ile Arg Phe His Asp Leu Leu Ser Gln  
 65                      70                      75                      80  
 Leu Asp Asp Gln Tyr Ser Arg Phe Ser Leu Glu Asn Asn Phe Leu Leu  
                                  85                      90                      95  
 Gln His Asn Ile Arg Lys Ser Lys Arg Asn Leu Gln Asp Asn Phe Gln  
                                  100                      105                      110  
 Glu Asp Pro Ile Gln Met Ser Met Ile Ile Tyr Ser Cys Leu Lys Glu  
                                  115                      120                      125  
 Glu Arg Lys Ile Leu Glu Asn Ala Gln Arg Phe Asn Gln Ala Gln Ser  
                                  130                      135                      140  
 Gly Asn Ile Gln Ser Thr Val Met Leu Asp Lys Gln Lys Glu Leu Asp  
 145                      150                      155                      160  
 Ser Lys Val Arg Asn Val Lys Asp Lys Val Met Cys Ile Glu His Glu  
                                  165                      170                      175

Ile	Lys	Ser	Leu	Glu	Asp	Leu	Gln	Asp	Glu	Tyr	Asp	Phe	Lys	Cys	Lys
			180					185					190		
Thr	Leu	Gln	Asn	Arg	Glu	His	Glu	Thr	Asn	Gly	Val	Ala	Lys	Ser	Asp
		195					200					205			
Gln	Lys	Gln	Glu	Gln	Leu	Leu	Leu	Lys	Lys	Met	Tyr	Leu	Met	Leu	Asp
	210				215					220					
Asn	Lys	Arg	Lys	Glu	Val	Val	His	Lys	Ile	Ile	Glu	Leu	Leu	Asn	Val
225				230					235						240
Thr	Glu	Leu	Thr	Gln	Asn	Ala	Leu	Ile	Asn	Asp	Glu	Leu	Val	Glu	Trp
				245					250					255	
Lys	Arg	Arg	Gln	Gln	Ser	Ala	Cys	Ile	Gly	Gly	Pro	Pro	Asn	Ala	Cys
			260				265						270		
Leu	Asp	Gln	Leu	Gln	Asn	Trp	Phe	Thr	Ile	Val	Ala	Glu	Ser	Leu	Gln
		275					280					285			
Gln	Val	Arg	Gln	Gln	Leu	Lys	Lys	Leu	Glu	Glu	Leu	Glu	Gln	Lys	Tyr
	290					295					300				
Thr	Tyr	Glu	His	Asp	Pro	Ile	Thr	Lys	Asn	Lys	Gln	Val	Leu	Trp	Asp
305					310					315					320
Arg	Thr	Phe	Ser	Leu	Phe	Gln	Gln	Leu	Ile	Gln	Ser	Ser	Phe	Val	Val
				325					330					335	
Glu	Arg	Gln	Pro	Cys	Met	Pro	Thr	His	Pro	Gln	Arg	Pro	Leu	Val	Leu
			340					345					350		
Lys	Thr	Gly	Val	Gln	Phe	Thr	Val	Lys	Leu	Arg	Leu	Leu	Val	Lys	Leu
		355					360					365			
Gln	Glu	Leu	Asn	Tyr	Asn	Leu	Lys	Val	Lys	Val	Leu	Phe	Asp	Lys	Asp
	370					375					380				
Val	Asn	Glu	Arg	Asn	Thr	Val	Lys	Gly	Phe	Arg	Lys	Phe	Asn	Ile	Leu
385					390				395						400
Gly	Thr	His	Thr	Lys	Val	Met	Asn	Met	Glu	Glu	Ser	Thr	Asn	Gly	Ser
				405					410					415	
Leu	Ala	Ala	Glu	Phe	Arg	His	Leu	Gln	Leu	Lys	Glu	Gln	Lys	Asn	Ala
			420					425					430		
Gly	Thr	Arg	Thr	Asn	Glu	Gly	Pro	Leu	Ile	Val	Thr	Glu	Glu	Leu	His
		435					440					445			
Ser	Leu	Ser	Phe	Glu	Thr	Gln	Leu	Cys	Gln	Pro	Gly	Leu	Val	Ile	Asp
		450				455					460				
Leu	Glu	Thr	Thr	Ser	Leu	Pro	Val	Val	Val	Ile	Ser	Asn	Val	Ser	Gln
465					470					475					480
Leu	Pro	Ser	Gly	Trp	Ala	Ser	Ile	Leu	Trp	Tyr	Asn	Met	Leu	Val	Ala
				485					490					495	

-169-

Glu Pro Arg Asn Leu Ser Phe Phe Leu Thr Pro Pro Cys Ala Arg Trp  
 500 505 510

Ala Gln Leu Ser Glu Val Leu Ser Trp Gln Phe Ser Ser Val Thr Lys  
 515 520 525

Arg Gly Leu Asn Val Asp Gln Leu Asn Met Leu Gly Glu Lys Leu Leu  
 530 535 540

Gly Pro Asn Ala Ser Pro Asp Gly Leu Ile Pro Trp Thr Arg Phe Cys  
 545 550 555 560

Lys Glu Asn Ile Asn Asp Lys Asn Phe Pro Phe Trp Leu Trp Ile Glu  
 565 570 575

Ser Ile Leu Glu Leu Ile Lys Lys His Leu Leu Pro Leu Trp Asn Asp  
 580 585 590

Gly Cys Ile Met Gly Phe Ile Ser Lys Glu Arg Glu Arg Ala Leu Leu  
 595 600 605

Lys Asp Gln Gln Pro Gly Thr Phe Leu Leu Arg Phe Ser Glu Ser Ser  
 610 615 620

Arg Glu Gly Ala Ile Thr Phe Thr Trp Val Glu Arg Ser Gln Asn Gly  
 625 630 635 640

Gly Glu Pro Asp Phe His Ala Val Glu Pro Tyr Thr Lys Lys Glu Leu  
 645 650 655

Ser Ala Val Thr Phe Pro Asp Ile Ile Arg Asn Tyr Lys Val Met Ala  
 660 665 670

Ala Glu Asn Ile Pro Glu Asn Pro Leu Lys Tyr Leu Tyr Pro Asn Ile  
 675 680 685

Asp Lys Asp His Ala Phe Gly Lys Tyr Tyr Ser Arg Pro Lys Glu Ala  
 690 695 700

Pro Glu Pro Met Glu Leu Asp Gly Pro Lys Gly Thr Gly Tyr Ile Lys  
 705 710 715 720

Thr Glu Leu Ile Ser Val Ser Glu Val  
 725

<210> 98

<211> 1575

<212> PRT

<213> Homo Sapiens

<400> 98

Arg Gly Arg Leu Leu Gly Leu Leu Asn Pro Ser Val Ser Leu Gly Arg  
 1 5 10 15

Pro Lys Val Arg Val Met Tyr Arg Asp Glu Cys Lys Lys His Leu Ala  
 20 25 30

Gly Leu Gly Ala Leu Gly Leu Gly Ser Leu Ile Thr Glu Leu Thr Ala  
 35 40 45

-170-

Asn	Glu	Glu	Leu	Thr	Gly	Thr	Asp	Gly	Ala	Leu	Val	Asn	Asp	Glu	Gly	50	55	60	
Trp	Val	Arg	Ser	Thr	Glu	Asp	Ala	Val	Asp	Tyr	Ser	Asp	Ile	Asn	Glu	65	70	75	80
Val	Ala	Glu	Asp	Glu	Ser	Arg	Arg	Tyr	Gln	Gln	Thr	Met	Gly	Ser	Leu	85	90	95	
Gln	Pro	Leu	Cys	His	Ser	Asp	Tyr	Asp	Glu	Asp	Asp	Tyr	Asp	Ala	Asp	100	105	110	
Cys	Glu	Asp	Ile	Asp	Cys	Lys	Leu	Met	Pro	Pro	Pro	Pro	Pro	Pro	Pro	115	120	125	
Gly	Pro	Met	Lys	Lys	Asp	Lys	Asp	Gln	Asp	Ser	Ile	Thr	Gly	Glu	Lys	130	135	140	
Val	Asp	Phe	Ser	Ser	Ser	Ser	Asp	Ser	Glu	Ser	Glu	Met	Gly	Pro	Gln	145	150	155	160
Glu	Ala	Thr	Gln	Ala	Glu	Ser	Glu	Asp	Gly	Lys	Leu	Thr	Leu	Pro	Leu	165	170	175	
Ala	Gly	Ile	Met	Gln	His	Asp	Ala	Thr	Lys	Leu	Leu	Pro	Ser	Val	Thr	180	185	190	
Glu	Leu	Phe	Pro	Glu	Phe	Arg	Pro	Gly	Lys	Val	Leu	Arg	Phe	Leu	Arg	195	200	205	
Leu	Phe	Gly	Pro	Gly	Lys	Asn	Val	Pro	Ser	Val	Trp	Arg	Ser	Ala	Arg	210	215	220	
Arg	Lys	Arg	Lys	Lys	Lys	His	Arg	Glu	Leu	Ile	Gln	Glu	Glu	Gln	Ile	225	230	235	240
Gln	Glu	Val	Glu	Cys	Ser	Val	Glu	Ser	Glu	Val	Ser	Gln	Lys	Ser	Leu	245	250	255	
Trp	Asn	Tyr	Asp	Tyr	Ala	Pro	Pro	Pro	Pro	Pro	Glu	Gln	Cys	Leu	Ser	260	265	270	
Asp	Asp	Glu	Ile	Thr	Met	Met	Ala	Pro	Val	Glu	Ser	Lys	Phe	Ser	Gln	275	280	285	
Ser	Thr	Gly	Asp	Ile	Asp	Lys	Val	Thr	Asp	Thr	Lys	Pro	Arg	Val	Ala	290	295	300	
Glu	Trp	Arg	Tyr	Gly	Pro	Ala	Arg	Leu	Trp	Tyr	Asp	Met	Leu	Gly	Val	305	310	315	320
Pro	Glu	Asp	Gly	Ser	Gly	Phe	Asp	Tyr	Gly	Phe	Lys	Leu	Arg	Lys	Thr	325	330	335	
Glu	His	Glu	Pro	Val	Ile	Lys	Ser	Arg	Met	Ile	Glu	Glu	Phe	Arg	Lys	340	345	350	
Leu	Glu	Glu	Asn	Asn	Gly	Thr	Asp	Leu	Leu	Ala	Asp	Glu	Asn	Phe	Leu	355	360	365	

-171-

Met	Val	Thr	Gln	Leu	His	Trp	Glu	Asp	Asp	Ile	Ile	Trp	Asp	Gly	Glu	370	375	380	
Asp	Val	Lys	His	Lys	Gly	Thr	Lys	Pro	Gln	Arg	Ala	Ser	Leu	Ala	Gly	385	390	395	400
Trp	Leu	Pro	Ser	Ser	Met	Thr	Arg	Asn	Ala	Met	Ala	Tyr	Asn	Val	Gln	405	410	415	
Gln	Gly	Phe	Ala	Ala	Thr	Leu	Asp	Asp	Asp	Lys	Pro	Trp	Tyr	Ser	Ile	420	425	430	
Phe	Pro	Ile	Asp	Asn	Glu	Asp	Leu	Val	Tyr	Gly	Arg	Trp	Glu	Asp	Asn	435	440	445	
Ile	Ile	Trp	Asp	Ala	Gln	Ala	Met	Pro	Arg	Leu	Leu	Glu	Pro	Pro	Val	450	455	460	
Leu	Thr	Leu	Asp	Pro	Asn	Asp	Glu	Asn	Leu	Ile	Leu	Glu	Ile	Pro	Asp	465	470	475	480
Glu	Lys	Glu	Glu	Ala	Thr	Ser	Asn	Ser	Pro	Ser	Lys	Glu	Ser	Lys	Lys	485	490	495	
Glu	Ser	Ser	Leu	Lys	Lys	Ser	Arg	Ile	Leu	Leu	Gly	Lys	Thr	Gly	Val	500	505	510	
Ile	Lys	Glu	Glu	Pro	Gln	Gln	Asn	Met	Ser	Gln	Pro	Glu	Val	Lys	Asp	515	520	525	
Pro	Trp	Asn	Leu	Ser	Asn	Asp	Glu	Tyr	Tyr	Tyr	Pro	Lys	Gln	Gln	Gly	530	535	540	
Leu	Arg	Gly	Thr	Phe	Gly	Gly	Asn	Ile	Ile	Gln	His	Ser	Ile	Pro	Ala	545	550	555	560
Val	Glu	Leu	Arg	Gln	Pro	Phe	Phe	Pro	Thr	His	Met	Gly	Pro	Ile	Lys	565	570	575	
Leu	Arg	Gln	Phe	His	Arg	Pro	Pro	Leu	Lys	Lys	Tyr	Ser	Phe	Gly	Ala	580	585	590	
Leu	Ser	Gln	Pro	Gly	Pro	His	Ser	Val	Gln	Pro	Leu	Leu	Lys	His	Ile	595	600	605	
Lys	Lys	Lys	Ala	Lys	Met	Arg	Glu	Gln	Glu	Arg	Gln	Ala	Ser	Gly	Gly	610	615	620	
Gly	Glu	Met	Phe	Phe	Met	Arg	Thr	Pro	Gln	Asp	Leu	Thr	Gly	Lys	Asp	625	630	635	640
Gly	Asp	Leu	Ile	Leu	Ala	Glu	Tyr	Ser	Glu	Glu	Asn	Gly	Pro	Leu	Met	645	650	655	
Met	Gln	Val	Gly	Met	Ala	Thr	Lys	Ile	Lys	Asn	Tyr	Tyr	Lys	Arg	Lys	660	665	670	
Pro	Gly	Lys	Asp	Pro	Gly	Ala	Pro	Asp	Cys	Lys	Tyr	Gly	Glu	Thr	Val	675	680	685	



-172-

Tyr Cys His Thr Ser Pro Phe Leu Gly Ser Leu His Pro Gly Gln Leu  
 690 695 700  
 Leu Gln Ala Phe Glu Asn Asn Leu Phe Arg Ala Pro Ile Tyr Leu His  
 705 710 715 720  
 Lys Met Pro Glu Thr Asp Phe Leu Ile Ile Arg Thr Arg Gln Gly Tyr  
 725 730 735  
 Tyr Ile Arg Glu Leu Val Asp Ile Phe Val Val Gly Gln Gln Cys Pro  
 740 745 750  
 Leu Phe Glu Val Pro Gly Pro Asn Ser Lys Arg Ala Asn Thr His Ile  
 755 760 765  
 Arg Asp Phe Leu Gln Val Phe Ile Tyr Arg Leu Phe Trp Lys Ser Lys  
 770 775 780  
 Asp Arg Pro Arg Arg Ile Arg Met Glu Asp Ile Lys Lys Ala Phe Pro  
 785 790 795 800  
 Ser His Ser Glu Ser Ser Ile Arg Lys Arg Leu Lys Leu Cys Ala Asp  
 805 810 815  
 Phe Lys Arg Thr Gly Met Asp Ser Asn Trp Trp Val Leu Lys Ser Asp  
 820 825 830  
 Phe Arg Leu Pro Thr Glu Glu Glu Ile Arg Ala Met Val Ser Pro Glu  
 835 840 845  
 Gln Cys Cys Ala Tyr Tyr Ser Met Ile Ala Ala Glu Gln Arg Leu Lys  
 850 855 860  
 Asp Ala Gly Tyr Gly Glu Lys Ser Phe Phe Ala Pro Glu Glu Glu Asn  
 865 870 875 880  
 Glu Glu Asp Phe Gln Met Lys Ile Asp Asp Glu Val Arg Thr Ala Pro  
 885 890 895  
 Trp Asn Thr Thr Arg Ala Phe Ile Ala Ala Met Lys Gly Lys Cys Leu  
 900 905 910  
 Leu Glu Val Thr Gly Val Ala Asp Pro Thr Gly Cys Gly Glu Gly Phe  
 915 920 925  
 Ser Tyr Val Lys Ile Pro Asn Lys Pro Thr Gln Gln Lys Asp Asp Lys  
 930 935 940  
 Glu Pro Gln Pro Val Lys Lys Thr Val Thr Gly Thr Asp Ala Asp Leu  
 945 950 955 960  
 Arg Arg Leu Ser Leu Lys Asn Ala Lys Gln Leu Leu Arg Lys Phe Gly  
 965 970 975  
 Val Pro Glu Glu Glu Ile Lys Lys Leu Ser Arg Trp Glu Val Ile Asp  
 980 985 990  
 Val Val Arg Thr Met Ser Thr Glu Gln Ala Arg Ser Gly Glu Gly Pro  
 995 1000 1005

-173-

Met	Ser	Lys	Phe	Ala	Arg	Gly	Ser	Arg	Phe	Ser	Val	Ala	Glu	His
1010						1015					1020			
Gln	Glu	Arg	Tyr	Lys	Glu	Glu	Cys	Gln	Arg	Ile	Phe	Asp	Leu	Gln
1025						1030					1035			
Asn	Lys	Val	Leu	Ser	Ser	Thr	Glu	Val	Leu	Ser	Thr	Asp	Thr	Asp
1040						1045					1050			
Ser	Ser	Ser	Ala	Glu	Asp	Ser	Asp	Phe	Glu	Glu	Met	Gly	Lys	Asn
1055						1060					1065			
Ile	Glu	Asn	Met	Leu	Gln	Asn	Lys	Lys	Thr	Ser	Ser	Gln	Leu	Ser
1070						1075					1080			
Arg	Glu	Arg	Glu	Glu	Gln	Glu	Arg	Lys	Glu	Leu	Gln	Arg	Met	Leu
1085						1090					1095			
Leu	Ala	Ala	Gly	Ser	Ala	Ala	Ser	Gly	Asn	Asn	His	Arg	Asp	Asp
1100						1105					1110			
Asp	Thr	Ala	Ser	Val	Thr	Ser	Leu	Asn	Ser	Ser	Ala	Thr	Gly	Arg
1115						1120					1125			
Cys	Leu	Lys	Ile	Tyr	Arg	Thr	Phe	Arg	Asp	Glu	Glu	Gly	Lys	Glu
1130						1135					1140			
Tyr	Val	Arg	Cys	Glu	Thr	Val	Arg	Lys	Pro	Ala	Val	Ile	Asp	Ala
1145						1150					1155			
Tyr	Val	Arg	Ile	Arg	Thr	Thr	Lys	Asp	Glu	Glu	Phe	Ile	Arg	Lys
1160						1165					1170			
Phe	Ala	Leu	Phe	Asp	Glu	Gln	His	Arg	Glu	Glu	Met	Arg	Lys	Glu
1175						1180					1185			
Arg	Arg	Arg	Ile	Gln	Glu	Gln	Leu	Arg	Arg	Leu	Lys	Arg	Asn	Gln
1190						1195					1200			
Glu	Lys	Glu	Lys	Leu	Lys	Gly	Pro	Pro	Glu	Lys	Lys	Pro	Lys	Lys
1205						1210					1215			
Met	Lys	Glu	Arg	Pro	Asp	Leu	Lys	Leu	Lys	Cys	Gly	Ala	Cys	Gly
1220						1225					1230			
Ala	Ile	Gly	His	Met	Arg	Thr	Asn	Lys	Phe	Cys	Pro	Leu	Tyr	Tyr
1235						1240					1245			
Gln	Thr	Asn	Ala	Pro	Pro	Ser	Asn	Pro	Val	Ala	Met	Thr	Glu	Glu
1250						1255					1260			
Gln	Glu	Glu	Glu	Leu	Glu	Lys	Thr	Val	Ile	His	Asn	Asp	Asn	Glu
1265						1270					1275			
Glu	Leu	Ile	Lys	Val	Glu	Gly	Thr	Lys	Ile	Val	Leu	Gly	Lys	Gln
1280						1285					1290			
Leu	Ile	Glu	Ser	Ala	Asp	Glu	Val	Arg	Arg	Lys	Ser	Leu	Val	Leu
1295						1300					1305			

-174-

Lys Phe Pro Lys Gln Gln Leu Pro Pro Lys Lys Lys Arg Arg Val  
 1310 1315 1320  
 Gly Thr Thr Val His Cys Asp Tyr Leu Asn Arg Pro His Lys Ser  
 1325 1330 1335  
 Ile His Arg Arg Arg Thr Asp Pro Met Val Thr Leu Ser Ser Ile  
 1340 1345 1350  
 Leu Glu Ser Ile Ile Asn Asp Met Arg Asp Leu Pro Asn Thr Tyr  
 1355 1360 1365  
 Pro Phe His Thr Pro Val Asn Ala Lys Val Val Lys Asp Tyr Tyr  
 1370 1375 1380  
 Lys Ile Ile Thr Arg Pro Met Asp Leu Gln Thr Leu Arg Glu Asn  
 1385 1390 1395  
 Val Arg Lys Arg Leu Tyr Pro Ser Arg Glu Glu Phe Arg Glu His  
 1400 1405 1410  
 Leu Glu Leu Ile Val Lys Asn Ser Ala Thr Tyr Asn Gly Pro Lys  
 1415 1420 1425  
 His Ser Leu Thr Gln Ile Ser Gln Ser Met Leu Asp Leu Cys Asp  
 1430 1435 1440  
 Glu Lys Leu Lys Glu Lys Glu Asp Lys Leu Ala Arg Leu Glu Lys  
 1445 1450 1455  
 Ala Ile Asn Pro Leu Leu Asp Asp Asp Asp Gln Val Ala Phe Ser  
 1460 1465 1470  
 Phe Ile Leu Asp Asn Ile Val Thr Gln Lys Met Met Ala Val Pro  
 1475 1480 1485  
 Asp Ser Trp Pro Phe His His Pro Val Asn Lys Lys Phe Val Pro  
 1490 1495 1500  
 Asp Tyr Tyr Lys Val Ile Val Asn Pro Met Asp Leu Glu Thr Ile  
 1505 1510 1515  
 Arg Lys Asn Ile Ser Lys His Lys Tyr Gln Ser Arg Glu Ser Phe  
 1520 1525 1530  
 Leu Asp Asp Val Asn Leu Ile Leu Ala Asn Ser Val Lys Tyr Asn  
 1535 1540 1545  
 Asp Asn Glu Cys Ser Ser Lys Ala Asn Asp Ile Val Cys Leu Ile  
 1550 1555 1560  
 Gln Tyr Cys Ser Ser Gln Ile Glu Glu Leu Arg Phe  
 1565 1570 1575

<210> 99  
 <211> 166  
 <212> PRT  
 <213> Homo Sapiens

-175-

&lt;400&gt; 99

Leu Cys Leu Lys Lys Lys Ile Pro Asn Met Asp Lys Pro Arg Lys Glu  
 1 5 10 15  
 Asn Glu Glu Glu Pro Gln Ser Arg Pro Arg Pro Met Arg Arg Gly Leu  
 20 25 30  
 Arg Trp Ser Thr Leu Pro Lys Ser Ser Pro Pro Arg Ser Ser Leu Arg  
 35 40 45  
 Arg Ser Ser Pro Arg Arg Arg Ser Ser Phe Leu Arg Ser Ser Cys Leu  
 50 55 60  
 Ser Ser Cys Leu Arg Cys Ser Ser Arg Arg Thr Pro Ser Ala Gly Leu  
 65 70 75 80  
 Ser Arg Lys Asp Leu Phe Glu Val Arg Pro Pro Met Glu Gln Pro Pro  
 85 90 95  
 Cys Gly Val Gly Lys His Asn Leu Glu Glu Gly Ile Phe Lys Glu Arg  
 100 105 110  
 Leu Ala Arg Ser Arg Pro Gln Phe Arg Gly Asp Ile His Gly Arg Asn  
 115 120 125  
 Leu Ser Asn Glu Glu Met Ile Gln Ala Ala Asp Glu Leu Glu Glu Met  
 130 135 140  
 Lys Arg Val Arg Asn Lys Leu Met Ile Met His Trp Arg Ala Lys Arg  
 145 150 155 160  
 Gly Gly Pro Tyr Pro Ile  
 165

&lt;210&gt; 100

&lt;211&gt; 245

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 100

Thr Lys Met Leu Lys Ser Trp Arg Ser Gly Arg Gln Ile Thr Gln Lys  
 1 5 10 15  
 Gly Thr Glu Asp Glu Leu Asp Lys Tyr Ser Glu Ala Leu Lys Asp Ala  
 20 25 30  
 Gln Glu Lys Leu Glu Leu Ala Glu Lys Lys Ala Thr Asp Ala Glu Ala  
 35 40 45  
 Asp Val Ala Ser Leu Asn Arg Arg Ile Gln Leu Val Glu Glu Glu Leu  
 50 55 60  
 Asp Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys Leu Glu Glu  
 65 70 75 80  
 Ala Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys Val Ile Glu  
 85 90 95

-176-

Ser Arg Ala Gln Lys Asp Glu Glu Lys Met Glu Ile Gln Glu Ile Gln  
 100 105 110  
 Leu Lys Glu Ala Lys His Ile Ala Glu Asp Ala Asp Arg Lys Tyr Glu  
 115 120 125  
 Glu Val Ala Arg Lys Leu Val Ile Ile Glu Ser Asp Leu Glu Arg Ala  
 130 135 140  
 Glu Glu Arg Ala Glu Leu Ser Glu Gly Gln Val Arg Gln Leu Glu Glu  
 145 150 155 160  
 Gln Leu Arg Ile Met Asp Gln Thr Leu Lys Ala Leu Met Ala Ala Glu  
 165 170 175  
 Asp Lys Tyr Ser Gln Lys Glu Asp Arg Tyr Glu Glu Glu Ile Lys Val  
 180 185 190  
 Leu Ser Asp Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu Phe Ala Glu  
 195 200 205  
 Arg Ser Val Thr Lys Leu Glu Lys Ser Ile Asp Asp Leu Glu Glu Lys  
 210 215 220  
 Val Leu Met Pro Lys Lys Lys Thr Leu Val Cys Ile Arg Cys Trp Ile  
 225 230 235 240  
 Arg Leu Tyr Trp Ser  
 245

<210> 101  
 <211> 267  
 <212> PRT  
 <213> Homo Sapiens

<400> 101

Leu Pro Val Leu Ala Ser Arg Ala Tyr Ala Ala Pro Ala Pro Gly Gln  
 1 5 10 15  
 Ala Leu Gln Arg Val Gly Ile Val Gly Gly Gln Glu Ala Pro Arg Ser  
 20 25 30  
 Lys Trp Pro Trp Gln Val Ser Leu Arg Val Arg Asp Arg Tyr Trp Met  
 35 40 45  
 His Phe Cys Gly Gly Ser Leu Ile His Pro Gln Trp Val Leu Thr Ala  
 50 55 60  
 Ala His Cys Val Gly Pro Asp Val Lys Asp Leu Ala Ala Leu Arg Val  
 65 70 75 80  
 Gln Leu Arg Glu Gln His Leu Tyr Tyr Gln Asp Gln Leu Leu Pro Val  
 85 90 95  
 Ser Arg Ile Ile Val His Pro Gln Phe Tyr Thr Ala Gln Ile Gly Ala  
 100 105 110  
 Asp Ile Ala Leu Leu Glu Leu Glu Glu Pro Val Lys Val Ser Ser His  
 115 120 125

-177-

Val His Thr Val Thr Leu Pro Pro Ala Ser Glu Thr Phe Pro Pro Gly  
 130 135 140  
 Met Pro Cys Trp Val Thr Gly Trp Gly Asp Val Asp Asn Asp Glu Arg  
 145 150 155 160  
 Leu Pro Pro Pro Phe Pro Leu Lys Gln Val Lys Val Pro Ile Met Glu  
 165 170 175  
 Asn His Ile Cys Asp Ala Lys Tyr His Leu Gly Ala Tyr Thr Gly Asp  
 180 185 190  
 Asp Val Arg Ile Val Arg Asp Asp Met Leu Cys Ala Gly Asn Thr Arg  
 195 200 205  
 Arg Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Lys Val  
 210 215 220  
 Asn Gly Thr Trp Leu Gln Ala Gly Val Val Ser Trp Gly Glu Gly Cys  
 225 230 235 240  
 Ala Gln Pro Asn Arg Pro Gly Ile Tyr Thr Arg Val Thr Tyr Tyr Leu  
 245 250 255  
 Asp Trp Ile His His Tyr Val Pro Lys Lys Pro  
 260 265

<210> 102  
 <211> 192  
 <212> PRT  
 <213> Homo Sapiens

<400> 102

Ala Arg Ala Ser Ser Cys Leu Ser Ala Asn Ala Ala Arg Met Ala Ser  
 1 5 10 15  
 Gln Asn Arg Asp Pro Ala Ala Thr Ser Val Ala Ala Ala Arg Lys Gly  
 20 25 30  
 Ala Glu Pro Ser Gly Gly Ala Ala Arg Gly Pro Val Gly Lys Arg Leu  
 35 40 45  
 Gln Gln Glu Leu Met Thr Leu Met Met Ser Gly Asp Lys Gly Ile Ser  
 50 55 60  
 Ala Phe Pro Glu Ser Asp Asn Leu Phe Lys Trp Val Gly Thr Ile His  
 65 70 75 80  
 Gly Ala Ala Gly Thr Val Tyr Glu Asp Leu Arg Tyr Lys Leu Ser Leu  
 85 90 95  
 Glu Phe Pro Ser Gly Tyr Pro Tyr Asn Ala Pro Thr Val Lys Phe Leu  
 100 105 110  
 Thr Pro Cys Tyr His Pro Asn Val Asp Thr Gln Gly Asn Ile Cys Leu  
 115 120 125  
 Asp Ile Leu Lys Glu Lys Trp Ser Ala Leu Tyr Asp Val Arg Thr Ile

130					135					140					
Leu	Leu	Ser	Ile	Gln	Ser	Leu	Leu	Gly	Glu	Pro	Asn	Ile	Asp	Ser	Pro
145					150					155					160
Leu	Asn	Thr	His	Ala	Ala	Glu	Leu	Trp	Lys	Asn	Pro	Thr	Ala	Phe	Lys
				165					170					175	
Lys	Tyr	Leu	Gln	Glu	Thr	Tyr	Ser	Lys	Gln	Val	Thr	Ser	Gln	Glu	Pro
			180					185					190		